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There is very little research on the psychosocial risk factors associated with psychotic 
major depression (PMD) and schizoaffective disorder, depressed type (SAD). Although 
there is much more research on the course and outcomes of these disorders, the studies 
have significant methodological limitations. Therefore, this thesis aimed to investigate 
the following while improving on the limitations of previous research: 1) the risk factors 
associated with PMD and SAD with a focus on psychosocial risk factors; and 2) the 
long-term course of illness and outcomes in cases with PMD and SAD.  
 
A case control study of incident psychosis cases was used to examine psychosocial risk 
factors in PMD and SAD cases compared with schizophrenia and bipolar disorder cases. 
A cohort study following up all cases identified in the case control study was conducted 
to investigate course of illness and outcomes.  
 
Findings on the risk factors suggest that less psychosocial risk factors are involved in 
the aetiology of PMD and SAD compared with schizophrenia and bipolar disorder. 
Exploratory analyses of life events indicate that humiliation life events could be an 
important factor in the development of PMD and requires further research. Findings on 
outcomes suggest that PMD cases are more likely to self-harm and attempt suicide but 
are less likely to use inpatient services and have a lower proportion of compulsory 
admissions. These findings have important clinical implications. Findings on risk 
factors and outcomes in SAD cases are similar but a lack of power due to low numbers 
limits the interpretation of the findings. 
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Important differences in both the risk factors and outcomes analyses were identified 
when based on the baseline and lifetime diagnoses. This highlights the importance of 
accounting for diagnostic change when examining these diagnostic groups.  
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CHAPTER 1. Introduction 
 
“Psychotic depression is a common and costly condition, but with no accepted best 
practice guidance for its management. More attention needs to be focused on this 
largely under-researched group.”1 
Crebbin et al. (2008) 
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1.1. Aims of the thesis 
Crebbin et al. claim that cases with a diagnosis of psychotic major depression are a 
“...largely under-researched group”.1 Therefore, the purpose of this thesis was to explore 
two key areas of research in this group: aetiology (with a particular focus on 
psychosocial risk factors); and long-term outcomes. 
 
1.2. Outline of thesis 
Chapter 2 of this thesis discusses the diagnosis of psychotic major depression (PMD) 
and the overlap with a similar diagnosis: schizoaffective disorder, depressed type 
(SAD). This highlights reasons for the decision to examine both diagnoses within this 
thesis. This chapter goes on to discuss the gaps in the literature which form the basis for 
this thesis. There is also some discussion about the key methodological issue of 
diagnostic stability. 
 
Chapters 3 and 4 are reviews of the literature. Chapter 3 discusses the concept of social 
adversity. This chapter goes on to review the literature on social adversity in the 
aetiology of depression and psychosis, and where available in PMD and SAD diagnostic 
groups specifically. Chapter 4 is a systematic review of the literature on outcomes in 
PMD and SAD cases. Following a review of the literature, a section discussing the 
methodological limitations of previous research highlights how the study reported in 
this thesis sought to improve on previous research. 
 
Chapter 5 describes the methodology used within this thesis. The methods are split into 
three parts: an overview of the AESOP study; a section on the case-control section of 
the thesis; and a section on the cohort section of this thesis. The overview describes the 
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context of the AESOP study, the data from which is the basis of this thesis. The case-
control section describes the methods which were used to test hypotheses on 
psychosocial risk factors in PMD and SAD cases. The cohort section describes the 
methods used to test hypotheses on long-term course and outcomes in PMD and SAD 
cases. 
 
Chapters 7 and 8 are results chapters. Chapter 7 presents results from the case-control 
study which aimed to test hypotheses around psychosocial risk factors. This is first 
based on baseline diagnoses and then based on the lifetime diagnoses, with a section 
comparing the two. Chapter 8 describes the results from the cohort study which aimed 
to test hypotheses about long-term outcomes of PMD and SAD cases compared with 
schizophrenia and bipolar cases. Similar to chapter 7, the results are first based on 
baseline diagnoses and then based on lifetime diagnoses. 
 
Finally, chapter 8 summarises the salient results and then explores the methodological 
considerations, comparisons to previous literature, theoretical implications and clinical 
implications. This is done separately for the case-control and cohort sections of the 
thesis. Future research and final conclusions are then considered.  
 
1.3. Statement of the candidate’s contribution 
The ÆSOP study was originally created by Professor Robin M Murray and Professor 
Julian Leff (Institute of Psychiatry, KCL). When I began on the ÆSOP study I 
examined data that had been collected at baseline and data that was being collected at 
follow-up. I then examined the literature on psychosis and found that there was a gap in 
the research on PMD. This information was then drawn together to create an outline of a 
PhD to investigate what has been described here. This was all done under the guidance 
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of Dr. Craig Morgan and Professor Tom Craig. Specifically, I developed the study 
hypotheses and decided to investigate differences in findings when based on baseline 
and lifetime diagnoses, which, as discussed throughout the thesis, is an important 
methodological advance. 
  
I was fully involved in all aspects of the cohort phase of the study, including tracing, 
consenting and collecting data from participants for over 2 years. I personally traced and 
recruited cases from all over the UK and even traced, recruited and conducted telephone 
interviews with one case in New Zealand and another in Norway.  
 
I have made a substantial contribution to the completion of Life Chart assessments with 
over a third of the London Life Charts completed by myself (n124). With an average 
follow-up of 10 years, this involved reading and summarising over 1,240 years of 
clinical notes. I have also been involved in diagnostic and life chart consensus meetings 
for over 200 participants. 
 
I entered all of the data from the cohort phase of the study into Access databases and 
conducted all data cleaning. I conducted all the data analysis presented in this thesis 









CHAPTER 2. Background 
 
“What yesterday appeared to be generally accepted and established, was today, to 
some, at best, a precarious working-hypothesis, to others a dogma to be fought, and to 





2.1. Myths in the literature... 
Two recent works dedicated to the understanding of PMD begin their opening chapter 
by recounting the story of Andrea Yates.
3, 4
 Andrea was a woman who drowned her five 
children in the bathtub one day as a result of her experiencing PMD. According to the 
author of the first book, “psychotic depression is highly dangerous” as patients 
contemplate suicide, and “psychotic depressions can also be risky for others… 
periodically there are terrible stories of psychotically depressed parents who murder 
their children…”.4 A much earlier journal article states: “Another reason for admitting 
severely depressed patients to hospital is that on occasion they murder their relatives or 
friends in an attempt to spare them imagined pain”. 5 
 
These authors paint a bleak prognostic picture for patients and their families who 
receive a diagnosis of PMD. A vital question is whether the prognostic picture for 
patients with a diagnosis of psychotic depression is as grim as these books would have 
us believe. Furthermore, what is the relationship between the prognosis of PMD and it’s 
very close cousin, SAD. The purpose of this thesis was to examine the long-term 
outcomes for these overlapping disorders and to examine who is at risk of receiving 
these diagnoses. 
 
Henceforth, psychotic major depression will be referred to as PMD and schizoaffective 
disorder, depressed type will be referred to as SAD. 
 
2.2. Diagnosis of PMD and SAD 
Diagnoses have been evolving since the start of psychiatry and are still evolving today.
2
 
PMD and SAD are no exception to this.
6




 and the historical context of schizoaffective disorder has already 




 Therefore, only the current 
most widely used diagnostic classification systems in Europe and the US will be 
examined: the International Classification of Diseases (ICD); and Diagnostic and 
Statistical Manual of Mental Disorders (DSM). 
 
2.2.1. ICD development 
The International Classification of Diseases (ICD) manual by the World Health 
Organisation (WHO) is a classification system which has undergone radical changes 
over its history. Before 1977 the WHO in its ICD manual simply listed diagnoses under 
certain headings.
9-11
 There were no criteria or descriptions of what was meant by each 
diagnosis, therefore leading to possible confusion and unreliable diagnoses among those 
using these tools, which would include clinicians and researchers. Under its depressive 
section (301.1), ICD-6
9
 (published in 1948) listed ‘insanity or psychosis, manic-
depressive, depressive’. Schizo-affective psychosis (300.6) was listed as a subtype of 
schizophrenic disorders (dementia praecox) and specified the subtypes of mixed 
schizophrenic and manic-depressive psychosis, schizo-affective psychosis and 
schizothymia. ICD-7
10
 (published in 1957) was the same as ICD-6 in terms of mention 
of depression and schizo-affective psychosis. ICD-8
11
 (published in 1967) heralded the 
first mention of the term ‘psychotic depression’ in the ICDs which is included as a 
subcategory of manic-depressive psychosis, depressed type (296.2). Schizo-affective 
type (295.7) was still listed as a subtype of schizophrenia. It had the subtypes of mixed 
schizophrenic and affective psychosis and schizo-affective psychosis but schizothymia 





 (published in 1977) by contrast, included a short description of what was 
meant by each item. However, without detailed information, the items were still open to 
interpretation, leading to the possibility of heterogeneous groups being labelled with the 
same diagnosis. ICD-9
12
 included ‘manic-depressive psychosis, depressed type’ (296.1) 
with a description of the disorder and ‘depressive psychosis’ and ‘psychotic depression’ 
as subgroups, although these terms had no definition. Schizoaffective disorder (295.7) 
was highlighted as a subtype of schizophrenic psychoses. It included the subtypes cyclic 
schizophrenia, mixed schizophrenic and affective psychosis, schizo-affective psychosis 
and schizophreniform psychosis, affective type. There were no specific diagnostic 
criteria for the subtypes, however there was a description of schizoaffective type: “A 
psychosis in which pronounced manic or depressive features are intermingled with 
schizophrenic features and which tend towards remission without permanent defect, but 
which is prone to recur. The diagnosis should be made only when both the affective and 
schizophrenic symptoms are pronounced”.12 
 
Despite the inclusion of the terms depression and psychosis in ICD-6, -7, -8 and -9, 
these descriptions would not be recognised as PMD in modern terms; psychosis was 





 (published in 1993) was the first edition to explicitly explain what 
was meant by each diagnosis by giving a list of symptoms which were used as criteria. 
This was the first overt description of what is currently understood by the term 
‘psychotic depression’ to come from the ICD diagnostic literature. This was an 
important development as it meant it was then possible for clinicians and researchers to 
discuss PMD and know that they were referring to the same cluster of symptoms and 
the same clinical picture. 
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ICD-10 has two versions: Clinical descriptions and diagnostic guidelines;
15
 and 
Diagnostic criteria for research.
14
 They are exactly what the titles suggest: clinical 
descriptions and diagnostic guidelines is a descriptive account of what is meant by each 
diagnostic name; and the Diagnostic criteria for research gives exact criteria that a 




 includes PMD under the depression section. An episode of PMD is included 
as a severe depressive episode with psychotic symptoms (F32.3).
14
 This must include at 
least two of the following: depressed mood; loss of interest and enjoyment; or increased 
fatigability. These must be accompanied by the following:  
a) at least 4 of the following: 
I. reduced concentration and attention; 
II. reduced self-esteem and confidence; 
III. ideas of guilt and unworthiness; 
IV. bleak and pessimistic views of the future; 
V. ideas or acts of self-harm or suicide; 
VI. disturbed sleep; 
VII. diminished appetite. 
b) Lasting at least 2 weeks unless very severe or very rapid onset. 
c) Interference with daily activities, i.e., work, social, domestic life. 
d) Plus delusions, hallucinations or depressive stupor. 
 
Delusions and hallucinations may be specified as mood-congruent or mood-
incongruent. ICD-10
14
 specifies that delusions usually surround ideas of poverty, sin or 
imminent disaster for which the patient is responsible. Auditory hallucinations are 
usually defamatory or accusatory, and olfactory hallucinations can be of rotting filth or 
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decomposing flesh. Depressive stupor must be differentiated from catatonic 
schizophrenia, dissociative stupor and organic forms of stupor. 
 
To have a diagnosis of recurrent depressive disorder, current episode severe with 
psychotic symptoms the patient must have had at least two episodes of the above which 
lasted a minimum of two weeks and were separated by several months without mood 
disturbance. Patients must also have no history of mood elevation or over activity that 
fulfils criteria for mania, but the diagnosis is still valid if there is evidence of brief 
episodes of mild mood elevation and over activity which fulfil criteria for hypomania 
immediately after a depressive episode.  
 
In contrast to all the other ICDs, the ICD-10
15
 does not include schizoaffective disorder  
as a subtype of schizophrenia but as a psychotic disorder distinct from schizophrenia 
(F25). The Diagnostic criteria for research version of the ICD-10
14
 states the criteria 
for gaining a diagnosis of schizoaffective disorder is as follows: 
a) at criteria met for one of the affective disorders to a moderate or severe degree 
b) symptoms from at least one of the groups below must be clearly present for a 
period of at least 2 weeks 
I. thought echo, insertion, withdrawal or broadcast 
II. delusions of control, influence or withdrawal 
III. hallucinatory voices giving a running commentary on the patient’s 
behaviour or discussing the patient or other hallucinatory voices coming 
from some part of the body 
IV. persistent delusions of other kinds that are culturally inappropriate but not 
merely grandiose or persecutory 
V. grossly irrelevant or incoherent speech 
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VI. intermittent but frequent catatonic behaviour 
c) criteria a and b must be present and prominent in the same episode of the 




 goes on to split schizoaffective disorder (for the first time) into subtypes 
linked to affective symptomatology: schizoaffective disorder, manic type (F25.0); 
schizoaffective disorder, depressive type (SAD; F25.1); schizoaffective disorder, mixed 
type (F25.2); other schizoaffective disorders (F25.8); and schizoaffective disorder, 
unspecified (F25.9). To gain the diagnosis of SAD, a patient must meet the criteria for 
schizoaffective disorder and the criteria for a depressive disorder – moderate severity at 
least. 
 
2.2.2. DSM development 
Dissatisfaction among American psychiatrists with the mental disorders proposed by 
ICD-6
16
 prompted the United States Public Health Service (USPHS) and American 
Psychiatric Association (APA) to create the Diagnostic and Statistical Manual of Mental 
Disorders (DSM). DSM-I
17
 (published in 1952) and DSM-II contained descriptions of 
disorders only. DSM-I included two categories that correspond to today’s definition of 
PMD: psychotic depressive reaction (defined as severe depression and gross 
misinterpretations of reality, including delusions and hallucinations); and involutional 
psychotic reaction (restricted to the involutional period, it was characterised by 
depression without a previous history of manic depressive episodes and could be 
manifested by a number of symptoms including delusional ideas). DSM-II
18
 (published 
in 1968) included the same two diagnoses but with slight modifications: psychotic 
depressive reaction now included impairment of function; and involutional psychotic 
reaction was replaced by involutional melancholia (characterized by worry, anxiety, 
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agitation, insomnia and delusional guilt or somatic preoccupations). Involutional 
melancholia was said to be distinguishable from schizophrenia as impaired reality 
testing was due to a disorder of mood and from psychotic depressive reaction in that the 
depression was not due to some life event. Swartz and Shorter
4
 claim that the psychotic 
reference in DSM-II to psychotic depressive reaction was actually an indicator of 
severity. This means that researchers and clinicians referring to this disorder would be 
referring to something different from what would be understood as PMD today. 
 
In terms of schizoaffective disorder, DSM-I
17
 designated schizoaffective as a subtype of 
schizophrenia (x27) – schizophrenic reaction, schizo-affective type, which described 
cases showing a significant mix of schizophrenic and affective reactions, although the 
picture may be predominantly schizophrenic with pronounced elation or depression, or 
predominantly affective with schizophrenia-like thinking or bizarre behaviour. DSM-
II
18
 differed only in that, schizoaffective was schizo-affective, excited (295.73) and 




 (published in 1980) was the first classification system which had 
operational definitions of psychiatric disorders and Mack et al.
 16
 claim it was 
independent of aetiology and theory. The DSM-III
19
 allowed for a diagnosis of major 
depressive episode as dysphoric mood or loss of interest or pleasure in all or almost all 
usual activities and pastimes, plus four of the following: 
 Significant weight loss or weight gain or increased / decreased appetite; 
 Insomnia or hypersomnia; 
 Psychomotor agitation or retardation; 
 Loss of interest or pleasure in usual activities or decrease in sexual drive; 
 Fatigue or loss of energy; 
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 Feelings of worthlessness or excessive/inappropriate guilt; 
 Diminished ability to think or concentrate, or indecisiveness; 
 Recurrent thoughts of death or suicidal thoughts or attempts. 
 
The definition in this version included a further specifier of psychotic features if there is 
a gross impairment of reality, i.e. delusions or hallucinations, or depressive stupor. The 
hallucinations and delusions can be further specified as either mood congruent 
psychotic features or mood incongruent psychotic features.  
 
There was little change in subsequent DSM iterations with DSM-III-R
20
 (published in 
1987) only removing stupor from the criteria and DSM-IV
21
 (published in 1994) 
stipulating severe depression. That brings us to the current version of the DSM. The 
DSM-IV-TR
22
 includes the same criteria as previous editions, but adds information. It 
states that hallucinations are typically auditory, transitory, not elaborate and normally 
berating the person for their shortcomings. The content of delusions and hallucinations 
are commonly consistent with depressive themes. These mood congruent delusions 
include delusions of guilt, deserved punishment, poverty and nihilistic or somatic 
delusions. Mood incongruent delusions are less common and include things such as 
persecutory delusions and delusions of thought insertion, thought broadcasting and 
control. 
 
In terms of schizoaffective disorder, the DSM-III
19
 moved schizoaffective disorder from 
a subtype of schizophrenia to psychotic disorders not elsewhere classified.  There were 
no diagnostic criteria for this diagnosis included here and it is designated to be used 
when “the clinician is unable to make a differential diagnosis with any degree of 
certainty between Affective Disorder and with Schizophreniform Disorder or 
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Schizophrenia”.19 DSM-III-R20 was the first to specify diagnostic criteria for 
schizoaffective disorder (295.70). DSM-III-R emphasizes temporal relationships 
between the schizophrenic and affective symptoms: cases who do not meet criteria for 
schizophrenia or mood disorders but who have experienced schizophrenic and mood 
symptoms at one time point and have presented with psychotic symptoms in the absence 
of mood symptoms at another time point. Specific criteria were as follows: 
a) a disturbance during which, at some time, there is either a Major Depressive or a 
Manic Syndrome concurrent with symptoms that meet the A criterion of 
Schizophrenia. 
b) during an episode of the disturbance, there have been delusions or hallucinations 
for at least two weeks, but no prominent mood symptoms. 
c) schizophrenia has been ruled out, i.e., the duration of all episodes of a mood 
syndrome has not been brief relative to the total duration of the psychotic 
disturbance. 
d) it cannot be established that an organic factor initiated and maintained the 
disturbance. 
 
There are two subtypes listed; bipolar type (previous or current manic syndrome); and 




 again emphasizes a temporal element as important, and specific diagnostic 
criteria are stated as follows: 
a) an uninterrupted period of illness during which, at some time, there is either a 
Major Depressive Episode, a Manic Episode or a Mixed Episode concurrent 
with symptoms that meet Criterion A for Schizophrenia. (Note: The Major 
Depressive Episode must include Criterion A1: depressed mood). 
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b) during the same period of illness, there have been delusions or hallucinations for 
at least 2 weeks in the absence of prominent mood symptoms. 
c) symptoms that meet criteria for a mood episode are present for a substantial 
portion of the total duration of the active and residual periods of the illness. 
d) the disturbance is not due to the direct physiological effects of a substance (e.g., 
a drug of abuse, a medication) or a general medical condition. 
 
Although the wording is different for these criteria they are essentially the same as for 
DSM-III-R.
20
 Like DSM-III-R the two subtypes stated are bipolar type (applies if a 
manic or mixed episode is part of the presentation) and depressive type (applies if only 
major depressive episodes are part of the presentation in the absence of mania). 
Schizoaffective disorder is the same in DSM-IV-TR
22




2.3. Symptom overlap between PMD and SAD  
PMD overlaps with SAD in terms of symptoms and only a few criteria distinguish them 
from one another. Within the ICD-10
14
 patients must have met criteria for a depressive 
disorder to a moderate or severe degree plus experience thought echo, insertion, 
withdrawal or broadcast; delusions; auditory hallucinations; grossly irrelevant / 
incoherent speech; or catatonic behaviour within the same episode concurrently for at 
least part of the episode to meet a diagnosis of SAD. Within DSM-IV-TR
22
 to meet 
criteria for a diagnosis of SAD, patients have to have experienced a depressive episode 
(which is present for a substantial proportion of the time) concurrent with at least one of 
either delusions, hallucinations, disorganized speech, disorganised or catatonic 
behaviour and negative symptoms. The psychotic symptoms must be experienced in the 
absence of a mood component for at least two weeks. 
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The literature around PMD is confused as each study uses a different diagnostic system 









). Some studies even 
modified the criteria of a diagnostic system. This has led to some studies claiming to 
measure PMD but actually capturing groups with PMD and SAD cases. 
 
In addition, symptoms of depression are evident in those with schizophrenia, often 
secondary to the schizophrenia. A study by Wassink et al.
24
 conducted a 5- year follow 
up study with patients with recent-onset schizophrenia. They found that less than 12% 
of cases had no symptoms of depression, more than one-third of the subjects met the 
criteria for a major depressive episode at the time of intake and the majority of cases 
had four symptoms of depression to at least a moderate degree. So, diagnosing PMD 
and SAD is far from straightforward – an issue rarely acknowledged in the literature.  
 
Figure 2-1: Representation of symptom overlap of psychotic and affective 
disorders 
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Figure 2-1 is a representation of symptoms overlap of affective and psychotic 
diagnoses. From this it can be seen that PMD and SAD inhabit the same symptomatic 
cluster of depressive symptoms and psychotic symptoms. However, the symptom 
picture is rarely so clear with depressive symptoms being common in schizophrenia and 
so the representation is very simplistic and compartmentalised. However, the overlap 
with the 2 disorders is clear and the distinction between the two seems arbitrary, giving 
rise to the aims of this thesis: to use both diagnoses to follow-up patients with 
substantial depressive and psychotic symptoms. 
 
2.4. Prevalence and incidence 
2.4.1. PMD 
General population estimates of the prevalence of PMD have been examined. Ohayon 
and Schatzberg reported a lifetime prevalence of PMD in the general population of the 
United Kingdom, Germany, Italy, Portugal, and Spain between 1994 and 1999. They 
measured PMD using Sleep-EVAL, a software system comprised of a standard 
questionnaire including questions to match criteria from the DSM-IV. This was 
collected via telephone interview. The authors reported the lifetime prevalence of PMD 
in these countries to be 0.4% (95% CI = 0.35-0.54%) with slightly higher rates for the 
UK at 0.5% (95% CI = 0.3%–0.7%).25 Perala et al.26 also reported a lifetime prevalence 
of PMD in the general population of Finland. They conducted medical examinations 
which included an assessment of mental disorder using the Composite International 
Diagnostic Interview. These were conducted with a random sample of individuals 
drawn from the National Population Register (which had a 93% response rate). The 
authors also reported an approximate lifetime prevalence of PMD to be 0.4% (95% CI = 
0.24-0.51%).
26
 This is compared with 0.87% (95% CI = 0.68-1.11%) for schizophrenia, 
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0.32% (95% CI = 0.21-0.46%) for schizoaffective disorder (SAD not reported) and 




 conducted an incidence study of all first episode psychosis cases referred 
to a single trust in the North of England between 1998 and 2001 using an observational 
database and ICD diagnoses. The authors reported that the ‘commonest diagnosis’ was 
PMD, accounting for 19% of all new cases. This was compared with 11% for paranoid 
schizophrenia and 7.5% for bipolar disorder. However, the authors do not report the 
incident rates for PMD. The authors also report subtypes of schizophrenia separately 




 examined incidence of psychosis in two rural counties in the Republic 
of Ireland from May 1995 to April 2003. DSM-IV diagnosis was achieved by consensus 
of the team following patient evaluation using the Structured Clinical Interview for 
DSM-III-R or via clinical notes when cases refused interview. Six months after 
presentation clinical material was reviewed to confirm or modify the initial DSM-IV 
diagnosis, again using consensus by the team. The authors reported an annual incidence 
(based on diagnosis at six months) of 6.4 per 100,000 population aged 15 or over (95% 
CI 4.5-8.7) for PMD cases compared with 7.0 per 100,000 population aged 15 or over 
(95% CI 5.1-9.4) for schizophrenia cases. However, the estimate for schizophrenia 
increased to 10.8 per 100,000 (95% CI 8.3-13.7) if all schizophrenia spectrum 
psychoses were included.  
 
From these incidence studies, it appears that PMD occurs at a similar rate to 
schizophrenia. However, Kirkbride et al.
29
 conducted a systematic review and meta-
analysis of the incidence of all psychotic disorders in England and reported that based 
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on the four studies with incidence data on PMD, the pooled estimates for PMD was 5.3 
(95% CI 3.7-7.6) per 100,000 person years compared with 3.7 per 100,000 person years 
(95% CI 3-4.5) for bipolar and 15.2 per 100,000 person years (95% CI 11.9-19.5) for 




Estimates of the incidence and prevalence of SAD are rare. Most studies include 
schizoaffective disorder (SA) overall (a mix of schizoaffective disorder depressed type, 
manic type, mixed type, other and unspecified). The DSM-IV
21
 states that details on the 




 reviewed the case notes of 3,800 first admission patients and then 
interviewed approximately 600 of these cases approximately 4 days after admission. 
Those cases who were positive for both depression and schizophrenic or paranoid 
symptoms had a full psychiatric evaluation using the Present State Examination (version 





 (mentioned above) in their incidence study of all first episode psychosis 
cases referred to a single trust in the North of England reported that the diagnosis of 
schizoaffective disorder was given to just 1.8% of all cases. This was the least common 
diagnosis apart from alcohol related psychoses. This was compared with 19% for PMD 
cases, 11% for paranoid schizophrenia, and 7% for bipolar disorder. However, the 
authors do not report the incident rates for schizoaffective cases.  
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Brockington and Leff conducted a review of case notes of all first admission patients 
from the Camberwell catchment area in 1973-4 and compared different diagnostic 
systems.
31
 They reported that schizoaffective cases made up 10% of the first admission 
patients from the Camberwell catchment area in 1973-4. This translated into estimated 
upper and lower limits of incidence of schizoaffective disorder of 0.3 to 5.7 per 100,000 
per year. This compared with an incidence of schizophrenia of 7.3 to 15.0 per 100,000 
and of mania of 1.7 to 3.3 per 100,000. The authors concluded that the incidence of 
schizoaffective disorder was probably around a quarter of that of schizophrenia and 
comparable to that of mania.
31
 The authors reported that 12 cases met criteria for 




The studies in this section indicate that not only is schizoaffective disorder relatively 
rare compared with other psychotic disorders, but also SAD is very rare, although 
comparative rates are not available. 
 
2.5. Gaps in the literature 
PMD and SAD are still relatively under-researched diagnoses. A crude search at the 
beginning of this PhD on Medline revealed there are just over 5000 articles involving 
PMD, only 45 articles mentioning SAD but almost 100,000 articles involving 
schizophrenia. The lack of research on PMD and SAD compared with schizophrenia 
can also be illustrated by National Institute for Health and Clinical Excellence (NICE) 
guidelines. The guideline for the treatment and management of depression in adults by 
NICE
32
 include the following paragraph on the management of depression with 
psychotic symptoms:  
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“1.10.3.1 For people who have depression with psychotic symptoms, consider 
augmenting the current treatment plan with antipsychotic medication (although 
the optimum dose and duration of treatment are unknown)”.32 
 
This is the only section on the treatment of PMD.  
 
The NICE guidelines on schizophrenia
33
 state they are concerned with the treatment and 
management of schizophrenia and related disorders including schizoaffective disorder. 
Despite this claim, there is no specific guidance on the treatment of schizoaffective 
disorder let alone SAD. Schizoaffective disorder is often excluded from studies on 
schizophrenia. However, even when schizoaffective disorder is included in a study, it is 
included in the schizophrenia group and therefore any important differences between 
schizophrenia and schizoaffective disorders are not identified.  
 
2.5.1. Risk factors 
Understanding the risk factors involved in the aetiology of a disorder is vitally 
important. It could lead to faster or better recovery via effective interventions.
34
 
Knowledge about risk factors may also aid in the understanding of the mechanisms 
underlying a disorder which could also eventually lead to prevention.
35
 This thesis 





 Chapter 3 discusses the fact that there 
are very few studies on psychosocial risk factors in psychosis which include PMD and 
SAD cases as diagnoses independent from other psychoses. The chapter will also 
discuss the methodological limitations surrounding these studies and the consequent 
need for more methodologically robust studies on the risk factors involved in PMD and 
SAD. 
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2.5.2. Course and outcome 
Prognosis is a key piece of information. Prognosis allows patients and their families to 
know what to expect and plan their future, and provides a basis for treatment 
decisions.
42
 Chapter 4 discusses the numerous papers that have examined course of 
illness and outcomes in PMD and SAD cases. There is also a discussion of the 
methodological limitations of these studies which make interpretation of the findings 
difficult and, hence, indicate the need for more methodologically robust studies on the 
long term outcomes of PMD and SAD. 
 
2.6. Issues with diagnostic systems 
Diagnosis in psychiatry has frequently come under fire. Robins and Guze
43
 discussed 
how clinical features, outcome and family history have to be used to create psychiatric 
nosological categories in the absence of clinical tests. The National Institute of Mental 
Health recently criticised the validity of DSM-5 and stated “Unlike our definitions of 
ischemic heart disease, lymphoma, or AIDS, the DSM diagnoses are based on a 
consensus about clusters of clinical symptoms, not any objective laboratory measure”.44 
Van Os and Tamminga
45
 stated that the numerous diagnostic categories that exist were 
created originally to bring order and aid scientific communication. They are designed to 
refer to broadly defined psychopathological syndromes rather than biologically defined 
diseases, but over time they have undergone a process of reification and become 
assumed to be concrete disease entities. By classifying patients arbitrarily into 
categories, these diagnoses may actually confuse the field. Van Os and Tamminga 
suggest that “Given the fact that we have not yet discovered the natural boundaries of 
psychosis, but only observe its properties, the only way to achieve progress is to 
periodically reassess all the evidence in the hope of catching a glimpse of its natural 
pathology”.45 
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There is also criticism regarding the dichotomy between affective and psychotic 
disorders. Craddock and Owen
46
 argue that for almost 100 years, psychiatric research 
has been based on the assumption that schizophrenia and affective disorders are 
“distinct entities with separate underlying disease processes and treatments” and that 
this ‘Kraepelinian dichotomy’ is a core component of current classification systems. 
The fact that some individuals experience both prominent psychotic and affective 
symptoms questions the assumption of distinct diseases.
46
 In a later publication, 
Craddock and Owen
47
 stated that compelling evidence had come to light indicating that 
genetic susceptibility and genetic mechanisms are shared between psychotic disorders 
and affective disorders, and hence, the assumed dichotomous relationship between these 
disorders needs to be reconsidered.  
 
Both of the points discussed above highlight the flawed nature of psychiatric diagnoses. 
These flaws lead to a lack of validity in diagnosis and in some cases, poor reliability and 
diagnostic misclassification. These issues must be borne in mind when conducting any 
research based around psychiatric diagnoses. However, the current diagnostic 
classification systems in use are the only things available to indicate that researchers 
and clinicians are referring to the same type of psychiatric disorder when they use 
diagnoses.  
 
Bearing in mind the problems with current diagnoses discussed above, the alternative of 
diagnosis based on a continuum of symptoms, or even a continuum of psychosis, needs 
consideration. Craddock and Owen
46
 have suggested that psychiatry need to move to a 
spectrum concept of diagnosis involving symptom dimensions. However, Lawrie et al.
48
 
argue that proponents of the continuum model of diagnosis offer this alternative to 
categorical diagnoses with no specific proposals, and also neglect to address the 
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potential limitations of such systems. Furthermore, the categorical diagnostic systems 
currently in use have evolved from clinical observation over long periods of time in 
order to aid treatment and prognosis, as well as to aid communication between 




It would potentially be possible to include cases who exhibit psychotic and depressive 
symptoms without using a categorical diagnostic system as an alternative to both 
categorical and continuum diagnostic systems. However, as mentioned above, the 
categorical systems currently in use are very useful for determining that different 
clinicians and researchers are examining and discussing the same clusters of symptoms 
within a patient, and are therefore likely to be examining the same disorder. This was 
part of the reason why such classification systems were created, to stop confusion about 
referring to potentially different disorders. Additionally, ICD diagnoses are currently 
used in clinical practice in the UK to diagnose patients. Therefore, to make this research 
relevant to clinical practice in the UK, and to be clear exactly what cluster of symptoms 





 describes how terms in psychiatry evolve over time and how through that 
evolution, confusion arises over the meaning. There have been certain periods in history 
when there has been no consensus on how schizoaffective disorder should be defined 





). Historically, and even now, there is no consensus about whether 





 highlights the fact that this term has had numerous 
meanings since it was first coined and introduced as a subtype of schizophrenia and 
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“represents one of the most confusing and controversial concepts in psychiatric 
nosology”.19  
 
A study by Brockington and Leff
31
 suggested that agreement about the symptoms of 
schizoaffective disorder is low. They conducted a study comparing the definitions of 
schizoaffective disorder according to eight different diagnostic systems;  ICD-8/9 
(referred to as a hospital diagnosis in the paper); Catego system (Wing et al.
52
); 
Kendell's criteria (patient must fulfil stated criteria for schizophrenia or paranoid 
psychosis and depression or mania); Kasanin's description;
53





 Spitzer's research diagnostic criteria;
56
 
and a combination diagnosis (when a patient meets 1 of 10 definitions of schizophrenia 
and 1 of 9 definitions of manic or depressive psychosis). The authors found a mean 
mutual concordance of 0.19 and concluded that there is very poor agreement about the 
meaning of the term schizoaffective. 
 
Similarly, PMD is known by various names; delusional depression; depressive 
psychosis; psychotic major depression; major depressive disorder with psychotic 
features. These names might all refer to the same disorder today, but as some point in 
the past, the term psychotic depression had a number of meanings including depression 





 identified 38 different psychiatric classification systems and that was 
not even a complete survey. 
 
This all highlights the importance of caution of comparing results between different 
classification systems and must be considered by anyone who is reviewing the literature 
in the area. 
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2.8. Diagnostic instability and implications for epidemiological studies 
Diagnosis is subject to change over time. Symptoms may be minimal at first 
presentation and may emerge as the course of an illness develops. Sometimes symptoms 
are unclear and take time to develop. PMD and SAD are no exception to this and a 
number of studies have examined diagnostic stability over time. One follow-up of 15 
years reported that 80% of participants with a diagnosis of PMD changed to bipolar at 
follow-up.
58
 Therefore, it is important not only to look at baseline diagnosis in relation 
to risk factors and outcomes but also to look at follow-up diagnosis (this is further 
discussed in chapters 3 and 4). 
 
2.9. Aims for the thesis 
In light of the literature discussed above, the aims of this PhD thesis were: 
1. To investigate the risk factors associated with PMD and SAD compared with 
other psychoses. 
2. To investigate the long-term course and outcomes of PMD and SAD cases 










CHAPTER 3. Review of social adversity in the aetiology of PMD and SAD 
 
“...if we wish to understand what keeps some societies healthy, yet others sick, we had 
better search among social facts for explanations.”59 






3.1. Aims of the chapter 
The aims of this chapter are to highlight the importance of psychosocial risk factors in 
the aetiology of psychosis and touch on the social concepts involved. This is followed 
by a review of the literature on social position and social experience risk factors for 
PMD and SAD, and a discussion of the methodological issues surrounding this 
literature. Finally, hypotheses leading from the literature are specified. 
 
3.2. Introduction 
As mentioned in chapter 2, an understanding of the risk factors involved in PMD and 
SAD could lead to better or faster recovery via effective interventions
34
 or even 
prevention of disorder.
35
 Risk factors in psychosis are commonly broken down into 
biological and psychosocial. Morgan et al.
60
 state that the role of psychosocial 
aetiological factors are often down played, even when examined within a larger 
biopsychosocial model. This is despite  many authors having highlighted the importance 
of the social environment, even in influencing biology,
61
 with recent findings suggesting 





 state that there is a problem with physical and genetic explanations of psychosis 
as studies assume that all psychosis has a genetic origin based on the finding that some 
people with psychosis have a family history. There is also often an assumption that 
genetic aetiological factors lead to social factors and then disorder.
63
 Bebbington et al.
63
 
also state that the way in which heritability is calculated is problematic because gene-
environment interactions are counted in the genetic component of equations. These 






There is strong evidence that social risk factors are important in the aetiology of 
psychosis. Bebbington et al.
63
 point out that psychotic symptoms are related to 
representations of the social world making social experiences important. However, this 
importance of social factors in aetiology is important in treatment too. Various authors 
have highlighted the fact that they can be used to design interventions to promote 
behaviour change and social inclusion and have been used successfully.
59, 65, 66 
 
The majority of studies of risk factors in psychosis focus on schizophrenia and bipolar 
disorder.
67
 Schizoaffective disorder is often included in the schizophrenia group or 
excluded from research all together. PMD is most commonly excluded from risk 
studies. This is highlighted in a short review by Smith et al.
68
 who conclude that 
although risk factors for other psychotic disorders have been extensively examined, 
little research exists on risk factors for PMD. The authors also state that it is unclear 
whether risk factors for PMD overlap with those for depression and/or other psychotic 
disorders. 
 
3.3. Review methodology  
A scope of the literature using the very broad search terms of ‘PMD/SAD’ (and 
variations of) and ‘social risk factors’, indicated that there was very limited research on 
risk factors for PMD and SAD disorders (only two papers). Therefore, rather than 
conduct a very limited systematic review of social risk factors in PMD and SAD, a 
narrative review was conducted that included findings from related disorders, i.e. non-
psychotic depression and psychosis in general. It was also possible to include findings 
on social risk factors in cases with a combination of psychotic and depressive symptoms 
but whom did not have a diagnosis of PMD or SAD. It was thought by the student that 
this research is relevant to creating sensible hypotheses. 
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3.4. Social concepts 
Social research in mental health has many overlapping and connected concepts.
66
 These 
include social disadvantage, social inclusion, social exclusion, social deprivation, social 
adversity, poverty, social experiences, social rejection, social isolation, social networks, 
social relationships, social capital, social processes, social integration and social 
fragmentation. The lack of definitions and use of numerous overlapping terms creates 
confusion about exactly what is being measured.
66
 March et al.
69
 state that social factors 
operate at many different levels: societies; regions; towns; neighbourhoods; families; 
and individuals. This thesis will focus on individual level risk factors. 
 
Morgan et al. (2007) discuss the importance of distinguishing between direct and 
indirect risk factors. Therefore, within this review, individual social experiences have 
been divided into direct and indirect measures of social experience. Direct measures of 
social experience explicitly gather information about events and experiences individuals 
have had.  They include childhood adversity and life events and difficulties. Indirect 
measures of social experience are proxies that indicate possible exposure to risk 
increasing experiences.  These include sociodemographic characteristics, educational 
attainment, social isolation and employment.  
 
This chapter will now outline the literature on individual level social experience in the 
aetiology of PMD and SAD. 
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 suggest that certain sociodemographic characteristics affect mental health 
as they influence social experience and can lead to social adversity. Sociodemographic 
characteristics can include age, gender, ethnicity and social class / socioeconomic status.  
 
Many studies have included PMD groups in their research and have reported on age, 
gender and more rarely, socioeconomic status. Several studies suggest that PMD is 
approximately twice as common in women than in men
25, 71, 72
 (although one study 
found it was almost five times as common in women
73
).  One review reported that the 
prevalence of PMD increases with age
68
 while another stated that PMD is more 
common among people from lower socioeconomic classes.
74
 However, much of the 
research has been based on samples which are not psychosis incidence samples, i.e. they 
have been either samples of cases in treatment (inpatients and outpatients) or only 
inpatients. Cases with a chronic course of illness and/or poor outcomes are more likely 
to be in contact with services and are therefore not necessarily representative of all 
PMD cases. Therefore, non-incident samples are likely to lead to biased estimates of 
associations with sociodemographic variables.  
 
In 2004, Proctor et al.
27
 examined first episode psychosis cases and reported an 
approximate even split of male and female cases with PMD (45% versus 55% 
respectively). They also reported more PMD cases in the 35-64 years age bracket 
compared with the non-affective psychoses (43% versus 30% respectively) and less 
cases in the 17-34 years age bracket (31% versus 48% respectively). However, these 
data were not central to the paper and the differences in sociodemographic variables 
between diagnoses were not examined statistically. Crebbin et al.
1
 examined first 
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episode cases in northern England between 1998 and 2005. The authors reported that 
PMD was far more likely to occur in patients over 36 years old (RR=2.07, 95% 
CI=1.41, 3.04) whereas schizophrenia was more likely to occur in patients under 36 
years (RR=1.56, 95% CI=1.01, 2.40). They reported that there were no differences in 
gender proportions in the PMD group but there was an interaction between age and 
gender with males under 36 years old being statistically significantly less likely (at p < 
0.05) to have a diagnosis of PMD and males over 64 years being much more likely to 
have a diagnosis of PMD.
75
 Women aged 36-64 were much more likely to be diagnosed 
with PMD than women in other age groups. Similar findings based on the same dataset 
were reported more recently.
76
 These studies indicate that there may be a gender-age 
interaction in the risk of PMD. These studies are based on first episode psychosis 
incidence samples, thus attempt to be representative of all cases presenting to services. 
However, neither of these studies have accounted for diagnostic change, the importance 




 examined the incidence of psychosis cases by gender using 6-month 
diagnosis. They reported an incidence of PMD in women of 7.4/100,000 population 
aged over 15 years compared with 5.4/100,000 for men. This is a stronger methodology 
as the authors were able to account for the potential diagnostic instability which is 




Ethnic differences in the incidence of psychosis have been found
29
 as well in specific 
psychotic symptoms in community samples.
79, 80
 Fearon et al.
81
examined differences in 
incidence rates of different diagnoses by ethnicity in a first episode psychosis incidence 
sample. The authors reported that the incidence rate for PMD was elevated for all 
minority ethnic groups (African-Caribbean incidence rate ratio (IRR) 3.1, Black African 
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IRR 2.1, Asian IRR 3.0, Other IRR 5.6, Mixed IRR 4.0 and White Other IRR 1.3) 
compared with White British. This was in contrast to the pattern in schizophrenia and 
mania cases which had particularly raised rates in African-Caribbean individuals (IRR 
9.1 for narrow schizophrenia and IRR 8.0 for manic psychosis), compared with rates for 
other ethnicities (narrow schizophrenia and manic psychoses: Black African IRR 5.8 
and 6.2; Asian IRR 1.4 and 2.7; Other 3.5 and 3.0; Mixed IRR 2.6 and 6.2; and White 
Other IRR 2.5 and 1.7). This study is based on data from AESOP study which this 
thesis is based upon. In a systematic review and meta-analysis, Kirkbride et al.
29
 
reported that the rates of PMD were elevated in Black African and Black Caribbean 
migrants and their descendants compared with baseline populations. Although these 
studies on ethnicity have been conducted using first episode psychosis incidence 
samples, they have not taken account of diagnostic instability and therefore, may not 
provide accurate estimates of incidence of PMD. The relationship between ethnicity and 
psychoses is also closely linked to migration status. Migration status should also be 




Social class and socioeconomic status were not addressed in this thesis as 
unemployment and education were included which are markers of socio-economic 
status. 
 
Previous research has found that “with increasing levels of urbanisation the incidence 
rates of psychosis and depression rose”.38 Although social context was not investigated 
here, the data in this thesis was collected from two centres which differed markedly by 
social context (see section 5.4), therefore, centre was included as a risk factor.  
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This section has demonstrated that although there are a handful of psychosis incidence 
studies on the social position risk factors involved in PMD, all but one of these have the 
methodological flaw that they have not accounted for diagnostic instability and 
therefore, may have produced biased findings (see section 3.8 for more details). Clearly, 
a study on the sociodemographic profile that indicates the social position in PMD and 
SAD cases is needed, that uses a psychosis incidence sample and accounts for 
diagnostic change. Based on the current literature, it was hypothesized that PMD and 
SAD would be associated with being of non-white British ethnicity, being female, being 
born outside the UK, being older and being in the London site. 
 
3.5.2. Educational attainment 
Education has been linked with various mental disorders, with reports of low 





having no formal qualifications being associated with affective psychoses (mix of PMD, 






 explored the aetiological factors leading to first admission in a 
population based study in Sweden. They reported that a number of factors including low 
educational attainment were strongly associated with psychosis and depression, 
especially for men (Men: psychosis: hazard ratio 2.52 (95% CI 2.17-2.93); depression: 
hazard ratio 1.31 (95% CI 1.18-1.45); Women: psychosis: hazard ratio 1.85 (95% CI 
1.62-2.10); depression: hazard ratio 1.45 (95% CI 1.33-1.58)). Although the authors 
examined first admissions rather than all incident psychosis cases which could have led 
to biased findings (only the most ill cases examined), it is impressive that they have 





 examined cumulative social adversity and isolation (defined using 
education, employment, living arrangements, housing, relationships and social 
networks) within the AESOP study in all incidence psychosis cases who presented to 
specialist mental health services in a defined period. The authors reported that affective 
cases were more likely to have no qualifications compared with controls (adjusted odds 
ratio 2.34, 95% CI 1.20–4.54). However, as this is affective psychoses, the sample is a 
mix of cases with PMD, mania and bipolar disorder, thus no conclusions can be drawn 




 assessed the prevalence of psychotic-like experiences in a population 
based sample of healthy controls examining a range of social adversity markers and 
reported that in unadjusted analyses, having completed further education was 
significantly associated with having experienced psychotic-like experiences (unadjusted 
odds ratio 2.48, 95% CI 1.13–5.43) compared with those with higher education and 
those with only a school education or no education completed.  
 
Only one study has examined educational attainment specifically within PMD or SAD. 
Jeste et al.
84
 examined clinical and neuropsychological characteristics of PMD cases 
with schizophrenia and non-psychotic major depression cases and found no difference 
in the groups in terms of level of education. However, this was not an incidence 
psychosis sample and as previously discussed, this can lead to biased findings plus there 
was no healthy control group to make comparisons with. There was also no accounting 
for diagnostic change which could lead to inaccurate findings. This study was also a 
comparison between psychiatric diagnoses rather than a comparison with controls so 
nothing can be said about differences between PMD cases and the general population. 
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To learn about educational attainment as an aetiological factor in PMD and SAD, an 
incidence psychosis study is needed. As mentioned previously, a study which accounts 
for diagnostic change would be advantageous as well as one that compares the cases to 
a control group representative of the general population. Based on the literature 
discussed above, it was hypothesized that lower educational attainment would be more 
frequent in PMD and SAD cases compared with controls. 
 
3.5.3. Social Isolation 
Berkman and Glass
85




 were the first to suggest a link 
between social isolation (lack of social resources and social support) and disease risk. 
The mechanisms by which social networks might influence disease patterns and the way 
they operate are discussed by Berkman and Glass
85
 but are beyond the scope of what 
was feasible in this thesis and so are not covered here. The authors discuss the complex 
ways of defining social networks; e.g. range/size; density; boundedness; homogeneity; 
frequency of contact; multiplexity; duration; and reciprocity. However, in order to keep 
this review as broad as possible and to inform future research, social isolation was 
broadly defined as any experience which could lead to reduced social contacts, social 
resources and social support. 
 
A number of studies have explored social isolation as a risk factor for mental disorder 
including psychosis and depression. Sundquist et al.
38
 examined living alone compared 
with cohabiting/married as risk factors for first admission in their population based 
study in Sweden. The authors reported that living alone was strongly associated with 
psychosis and depression in women (psychosis hazard ratio 3.23 (95% CI 2.98-3.49); 
depression hazard ratio 1.66 (95% CI 1.58-1.75)), but especially so for men (psychosis 




 Drukker et al.
40
 conducted a study in the Netherlands examining indicators of 
social adversity in first episode schizophrenia cases compared with controls. They 
reported that being divorced, single or widowed were associated with higher risk of 
treated psychotic disorder (OR 71.95, 95% CI 22.42-230.95; OR 46.39, 95% CI 9.63-
223.39; OR 41.22, 95% CI 7.87-215.98 respectively) but living alone or with non-
family was associated with a reduced risk of treated psychotic disorder (OR 0.14, 95% 




Within the AESOP study, several papers have examined social isolation within a sample 
of all first episode psychosis cases who presented to services in a defined period. 
Morgan et al.
88
 examined individual indicators of social isolation and reported that the 
following factors were associated with the ‘all psychoses’ group: having no close 
confidants (OR 7.8, 95% CI 4.9-12.5), never having a long-term relationship (OR 4.0, 
95% CI 2.9-5.7) and having been unemployed for more than a year (OR 2.0, 95% CI 
1.5-2.6). Morgan et al.
83
 examined cumulative social isolation within the concept of 
‘social adversity and isolation’ defined by using data on education, employment, living 
arrangements, housing, relationships and social networks. The authors reported that in 
the affective cases, the following social isolation factors had significantly higher odds 
ratios: being currently unemployed (adjusted OR 2.56, 95% CI 1.56-4.20); living alone 
or with relatives (adjusted OR 2.09, 95% CI 1.28-3.40; adjusted OR 4.45, 95% CI 2.18-
9.07 respectively); being single (adjusted OR 2.04, 95% CI 1.31-3.16); never having 
had a long-term relationship (adjusted OR 2.61, 95% CI 1.57-4.34); having contact with 
friends less than daily (adjusted OR (weekly contact) 2.56, 95% CI 1.49-4.39; adjusted 
OR (less than weekly contact) 3.62, 95% CI 1.97-6.66); and having no close confidants 
(adjusted OR 5.20, 95% CI 2.85-9.49). Within the same sample, Reininghaus et al.
89
 
reported that the odds of being a case increased as levels of social contacts decreased 
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and that non-affective psychosis cases were more likely to experience lower levels of 
social contacts (low versus high social contacts, unadjusted OR 3.01, 95% CI 1.64–
5.52; medium versus high social contacts, unadjusted OR 1.85, 95% CI 1.04–3.26) but 
this was not true for affective psychosis cases (low versus high social contacts, 
unadjusted OR 1.67, 95% CI 0.84–3.32; medium versus high social contacts, unadjusted 




 further examined the association between social isolation and psychotic-
like experiences in a healthy population. They reported that never having been in a 
long-term relationship was associated with psychotic-like experiences (unadjusted OR 
1.85, 95% CI 1.02–2.39) but there was no association for having no close confidants, 
and having infrequent contact with friends and/or family.  
 
None of the papers on social isolation have specifically examined PMD or SAD as these 
diagnoses have been excluded or amalgamated into larger diagnostic groups. Therefore, 
no conclusions can be drawn about PMD or SAD and clearly further research on social 
isolation as a risk for PMD and SAD is needed. Based on the above literature, it was 
hypothesized that factors associated with social isolation, such as living situation, 
relationship status and contact with friends, would be more frequent in PMD and SAD 
cases compared with controls. 
 
3.5.4. Employment 
As suggested above, employment could be conceptualised within social isolation but it 
is also an important factor in itself. The link between unemployment and health, mental 
health and wellbeing has been well documented.
90-92
 Warner highlights the importance 
of employment as increasing income, expanding social support and bringing a sense of 
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meaning to life with unemployment bringing alienation and isolation.
93
 Kasl and Jones 
in their review of the area state that “unemployment clearly increases psychological 
distress, particularly symptoms of depression...”.90 
 
A number of studies have found a link between psychosis and unemployment. Drukker 
et al.
40
 conducted a study in the Netherlands examining neighbourhood and individual 
level indicators of social adversity in schizophrenia cases compared with controls. 
Specifically for employment they reported that unemployment was associated with a 
higher risk of treated psychotic disorder (OR 11.13, 95% CI 6.62-18.72). Importantly 
the authors acknowledge that they were examining treated psychosis only. As 
mentioned above, the AESOP study (first episode psychosis study) has reported that, in 
their sample, current unemployment (adjusted OR 3.61, 95% CI 2.19–5.96) and being 
unemployed for 1 year or more (adjusted OR 2.44, 95% CI 1.40–4.25) were both 
associated with psychosis in general whereas only current unemployment was 
associated with affective psychosis at p < 0.05 (adjusted OR 2.56, 95% CI 1.56–4.20).83  
 
Some of these studies included PMD and SAD cases but no study has examined 
employment in the aetiology of PMD or SAD specifically. However, one study by 
Shevlin et al. examined symptoms rather than diagnoses and reported that the odds ratio 
of having experienced visual hallucinations was decreased for those who were working 
at the time of interview (OR 0.57, 95% CI 0.34-0.95).
79
 Morgan et al.
80
 assessed the 
prevalence of psychotic-like experiences in a population based sample of healthy 
controls examining a range of social adversity markers including current and long-term 
(1+ year) unemployment. They reported that both definitions of unemployment were 
not associated with having experienced psychotic-like experiences. 
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No study has examined employment in the aetiology of PMD and SAD. As 
unemployment is a risk factor for psychosis in general as well as for affective psychosis, 
and as unemployment has been linked with depression, it was hypothesized that 
unemployment would be more frequent in PMD and SAD cases compared with 
controls. In order to test this hypothesis, and overcome key methodological limitations 
of other research, a study of incidence psychosis PMD and SAD cases was needed and 
as previously mentioned, one which accounts for diagnostic change.  
 
3.6. Direct measures of social experience 
Direct measures of adverse social experience included in this thesis are childhood 
adversity and life events and difficulties pre onset of psychosis. 
 
3.6.1. Childhood adversity 
3.6.1.1. Definitions and importance 
Childhood adversity is a term used to capture a variety of negative experiences that have 
occurred in childhood. These include, but are not restricted to, physical abuse, sexual 
abuse, emotional abuse, neglect and separation from parents. Within the review of the 
literature for this thesis, the term childhood adversity has been used in the broadest 




 highlights the importance of studying childhood adversity as this will “...help to 
clarify heterogeneity and provide pointers to mechanisms based on different 
developmental pathways”. As well as helping to understand the possible causes of 
psychosis, identifying patients with experience of childhood adversity may reveal 
different treatment needs of patients.
37
 This may lead to the potential for creating more 
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 identified that certain types of abuse predict course of depressive 
illness, thus identifying childhood adversity in PMD may also be useful in terms of 
prognosis.  
 
3.6.1.2. PMD, SAD and childhood adversity 
A large number of studies have been conducted on the link between childhood adversity 
and mental illness. However, only a single study has been conducted on the role of 
childhood adversity in the aetiology of PMD or SAD. Other studies have included 
PMD
95
 or SAD cases
96-98
 but  these cases are amalgamated into broader diagnostic 
groups such as schizophrenia broadly defined or ‘psychosis’, severely limiting the 
conclusions about PMD/SAD and childhood adversity.  
 
However, studies on childhood adversity as an aetiological factor in non-psychotic 
depression and general psychosis are relevant to PMD and SAD as they are a 
combination of the two symptoms clusters. These studies may be able to inform 
hypotheses on childhood adversity as a risk factor for PMD and SAD.  
 
3.6.1.3. Depression 
It has long been recognised that childhood adversity is a risk factor for depression..
41
 In 
his review in 2006, Hill
37
 stated that studies reporting an association between child 
maltreatment and adult depression have been remarkably consistent in their findings of 
a positive association. Hill discusses some of the earliest studies examining depression 
and childhood adversity which focussed on loss of a parent. However, childhood 
adversity goes far beyond this and a number of different types of childhood adversity 
have been associated with depression. As well as parental loss
99-102















Childhood sexual abuse (CSA) and its role in the aetiology of depression has been a 
major area of research. CSA has been consistently associated with a diagnosis of 
depression in adulthood.
103, 104, 108, 110, 111
 A systematic review and meta-analysis of 17 
case control studies and 20 cohort studies reported that there was a significant 
association between CSA and depression (OR 2.66, 95% CI 2.14-3.30) regardless of 






 examined CSA and depression in a sample of women over a two year 
period. More women who had experienced CSA had depression during the period 
(64%) compared with those with no experience of CSA (26%). The authors also found 
that CSA was associated with other early stressful experiences such as parental 
indifference, violence and institutional stay. This finding highlights the importance of 
examining multiple types of childhood adversity as adversities are often associated with 
each other. 
 
Many studies have examined multiple types of childhood adversity within the same 
study. Young et al.
105
 examined childhood adversity which they defined as emotional, 
physical or sexual abuse. They found that childhood adversity was extremely common 
in patients with mood disorder, however, there was no control group for comparison. 
Kessler et al.
113
 examined occurrence of mental disorders in a household population 
survey comparing those who had experienced childhood adversity with those who had 
not. Childhood adversity was defined as loss events (death, separation from parents or 
parental divorce/separation), parental psychopathology (depression, anxiety, 
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drug/alcohol use, antisocial personality disorder), interpersonal traumas (sexual or 
physical abuse, aggression, kidnapping) and other adversity (accident, natural / 
manmade disasters, witnessed trauma, other post-traumatic stress disorder events, 
shocked)). The authors reported that overall adversity was associated with a range of 
disorders including depression. Bernet and Stein
94
 examined childhood trauma 
retrospectively among a cohort of depressed outpatients compared with a control group. 
They reported that depressed cases had higher scores on the Childhood Trauma 
Questionnaire (CTQ) which covers sexual abuse, physical abuse, emotional abuse, 
physical neglect and emotional neglect. Depressed cases also scored higher on the 
emotional and physical abuse subscales as well as on the emotional neglect subscales, 
but not on the physical neglect and sexual abuse subscales.  
 
One of the most recent studies on depression and childhood adversity is by Wingenfeld 
et al.
114
 They examined childhood adversity, adulthood adversity and stress in the 
previous year in a sample of inpatients with major depressive disorder compared with 
patients with borderline personality disorder and controls. They assessed childhood 
adversity using the Early Trauma Inventory
115
 which is a semi-structured interview that 
includes general trauma, physical abuse, sexual abuse and emotional abuse. The authors 
reported that the depressed patients scored significantly higher on the general trauma, 
physical abuse and emotional abuse sections of the early trauma inventory compared 
with controls but not on the sexual abuse section. Depressed cases also scored higher on 
the Trauma Assessment for Adults.
116
 The authors stated that regression analyses 
revealed that depressive symptoms were predicted by emotional abuse in childhood and 
violent experiences in adulthood. The finding that childhood and adulthood depression 
is associated with depression has also been reported by Kendler et al.
117
 in their 
population-based sample of women. The authors reported that onset of depression was 
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best predicted by childhood sexual abuse, severe life events and neuroticism. The 
authors further found that cases who had experienced childhood sexual abuse had an 
increased sensitivity to severe life events. These two studies highlight the importance of 
studying both life events and childhood adversity simultaneously. In fact, the finding 
that life events and childhood adversity are associated in patients with depression or 
depressive symptoms is not a new finding with various studies having found this 
association in a variety of settings including women presenting to an emergency room 





In 2009, a review of the literature by Manning and Stickley
41
 highlighted that a number 
of studies have found an association between childhood abuse and a range of mental 
illnesses including psychosis. The authors’ key findings were that “a significant 
proportion of people appear to develop psychosis following all types of childhood 
abuse”. They also stated that positive symptoms of psychosis appeared to be the most 
strongly correlated with childhood abuse. Schafer & Fisher
121
 reviewed the evidence for 
an association between childhood adversity and psychosis in population-based studies. 
They concluded that “the evidence for an association between childhood trauma and 
psychosis is steadily accumulating” and go on to state that this is further supported by 
studies which have found a ‘dose response’ relationship.  
 
Some studies have found the association between childhood adversity and psychosis to 
be present for only certain types of adversity. Shevlin et al.
97
 investigated childhood 
rape, serious assault, physical abuse, neglect and sexual molestation using data from an 
epidemiological population survey. They reported that only physical abuse predicted 
psychosis in later life. They also reported that childhood rape was predictive of 
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psychosis in male cases only. Thus, serious assault, neglect and sexual molestation were 
not found to be associated with psychosis in this study. 
 
Some studies have even found a lack of association between psychosis and childhood 
adversity. Spataro et al.
110
 used a data linkage design to examine the link between 
childhood sexual abuse and mental health, innovatively using records of medical 
examination that confirmed abuse and linking this to mental health treatment records. 
They included both male and female cases and reported that there was no increased 
relative risk for schizophrenic disorders in those with a history of CSA. An extension of 
this study was performed and reported by Cutajar et al.
103
 Information on abuse 
confirmed by a medical examiner was extracted from medical records and was again 
linked to psychiatric records to create a 12-43 year follow-up. The authors reported that 
exposure to CSA did increase risk for a variety of disorders including psychosis (OR 
2.13, 95% CI 1.44–3.17). The systematic review and meta-analysis by Chen et al.112 
which included 3,162,318 participants with a range of psychiatric disorders reported 




 investigated lifetime victimisation experiences in a population 
sample examining participants with a probable psychosis, a current neurotic disorder, an 
alcohol dependence or a drug dependence. The authors reported that participants with a 
probable psychosis had an increased odds (compared with no disorder controls) of 
having experienced sexual abuse (OR 15.47, 95% CI 8.2-29.2), bullying (OR 4.24, 95% 
CI 2.3-7.8), being taken into care (OR 10.71, 95% CI 5.2-22.0), violence at home (OR 
8.97, 95% CI 4.8-16.6), running away from home (OR 11.49, 95% CI 6.2-21.2), time in 
a children’s institution (OR 11.87, 95% CI 6.1-23.2), homelessness (OR 11.34, 95% CI 
6.0-21.3), being victim of a serious injury, illness or assault (OR 5.21, 95% CI 3.0-9.1) 
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and violence at work (OR 3.66, 95% CI 1.4-9.5) but not expulsion from school (OR 
0.88, 95% CI 0.1-6.3). The probable psychosis group had a higher odds ratio on all 
these variables compared with participants with a common mental disorder or drug / 
alcohol dependence except on expulsion from school. However, when clustering of 
victimisation experiences was controlled for, only six of the risk factors remained 
statistically significant and the odds ratios for all experiences were reduced. This 
demonstrates the importance of examining multiple types of childhood adversity due to 
their interaction. One of the problems with this study, however, was that the experiences 
investigated occurred at an unspecified time in the participants’ lives. Some of the 
experiences can be assumed from the nature of the event (e.g. being expelled from 
school) but not for others (e.g. being homeless). Bebbington et al.
122
 also found that 
lifetime victimisation experiences co-occurred which may be due to early adversity 
predisposing to later adverse events which they called a “clustering of disadvantage”. 





 in their critical review of the area, highlight the issues with 
research on the link between psychosis and childhood trauma. They point out that most 
studies focus on small samples of heterogeneous and chronically ill samples and stress 
that this is not informative about the aetiological role of childhood adversity in 
psychosis. The authors point out that differences between studies in the definition and 
measurement of trauma makes comparisons difficult and may explain the variation in 
findings. Morgan and Fisher advise caution in the over interpretation of findings from 
childhood trauma and psychosis due to the literature being inconsistent and the many 





3.6.1.5. Symptoms not diagnoses 
From the above literature, it appears that the association between childhood adversity 
and depression is well established. However, the association between childhood 
adversity and psychosis is a little less certain. This makes it difficult to hypothesize 
what the relationship between PMD/SAD and childhood adversity might be. However, 
studies examining psychotic symptoms rather than specific diagnoses might be more 
helpful due to issues surrounding diagnostic classification (see Chapter 2). 
 
Several studies have examined the relationship between psychotic experiences and 
childhood adversity. As part of a prospective study of the incidence of mental illness in 
the Netherlands, Janssen et al.
124
 assessed childhood abuse using a semi-structured 
interview which assessed emotional, physical, psychological and sexual abuse before 
the age of 16 years old. The authors reported that childhood abuse was associated with: 
Brief Psychiatric Rating Scale (BPRS) any psychosis (any rating of over 1 on the BPRS 
items ‘unusual thought content’ and ‘hallucinations’); and BPRS pathology level of 
psychosis (any rating of over 3 on the BPRS items ‘unusual thought content’ and 
‘hallucinations’). After controlling for various sociodemographic and clinical variables 
plus urbanicity, the odds ratios of experiencing psychosis in the presence of a history of 
child abuse reduced from 11.5 (95% CI 2.6–51.6) to 7.3 (95% CI 1.1–49.0) but 
remained statistically significant. Further analysis of multiple adversities revealed a 




 examined the relationship between multiple adverse childhood 
experiences and hallucinations in a sample of participants who were members of a 
health maintenance organization in the US. The adverse childhood experiences included 
were: emotional abuse; physical abuse; sexual abuse; battered mother; household 
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substance abuse; mental illness in household; parental separation or divorce; or 
incarcerated household member. The authors reported that the risk of hallucinations 
were increased 1.2- to 2.5-fold by any adversity (although the incarcerated household 
member item had a CI which crossed zero and therefore would not be statistically 
significant). The authors also reported a graded relationship between number of 




 conducted a study similar to Whitfield et al. but they only included 
childhood physical assault, rape and sexual assault. This was part of a national 
epidemiological survey in the US. The authors reported that rape, sexual assault and 
physical assault were associated with both auditory and visual hallucinations. When the 
authors adjusted for multiple adversity and demographic variables, the relationship 
between physical assault and rape with visual and auditory hallucinations remained 
(physical assault: visual hallucinations OR 3.22 (95% CI 1.46–7.09); auditory 
hallucinations OR 4.55 (95% CI 1.96–10.57)); rape: visual hallucinations OR 3.41 (95% 
CI 1.72–6.76); auditory hallucinations OR 2.97 (95% CI 1.39–6.33)) but the 
relationship of both types of hallucinations and other sexual assault became non-
statistically significant (visual hallucinations OR 1.57 (95% CI 0.80–3.06); auditory 
hallucinations OR 0.73 (95% CI 0.32–1.64)). The authors also examined multiple 
adversity and reported that cases with one adverse experience were almost three times 
more likely to experience visual hallucinations whereas those who experienced two 
adverse experiences were almost six times more likely to experience visual 
hallucinations, and almost 14 times for those who experienced three types. This 
indicates a dose response relationship in visual hallucinations. 
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Several studies have even examined psychotic symptoms in children with adverse 
experiences. Studies have reported various types of trauma are positively associated 
with clinical and non-clinical psychotic symptoms in childhood and adolescence.
126-128
 




This section has demonstrated that psychotic experiences which are experienced in 
PMD and SAD are associated with childhood adversity. 
 
3.6.1.6. Depression and Psychosis 
The studies mentioned above, examine depression and psychosis as separate entities. 
However, in PMD and SAD, there is a mixture of depressive and psychotic symptoms. 
Therefore, studies which examine the interaction between psychotic and depressive 




 examined depressive symptoms in a sample of patients with psychotic 
disorders (mostly schizophrenia) involving auditory hallucinations. The authors 
reported that a history of child sexual abuse in these patients was associated with a 
higher level of depression. The study by Bebbington et al.
122
 (mentioned above) in 
which a range of victimisation experiences were elevated in probable psychosis cases 
compared with no disorder controls also found that when controlling for depression the 
odds ratios decreased but remained significant for all items except bullying, being taken 
into care, violence at home and violence at work. The authors interpret this as 




 investigated childhood maltreatment (defined as physical abuse, sexual 
abuse and neglect) in psychiatric inpatients with a schizophrenia spectrum disorder. The 
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authors reported that patients with a history of childhood maltreatment were more likely 
to have elevated symptoms of depression on the BPRS. A further study by Bebbington 
et al.
129
 used a general population sample to explore the relationship between childhood 
sexual abuse and psychosis. They identified potential psychotic cases by using the 
Psychosis Screening questionnaire and asking about participants having a diagnosis of 
psychosis, being on antipsychotics or having been admitted for mental health problems. 
Anyone who was positive for any of these were then interviewed using the Schedules 
for Clinical Assessment in Neuropsychiatry. Interestingly, when controlling for 
depression the odds ratios decreased from 3.5 to 2.3 (95% CI 1.2–4.1) but remained 
statistically significant. This led the authors to conclude that although depressed mood 
did attenuate the relationship between psychosis and victimisation experiences, that 
relationship was still independent of depressed mood.  
 
3.6.1.7. PMD 
Only one study has examined the association between PMD and childhood adversity. 
This was conducted by Fisher
130
 who reported on data from the AESOP first episode 
psychosis study. Fisher reported on severe childhood maternal physical abuse, 
childhood maternal separation and childhood sexual abuse and found an odds ratio of 
3.81 (95% CI 1.07-13.60), 1.97 (95% CI 0.78-4.97) and 1.82 (95% CI 0.56-5.91) 
respectively. When this analysis was adjusted for potential confounding variables 
(gender, age at interview, ethnicity, study centre and parental social class), these odds 
ratios became 1.94 (95% CI 0.30-12.67) for maternal physical abuse, 1.08 (95% CI 
0.31-3.70) for maternal separation and 1.99 (95% CI 0.51-7.79) for sexual abuse, with 
none remaining statistically significant. There is no analysis of overall childhood 
adversity and its association with PMD or with number of types of different adversity. 
There is also no accounting for diagnostic stability. 
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3.6.1.8. Summary of childhood adversity 
The literature reviewed in this chapter suggests that there is an association between 
childhood adversity and both depression and psychosis, both of which are major 
components of PMD and SAD. A link between childhood adversity and specific 
depressive and psychotic symptoms has also been supported. This led to the hypothesis 
that childhood adversity would be more frequent in PMD and SAD cases compared 
with controls. 
 
3.6.2. Life events and life difficulties 
3.6.2.1. Definitions and importance 
Life events have been viewed and defined in a number of different ways. Dohrenwend 
and Dohrenwend
131
 defined life events as “stressful stimuli or situations to which 
everyone is exposed to a greater or lesser extent in the natural course of life”. Brown 
and Harris
36
 view life-events in terms of the emotions they arouse and highlight the 
importance of the meaning of events rather than the events themselves. Brown
132
 states 
that life events have become a useful way to explore stress and explore whether stress is 
an internal response to external events or whether it is the external event itself. Brown
132
 
highlights that although life events do not mean anything to the person until they have 
translated it, life events do exist independently of any such translation.  
 
Life events have been referred to in a number of different ways: ‘life stress’;133 ‘severe 
events and major difficulties’;134 ‘victimization experiences and traumatic events’;135 
‘trauma’;136 ‘stressful life events’;137 ‘traumatic events’;138 ‘chronic and acute stress’;139 
and ‘psychosocial stress’140 among others. Within this review, life events were 
considered as broadly as possible in order to not miss any relevant research in the area. 
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The importance of examining life events and difficulties was highlight by Turner et al.
70
 
as there is the potential for targeting stressful events and life circumstances as part of 
future prevention strategies. Therefore, understanding the distribution of these factors 
and their interaction with other risk factors is important. 
 
3.6.2.2. Depression 
Evidence demonstrating a relationship between stressful life events and the onset of 
mental illness, especially depression, has been steadily accumulating.
140
 A thorough 
exploration of the historical research that has led to current understandings about life 





and this is not repeated here. However, it is worth mentioning one of the first studies to 
examine depression specifically by Paykel et al.
142
 in 1969. Paykel et al.
142
 studied 
depressed patients who were a combination of inpatients and outpatients and compared 
these with controls recruited as part of an epidemiological community survey. They 
used a life events list which covered 6-months prior to onset. The study revealed that 
patients reported almost three times as many events as controls. This was the first study 
to use general population controls thus improving on previous work.  
 
In a landmark study, Brown and Harris
36
 identified the ‘contextual threat’ of life events 
as the important aetiological factor in depression rather that the life event itself. The 
authors conducted interviews with working class women in London focussing on life 
events and ongoing difficulties. The authors were able to improve on previous research 
on life events by rating the level of threat that most people would experience in a similar 
situation to stop the problem of subjective interpretation of life events. This study 
confirmed previous findings of a relationship between life events and depression while 
using a less subjective methodology. They also demonstrated that loss, entrapment and 
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humiliation are particularly important and the six month period pre-onset is the salient 
time period. 
 
 In their literature review, Brown and Harris,
143
 discuss research from two types of study 
sample which replicate the original study by Brown and Harris.
36
 The first study sample 
involved population based studies conducted over a variety of time periods, in a variety 
of settings, with a variety of different populations. Nine studies based on this sample 
reported that severe events or major difficulties were much more common in the period 
before onset in depressed patients compared with controls. Severe events or major 
difficulties occurred in 25-39% of controls compared with 62-94% of cases.
143
 The 
second type of study sample involved examining life events and onset of depression in 
psychiatric patients. Eleven studies reported that 18-73% of cases experienced at least 
one event compared with 8-30% in the control groups.
143
 These studies therefore 
demonstrated that the association between life events and depression exists in more than 




 examined stressful life events in a population based twin study in the 
US. High threat severe life events were documented using the LEDS and loss, 
humiliation, entrapment and danger were specifically selected and rated. High ratings of 
loss and humiliation predicted onset of major depression as did the loss subcategories of 
death and respondent-initiated separation. The combination of humiliation and loss 
events was more ‘depressogenic’ than pure loss (even than death). The authors 
concluded that “in addition to loss, humiliating events that directly devalue an 
individual in a core role were strongly linked to risk for depressive episodes”.   
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Some studies have looked at depressive symptoms rather than a diagnosis of clinical 
depression. McGonagle et al.
139
 examined acute and chronic stressors and depressive 
symptoms in a community survey of married men and women in Detroit. Depressive 
symptoms were measured using the Hopkins Symptom Checklist and included a period 
of only 30 days prior to interview. Chronic and acute stress over the 12 months prior to 
interview were measured using questions from lists compiled by Brown and Harris
145
 
and Dohrenwend, Krasnoff, Askenasy and Dohrenwend.
146
 A chronic stress was defined 
as a stress that started more than 12 months before the interview. An acute stress was 
defined as a stress that started within 12 months of the interview. All point-in-time 
events were coded as acute stressors. The authors found that both acute and chronic 
stress were associated with depressive symptoms in both men and women. The authors 
conclude that chronic stressors were more strongly associated with depressive 
symptoms than acute stressors in all (physical illness, marital conflict and interpersonal 




 examined the relationship between social stress (life events and life 
difficulties) and depressive symptoms as well as depressive disorder. This was done 
within the context of a population based study of residents of Toronto. They measured 
stressful life events using a 34-item checklist and chronic stressors using a 51-item 
inventory. The authors reported that recent life events and chronic stress were both 
correlated with depressive symptoms and major depressive disorder. 
 
Many studies have also examined the relationship between life events and depression 
within the context of other risk factors. Turner et al.,
70
 for example, examined the 
influence of social statuses (age, gender, marital status and occupation). They reported a 
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clear association between life events and sex, age, marital status and occupational 
status. 
 
As mentioned above, a number of studies have examined the interaction of life events 
and childhood adversity on depression and found a relationship between these two risk 
factors.
117, 147
 Briere et al.
119
 examined overall psychiatric problems in women 
presenting to an emergency room. The authors reported that child and adult 
victimizations were intercorrelated and that both were uniquely associated with 
psychiatric difficulties, even after controlling for other relevant factors. They found that 
three clinical variables including depressive disorder was associated with having been 
battered within a sexual relationship. 
 
3.6.2.3. Psychosis 
One of the earliest studies on the link between life events and psychosis was by Brown 
and Birley.
39
 The authors investigated the rate of crises and life changes in the 12 weeks 
prior to onset of schizophrenia (split into four 3-week periods) compared with a non-ill 
comparison group. Case notes of all patients admitted to hospital in a defined area were 
examined and any patients who might have had schizophrenia were interviewed. The 
researchers went through a list of events which (based on common sense) were thought 
to be likely to produce an emotional disturbance in most people. Events involved 
danger; significant changes in health, status or way of life; the potential for significant 
changes in health, status or way of life; and important disappointments. The authors 
reported that the patient group had more life events, independent life events and 
possibly independent life events compared with the controls in the 3 week period closest 
to onset, but not in the other 3-week periods prior to and further away from onset. The 
authors interpret the findings as evidence that environmental factors can precipitate an 
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episode but state that life events are not a sufficient cause. The authors suggest that “...a 
number of factors must contribute and perhaps coincide to produce the conditions 
necessary for an acute schizophrenic attack...”.39 The investigation of independent life 
events here is an important methodological advance.
148
  This is because events which 
are a consequence of illness rather than a cause, will lead to mistaking direction of 
causation. 
 
In his review of the area, Day
149
 stated that if we evaluate the evidence “...we find that a 
substantial majority of all the relevant studies in this area have produced findings that, 
although less than definitive, still support the existence of a causal association between 
stressful life events and the acute onset of positive symptoms in schizophrenic patients”. 
He goes on to state that there are no more than a handful of studies which report 
negative findings,
149
 although it is important to remember that negative findings are less 
likely to get published.
150
 Day points out that although an association has been 
identified between schizophrenia and life events in a variety of studies, this does not 
necessarily mean a causal link. However, the alternative explanations of an artifactual 
association or indirect association is questioned by Day who claims that researchers’ 
careful attention to the issue of temporal sequence in life events rules it out and he 
concludes that the association between stressful life events and episodes of 
schizophrenia are probably causal.  
 
Work on life events and psychosis has also been conducted more recently. As 
mentioned in the childhood adversity section, Bebbington et al.
122
 investigated lifetime 
victimisation experiences in a population sample. Although the experiences investigated 
occurred at unspecified times in the participant’s lives, one of the experiences is much 
more likely to have been in adulthood – violence at work. On this item, the probable 
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psychotic disorder group had an odds ratio of 3.66 (95% CI 1.4-9.5) compared with 
controls. However, when clustering was controlled for, this reduced to an odds ratio of 
1.22 (95% CI 0.4-3.6, p=0.72). 
 
Some researchers have even examined life events and psychotic symptoms. Newman et 
al.
151
 examined victimization and traumatic experiences in consecutive admissions of 
patients with schizophrenia and schizoaffective disorder using the stressful life events 
screening questionnaire. Victimization was defined as incidents that were of a violent 
and interpersonal nature and involved a perpetrator. Traumatic experiences were 
defined as non-interpersonal incidents, events without a perpetrator, e.g. natural 
disasters or motor vehicle accidents. There was evidence of associations between 
traumatic events and PANSS positive symptoms (beta coefficient of 0.92), PANSS 
cognitive/autistic symptoms (beta coefficient of 0.89) but not with the PANSS 
dysphoric symptoms. The authors reported that non-interpersonal traumatic experiences 
were associated with severity of psychosis and concluded that “past traumatic and 
victimisation experiences are significantly associated with schizophrenia patients’ 
symptom severity”.  
 
Despite these positive findings it should be borne in mind that findings on the 
hypothesis that life events trigger onset or relapse of schizophrenia are mixed and that 
the retrospective nature of most of the studies questions the validity of the findings.
152
 
However, due to the nature of the exposure and the rarity of the outcomes, prospective 
studies of life events and psychosis are not feasible. 
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3.6.2.4. PMD and SAD 
Studies have included SAD cases as part of a broader diagnostic group,
153, 154
 but none 
have reported on SAD separately from other diagnoses. However, studies on life events 
in PMD have been conducted.  
 
A paper by Brown et al.
134
 examined life events and difficulties in psychotic and 
neurotic depressed patients. However, there is no mention of the diagnostic 
classification system that was used in this study. Chapter 2 discusses issues surrounding 
the use of the term ‘psychotic depression’ to refer to severity of depression not 
depression with psychotic features. Considering the era that this paper is from and the 
fact the authors compared the group to ‘neurotic’ depression patients, it is highly 
unlikely that the psychotic depressed group are what we would refer to as PMD. 
Therefore, this paper is not necessarily relevant to this discussion. 
 
Other studies have looked at the role of life events in PMD as would be defined today. 
A study by Samuel and Varghese in 2003
155
 randomly selected a sample of 30 patients 
with PMD from an outpatient clinical in India. They found that precipitating factors in 
the form of life events were reported in 53% of patients. These events included recent 
marriage, job loss and residential upheaval. Unfortunately, the authors did not include a 
control group and 60% of the PMD cases had a history of bipolar disorder, bringing into 
question whether they were actually PMD cases at all. This was the only publication 




 examined patients hospitalised for psychotic disorders in the UK. 
They found that 10/14 (71.4%) of patients with PMD reported moderate/severe life 
events (independent and possibly independent) in the three months prior to onset of the 
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index episode. This is compared with 51.9%, 45.2% and 10.1% for the schizophrenia, 
mania and control groups respectively. When examining independent moderate/severe 
events only, 50% of PMD cases were positive for having experienced these events 
compared with 34.6%, 25.8% and 7.2% for the schizophrenia, mania and control groups 
respectively. Whether examining life events which were moderate/severe or mild and 
examining 3 months before the onset of the disorder or four to six months before the 
disorder, the PMD consistently had higher proportions of cases who experienced life 
events compared with the other three groups (except independent mild events at four to 
six months). These findings indicated that life events were more highly associated with 
PMD compared with schizophrenia and psychotic mania. However, the study only 
examined inpatients so arguably focussed on the more severely ill cases of psychosis. 
The sample also only included 35 out of 97 cases who were first episode. Therefore, the 
findings are mostly relevant for life events as a risk factor for admission rather than as a 
risk factor for onset of the disorder. To answer the question of whether life events and 
difficulties are risk factors for the onset of PMD, a study examining first episode 
inpatients and outpatients needs to be conducted.   
 
3.6.2.5. Summary of life events and difficulties 
Van Os et al.
157
 argued that “The associations between life events and illness onset is 
not specific to any particular diagnostic category within the functional psychoses, but 
there is some evidence that the effect sizes are greater in affective illness than in 
schizophrenia”. Based on this and the literature above, it was hypothesized that 
independent life events would be more frequent in PMD and SAD cases in the year 
prior to illness onset compared with controls.  
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3.7. Family history of psychosis 
Genetics clearly play an important part in the aetiology of psychosis.
158
 Although this 
thesis is concerned with the psychosocial risk factors involved in PMD and SAD it 
would be foolhardy to ignore the role of genetics completely. In fact, studies have found 
that there are interactions between genetics and various psychosocial factors in 
psychosis and depression (e.g. childhood adversity
130
 and life events
159
). Therefore, 
although this thesis is concerned with the psychosocial risk factors involved in PMD 
and SAD, the analyses will include a measure of family history of psychosis / mental 
illness. However, there will be no way to determine if this family history indicates the 
aetiological importance of genetics or environment. 
 
3.8. Methodological issues 
This review has picked up upon some key methodological challenges in studies on the 
aetiology of psychoses which have not been addressed by previous research on PMD 
and SAD cases. Firstly, PMD and SAD cases are often amalgamated into other 
diagnostic groups meaning that no conclusions can be drawn about the aetiology of 
PMD and SAD cases. 
 
Secondly, diagnostic stability is something that is rarely, if ever, considered in studies of 
risk factors. Schwartz et al.
160
 stated that “… the psychiatric diagnoses people receive at 
the time of onset are often inaccurate...” and the authors therefore recommend that 
longitudinal studies are needed to clarify the nature of the patient’s illness. In studies 
which only examine baseline diagnosis in relation to risk factors, the findings could be 
inaccurate especially in relation to PMD and SAD which have low diagnostic stability 
(further discussed in section 4.4.2.1).  
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Finally, there is the issue of sampling. The majority of studies on risk factors are based 
on non-first episode illness samples. Within this thesis, incidence samples (all new cases 
of first episode psychosis in a given area) have been deemed as the most accurate 
studies in informing researchers as to the aetiology of PMD and SAD. This is because 
studies which recruit cases from non-first episode samples, are effectively sampling 
cases in treatment. Cases with a chronic course of illness and poor outcomes are more 
likely to be in contact with services and this may lead to sampling from a more unwell 
population than from all psychosis incidence cases. This may lead to an inaccurate 
estimation of the effect of aetiological factors. Similarly, studies which only focus on 
inpatients are arguably sampling from a more ill population and therefore give a skewed 
picture of the aetiology of a disorder. Incidence studies provide a more representative 




The above literature highlights several important points. Firstly, there are very few 
studies on psychosocial risk factors in psychosis which include PMD and SAD. 
Secondly, the psychosocial risk factors reviewed above are clearly important in the 
aetiology of psychosis in general and non-psychotic depression and therefore are likely 
to be important in PMD and SAD. Finally, studies which have been conducted have 
some very important limitations (see section 3.8). Therefore, this thesis aimed to 
examine the psychosocial risk factors mentioned above in PMD and SAD cases, but 
within a study that overcomes these three major methodological issues (separating PMD 
and SAD cases from other diagnoses, sampling from a first episode psychosis sample, 
accounting for diagnostic stability).  
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The literature review above indicated that interactions between various risk factors are 
potentially important. However, as there was very little research available on the risk 
factors for PMD and SAD, the aim of this thesis was to conduct preliminary analyses on 
the risks for these disorders on which future studies can build. 
 
3.10. Hypotheses 
The following hypotheses were based on the literature discussed above: 
1. PMD and SAD would be associated with being of non-white British ethnicity, 
being female, being born outside the UK, being older and being in the London 
site. 
2. Lower educational attainment would be more frequent in PMD and SAD cases 
compared with controls. 
3. Factors associated with social isolation, such as living situation, relationship 
status and contact with friends, would be more frequent in PMD and SAD cases 
compared with controls. 
4. Unemployment would be more frequent in PMD and SAD cases compared with 
controls. 
5. Childhood adversity would be more frequent in PMD and SAD cases compared 
with controls. 
6. Independent life events would be more frequent in PMD and SAD cases in the 
year prior to illness onset compared with controls. 
 
Within this thesis, as well as examining the risk factors associated with PMD and SAD 
compared with controls, these factors were also examined in schizophrenia and bipolar 











CHAPTER 4. A systematic review of the course of illness and outcome of PMD 
and SAD 
 
“When a patient or family member asks how much time is needed to recover from an 





4.1. Aims of the chapter 
The aims of this chapter were to describe and report a systematic review of the course of 
illness and outcome of PMD and SAD, and to detail hypotheses derived from the 
review. 
 
4.2. Why it is important to do this review 
Although there have been a number of literature reviews on the outcomes of PMD and 
SAD,
162-166
 there have been no systematic reviews of the literature. Therefore, the aim 
of this chapter was to report findings from a systematic review of all literature reporting 
on any outcomes over any time periods for PMD and SAD. 
 
4.3. Systematic review methodology 
This review is reported in line with the recommendations from the PRISMA (Preferred 




4.3.1. Criteria for considering studies for this review 
4.3.1.1. Types of studies 
This review included all follow-up, longitudinal, retrospective and prospective studies 
with primary data (there was no minimum follow-up period). Literature reviews and 
systematic reviews were excluded but reference lists from reviews were checked for 
potentially relevant papers that had not been identified in the searches. RCTs and 
clinical trials were excluded. Papers of all languages were included. 
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4.3.1.2. Types of participants 
Participants of both genders, aged 16+ years were included in the review. At least some 
of the participants in the study must have had a diagnosis of PMD or SAD (no 
minimum percentage was set, even if studies had one PMD or SAD participant they 
were included) based on any diagnostic system. Studies focussing on adolescents, those 
with diagnostic groups which included mixed diagnostic groups (e.g. PMD cases and 
schizophrenia cases analysed together in the same group) and studies in which the 
diagnosis was unclear were excluded. Papers focussing solely on older adults (all 
participants age over 60) were also excluded as this was not the focus of this thesis. 
 
4.3.1.3. Types of outcome measures 
The outcomes of interest were: mortality and suicidality (e.g. deaths, completed suicide, 
suicide attempts, self-harm); diagnostic stability; course of illness (e.g. recovery, 
remission, relapse (defined by the author of each paper)); all psychosocial outcomes 
(e.g. functioning as measured by the GAF, relationship status, employment status); and 
service use. Any other biological or medical outcomes were not included. 
 
4.3.2. Search strategies for identification of studies 
4.3.2.1. Electronic searches 
The following electronic databases were searched: Ovid SP PsychInfo (1806 to April 
week 5 2010); Ovid SP EMBASE Classic and EMBASE (1947 to 2010 week 17); and 
OVID Medline (R) (1950 to April week 5 2010).    
 
The following search strategy was used: 
1. schizoaffective/ 
2. schizoaffective.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
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3. delusional depress*.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
4. psychotic depress*.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
5. depressive psycho*.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
6. psychotic major depress*.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
7. major depression with psychotic features.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
8. 1 or 2 or 3 or 4 or 5 or 6 or 7 
9. case control studies/ 
10. case control studies.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
11. case control.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
12. cohort studies/ 
13. cohort studies.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
14. cohort.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
15. follow-up studies/ 
16. follow-up studies.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
17. follow-up.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
18. retrospective studies/ 
19. retrospective studies.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
20. retrospective.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
21. prospective studies/ 
22. prospective studies.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
23. prospective.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
24. systematic review/ 
25. systematic review.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
26. literature review/ 
27. literature review.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
28. meta analysis/ 
29. meta analys*.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
30. qualitative research/ 
31. qualitative.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
32. quantitative research/ 
33. quantitative.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
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34. longitudinal studies/ 
35. longitudinal.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
36. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 
or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 
37. 8 and 36 
38. limit 37 to human 
39. 38 not experimental design.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
40. 39 not drug therapy.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
41. 40 not treatment effectiveness.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
42. 41 not trial.mp. [mp=ti, ot, ab, nm, hw, ui, an, tc, id, sh, tn, dm, mf] 
43. remove duplicates from 42 
 
4.3.2.2. Searching other resources 
Further potentially relevant material was searched for by checking reference lists of 
included papers and checking reference lists of reviews found in the search as well as 
reviews already known about.  
 
4.3.3. Data Collection and Analysis 
4.3.3.1. Selection of studies 
The following steps were followed: 
1. The search was completed as specified, all results were added into a reference 
manager and duplicates removed. 
2. All titles and abstracts were examined to remove obviously irrelevant papers. If 
there was any uncertainty about whether the study met criteria based on title and 
abstract, the full paper was obtained. 
3. The full text of all potentially relevant papers were retrieved. 
4. The full text of papers were examined for consistency with study criteria. 
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5. Two independent reviewers discussed and resolved any differences in opinion 
about studies which were included/excluded. 
6. Multiple reports of the same study were linked together. 
7. Reference lists of included papers and reviews were checked to make sure no 
papers had been missed. 
 
4.3.3.2. Data extraction and Management 
Two investigators independently extracted data from the studies. Any disagreements in 
the data extraction were resolved by discussion.  Forms were designed for the purpose 
of recording extracted data (see Appendix A). The following information was collected 
from each study: 
Methods: Study design, duration of study / follow-up period, study setting, country. 
Within this review, the following definitions were used; prospective study - recruits 
participants and follows them forward in time; retrospective study – recruits participants 
and looks back at their history; historical study - selects participants from historical case 
notes, locates the participant and follows them forward in time. 
Participants: Total number entered into study, diagnostic tool used, sample selection 
and recruitment, comparison group (if applicable). 
Outcomes: Any outcome measures were acceptable. 
Results: Total number of participants followed up / entered into the analyses, summary 
data for groups (mean and SD, median and range or frequencies and percentages for 




4.3.3.3. Assessment of quality in included studies  
The Newcastle-Ottawa Scale was used as a quality assessment (this version is no longer 
available online but the newer version can be viewed at: 
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp for newer version). The 
scale was modified for the purpose of this review by removing a question deemed to be 
irrelevant (“Demonstration that outcome of interest was not present at start of study”) 
and including 3 questions on multivariable analyses, appropriate analyses and 
confidence intervals (see Appendix B for the modified version of the scale). Some of 
the questions were considered to be subjective so criteria were set to ensure consistency 
(see Appendix B). Criteria on the representativeness of the exposed cohorts were 
decided upon by both of the reviewers. Criteria on adequacy of the follow-up of the 





Although a quality assessment scale was used, during the course of the review it became 
apparent that a more critical indication of study quality was based on what participant 
selection was used (this is discussed further in section 4.4.2). Therefore, although 
Newcastle-Ottawa Scale scores were reported in the included studies information, 
throughout the results, participant selection is referred to in relation to quality. 
 
4.4. Results 
4.4.1. Description of studies 
4.4.1.1. Results of the search 
The PsychInfo search produced 788 results, EMBASE 1860 results and Medline 1101 
results (see figure 4-1 for flow diagram). This gave a total of 3749 papers found from 
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searches. To this, 63 papers, which were identified from the reference lists of literature 
reviews and included papers, were added to give a total of 3812 papers. When 
duplicates were removed a total of 2737 remained. After reading all titles and abstracts, 
2270 were removed leaving a total of 467 papers, of which 44 were in languages other 
than English. Efforts were made to retrieve all foreign language articles but 
unfortunately a small number (4) were unavailable from the British library (and via 
contacting the authors directly) and were therefore excluded. All available foreign 
language articles were either already in translated form or were translated by native or 
fluent speakers. After reading all 467 possibly relevant papers, 364 were excluded as 
they did not meet inclusion and exclusion criteria leaving a total of 103 papers from the 
systematic search.   
 
4.4.1.2. Excluded studies 
Reasons for papers excluded are given in Table 4-1.  
 
Table 4-1: Reason for paper exclusion 
Reason for exclusion Number 
Review article 39 
No course / outcome data 52 
No PMD/SAD group 155 
PMD/SAD mixed with other groups for outcome 88 
Discussion / editorial 8 
Sample under 18 years old 2 
Not available from British Library 4 
Other 7 
Focus on older adults 9 
 
 
4.4.1.3. Included studies 
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Figure 4-1: Consort diagram of paper exclusion 
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PMD 161 at follow-up 




















PMD 188 at follow-up 
(39 at follow-up) 
97% 
(100%) 
All first episode inpatient 
and outpatient psychosis 
or manic cases referred 
to secondary services 










PMD 120 at follow-up 
(54 at follow-up ) 
Retrospective Consecutively admitted 
depressed inpatients 
 









PMD no comparison 
group 
(150 at follow-up) 
100% All inpatients given a 
discharge diagnosis of 
psychotic depressive 
reaction 









PMD 47 at follow-up 
(29 at follow-up) 
94% for some 
outcomes but 
less for a lot of 
others 
(unclear) 
Consecutive series of 
inpatients from various 
hospitals with a primary 
diagnosis of depression 
Non standardised 
 
PMD: True delusion / 
hallucination, depression 
worse in the mornings, 
diminution of sexual 
interest, loss of appetite, 




Depression worse in 
evenings, hard to sleep, 
no/slight diminution of 




















Selection process Diagnostic tools Study type  Quality 
assessment 
score 
loss of appetite, < 10lbs 
weight loss, many neurotic 
symptoms e.g. anxiety, 









PMD 178 at follow-up 
(105 at follow-up) 
100% 
(100%) 
Inpatients and outpatients 
who had contact with the 
consultant following first 
episode of psychosis  












PMD 204 at follow-up 
(not reported) 
Retrospective Inpatients discharged 
between 1993-1994 with 












PMD 64 at follow-up 
(30 at follow-up) 
not reported Inpatients with 
depression who had 














PMD 264 at follow-up 
(145 at follow-up) 
Retrospective Selected inpatients 
discharged with 
depression 
RDC (psychotic depression 












PMD 63 at follow-up 





RDC – only mood 
congruent, paranoid 














PMD No comparison 
(13 at follow-up) 
no comparison 
(100%) 
All inpatients with PMD 
with 2 or more 
admissions 



























PMD 67 at follow-up 




inpatients admitted with 
recent onset 
 










PMD 93 at follow-up 


















PMD 70 at follow-up 
(24 at follow-up) 
Retrospective Random sample of all 
suicides with depression 












PMD 117 at follow-up 




admission inpatients with 
functional psychosis  
 









PMD 624 at follow-up 




sample with a 
lifetime diagnosis of 
PMD or non-psychotic 
major depression 
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First ever discharge from 
inpatient services with a 
depressive diagnosis 
 











PMD 144 at follow-up 
(11 at follow-up) 
not reported Consecutively admitted 
female inpatients 
admitted for manic, 
mixed, depressive or SA 
episode 

























PMD 165 at follow-up 
(25 at follow-up) 
Retrospective Alphabetically 
consecutive former 
patients from inpatients 
and outpatients excluding 
SA ps.  
 
DSM3R / RDC to exclude 











PMD 73 at follow-up 




with unipolar depression 
 











PMD 331at follow-up 























PMD 70 at follow-up 
(35 at follow-up) 
unclear Consecutively diagnosed 
depressed inpatients and 
outpatients  
 
DSM3 / RDC / ICD9 
(PMD met DSM3 criteria 
for melancholia and 
psychosis, RDC criteria for 
endogenous depression and 















PMD No comparison 
group 
(568 at follow-up) 
100% All inpatient and 
outpatients who received 
a diagnosis of PMD on 
their initial registration 
(not first episode) 
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PMD 102 at follow-up 
(52 at follow-up) 
98% 
(100%) 
Inpatients admitted with 
depression  
RDC - (those with only 
hallucinations or depressive 











PMD 39 at follow-up 
(6 definite, 
possibly 10 at 
follow-up) 
Retrospective Every patient who 
committed suicide from 
1955-1980 










PMD 492 at follow-up 




inpatients to the early 
psychosis prevention and 
intervention centre 










PMD 283 at follow-up 
(10 at follow-up) 
missing First admission inpatients 
admitted for at least 21 
days 
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major depression and 
attempted suicide 
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 admission inpatient 
women with first episode 
of psychosis within 12 
months of parturition  











PMD 120 at follow-up 
(61 at follow-up) 
100% 
(100%) 
Inpatients who had 
participated in a prior 
study 
 
RDC / DSM3 / DSM3R – 
PMD defined by 










PMD 114 at follow-up 
(64 at follow-up) 
89% 
(not reported) 
First admission inpatients 
with schizoaffective and 
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PMD 147 at follow-up 





1st episode psychosis 
cases presenting to 
inpatients and outpatient 
services 










PMD 92 at follow-up 
(46 at follow-up) 
Retrospective Inpatients admitted to a 
depression ward 
 













PMD 55 at follow-up 
(27 at follow-up) 
76% 
(75%) 
All inpatients and 
outpatients referred with 
major depressive 
disorder 
DSM3 Prospective 6 










PMD 294 at follow-up 
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81% 
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PMD 388 at follow-up 





Admitted inpatients with 













PMD 89 at follow-up 
(29 at follow-up) 
Retrospective Admitted inpatients with 
affective and 
schizoaffective disorders 
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inpatients who received 
outpatient treatment for 
at least 6 months 
 











PMD 52 at follow-up 
(42 at follow-up) 
unclear Delusional depressive 
inpatients admitted and 
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*Aronson study discharged in remission 
and follow-up for at least 








* Coryell 86 
USA 
Iowa 
PMD 65 at follow-up 
(65 at follow-up; 
23 congruent, 42 
incongruent) 
not stated Selected from inpatients 
consecutively admitted 
for depressive symptoms 
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PMD 90 at follow-up 
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PMD 1593 at follow-up 
(183 at follow-up) 
unclear 
possibly 100% 
Inpatients with an 
affective disorder 
followed up on a death 
register 
 














unclear Admitted inpatients with 
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Consecutive inpatients 
with unipolar depression 
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Historical short 















































up (congruent 95, 
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5 years follow-up 
(congruent 26, 
incongruent 21) 
unclear All admissions with a 
primary discharge 
diagnosis of affective 
disorder or schizophrenia  










PMD 602 at follow-up 
(190 at follow-up) 
94% 
(94%) 
















PMD No comparison 
(559 at follow-up) 
not reported Consecutive inpatients 
and new outpatients 
excluding those with a 
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PMD 506 at follow-up 
(55 at follow-up) 
87.8%  
(not reported) 
Inpatients and outpatients  
with non-bipolar 
depression 
RDC modified – 
hallucinations and 
delusions; FTD, stupor and 
severe impairment were not 















PMD 327 at follow-up 
(58 at follow-up) 
69% 
(71%) 
Sample of inpatients and 
outpatients seeking 
treatment in tertiary care 
centres with MDD, 
mania or SA. 
RDC – broadened to 
approximate DSM-IV more 
closely – RDC SA subtypes 
included as PMD with the 
exception of mainly 
schizophrenia subtype. 













PMD no comparison 
(140 at follow-up) 
no comparison 
(89%) 
First admission inpatients 
with affective psychoses 










PMD 102 at follow-up 
(15  at follow-up) 
100% 
(100%) 
First admission inpatients 
with psychosis 











PMD 181 at follow-up 
(45 at follow-up) 
83%  
(75%) 
First admission inpatients 














PMD 257 at follow-up 
(44 at follow-up) 
85.5-86.8% 
(not reported) 
First episode inpatients 
with psychosis 




























PMD 74 at follow-up 






RDC with no prior history 











PMD 123 at follow-up 




for bipolar I disorder, 
PMD or NPMD 











PMD 124 at follow-up 
at 7-8 years 
(17 at follow-up 
at 7-8 years) 
79% at 7-8 
years 
(63%) 
Relatively early young 
inpatients 
 
RDC Prospective 7-8 
year follow-up 
with 4.5 year 












PMD 110 at follow-up 
(31 at follow-up) 
not reported Admitted inpatients from 
2 sites 
RDC Prospective 14 
month follow-











PMD 94 at follow-up 
(31 at follow-up) 
85% 
(not reported) 
















PMD 92 at follow-up 





RDC Prospective 2 










PMD 202 at follow-up 





  admission (within 6 
months) inpatients with 
psychosis 










PMD 202 at follow-up 
(42 at follow-up) 
90% 
(not reported) 
first admission inpatients 
with psychosis 
















Selection process Diagnostic tools Study type  Quality 
assessment 
score 









PMD 335 at follow-up 
(70 at follow-up) 
89% 
unclear 
First admission inpatients 
with psychosis 













PMD 567 at follow-up 
(89 at follow-up) 
90% 
(not reported) 
First admission inpatients 
with psychosis 










PMD No comparison 
(87 at follow-up) 
No comparison 
(94%) 
First admission inpatients 
with psychosis 
 











PMD 150 at follow-up 
(27 at follow-up) 
49% 
not reported 
First admission inpatients 
with psychosis 











PMD No comparison 





 admission inpatients 
with psychosis 
 











PMD 547 at follow-up 
(103 at follow-up) 
88%  
(not reported) 
First admission inpatients 
with psychosis 
 












SAD 194 at follow-up 
(75 at follow-up) 
not reported Inpatients admitted 
between Dec 1972 – Dec 
1974 
CATEGO and RDC Retrospective 
case control 










SAD 43 at follow-up 
(29 at follow-up) 
not reported Consecutively admitted 
inpatients with a 
functional psychosis 
excluding mania 



















Selection process Diagnostic tools Study type  Quality 
assessment 
score 










SAD 120 at follow-up 
(24 at follow-up) 
78-83% 
(not reported) 
Inpatients admitted to 
one of two research 
hospitals 











SAD 206 at follow-up 
(15 at follow-up) 
unclear All schizophrenia 
inpatients born after 
1930 and a random 
sample of 75% of 










USA SAD 1213 at follow-up 
(7 at follow-up) 
76% 
(not reported) 










SAD 68 at follow-up 
(33 at follow-up) 
78% 
(75%) 
Severely ill inpatients at 
a long-term residential 
treatment place 













SAD 75 at follow-up 
(19 at follow-up) 
80% 
(79%) 
Inpatients and outpatients 
with affective disorders 
referred for treatment 














SAD 406 at follow-up 
(49 at follow-up) 
100% 
(100%) 
All inpatients with 
affective and 
schizoaffective patients 
admitted to clinic 
between 1959 – 1963 
ICD9 (Unipolar depression 
defined as depression only, 
any occurrence of 
hypomania was classified as 
bipolar. SA disorder was 

































SAD 406 at follow-up 
(49 at follow-up) 
100% 
(100%) 
All inpatients with 
affective and 
schizoaffective patients 
admitted to clinic 
between 1959 – 1963 











SAD 406 at follow-up 
(42 at follow-up) 
100% 
(100%) 
All inpatients with 
affective and 
schizoaffective patients 
admitted to clinic 
between 1959 – 1963 











SAD 72 at follow-up 
(37 at follow-up) 
not reported Inpatients admitted 
between 1950-1979 











SAD 72 at follow-up 
(37 at follow-up) 
not reported Inpatients admitted 
between 1950-1979 











SAD 72 at follow-up 
(37 at follow-up) 
not reported Inpatients admitted 
between 1950-1979 











SAD N/A (only SAD 
data useable) 
(36 at follow-up) 
not reported Inpatients admitted 
between 1950-1979 











SAD 72 at follow-up 
(37 at follow-up) 
not reported Inpatients admitted 
between 1950-1979 











SAD 72 at follow-up 
(37 at follow-up) 
not reported Inpatients admitted 
between 1950-1979 










SAD 72 at follow-up 
(37 at follow-up) 
not reported Inpatients admitted 
between 1950-1979 
















Selection process Diagnostic tools Study type  Quality 
assessment 
score 








SAD 207 at follow-up 
(45 at follow-up) 
not reported Inpatients admitted 
between 1950-1979 











SAD 207 at follow-up 
(45 at follow-up) 
not reported Inpatients admitted 
between 1950-1979 











SAD 355 at follow-up 
(48 at follow-up) 
not reported Inpatients admitted 
between 1950-1979 











SAD 72 at follow-up 
(37 at follow-up) 
not reported Inpatients admitted 
between 1950-1979 












160 at follow-up 
(PMD: 38 at 
follow-up 




First admission inpatients 
with an ICD-9 diagnosis 
of 295, 296, 297 or 298 












177 at follow-up 
(PMD: 50 at 
follow-up 





















65 at follow-up 
(17 Mood 















































inpatients with delusions 
and hallucinations were 



















122 at follow-up 
(PMD: 14 at 
follow-up 
SAD: 17 at 
follow-up) 
not reported Hospitalised inpatients 
aged 18-30 
RDC Prospective 4.5 













187 at follow-up 
(PMD: 17 at 
follow-up 
SAD: 31 at 
follow-up) 
not reported Consecutively admitted 
inpatients between 18-35 
RDC 3
rd











site 1: 125 at 
follow-up 
site 2: 75 at 
follow-up 
(various) 
site 1: 93% 
site 2: 69% 
site 1: Consecutively 
admitted patients from 
1966-1968 with a 
diagnosis of 
schizophrenia, paranoid 
psychosis, mania and 
PMD 
site 2: schizoaffective 
inpatients sampled from 
1972 - 1975 
ICD-8 
(Catego; RDC; DSM) 
 




















Not reported Inpatients with functional 
psychoses with a 
subsequent follow-up 
over several years 
Own criteria: Melancholic 
schizoaffective – depressed 
mood, psychomotor 

















Selection process Diagnostic tools Study type  Quality 
assessment 
score 
12 SA depressive 
at follow-up) 
mood congruent delusions / 
hallucinations 
Depressive schizoaffective: 
same as melancholic but 
with incongruent delusions / 
hallucinations. Affective 
and schizophrenia can be 
















Sample of inpatients and 
outpatients seeking 
treatment in tertiary care 
centres with MDD, 
mania or SA. 



















admissions between 1982 
and 1984 













69 at follow-up 
(22 PMD/SAD at 
follow-up 
29 schizophrenia 
at follow-up  






organic and non-manic 
psychosis, split into those 
consistently diagnosed as 
schizophrenia or 
schizoaffective mainly 
schizophrenic in type 
versus PMD or 
schizoaffective mainly 
affective versus those 
who did not have a 
consistent diagnosis  





One hundred and three papers (from 60 studies) reported on the course and outcome of 
PMD and SAD. The related papers are included within this review but are highlighted 
throughout to prevent double counting of the same data. Seventy papers reported on the 
outcomes for patient groups with PMD, 22 reported on the outcomes for patient groups 
with SAD, 6 reported on the outcomes for PMD and SAD groups separately and 5 
reported on the outcomes for these groups combined.  
 
The papers were based on data collected in numerous countries spanning 4 continents: 
Asia; Australia; Europe; and North America. The majority (101) were from Europe and 
North America (42 and 59 papers consecutively). The articles included 71 papers from 
prospective studies, 13 papers from retrospective studies, 9 papers from historical 
studies and 10 papers which came from studies which used multiple methods (9 papers 
which report on data from retrospective and prospective data and 1 which reports on 
data from historical and prospective sources). The prospective studies ranged from 6 
weeks to 39 years. The historical studies ranged from 6 months to 65 years follow-up.  
The participant selection from all the studies can loosely be grouped into six categories: 
first episode inpatients and outpatients (incidence samples; n4); first admission patients 
(n18); inpatients only (not first episode; n67); non-first episode inpatients and 
outpatients (n10); first episode inpatients (n1); and other (n3). As discussed in section 
3.8, incidence samples minimise biasing results toward more ill patients and therefore 
poor outcomes and, within this review, studies based on these samples are therefore 
judged to be superior in quality.  
 
The included papers used a variety of diagnostic classification systems including feigner 
criteria, RDC, and a number of DSM and ICD iterations. As discussed in chapter 2, 
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definitions of PMD and SAD have changed over time and different diagnostic 
classifications do not always match exactly making comparisons between studies 
difficult. This is especially the case in the studies that used non-standardised 
definitions,
172, 264
 others which used modified criteria
175, 189, 209, 216, 268-270
 and several 
which do not state what diagnostic classification they used.
245, 271, 272
 However, the 
majority of the studies used either the RDC or DSM-3 or later versions of the DSM, all 
of which are the most consistent criteria for what is defined as PMD and SAD currently. 
 
In terms of diagnostic comparison groups, of the 103 papers, 13 had no comparison 
groups, 38 compared the target group to other affective groups, 30 compared the target 
group to other psychotic disorders, and 22 compared the target group to a combination 
of psychotic and affective diagnostic groups. Within this thesis, PMD and SAD cases 
compared with the other major psychotic diagnostic groups of schizophrenia and bipolar 
cases are the main interest so will be focussed on in this review, although results are 
displayed for all diagnostic groups.  
 
Due to the methodological, clinical and statistical heterogeneity of the studies and data, 
it was not valid to conduct meta-analyses on the data so the findings are reported as a 
narrative review. Due to the large number of papers identified and the range of outcome 
measures examined, the results of the review were divided into 6 sections: diagnostic 
stability; course of illness; mortality and suicidality; psychosocial outcomes; and service 
use. 
 
4.4.2.1. Diagnostic stability 
Of the 103 papers identified for this review, 28 had data on diagnostic change or 
stability. The studies on diagnostic change can be split into those on prospective 
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consistency and those on retrospective consistency. Prospective consistency is defined 
as the proportion of cases who have the same diagnosis at follow-up as they did at 
baseline. Retrospective consistently is defined as the proportion of cases who have the 
same diagnosis at baseline as they do at follow-up. 
 
4.4.2.1.1. Prospective consistency 
Of the 28 papers which reported on prospective consistency, 24 had useable data. Table 
4-3 shows the prospective consistency for each diagnostic group. When all studies are 
included the prospective consistencies range from 24-100% for PMD, 18-83% for SAD, 
30-97% for psychotic bipolar disorder and 50-100% for schizophrenia. This wide 
variation in prospective consistency is likely due to the large amount of heterogeneity of 
the studies included in the review (i.e. different diagnostic tools, widely varying follow-
up lengths, differing samples and differing quality). 
 
If only long-term studies are included (defined here as 8+ years), then the range of 
prospective consistencies reduces dramatically for schizophrenia but not for the other 
disorders: 20-93% for PMD; 58-84% for SAD; 33-75% for psychotic bipolar disorder; 
and 90-100% for schizophrenia cases. If the most recent versions of the DSM and ICD 
are used (or second most recent for DSM as there are no studies examining the most 
recent version of the DSM), then the prospective consistencies get much narrower 
especially for PMD and psychotic bipolar disorder indicating that more current 
classification systems may be more valid for these disorders: 65-100% for PMD; 64-
97% for psychotic bipolar disorder; and 58-97% for schizophrenia. There were no 
studies on SAD which used ICD-10 or DSM-IV.  
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If only studies based on an incidence samples are included,
1, 77, 78, 197
 the prospective 
consistencies are 65-95% for PMD, compared with 78-97% for psychotic bipolar 
disorder and 82-96% for schizophrenia. No incidence sample studies examined SAD 
cases. These estimates are a lot narrower and more similar to each other but the longest 
of these is only four years, thus the long term prospective consistency is unknown.  
 
Based on incidence studies, PMD cases have a wider range of prospective consistencies 
which include lower boundaries compared with schizophrenia and bipolar cases. 
Therefore, it was hypothesized that PMD would have lower prospective consistency 
compared with schizophrenia and bipolar cases. Data on SAD cases was not available 
from incidence studies. However, due to the similarities between PMD and SAD cases 
in terms of symptoms (see Chapter 2) and the fact that the range of prospective 
consistencies are similar between PMD and SAD in the comparisons based on all 
studies and based on 8+ years studies, it was also hypothesized that SAD would have 
lower prospective consistency compared with schizophrenia and bipolar cases. 
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Table 4-3: Prospective consistency (expressed as a percentage) 




































































































































DSM-IV 4 years 73 - - - 80 96 0-42 - 
Coryell
276
 Feigner  criteria (excluding stupor) 20 years 87 - 88 - - - - - 
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*Chicago Follow-up Study 
RDC with no prior history of mania or 
hypomania 






DSM3R /  
DSM4 






PMD: True delusion / hallucination, 
depression worse in the mornings, 
diminuation of sexual interest, loss of 
appetite, 10lbs + weight loss, unvarying 
depression, blames self. 





















RDC 6 years - 
 





*Angst & Preisig 1995 papers 





RDC 1-6.5 years 93% 18% - - - - - - 
NPMD = non-psychotic major depression; NPBP = non-psychotic bipolar disorder; PBP = psychotic bipolar disorder; SZ = schizophrenia.
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4.4.2.1.2. Retrospective consistency 
Only three papers examined retrospective consistency (see Table 4-4). These papers 
reported a retrospective consistency of 82-100% for PMD, 76-89% for psychotic bipolar 
disorder and 50-73% for schizophrenia (no papers included data on SAD cases). Only 
one of the studies was based on an incidence sample and this indicated high 
retrospective consistency for PMD (100%) compared with schizophrenia and psychotic 
bipolar disorder (71% and 76% respectively). However, none of these papers were 
based on long-term studies highlighting the need for long-term studies on retrospective 
consistency in PMD and SAD cases. 
  
Based on the literature above, it appears that in contrast to the findings on prospective 
consistency, retrospective consistency is higher in PMD cases compared with 
schizophrenia and bipolar cases. Therefore it was hypothesized that PMD would have 
higher retrospective consistency compared with schizophrenia and bipolar cases, and 
due to the similarities between PMD and SAD, it was hypothesized that SAD would 




Table 4-4: Retrospective consistency (expressed as a percentage) 











DSM3R /  
DSM4 





DSM-IV 1.5 years 100 89.2 50.2 57.1 95 83.3 86.7 100 
PBP = psychotic bipolar disorder; SZ = schizophrenia; SA general = schizoaffective disorder (general); Szform = schizophreniform.
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4.4.2.2. Course of illness 
Papers on course of illness included a large number of very heterogeneous outcomes 
including recovery, remission, recurrence, relapse, average number of episodes, average 
time in episode, time to recovery / remission, mean relapses and cycles. This makes 
grouping together similar outcomes very difficult. Therefore, this review has focussed 
on a few key course of illness markers: course type (episodic versus continuous); length 
and number of episodes; remission lengths; and amount of time psychotic.  
 
Of the 103 papers identified for this review, 62 had data on course of illness in PMD 
and SAD (see Table 4-5). In terms of course of illness in relation to schizophrenia, three 
papers reported on course type in PMD and schizophrenia cases. All three papers 
reported PMD cases to have a less continuous illness (0% versus 10%;
258
 5% versus 
41%;
200
 13% versus 34%
229
), and one reported PMD to have a more episodic course of 
illness (92% versus 16%), compared with schizophrenia cases. Opjordsmoen
258
 also 
reported SAD cases to have a more episodic (82% versus 16%) and less continuous (0% 
versus10%) course type compared with schizophrenia cases. All three of these papers 
are based on inpatient only samples, although two are based on first admission inpatient 
samples,
229, 258
 and two out of three of them are based on very long follow-ups (2-32 
years
200
 and 3-39 years
258
). Although none of these studies were compared statistically, 
they do indicate a trend. Based on this, it was hypothesized that PMD and SAD groups 
would have a higher proportion of cases with an episodic course of illness and less with 
a continuous course of illness compared with schizophrenia cases.  
 
In relation to other key course of illness outcomes, only two papers reported on episode 
frequency or length. Opjordsmoen
258
 reported that PMD and SAD cases had more 
episodes (mean 3.1 and 3.3 respectively versus 1.6) but shorter episodes (mean longest 
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episode 1.6 years and 4 years versus 26 years) compared with schizophrenia cases. 
Conversely, Tohen et al.
218
 reported that PMD cases had longer episodes (days to 
recovery; mean 69 days (35.8 SD) versus 60 days (35.7 SD)). However, this study was 
only a 6-month follow-up study compared with the Opjordsmoen
258
 paper which was 
based on a 3-39 year follow-upand neither paper compared the groups statistically. 
Although the literature on episode frequency and length is very limited, it was 
hypothesized that PMD and SAD would have: more episodes and shorter episodes 
compared with schizophrenia cases.  
 
Of the 12 papers that included both PMD and schizophrenia course of illness 
information, nine reported on recovery or remission, with consistent findings: eight out 
of the nine reporting that PMD groups had more cases remitting/recovering compared 
with schizophrenia cases
200, 227, 229, 259, 279-282
 (only one reported PMD to have shorter 
recovery times compared with schizophrenia cases
218
). All of these papers were based 
on data from inpatient samples (first admission and non-first admission). Although only 
2 of these were statistically compared (and showed PMD to have statistically 
significantly better recovery), the studies indicate a trend. Based on this, it was 
hypothesized that PMD would have longer remissions and spend a smaller percentage 
of the follow-up psychotic compared with schizophrenia cases. Only two papers 
reported on recovery in SAD and schizophrenia cases and while one reported the same 
percentage recovered in each group,
259
 the other reported higher recovery in the SAD 
group
283
 (neither compared statistically). However, although both based on inpatient 
only samples, the second study was based only a six month follow-up
284
 where as the 
first one was based on an 8 year historical study.
259
 Based on these inconsistent and 
limited results, and the similarity between PMD and SAD cases in terms of symptoms 
plus the hypothesis based on PMD cases, it was hypothesized that SAD cases would 
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have longer remissions and spend a smaller percentage of the follow-up psychotic 
compared with schizophrenia cases. 
 
There were also a number of studies which compared PMD and SAD groups to bipolar 
cases. Fifteen papers reported on course of illness in PMD and bipolar cases. The five 
papers which reported on course type had conflicting results. In terms of continuous 
course type, one study reported more PMD cases had a continuous course type 
compared with bipolar cases (24% congruent PMD and 21% incongruent PMD versus 
5% congruent bipolar and 20% incongruent bipolar),
285
  while another reported the 
opposite (5% PMD continuous versus 32% bipolar).
200
 Both of these studies were long-
term studies follow-ups based on inpatient samples. In terms of episodic course type, 
one paper reported PMD cases to be more episodic (9% PMD versus 5% bipolar),
286
 
while another two (both based on the same dataset) reported bipolar cases to be more 




In relation to bipolar comparisons on episodes, Angst et al.
288
 includes details on 
number of episodes and reports PMD cases to have less episodes compared with bipolar 
cases (median 4 in congruent PMD and 5 in incongruent PMD versus 8.5 in congruent 
bipolar and 5 in incongruent bipolar) although this was not statistically tested 
(Winokur
289
 also reports this but is based on the same dataset). Angst
290
 also includes 
details on length of episodes and reports PMD cases to have longer episodes (median 5 
months in congruent and incongruent PMD versus 4 months in congruent and 
incongruent bipolar). This trend is also reported by Lenzi et al.
182
 who report a mean 
episode of 2.4 months in recurrent PMD cases and 4.7 months in single episode PMD 
cases compared with 1.1 and 2.5 months in psychotic bipolar I disorder and psychotic 
bipolar II disorder cases respectively. Again, neither of these comparisons are tested 
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statistically. The literature on number and length of episodes in PMD and bipolar cases 




 also include several other relevant course of outcome variables. They 
report that time in episode was 28% and 21% for congruent and incongruent PMD cases 
respectively compared with 15% and 20% for congruent and incongruent bipolar cases 
respectively. They also report that time in remission was 40% and 19% for congruent 
and incongruent PMD cases respectively compared with 45% and 20% for congruent 
and incongruent bipolar cases respectively.
292
 Neither of these outcomes have the 
statistical comparison tested between the groups. There are no other papers that report 
on these outcomes in PMD and bipolar cases.  
 
Two studies report on number of episodes in SAD cases compared with bipolar cases. 
Maj
242
 reported SAD cases to have a mean of 1.3 episodes (1.1 S.D.) prospectively 
compared with 0.8 episodes (1.4 S.D.) in the non-psychotic mania group. Angst et al.
293
 
reported a median of 6 episodes in the SAD group compared with 10 in the non-
psychotic bipolar group. Angst et al.
294
 also reported a median length of episodes of 3 
months in SAD compared with 4.3 months in the non-psychotic bipolar group, and an 
average of 15% of time spent in illness in SAD cases compared with 19% in the non-
psychotic bipolar group. There are no other papers that report on these outcomes in 
SAD and bipolar cases, or any papers which report on course type or length of 
remissions in SAD and bipolar cases. 
 
The literature on course of illness in PMD and SAD cases compared with bipolar cases 
is sparse and conflicting. The inconsistency is likely due to the methodological 
differences between the studies included. These differences are also applicable to the 
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studies which compare PMD and schizophrenia cases. These include time period, 
sample and diagnostic system, but also, vitally, different ways of defining and 
measuring course of illness. As mentioned previously, incidence studies are of 
particular importance but there are no incidence studies examining course of illness. 
Due to the inconsistency of the findings comparing PMD and SAD with bipolar 
disorder, no hypotheses are stated. 
 
Table 4-5: Course of illness 






95% were discharged home after hospital 
76/150 had no subsequent psychiatric care 
45/150 had 1 more occurrence of PMD. 







12/13 had previous/subsequent psychotic depressive episodes.  
Previous: 1/13 had a purely psychotic previous admission. 1/13 had a 
mixed (psychotic and depressed) previous episode. 11/13 had a 
subsequent psychotic episode. 3/13 had a non-psychotic previous 
episode. 
Subsequent: 11/13 had a subsequent psychotic episode.  1/13 had a 







PMD: 6% had only the baseline contact with services, 50% had a 
clear episode, received treatment and never had contact again, 24% 
had more than 1 episode, 20% had further episode that were not 
















PMD: 46.9% were experiencing 1
st
 episode of depression 
58.5% had at least 1 period of full remission lasting at least 2 
months, 40% had a remission lasting at least 19/24 month follow-up.  
Of the participants who did not get a full remission, 41.2% were 









PMD: 60/87 achieved a period of complete remission by 4 years, 
20/87 had a partial remission, 7/87 did not remit at all.  
Median time to complete remission was 22.2 weeks.  
Cumulatively, 11.7% of remitters achieved this by 1 month, 36.7% 
by 3 months, 55% by 6 months, 71.7% by 1 year. 
43.3% of remitters relapsed. 7 more experienced a partial relapse. 







PMD: 72/89 (81%) had at least one further episode of depression.  
NPMD: not reported. 
Depression with preoccupations: 88/123 (72%) had at least one 











SAD: 1 episode = n1, 2 = n1, 3 = n7, 4 = n6, 5 = n3, 6 = n3, 7 = n5, 
8 = n4, 9 = n0, 10 = n2, 11-15 = n10, 16-20 = n0, 20+ = n0. 
SAM: 1 episode = n0, 2 = n1, 3 = n2, 4 = n3, 5 = n8, 6 = n6, 7 = n11, 
8 = n10, 9 = n3, 10 = n7, 11-15 = n20, 16-20 = n20, 20+ = n18.  
NPMD: 1 episode = n20, 2 = n31, 3 = n17, 4 = n18, 5 = n13, 6 = 
n10, 7 = n10, 8 = n4, 9 = n2, 10 = n4, 11-15 = n8, 16-20 = n5, 20+ = 
n2. 





Reference Findings Comparisons 






SAD: Mean episodes 3.3 (1-14, NO SD), More than 1 episode 18/33 
(55%), Mean longest episode 4 years,  mean cycle duration 5 years 
(1-14, NO SD), 27/33 had an acute course of illness, 0/33 steadily 
psychotic, healthy by follow-up 14/33 (42%).  
 
PMD: Mean episodes 3.1 (1-16), More than 1 episode 23/50 (46%), 
Mean longest episode 1.6 years, mean cycle duration 9 years (1.3-
36), 46/50 had an acute course of illness, 0/50 steadily psychotic, 
healthy by follow-up 33/50 (66%). 
 
SZ: Mean episodes 1.6 (1-10), More than 1 episode 8/94 (9%), Mean 
longest episode 26 years, mean cycle duration missing, 15/94 had an 
acute course of illness, 9/94 steadily psychotic, healthy by follow-up 
9/94 (10%). 
 
Acute = without substantial residual symptoms between episodes. 
Mean duration of cycle = time from 1
st
 symptoms in 1
st
 episode to 1
st
 









SAD: 0.78 (0.56SD) mean relapses.  










PMD: 45/70 had complete remission, 16/70 had partial remission, 
9/70 continuously ill.  
Sz/SA: 21/149 had complete remission, 77/149 had partial remission, 
51/149 continuously ill.  
PBP: 93/116 had complete remission, 18/116 had partial remission, 








* Coryell 86 
55% of congruent group recovered. 
33.3% of incongruent group recovered. 
 









PMD: Days to recovery mean 69 (35.8 SD), days to recurrence mean 
50 (64.3 SD), 11/14 had syndromal recovery, 3/13 had functional 
recovery, 1/10 had a relapse at 6 months, 7/15 had recovery at 
discharge.  
 
BP: Days to recovery mean 43 (31.9 SD), days to recurrence mean 
99 (56.7 SD), 45/53 had syndromal recovery, 34/50 had functional 
recovery, 8/42 had a relapse at 6 months, 31/60 had recovery at 
discharge. 
 
SZ: Days to recovery mean 60 (35.7 SD), days to recurrence mean 
56 (26.1 SD), 4/6 had syndromal recovery, 2/3 had functional 
recovery, 2/3 had a relapse at 6 months, 2/10 had recovery at 
discharge. 
 
Delusional disorder: Days to recovery mean 41 (17.8 SD), days to 
recurrence mean 43 (40.3 SD), 6/8 had syndromal recovery, 2/7 had 
functional recovery, 1/6 had a relapse at 6 months, 4/9 had recovery 
at discharge.  
 
Psychosis NOS / brief reactive psychosis: Days to recovery mean 50 
(64.7 SD), days to recurrence mean 40 (- SD), 5/7 had syndromal 
recovery, 2/4 had functional recovery, 1/4 had a relapse at 6 months, 









PMD: 50/53 had a syndromal recovery, 13/45 had a functional 
recovery. 






Reference Findings Comparisons 
 
Syndromal recovery was defined as no longer meeting criteria for an 
on-going DSM-IV illness episode. 
Functional recovery (yes/no), defined by comparing ratings on the 






PMD: syndromal recovery 75.0%, functional recovery 31.8%. 39.0 
(11.5 SE) mean days to 25% recovery.  
BP manic: syndromal recovery 85.7%, functional recovery 32.6%. 
29.0 (2.2 SE) mean days to 25% recovery.  
BP mixed: syndromal recovery 65.0%, functional recovery 47.4%. 
30.0 (2.6 SE) mean days to 25% recovery.  
BP NOS: syndromal recovery 100.0%, functional recovery 55.6%. 
38.0 (11.5 SE) mean days to 25% recovery.  
Psychosis NOS: syndromal recovery 72.4%, functional recovery 
18.5%. 14.0 (2.3 SE) mean days to 25% recovery.  
Delusional disorder: syndromal recovery 71.4%, functional recovery 
38.5%. 22.0 (15.9 SE) mean days to 25% recovery.  
Szform: syndromal recovery 100%, functional recovery 20.0%. 33.0 
(15.9 SE) mean days to 25% recovery. 
SA: syndromal recovery 70.0%, functional recovery 0%. 31.0 (11.0 
SE) mean days to 25% recovery.  
SZ: syndromal recovery 35.7%, functional recovery 15.4%. 65.0 
(98.9 SE) mean days to 25% recovery.  
 
Syndromal recovery = no longer meeting criteria for illness. 











PMD: Global functioning; 5% continuous incapacitation; 21% 
recovered. 
SA: Global functioning; 29% continuous incapacitation;  0% 
recovered.   
SZ: Global functioning; 41% continuous incapacitation;  6% 
recovered.  
BP: Global functioning; 32% continuous incapacitation;  11% 









PMD congruent: 28% time in episode, median 4 episodes, median 5 
months length of episodes, median 4.2 years length of cycle, 40% 
time in remission, 32% more than 5 years relapse free, 24% chronic 
course. N25 
PMD incongruent: 21% time in episode, median 6 episodes, median 
5.4 months length of episodes, median 5.1 years length of cycle, 
19% time in remission, 35% more than 5 years relapse free, 21% 
chronic course. N48  
NPMD: 19% time in episode, median 4 episodes, median 5.4 months 
length of episodes, median 4.6 years length of cycle, 33% time in 
remission, 48% more than 5 years relapse free, 7% chronic course. 
N100 
NPBP: 18.4% time in episode, median 10 episodes, median 3.9 
months length of episodes, median 2.2 years length of cycle, 24% 
time in remission, 25% more than 5 years relapse free, 12% chronic 
course. N72 
PBP congruent: 15.3% time in episode, median 8.5 episodes, median 
4.3 months length of episodes, median 3.8 years length of cycle, 
45% time in remission, 40% more than 5 years relapse free, 5% 
chronic course. N20  
PBP incongruent: 20% time in episode, median 10 episodes, median 
4.2 months length of episodes, median 2.9 years length of cycle, 
20% time in remission, 24% more than 5 years relapse free, 20% 







 SAD: 23/75 (31%) failed to recover,  Diagnostic 
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1980 SZ: 35/53 (66%) failed to recover,  










SAD: Median length of illness 23.6 years. Number of episodes = 6. 
Episodes per year = 0.19. Length of episode = 3.0 months. Length of 
cycles = 62 months. Time spent in illness = 15%. Length of last 
episode = 3.0 months.  
 
NPMD: Median length of illness 15.1 years. Number of episodes = 
4. Episodes per year = 0.22. Length of episode = 5.6 months. Length 
of cycles = 54.3 months. Time spent in illness = 23%. Length of last 
episode = 4.0 months. 
 
NPBP: Median length of illness 25.0 years. Number of episodes = 
10. Episodes per year = 0.37. Length of episode = 4.3 months. 
Length of cycles = 32.4 months. Time spent in illness = 19%. Length 
of last episode = 3.5 months.  
 
SAM: Median length of illness 29.7 years. Number of episodes = 11. 
Episodes per year = 0.35. Length of episode = 4.0 months. Length of 
cycles = 34.7 months. Time spent in illness = 19%. Length of last 
episode = 4.0 months. 
 
181 examined retrospectively 










PMD: 17/29 (58.6%) recovered by follow-up;  
SAD: 18/46 (39.1%) recovered by follow-up;  
SZ: 2/20 (10.0%) recovered by follow-up;  
 








PMD: 6/64 episodic, 47/64 chronic, 11/64 indeterminable. 
Mania: 1/13 episodic, 7/13 chronic, 5/13 indeterminable. 
Depression and Mania: 0/13 episodic, 9/13 chronic, 4/13 
indeterminable. 
Prominent affective symptoms: 2/20 episodic, 16/20 chronic, 2/20 
indeterminable. 










PMD: n10 long-term global follow-up mean 1.1 (1.1 SD), discharge 
status mean 1.5 (0.9).  
SZ: n 129 long-term global follow-up mean 2.0 (1.3 SD), discharge 
status mean 1.7 (1.0). 
SA: n 52 long-term global follow-up mean 1.6 (1.3 SD), discharge 
status mean 1.5 (0.9).  
Unspecified psychosis: n92 long-term global follow-up mean 1.2 
(1.1 SD), discharge status mean 1.5 (1.1). 
 
Discharge status: 3 = unchanged; 2=slightly improved; 1=improved; 
0=markedly improved. 
Global long-term follow-up: 0 = recovered, 1 = marked 








PMD: 35/42 had a recurrent course. 









PMD: 35/42 recurrent course, Of the recurrent, 7/35 reported 
episodes of non-delusional depression prior to index episodes but 
none after and 30/35 recurrent cases had only relapses of PMD. 
 
PBP: 10/10 relapsed with recurrent episodes of delusional 
depression, mania and mixed bipolar. 0/10 experienced nonpsychotic 











PMD: Complete remission; 47% at 10 years, 35% at 7.5 years, 41% 
at 4.5 years and 27% at 2 years.  
BP: Complete remission; 41% at 10 years, 38% at 7.5 years, 47% at 
4.5 years and 26% at 2 years.  
NPMD: Complete remission; 63% at 10 years, 63% at 7.5 years, 
49% at 4.5 years and 40% at 2 years.  
 
Good outcome = adequate functioning with minimal or no 









PMD: 50% had a full remission, 20% had a partial remission, 30% 
had new or original disorder (n 2 missing).  
SZ: 13.7% had a full remission, 34.7% had a partial remission, 
51.6% had new or original disorder (n 1 missing).  
BP: 52.4% had a full remission, 17.5% had a partial remission, 









PMD: 50% had a full remission, 20% had a partial admission, 30% 
had no remission.  
SZ: 13.7% had a full remission, 34.7% had a partial admission, 
52.6% had no remission.  
BP: 52.4% had a full remission, 17.5% had a partial admission, 
30.2% had no remission. 
 
Full remission = symptom free for at least 4 weeks (including 
positive and negative symptoms).  
Partial remission = having some symptoms but not meeting criteria 







PMD: 39/54 (72%) had prior depressive episodes, mean 2.5 (2.33) 
prior episodes.  37/39 (95%) with recurrent illness had a previous 
episode of PMD.  
 
NPMD: 50/66 (76%) had prior depressive episodes, mean 2.52 
(1.94) prior episodes 4/50 (8%) with recurrent illness had a previous 




















PMD: 69% relapse at least once, 1.6 mean episodes of depression, 
2.3 mean outcome. 
Retro: 1.6mean previous episodes. 
 
Neurotic depression: 44% relapse at least once, 0.6 mean episodes of 
depression, 3.1 mean outcome. 


























PMD: 2.82 (0.16) mean episodes, 4mths 19 days average duration, 
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free intervals. 
 
NPMD: 3.05 (0.19) mean episodes, 4mths 1 day average duration, 3y 
5m 19d periodicity, 3 years 1 months 18 days duration of illness free 
intervals. 















PMD: 1.1 (1.4 SD) previous episodes, 0/21 (0%) had a spontaneous 
remission within 2 weeks of psychosocial and placebo treatment. 
 
NPMD: 1.9 (1.8 SD) previous episodes, 18/60 (30%) had a 














PMD: Course: remitting 5/38 (13%), intermitting 27/38 (71%), 
chronic 6/38 (16%). 
NPMD: Course: remitting 39/55(71%), intermitting 14/55(25%), 
chronic 2/55(4%).  
Course: 





PMD: Median time to relapse = 2.6 years. 










PMD 3/11 (27%) had single episode.  
PMD recurrent: 7/8 had good recovery, 2.4 mean months of episode. 
PMD single episode: 4.7 mean months of episode.   
 
NPMD 9/39 (23%) had single episode. 
NPMD recurrent: 18/30 had good recovery, 7.1 mean months of 
episode. 
NPMD single episode: 6.4 mean months of episode. 
 
PBP-I: 17/22 had good recovery, 1.1 mean months of episode. 
NPBP-I: 34/44 had good recovery, 4.2 mean months of episode. 
 
PBP-II: 3/4 had good recovery, 2.5 mean months of episode. 




PMD > NPMD 
single episode 










PMD: Mean number of previous episodes was 3.4 (0.3).  22/25 had 
recurrent depression. 3/25 had only 1 episode of depression. Mean 





 episode was 5.33 years. 
 
NPMD: Mean number of previous episodes was 1.4 (0.07).  44/120 
had recurrent depression. 96/140 had only 1 episode of depression. 














NPMD > PMD 
p<0.0001 
 
Only 1 episode 
of depression: 






NPMD > PMD 
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PMD: 9/32 (28%) did not fully recover at all over the follow-up.  
Mean 1.74 (1.3) depressive episodes per patient. 6/32 with a chronic 
course. 9/32 had a major depressive episode by the end of follow-up.  
64 total depressive episodes, 49 psychotic, 15 not psychotic. 
 
NPMD: 6/41 (15%) did not fully recover at all over the follow-up. 
Mean 2.22 (1.06) depressive episodes per patient. 5/41 with a 
chronic course. 12/41 had a major depressive episode by the end of 
follow-up.  
 



















episode by the 
end of follow-












PMD: 17% (6/35) had a clear and persisting remission, 26% (9/35) 
had incomplete remission or relapse, 57% (20/35) had a slight or 
transitory improvement.  
NPMD: 31% (11/35) had a clear and persisting remission, 46% 
(16/35) had incomplete remission or relapse, 23% (8/35) had a slight 








PMD: clinical status over the first year – asymptomatic 22/52, 
chronically ill 15/52, episodically ill 13/52, other/ unknown/dead 
2/52. 
NPMD: clinical status over the first year – asymptomatic 32/52, 
chronically ill 3/52, episodically ill 14/52, other/ unknown/dead 
3/52. 
 
Chronically ill = patient being symptomatic of either psychosis only 
or a major depressive episode with or without delusions continuously 
for 9 months or longer during the follow-up period. 
Episodically ill = episodes of psychosis or major depression lasting 

























PMD mood congruent: Number of episodes at 7 years; NPMD 22, 
37%; PMD congruent 29, 48%; PMD incongruent 4, 7%; other 5, 
8%. 
NPMD: Number of episodes at 7 years; NPMD 47, 80%; PMD 
congruent 8, 13%; PMD incongruent 1, 2%; other 3, 5%. 
 
Frequency   of 
various 
episode types: 




 PMD: 3 episodes. Episodes: 
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1985 
*Angst 86? 
NPMD: 3 episodes. 
PBP: 4.5 episodes. 
NPBP: 4 episodes. 
PMD = NPMD 
 







PMD: 17/46 recovered narrow, 24/46 recovered broad, 32.2 mean 
weeks without depressive symptoms, 36.3 mean weeks with full 
depressive symptoms. 
 
NPMD: 41/159 recovered narrow, 91/159 recovered broad, 20.6 
mean weeks without depressive symptoms, 32.5 mean weeks with 
full depressive symptoms. 
 
Narrow recovered = a minimum of 8 week period with no criteria 
symptoms at all. 
Broader recovered = no more than 1 or 2 symptoms to a mild degree 
for the best 8 week period. 
All outcomes: 






PMD congruent: 31% (24/76) no relapse.  
PMD incongruent: 52% (31/60) no relapse.  
NPMD: 50% (302/604) no relapse.  
NPBP: relapse not reported.  
PBP congruent: relapse not reported.  
PBP incongruent: relapse not reported. 
PMD = NPMD 
 







PMD: Condition at discharge: recovered 34/121, improved 23/121, 
unimproved 64/121, discharged to community 46/121.  
Short term follow-up: 3.4yrs, Recovered 51/108, improved 23/108, 
unimproved 34/108. 
 
NPMD: Condition at discharge: recovered 47/102, improved 18/102, 
unimproved 37/102, discharged to community 63/102.  






































PMD congruent: recovered 46.3%, improved 31.6% 
PMD incongruent: recovered 39.8%, improved 31.8%. 
 
Recovery at 5 year follow-up: 
PMD congruent: 76.5% 
PMD incongruent: 71.4% 
 
2-3 years for non-somatic therapies only: 
NPMD: recovered – 69.2%, improved – 10.3%, unimproved 21.8% 
PMD congruent: recovered – 43.7%, improved – 21.1%, unimproved 
2-3 years for 
non-somatic 
therapies only: 







SZform & SZ 
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35.2% 
PMD incongruent: recovered – 32.6%, improved – 32.6%, 
unimproved 34.9% 
Szform: recovered – 16.6%, improved – 18.8%, unimproved 64.6% 
Sz: recovered – 7.0%, improved – 15.8%, unimproved 77.2% 
 
Recovery defined as returned to premorbid level of functioning and 
had a complete remission of symptoms. 
Improved defined as returned to usual occupation without remission 
or remitted without returning to premorbid functioning 




























PMD: 6mths: 53% recovered from index episode. 
2 years: 75% recovered from index episode. Of the 14/55 patients 
who did not recover by 2 years, 64% had no partial recovery while 
36% did have partial recovery. Of those 41/55 who recovered by 2 
years, 76% had complete recovery, 24% had an incomplete recovery, 
29% had no subsequent episode, 44% had only 1 subsequent episode 
and 7% had more than 1 other episode.  
Median time to recovery = 26.3 weeks. 
 
NPMD: 6mths: 58% recovered from index episode.  
2 years: 83% recovered from index episode. Of the 78/451 patients 
who did not recover by 2 years, 39% had no partial recovery while 
55% did have partial recovery. Of those 373/451 who recovered by 2 
years, 72% had complete recovery, 28% had an incomplete recovery, 
19% had no subsequent episode, 32% had only 1 subsequent episode 
and 13% had more than 1 other episode.  
Median time to recovery = 18.5 weeks.  
 
 
Recovery = a cross sectional judgement – not sustained recovery. 
Recovery at 6 months = minimum 8 consecutive weeks with no more 
than ½ depression symptoms of mild intensity. 
All outcomes: 







PMD: 6/17 (35%) high-moderate, sub threshold or full major 
depressive syndrome was present. 
BP: 9/30 (30%) high-moderate, sub threshold or full major 
depressive syndrome was present. 
NPMD: 24/77 (31%) high-moderate, sub threshold or full major 
depressive syndrome was present. 
PMD = BP 







PMD: follow-up year: 6/31 remitted, 14/31 had subsyndromal 
depression, 11/31 had the full syndrome.  
11/31 had no signs of psychosis, 7/31 had suspected signs of 
psychosis, 13/31 had definite signs of psychosis. 
 
NPMD: follow-up year: 18/63 remitted, 24/63 had subsyndromal 
depression, 21/63 had the full syndrome.  
53/63 had no signs of psychosis, 3/63 had suspected signs of 
psychosis, 7/63 had definite signs of psychosis.  
Depression: 
NPMD = PMD 
 
Psychosis: 












PMD: mean of 102.2 (114.9 SD) weeks in full syndrome. 




NPMD > PMD 
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SAD: 6 months: recovered from depressive syndrome 27.6%, 
recovered from psychosis with insight 27.6%, 62.1% with no partial 
remission.  
12 months: recovered from depressive syndrome 41.4%, recovered 
from psychosis with insight 37.9%, 51.7% with no partial remission.  
 
SABP: 6 months: recovered from depressive syndrome 28.6%, 
recovered from psychosis with insight 64.3%, 42.9% with no partial 
remission. 
12 months: recovered from depressive syndrome 64.3%, recovered 






































SAD: Mean (SD) Levels of functioning scale - Course 2.9 (0.8). 
Duration of illness - 70 months (90 SD). 
SABP: Mean (SD) Levels of functioning scale – Course 2.8 (0.4). 
Duration of illness - 70 months (78 SD). 
SZ: Mean (SD) Levels of functioning scale – Course 3.4 (0.8). 
 
Level of functioning 1 (poor) – 5 (good). 
Levels of 
functioning: 
















SAD: RETROSPECTIVE - Mean duration of illness 7.2 years (5.8), 
mean episodes per year 0.5 years (0.3), 
PROSPECTIVE – 1.3 (1.1) mean morbid episodes, 2.1 (1.9) total 
months morbidity,  
 
SAM: RETROSPECTIVE - Mean duration of illness 9.8 years (3.1), 
mean episodes per year 0.6 years (0.3),  
PROSPECTIVE – 0.9 (1.5) mean morbid episodes, 1.1 (1.4) total 
months morbidity, 0.4 (0.6) mean hospitalisations,  
 
NPMania: RETROSPECTIVE - Mean duration of illness 8.5 years 
(3.8), mean episodes per year 0.5 years (0.2),  
PROSPECTIVE – 0.8 (1.4) mean morbid episodes, 0.8 (1.4) total 
months morbidity, 0.4 (0.6) mean hospitalisations. 
 
NPMD: RETROSPECTIVE - Mean duration of illness 9.6 years 
Duration of 
illness: 












NPMD > SAD 
p<0.05 
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(4.5), mean episodes per year 0.5 years (0.2),  
PROSPECTIVE – 0.8 (0.9) mean morbid episodes, 1.0 (1.2) total 
months morbidity. 
 
SAD vs. SAM 
& NPMania 








SAD: 24% recovered, 10% chronic. 
NPMD: 26% recovered, 14% chronic. 
SABP: 16% recovered, 19% chronic.  
NPBP: 16% recovered, 12% chronic. 
Chronic: 














SAD: 3.36 mean episodes, 3 median episodes. Annual frequency of 
episodes mean 0.13, 0.12 median episodes. Annual frequency of 
cycles mean 0.23, median 0.25. 
 
SABP: 5.46 mean episodes, 6 median episodes. Annual frequency of 
episodes mean 0.26, 0.28 median episodes. Annual frequency of 
cycles mean 0.40, median 0.48. 
Median 
episodes: 



















SAD: Average cycle length mean 35.59 months, median 45.5. 
SABP: Average cycle length mean 22.52 months, median 26.1. 







SAD: Median inactivity period of 19 months. 
SABP: Median inactivity period of 9 months. 
 







SAD: median 3, mean 4.33 (3.41) episodes, annual frequency of 
episodes median 0.12 mean 0.16 (0.11), number of cycles median 2, 
mean 3.87 (3.38), annual frequency of cycles median 0.25 mean 0.34 
(0.32). Average length of cycles median 45.5 mean 74.07 (62.15), 
average length of episode per patient 2.42 median months 2.77 
(2.18) mean months, average length of intervals per patient 43.5 
median months, 69.24 (59.40) mean months.  
 
SABP: median 6, mean 6.88 (4.36) episodes, annual frequency of 
episodes median 0.28 mean 0.35 (0.27), number of cycles median 6, 
mean 6.44 (4.15), annual frequency of cycles median 0.48 mean 0.51 
(0.33). Average length of cycles median 26.07 mean 40.21 (33.49), 
average length of episode per patient 1.75 median months 2.09 
(1.34) mean months, average length of intervals per patient 22.97 





SAD > SABP 
p=0.007 
 
Annual freq of 
episodes:  





SAD > SABP 
p=0.002,  
 
Annual freq of 
cycles: 




of cycles:  
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Average length 
of episode:  











SAD: polyphasic course 42.2%, activity of illness mean 13.3 years 
(11.2 s.d.), inactivity of illness mean 16.6 years (9.3 s.d.).  
NPMD: polyphasic course 46.1%, activity of illness mean 15.9 years 
(12.8 s.d.), inactivity of illness mean 15.6 years (7.1 s.d.)  
SABP: polyphasic course 75.0%, activity of illness mean 15.7 years 
(10.9 s.d.), inactivity of illness mean 11.7 years (7.9 s.d.).  
NPBP: polyphasic course 66.7%, activity of illness mean 15.3 years 
(11.7 s.d.), inactivity of illness mean 12.3 years (6.4 s.d.).  
polyphasic 
course: 























Mood congruent PMD: recovered from psychosis: 10/17 (58.8%) 
Mood incongruent PMD: recovered from psychosis: 4/15 (26.7%) 
SAD: recovered from psychosis: 0/11 (0%) 









PMD > SZ 
 
Combined 
PMD > SAD 
 
Combined 
PMD > SZ  
 








PMD: No depression in follow-up 5/17 (29%).  
SAD: No depression in follow-up 9/31 (29%),  
SZ: No depression in follow-up 17/70 (24%). 
NPMD: No depression in follow-up 25/69 (36%).  
PMD = SAD = 





PMD/SAD mixed  
 
CATEGO 
PMD: 11/16 had persistent depression, 0.89 mean episodes / year, 
3.0 mean schizoaffective episodes, 1.8 mean PMD episodes, 6/16 
with at least 1 schizoaffective episode. 
Neurotic depression: 6/20 had persistent depression, 0.59 mean 
episodes / year, 2.0 mean schizoaffective episodes, 0.7 mean PMD 
episodes, 1/20 with at least 1 schizoaffective episode. 
Retarded depression: 6/18 had persistent depression, 0.38 mean 
episodes / year, 1.1 mean schizoaffective episodes, 0.5 mean PMD 
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PMD: 6/55 failed to recover, 12/55 with at least 1 schizophrenic 
symptom, 4/55 with at least 1 schizophrenic episode, 9/55 with at 
least 1 SA episode. 
SAD: 6/11 failed to recover, 9/11 with at least 1 schizophrenic 
symptom, 9/11 with at least 1 schizophrenic episode, 6/11 with at 
least 1 SA episode. 
 
DSM - combo vs. NPMD 
PMD Mood congruent: 7/11 with at least 1 SA episode, 2/11 failed 
to recover. 
PMD Mood incongruent: 8/14 with at least 1 SA episode, 7/14 failed 
to recover. 



































PMD > SAD 
p<0.01 
 
At least 1 
schizophrenia 
symptoms: 
PMD > SAD 
p<0.001 
 
At least 1 
schizophrenia 
episode:  
PMD > SAD 
p<0.05 
 
At least 1 SA 
episode:  
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*DST 6 month 
study 
Recovered:  
PMD/SAD 18/22 (81.8%) 
Schizophrenia 6/29 (20.7%) 













< means worse than; > means better than; = means equivalent outcomes 
SZ = schizophrenia; BP = bipolar disorder; SA = schizoaffective disorder (general); Szform = 
schizophreniform; NPMD = non-psychotic major depression; NPBP = non-psychotic bipolar disorder; 
PBP = psychotic bipolar disorder; SABP = schizoaffective disorder bipolar type; SAM = schizoaffective 
disorder manic type; NPMania = non-psychotic mania. 
  
4.4.2.3. Mortality and suicidality 
Of the 103 papers identified for this review, 35 had data on a mortality or suicidality 
related outcome. Twenty papers reported on mortality, 18 on completed suicide, 12 on 
suicide attempts and 3 on suicidal ideation. Of the 35 papers, 28 were on PMD, 4 were 
on SAD, 2 were on PMD and SAD and 1 was on PMD/SAD mixed together.  
 
4.4.2.3.1. Mortality 
Of the 19 papers which reported on mortality (presented in Table 4-6) only 18 contained 
useable data. One paper combined PMD and SAD cases into the same group making 
interpretation of the findings difficult but also provided no comparison groups.  
 
Of the remaining 17 papers, only three report on PMD and schizophrenia cases within 
the same study. Two of these are long-term studies and both report a higher percentage 
of PMD cases died over the follow-up (43-78% versus 42%;
323
 and 34% versus 19%
258
). 
The one paper which reports similar death rates (10% in each group) was based on only 
a one year follow-up study.
1
 One study reports on deaths in SAD and schizophrenia 
cases, and reports 67% of SAD cases were dead at 28-32 year follow-up compared with 
 141 
19% of schizophrenia cases.
258
 Although none of these studies compare the groups 
statistically, the findings indicate that over the long-term, death rates may be higher in 
PMD and SAD cases compared with schizophrenia cases. 
 
Four papers reported on PMD and bipolar cases within the same study. Three of these 
papers indicated that PMD cases had more deaths compared with bipolar cases even 
though one study was only a two year follow-up (10-20% versus 3-6%
210
) and the other 
two were long term follow-ups (0-14 years (11% versus 6-8%)
209
 and 10 year (8% 
versus 3%)
230
). The fourth study had overlapping percentages of deaths (12-15% in 
PMD versus 5-18% in bipolar disorder). None of these studies compared PMD and 
bipolar statistically but the trend from these studies indicate that PMD cases may have 
higher death rates compared with bipolar cases. One study reported on deaths in SAD 
and bipolar cases and reports 63% of SAD cases were dead at 28-32 year follow-up 
compared with 70% of bipolar cases.
324
 Again, this difference was not statistically 
tested. 
 
Within these studies on mortality, there were two papers based on incidence studies
1, 197
 
but these do not report on long-term mortality. There are 10 long-term studies, but none 
of these are incidence studies. This indicates a need for long-term incidence studies. 
 
Based on the trends discussed above, from the current literature, it was hypothesized 
that PMD and SAD cases would have a higher proportion of cases who die (from all 
causes) over the follow-up period compared with schizophrenia and bipolar cases. 
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Table 4-6: Mortality 
Paper Time 
period 
PMD SAD PMD /SAD 
mixed 











































































4.2 years 2.48 RRR   0.83-1.17 
RRR 
   None 
Coryell
330




PMD SAD PMD /SAD 
mixed 



















































Overall = p<0.01 
 





*DST 6 month study 
17 years   24%     None 
SZ = schizophrenia; BP = bipolar disorder; SA = schizoaffective disorder (general); Szform = schizophreniform; NPMD = non-psychotic major depression; SAM = schizoaffective 
disorder manic type; n/s = non significant.
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4.4.2.3.2. Completed suicides 
Eighteen papers reported on completed suicide, 17 of which had useable data. Table 4-7 
shows the findings from the 17 papers that report on completed suicides. Only two 
studies report on completed suicide in schizophrenia and PMD cases within the same 
study.
190, 200
 Both studies report that more PMD cases had a completed suicide 
compared with schizophrenia cases (6/39 PMD cases versus 4/39 cases;
190
 18% versus 
8%
200
). However, one study did not conduct statistical tests on the PMD-schizophrenia 
comparison and the other found no differences between the groups. Although both of 
these papers are based on long-term studies, neither of them are based on incidence 
samples. No papers reported on SAD and schizophrenia cases. Although not statistically 
significant or not statistically tested, the evidence indicates that completed suicide may 
be higher in PMD cases (and SAD cases as PMD and SAD is similar in terms of 
symptoms) compared with schizophrenia cases. 
 
Six papers reported on PMD and bipolar disorder
190, 200, 209, 210, 230, 332
 and all except 
one
190
 report that PMD cases has higher percentages of completed suicides.
200, 209, 210, 230, 
333
 However, all of these studies either reported no statistical difference between PMD 
and bipolar disorder or did not report any statistics. Only one study reported on SAD 
cases compared with bipolar cases. This paper reported that 8% of cases completed 
suicide over a 27 year follow-up compared with 7% in bipolar cases (no statistical tests 
were conducted).
334
 Although not statistically significant, or even tested in some cases, 
the evidence indicates a trend that completed suicide may be higher in PMD and SAD 
cases compared with bipolar cases. 
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Table 4-7: Completed suicides 
Paper Time period PMD SAD PMD/SAD 
mixed 










Time scale not 
reported 































































retrospective 5.3 OR 
 
raw 
  1 OR 
 
raw numbers: 
raw numbers: 4/39 raw numbers: 
8/39 





Paper Time period PMD SAD PMD/SAD 
mixed 
NPMD Schizophrenia BP Other Statistical tests 
numbers: 
6/39 





















*Angst & Preisig 
1995 papers 





*DST 6 month study 
17 years   7%    No comparison - 
SZ = schizophrenia; BP = bipolar disorder; SA = schizoaffective disorder (general); Szform = schizophreniform; NPMD = non-psychotic major depression; SABP = schizoaffective 
disorder bipolar type; n/s = non significant.
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4.4.2.3.3. Suicide attempts 
Suicide attempts were reported in 12 papers but only 11 had useable data (see Table 
4-8). There was very little research on suicide attempts comparing PMD cases to 
schizophrenia and bipolar disorder cases and no data on SAD cases. There were also no 
incidence based studies and only one long-term study, the others being based on short-
medium term studies or retrospective case reviews. Only one paper reported on PMD 
and schizophrenia within the same study: Radomsky et al.
188
 examined attempted 
suicide rates in PMD compared with schizophrenia, schizoaffective disorder general and 
other psychoses. They reported that 42% of PMD cases had attempted suicide in their 
lifetime compared with 27% of schizophrenia cases (however, this was not tested 
statistically).
188
 Therefore, it was hypothesized that PMD cases would be more likely to 
attempt suicide compared with schizophrenia cases. 
 
Two papers compared attempted suicide rates for PMD with bipolar disorder. Winokur 
et al.
210
 reported 3-4% of PMD cases compared with 1-10% of bipolar cases attempted 
suicide over a 2 year follow-up. Radomsky et al.
188
 in their review of case notes 
reported that 42% of PMD cases and only 26% of bipolar cases had ever attempted 
suicide in their lifetime. However, neither result was statistically tested. The difference 
in findings could be due here to data collection differences (retrospective case notes 
review versus prospective study) or the follow-up time difference (retrospective versus 
2 year follow-up). However, based on the hypotheses from section 4.4.2.3.2, that PMD 
cases are more likely to complete suicide than bipolar cases, it was hypothesized that 
PMD cases are more likely to attempt suicide compared with bipolar cases. 
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Table 4-8: Suicide attempts 































































retro 42%    27% 26% SA 43% 
Other 25% 
None 
SZ = schizophrenia; BP = bipolar disorder; SA = schizoaffective disorder (general); NPMD = non-psychotic major depression; n/s = non significant.
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4.4.2.3.4.  Self-harm 
Only one paper reported on self-harm in PMD or SAD cases.
1
 This paper reported that 
33% of PMD cases self-harmed compared with 18% of schizophrenia cases (p<0.01).
1
 
This study was a one year follow-up of an incidence sample. Therefore longer term 
studies are needed to examine the long term outcomes for PMD cases in terms of self-
harm. However, based on this single study, it was hypothesized that PMD and SAD 
cases (due to the similarity between the diagnoses) would be more likely to self-harm 
compared with schizophrenia and bipolar cases. 
 
4.4.2.4. Psychosocial functioning 
Of the 103 papers identified for this review, 30 had data on psychosocial outcomes. Of 
these, 14 were on PMD, 9 were on SAD, 5 were on PMD and SAD and 2 were on 
PMD/SAD mixed. The papers on psychosocial outcomes report on a wide range of 
outcomes: social network and relationship related outcomes (e.g. social status, marital 
status, living situation, social functioning / contacts, autarky); employment related 
outcomes (e.g. employment, activities and financial dependence); psychologically 
related outcomes (e.g. satisfaction, motivation, self-harming); disability and major 
illness; and overall functioning (e.g. Global Assessment of Functioning, Global 
Assessment Scale). Within this review, the following areas have been focussed on as 
they will be the focussed on in the results of the thesis due to available data: 
employment; relationship status; social contacts; and prison time. 
 
4.4.2.4.1. Employment outcomes 
Seventeen papers reported on occupation related papers (these are author defined; Table 
4-9). Of the eight papers which examined PMD, five compared it to schizophrenia. All 
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five papers reported that PMD groups had better employment outcomes compared with 
schizophrenia groups,
180, 227, 258, 259, 262
 and this was a statistical difference in five out of 
the seven comparisons
180, 258, 259, 262
 (one was not compared statistically
227
 and one had 
no difference
262
). Four papers compared SAD to schizophrenia, all of which found SAD 
cases to have better outcomes compared with schizophrenia cases.
239, 258, 259, 262
 
However, this was a statistical difference in only one out of the four comparisons
258
 as 
one study did not compare the groups statistically
239
 and two others found no statistical 




Only two studies compared PMD cases with bipolar disorder cases. One of these papers 
reported that 75% of PMD cases did not work for three out of the six month follow-up 
compared with 71% of bipolar cases but this was not statistically compared.
227
 The 
other study only reported on work satisfaction rather than actual employment 
outcomes.
223
 There were no studies comparing SAD to bipolar disorder. 
 
Based on the literature discussed above, it was hypothesized that PMD and SAD cases 
would have a higher proportion of cases who were employed over follow-up compared 
with schizophrenia cases. 
 










Schizophrenia (n): Occupational level 1 (n11, 26%); 
2 (n20, 48%); 3 (n4, 10%); 4 (n4, 10%); 5 (n3, 7%).  
Average 2.2. (no standard deviations) 
SA melancholic (n): Occupational level 1 (n10, 
83%); 2 (n2, 17%); 3 (n0); 4 (n0); 5 (n0). Average 
1.2. (no standard deviations) 
SAD/PMD mixed (n): Occupational level 1 (n4, 
33%); 2 (n3, 25%); 3 (n4, 33%); 4 (n1, 8%); 5 (n0). 
Average 2.2. (no standard deviations) 
SA manic congruent (n): Occupational level 1 (n4, 
57%); 2 (n3, 43%); 3 (n0); 4 (n0); 5 (n0). Average 
1.4. (no standard deviations) 








30%); 2 (n4, 40%); 3 (n2, 20%); 4 (n1, 1%); 5 (n0). 
Average 2.1. (no standard deviations) 
NPMD (n): Occupational level 1 (n19, 66%); 2 (n7, 
24%); 3 (n2, 7%); 4 (n1, 3%); 5 (n0). Average 1.5. 
(no standard deviations) 
NPBP (n): Occupational level 1 (n12, 57%); 2 (n7, 
33); 3 (n1, 5%); 4 (n1, 5%); 5 (n0). Average 1.6. (no 
standard deviations) 
 
The paper reports p<0.01 but it is unclear between 
which diagnostic comparisons the differences lie. 
 







PMD: 75% did not work for more than 3 months out 
of 6 in follow-up. 
BP: 71% did not work for more than 3 months out of 
6 in follow-up. 
SZ: 87.4% did not work for more than 3 months out 
of 6 in follow-up,  
 








PMD mood congruent: Mean DAS; household acts 
1.0 (0.6SD); work performance 0.8 (0.8 SD). 
NPMD: Mean DAS; household acts 1.1 (0.5 SD); 
work performance 0.9 (0.7 SD). 
  








PMD: 31.2 mean employment score. 
SAD: 43.0 mean employment score. 
 
Higher scores indicate poorer adjustment. 
Employment score: 






SAD: 69.0% missed more than 5 weeks of work due 
to psychopathology.  
SABP: 64.3% missed more than 5 weeks of work due 
to psychopathology.  
Missed work: 






Study for the Affective 
Disorders 
PMD: 9/32 (28%) had mild-severe work impairment 
at 2 yrs. 
NPMD: 99/325 (30%) had mild-severe work 
impairment at 2 yrs. 
 
Work impairment: 





PMD: 78.9% in regular employment. 
NPMD: 78.1% in regular employment.  
SZ: Mean: 46.9% in regular employment. 
 
Regular employment:  
NPMD = PMD 
p=0.945 





PMD: 27.4% welfare or disability.  
NPMD: 11.2% welfare or disability.  
Welfare or disability:  






SAD: Mean (SD) Levels of functioning scale – 
quantity of useful work 3.3 (1.5), quality of useful 
work 2.9 (1.2). 
Affective illness: Mean (SD) Levels of functioning 
scale – quantity of useful work 3.7 (1.3), quality of 
useful work 3.5 (1.0). 
SABP: Mean (SD) Levels of functioning scale –
quantity of useful work 2.8 (1.1), quality of useful 
work 3.0 (1.1). 
SZ: Mean (SD) Levels of functioning scale –quantity 
of useful work 1.9 (1.1), quality of useful work 2.0 
Unclear between 



















SAD: Occupational drift: down 24%, 9/37, none 76% 
28/37. Premature retirement: 5/22 23%.  
SABP: Occupational drift: down 38%, 13/34, none 
62% 21/34. Premature retirement: 8/27 30%.  
 
GAS: Higher score indicates better adjustment 
Occupational drift, 
down: SABP = SAD 
p=0.2054 
 
Premature retirement:  









SAD: Downward occupational drift 29%, premature 
retirement 19.4%.  
 
NPMD: Downward occupational drift 29%, 
premature retirement 25.8%. 
 
SABP: Downward occupational drift (20/38) 52.6%, 
premature retirement (12/38) 31.6%.  
 
Downward 
occupational drift:  





















PMD: mean employment score 3.5 (0.9), employed 
or receiving pension 69%. 
SAD: mean employment score 2.7 (1.4), employed or 
receiving pension 46%. 
SZ: mean employment score 1.3 (1.5), employed or 
receiving pension 20%. 
 
Employment: higher score indicates better 
adjustment. 
Employment score:  
PMD > SZ 
p<0.001 
SAD > SZ 
p<0.01 




receiving pension:  
PMD > SZ 
p<0.001 
SAD > SZ 
p<0.05 








Mean Life satisfaction at 7-8 years, work 2.0 (0.8 
SD), economic 2.9 (1.3 SD). 
4.5 years, work 2.3 (1.0 SD), economic 2.7 (1.2 SD). 
2 years, work 2.3 (1.2 SD), economic 2.8 (1.3 SD). 
 
NPMD:  
Mean Life satisfaction at 7-8 years, work 2.1 (0.9 
SD), economic 2.6 (1.2 SD). 
4.5 years, work 2.2 (1.2 SD), economic 2.6 (1.4 SD). 
2 years, work 2.5 (1.2 SD), economic 2.7 (1.4 SD). 
Paper reports no sig differences in any life 
satisfaction domains across diagnostic groups. 
 
BP:  
Mean Life satisfaction at 7-8 years, work 2.3 (1.0 
SD), economic 2.5 (1.3 SD). 
4.5 years, work 2.2 (1.1 SD), economic 3.0 (1.6 SD). 
2 years, work 1.8 (1.1 SD), economic 3.0 (1.7 SD). 
  
All time points 
Work: NPMD = PMD 
= BP 
 
Economic: PMD = 
















PMD: Employment - FT 40%, PT/some 60%, none 
0% (0/10). Activity (non- work) level – active 40%, 
marginal 50%, none 10% (1/10).  
SAD: Employment - FT 24%, PT/some 41%, none 
35%. Activity (non-work) level – active 35%, 
marginal 47%, none 18%.  
NPMD: Employment - FT 56%, PT/some 27%, none 
18% (6/34). Activity (non-work) level – active 71%, 
marginal 18%, none 12% (4/34).  
SZ: Employment - FT 14%, PT/some 20%, none 
66%. Activity (non-work) level – active 36%, 
marginal 37%, none 37%.  
 
Employment:  NPMD 
= PMD 
Activity: NPMD = 
PMD 
 
Employment: PMD > 
SZ 
p<0.05 
Activity: SZ = PMD 
 
Employment, none: 
NPMD > SAD 
p<0.05 
Activity, none: SAD 
= NPMD  
 
Employment: SZ = 
SAD 
Activity: SZ = SAD 
 
Employment, none: 
SAD = PMD 






Mood congruent PMD:  
SCS: employment score – mean 2.7, S.D 1.7 
Mood incongruent PMD: 
SCS: employment score – mean 2.9, S.D 1.6 
SAD:  
SCS: employment score – mean 1.4, S.D 1.6 
Schizophrenia: 
SCS: employment score – mean 1.1, S.D 1.4 
 
Strauss carpenter (SCS): higher score indicates better 
adjustment. 
Employment scores:  
Mood congruent & 
mood incongruent 
PMD groups > SZ 
p=0.0004 
 
SZ = SAD 
 
Mood congruent 
PMD & Mood 







*DST 6 month study 
PMD/SAD: Mean SADS occupational functioning in 
the past year (SD): 3.3 (3.4). 
 
Schizophrenia: Mean SADS occupational functioning 
in the past year (SD): 7.2 (3.2). 
 
Unstable diagnoses group: Mean SADS occupational 
functioning in the past year (SD): 3.8 (2.8). 
 
SADS occupational functioning: 1=no time out of 
work, 9=worked none due to psychopathology. 
Occupational 
functioning: 












4.4.2.4.2. Relationship status 
Only three papers reported on relationship status in PMD or SAD cases (Table 4-10). 
Only one of these papers compared PMD cases with schizophrenia cases. This paper 
reported that 61% of PMD cases were in a stable relationship at the end of a 15 year 
historical follow-up compared with 23% of schizophrenia cases (p=0.002).
180
 No 
studies compared SAD cases with schizophrenia cases, or PMD or SAD cases with 
bipolar cases.  
 
Based on this very limited literature, it was hypothesized that PMD and SAD cases 
would have a higher proportion of cases who were in a relationship over follow-up 
compared with schizophrenia cases. 
 










Study for the Affective 
Disorders 
PMD: 9% married at intake were divorced at 
follow-up. 56% had fair-very poor friendships at 
2yrs. 
 
NPMD: 9% married at intake were divorced at 
follow-up. 46% had fair-very poor friendships at 
2yrs.  
 
Divorced: PMD = 
NPMD 
 







PMD: 61.1% in stable relationship. 
NPMD: 66.7% in stable relationship. 
SZ: 23.4% in stable relationship. 
 
Stable relationship:  
PMD = NPMD 
 







SAD: 64% ever married. N33 
SAM: 42% ever married. N19 
SABP: 56% ever married. N 16 
Ever married:  
SAM = SAD 
SABP = SAD 
< means worse than; > means better than; = means equivalent outcomes 
 
4.4.2.4.3. Social contact 
Nine papers reported on social contact (see Table 4-11). Four papers reported on PMD 
and schizophrenia cases. Two papers reported PMD cases to have better scores on social 
contacts compared with schizophrenia cases,
258, 259




 the other found no statistical difference.
259
 Craig et al.
348
 
reported PMD cases to have lower (and therefore worse) scores on social outcomes 
compared with schizophrenia cases (mean 2.34 (1.37 S.D.) versus 2.89 (1.42 S.D.)) but 
this comparison was not statistically tested. Sands et al.
262
 reported that less PMD cases 
had adequate social functioning (40% versus 49%) but the same amount had 
impoverished functioning (20% versus 20%) but there were no significant difference 
between the groups. Four papers reported on SAD and schizophrenia cases. All four 
papers reported SAD had better social contact outcomes (frequency / quality / social 
functioning / social contact scores) compared with schizophrenia.
239, 258, 259, 262
 Only one 
reported the differences to be statistically different,
258
 the others reported no statistical 
difference.
239, 259, 262
 Within this thesis, data was available on a type of social contact 
outcomes: close confidants. However, no study reported on close confidants in PMD 
and SAD cases. Therefore, based on the literature above, it was hypothesized that PMD 
and SAD cases would have a higher proportion of cases who have close confidants 
compared with schizophrenia cases. 
 
While no papers examined social contacts in SAD and bipolar cases, two papers 
reported on social contacts in PMD and bipolar cases within the same sample. However, 
one of these only reported on satisfaction with social contacts.
223
 The other paper by 
Craig et al.
349
 reported PMD cases to have lower (and therefore worse) scores on social 
outcomes compared with bipolar cases (mean 2.34 (1.37 S.D.) versus 4.19 (1.39 S.D.)) 
but this comparison was not statistically tested. Based on this very limited literature, the 















PMD (n42): social mean 2.34 (1.37 SD). 
BP (n64): social mean 4.19 (1.39 SD). 
SZ (n96): social mean 2.89 (1.42 SD). 
 
All p<0.001 but unclear between which diagnoses. 
 









PMD mood congruent: Mean DAS; social 
withdrawal 0.4 (0.6 SD); social contacts 0.7 (0.5 
SD). 
 
NPMD: Mean DAS; social withdrawal 0.4 (0.4 
SD); social contacts 0.6 (0.6 SD) 
 









PMD: 33.9 mean social involvement score.  
SAD: 47.9 mean social involvement score. 
 
Social: higher scores indicate poorer adjustment. 
Social involvement: 






SAD: 48.3% impaired social functioning.  
SABP: 14.3% impaired social functioning. 
Impaired social 
functioning: 









PMD: Social functioning – adequate 40%, 
restricted 40%, impoverished 20%.  
 
SAD: Social functioning – adequate 59%, 
restricted 24%, impoverished 18%.  
 
NPMD: Social functioning – adequate 56%, 
restricted 24%, impoverished 21%   
 
SZ: Social functioning – adequate 49%, restricted 
31%, impoverished 20%.  
 
No significant differences in social functioning 
Social functioning:  









Mean Life satisfaction at 7-8 years, social 2.6 (1.4 
SD). 
4.5 years, social 2.4 (1.3 SD). 
2 years, social 2.8 (1.4 SD).  
 
NPMD:  
Mean Life satisfaction at 7-8 years, social 2.7 (1.3 
SD). 
4.5 years, social 2.8 (1.2 SD). 
2 years, social 2.7 (1.3 SD).  
 
BP:  
Mean Life satisfaction at 7-8 years, social 2.7 (1.2 
SD). 
4.5 years, social 2.9 (1.3 SD). 
2 years, social 2.9 (1.4 SD).  
 
No sig differences in any life satisfaction domains 
across diagnostic groups. 
All time points: 
 
Social: NPMD = PMD 
=BP 
 
Living: PMD = 















SAD: Mean (SD) Levels of functioning scale –
Frequency of social contacts 2.8 (1.3), quality of 
social relations 2.3 (1.1). 
 
Affective illness: Mean (SD) Levels of functioning 
scale –Frequency of social contacts 4.2 (1.3), 
quality of social relations 3.7 (1.2). 
 
SABP: Mean (SD) Levels of functioning scale –
Frequency of social contacts 3.5 (1.6), quality of 
social relations 3.0 (1.5). 
 
SZ: Mean (SD) Levels of functioning scale –
Frequency of social contacts 2.2 (1.4), quality of 
social relations 1.6 (0.8). 
 
Levels of functioning: higher score indicates better 
adjustment. 
SAD not statistically 
compared with 




SAD = SABP 
 
Quality of social 
relations: 
SAD = SABP 
 
Ability to meet own 
needs: 







PMD: mean social contact score 2.5 (1.4). 
SAD: mean social contact score 1.7 (1.6). 
SZ: mean social contact score 0.8 (1.3). 
 
Social scores: higher score indicates better 
adjustment. 
Social contacts:  
PMD > SZ 
p<0.001 
 
SAD > SZ 
p<0.01 
 






Mood congruent PMD: 
SCS: social contacts score – mean 2.6, S.D 1.3 
 
Mood incongruent PMD: 
SCS: social contacts score – mean 2.7, S.D 1.6 
 
SAD:  
SCS: social contacts score – mean 2.5, S.D 1.3 
 
Schizophrenia: 
SCS: social contacts score – mean 2.3, S.D 1.4 
 
Strauss carpenter (SCS): higher score indicates 
better adjustment. 
Social contacts:  
Mood congruent & 
mood incongruent 
PMD groups = SZ  
 
SZ = SAD 
 
SAD = Mood 





No papers reported on outcomes involving prison with PMD or SAD cases. However, in 
line with the findings reported above that PMD cases seem to have better psychosocial 
outcomes in other areas, it was hypothesized that PMD and SAD cases would have a 
lower proportion of cases who had been to prison compared with schizophrenia cases. 
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4.4.2.5. Service use 
Of the 103 papers identified for this review, 35 of them had data on service use. Of 
these, 27 were on PMD, 4 were on SAD, 3 were on PMD and SAD and 1 was on 
PMD/SAD mixed. The papers on service use were focused mainly on inpatient service 
use (readmissions, time as an inpatient, continuously hospitalised etc) but there were 
also a number of papers which reported on other outcomes: outpatient events (mean 
time with service, proportion of groups using service); emergency room use; treatment 
(ECT, medication); follow-up service use status; and course of service use (e.g. one 
contact with services, continuous contact with services). However, the majority (28 out 
of 35) of the papers examined inpatient use. The finding that inpatient usage is the most 
researched area of service use is likely to be a reflection of the fact that inpatient use is 
generally the biggest cost driver.
352
 Due to the dominance of literature on inpatient use, 
only inpatient use will be examined in this review. 
 
4.4.2.5.1. Inpatient service use  
Twenty-eight papers reported on inpatient service use. Nine of these papers reported on 
PMD and schizophrenia cases. Six of the nine papers report that PMD cases had better 
inpatient outcomes compared with schizophrenia cases (less rehospitalisations, lower 
scores on hospital outcomes, continuous hospitalisations).
180, 227, 229, 259, 262, 353
 However, 
three papers report PMD cases to have worse inpatient outcomes compared with 




Four papers examined SAD and schizophrenia cases in the same study. Three reported 
that the inpatient outcomes were better in SAD cases (in terms of less hospitalisations, 
lower hospitalisation scores and less time in hospital)
259, 262, 355
 compared with 




 and the other was not tested
356
). Only one study reported that SAD 
cases had better outcomes compared with schizophrenia cases. This was a 3-39 year 
follow-up of first admission patients by Opjordsmoen et al.
258
 They reported that 3.4 
mean hospitalisations (1.0 S.D.) in SAD cases compared with 2.4 in schizophrenia cases 
(1.5 S.D.; p<0.05).  This literature shows a slight trend towards SAD having better 
inpatient outcomes. 
 
Four studies reported on PMD and bipolar cases within the same study with very mixed 
results. One paper by Bromet et al.
227
 reported PMD cases to have worse inpatient 
outcomes with 20.5 % of PMD cases being rehospitalised or never discharged in a six 
month follow-up compared with 17.7 % of bipolar cases being rehospitalised or never 
discharged. This result was not statistically significant. In a 6 month follow-up, Craig et 
al.
357
 reported mixed results with less PMD cases being continuously hospitalised (0% 
versus 2%; not statistically tested) but more PMD cases being rehospitalised (20.5% 
versus 17.7%; not statistically different) compared with bipolar cases. A related paper 
by Craig et al.
229
 based on the same sample reported on a two year follow-up and 
reported less PMD were rehospitalised compared with bipolar cases (29% versus 33%). 
A further paper by Winokur et al.
358
 reported PMD cases to have less average 
hospitalisations compared with bipolar cases (3 versus 4) although this was not 
statistically significant. Only one paper reported on SAD and bipolar. Angst et al.
359
 
reported that 73% of SAD episodes involved hospitalisations but this was compared 
with a non-psychotic bipolar disorder group who had 56% of episodes involving 
hospitalisations. 
 
Based on this literature it was hypothesized that PMD and SAD cases would have better 
service use outcomes compared with schizophrenia cases. In this thesis the service use 
 160 
outcomes were proportion of cases admitted, number of hospitalisations, days 
hospitalised, percentage of the follow-up spent as an inpatient, percentage of 
compulsory admissions, proportion of cases being compulsorily admitted and 
percentage of hospitalisations involving the police. Therefore, the specific hypothesises 
were that PMD and SAD cases would have: a lower proportion of cases admitted; less 
hospitalisations; less days hospitalised; a lower percentage of the follow-up spent as an 
inpatient; a lower percentage of compulsory admissions; a lower proportion of cases 
being compulsorily admitted; and a lower percentage of hospitalisations involving the 
police, all compared with schizophrenia. 
 
Table 4-12: Inpatient Service Use 























SAD:  mean 20.3% time in hospital. (+/- 15.2, n75) 
SZ:  mean 36% time in hospital. (missing s.d., 53) 
PMD & PBP: mean 17% time in hospital. (missing s.d., n66) 
 
No statistics in the 










PMD: 22/75 (29%) rehospitalised.  
Sz/SA: 83/155 (54%) rehospitalised.  
PBP: 39/119 (33%) rehospitalised.   





PMD: 81/105 (77%) patients admitted.  
SZ: 47/73 (64%) patients admitted.  





PMD: 57.3% (731/1275) were readmitted. 
Severe depression without psychotic symptoms: 54.2% 
(888/1639) were readmitted.  
Mild/moderate depression without melancholia: 48.5% (142/293) 
were readmitted. 
Mild/moderate depression with melancholia: 49.2% (122/248) 






PMD: time in hospital in follow-up mean 0.5 (0.7 SD), months 
hospitalises mean 6.6 (5.1 SD). 
SZ:  time in hospital in follow-up mean 1.6 (1.6 SD), months 
hospitalises mean 5.1 (4.2 SD).  
SA: time in hospital in follow-up mean 1.3 (1.4 SD), months 
hospitalises mean 6.0 (6.8 SD). 
Unspecified psychosis: time in hospital in follow-up mean 0.8 
(1.1 SD), months hospitalises mean 5.2 (5.7 SD). 
 
Proportion of time hospitalised during follow-up: 1 = </= 10%, 2 








SAD: Episodes with hospitalisations = 73% (77/106) 
NPMD: Episodes with hospitalisations = 61% (84/137) 





Reference Finding Comparisons 
Preisig 1995 
papers 







PMD: 20.5 % rehospitalised or never discharged.  
SZ: 24.5 % rehospitalised or never discharged.  
BP: 17.7 % rehospitalised or never discharged.   
PMD = BP 





PMD: 2.54 (1.78) prior hospitalisations.  
NPMD: 2.17 (1.66) prior hospitalisations. 
 





PMD: 1.5 mean readmissions due to depression, 0-2.5 years – 
mean 13 weeks as inpatient, total hospital surveillance 60 weeks, 
2.5-5 years – mean 7 weeks an inpatient), total hospital 
surveillance 31 weeks. Hospital surveillance mean 91 weeks. 
Immediate outcome = 10 weeks in hospital. 
 
Neurotic depression: 0.2 mean readmissions due to depression, 0-
2.5 years – mean 1.3 weeks as an inpatient, total hospital 
surveillance 16 weeks, 2.5-5 years - mean 0.3 weeks as an 
inpatient, total hospital surveillance 1.9 weeks. Hospital 
surveillance mean 18 weeks. 
Immediate outcome = 8 weeks in hospital.  
Mean 
readmissions: 
NPMD > PMD 
p<0.02 
 
2.5 year mean 
inpatient weeks:  
NPMD > PMD 
p<0.01 
 
2.5 year hospital 
surveillance:  
NPMD > PMD 
P<0.001 
 
5 year mean 
inpatient weeks: 
PMD = NPMD 
 
Total 5 year 
hospital 
surveillance:  
















PMD: - 16/46 (35%) rehospitalised 














PMD: Of the 46 hospitalised at intake, 26% (12/46) were 
rehospitalised only once, 9% (4/46) twice and 13% (6/46) more 
than twice. N46 
NPMD: Of the 318 hospitalised at intake, 21% (67/318) were 
rehospitalised only once, 10% (32/318) twice and 11% (35/318) 
more than twice. N318  
 
Rehospitalised 








more than twice: 







PMD: 0/42 (0%) continuously hospitalised. 20.5% rehospitalised. 
SZ: 4/96 (4%) continuously hospitalised. 23.4% rehospitalised. 







Reference Finding Comparisons 
Rehospitalised:  
PMD = BP 





PMD: 54.3 inpatient days required. 
NPMD: 39.8 inpatient days required. 
Inpatient days: 






PMD: mean 2.8 rehospitalisations.  
NPMD: mean 1.3 rehospitalisations. 
SZ: mean 2.9 rehospitalisations.  
 
Rehospitalisations  
SZ = PMD 
 






PMD: 0 new hospitalisations, 10.9% medical hospitalisations. 













PMD: mean 1.75 (0.91) hospitalisations.  
NPMD: mean 1.32 (0.62) hospitalisations.  





PMD: Retrospective: 3.9 mean prior hospitalisations. 
NPMD: Retrospective: 2.7 mean prior hospitalisations. 
Depression with preoccupations: Retrospective: 3.3 mean prior 
hospitalisations. 
Hospitalisations: 











PMD: 91% (32/35) were admitted. 
NPMD: 66% (23/35) were admitted. 
 
PMD: 48% (17/35) were readmitted. 
NPMD: 26% (9/35) were readmitted. 
Admitted: 









PMD: patients hospitalised 11/52, total number of 
hospitalisations 18. 




PMD = NPMD 
 
Hospitalisations: 






PMD: 3 hospitalisations 
NPMD: 2 hospitalisations 
PBP: 4 hospitalisations 
NPBP: 2 hospitalisations 
PMD = NPMD 
 
PMD vs. PBP vs. 









SAD: RETROSPECTIVE - mean hospitalisations 1.8 mean (1.3).  
PROSPECTIVE –0.6 (0.7) mean hospitalisations, 0.8 (0.9) mean 
months in hospital. 
SAM: RETROSPECTIVE - mean hospitalisations 1.8 mean 
(1.4). 
PROSPECTIVE – 0.4 (0.6) mean hospitalisations, 0.4 (0.5) mean 
months in hospital.  
Non-psychotic Mania: RETROSPECTIVE - mean 
hospitalisations 1.9 mean (0.9).  
PROSPECTIVE –0.4 (0.6) mean hospitalisations, 0.3 (0.4) mean 
months in hospital. 
NPMD: RETROSPECTIVE - mean hospitalisations 2.2 mean 
(1.0). 
PROSPECTIVE –0.5 (0.6) mean hospitalisations, 0.5 (0.9) mean 
months in hospital. 
Retrospective: 
Hospitalisations:  


















SAD: Length of stay at Chestnut Lodge 39 months 
SAM: Length of stay at Chestnut Lodge 37 months 
SABP: Length of stay at Chestnut Lodge 69 months 
Length of stay: 
SAD = SABP 
SAD = SAM 
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Mood congruent PMD:  SCS: Hospitalisation score - mean 3.3, 
S.D 1.3 n17 
Mood incongruent PMD: SCS: Hospitalisation score - mean 3.3, 
S.D 1.4 n 15 
SAD: SCS: Hospitalisation score - mean 3.0, S.D 1.2 n 11 
Schizophrenia:  SCS: Hospitalisation score - mean 2.7, S.D 1.5 
n22 
 
Strauss carpenter (SCS): higher score indicates better adjustment. 
Hospitalisation 
score:  
SZ = SAD = 
Mood congruent 







SAD: Mean hospitalisations 3.4 (1.0),  
PMD: Mean hospitalisations 3.8 (0.5),  
SZ: Mean hospitalisations 2.4 (1.5),   
Mean 
hospitalisations: 
SAD > PMD 
p < 0.05 
 
SZ > PMD 
p < 0.05 
 
SZ > SAD 








PMD: Rehospitalisations – None 90%, Less than 3 months 10%, 
3 months + 0%. 
SAD: Rehospitalisations – None 76%, Less than 3 months 29%, 
3 months + 0%. 
SZ: Rehospitalisations – None 49%, Less than 3 months 40%, 3 
months + 11%.  
NPMD: Rehospitalisations – None 73%, Less than 3 months 
27%, 3 months + 0%. 
Rehospitalisations: 
PMD = SAD 
PMD = SZ 
PMD = NPMD 
SAD = SZ 






PMD: 16.8% mean time spent in hospital. 
SAD: 10.0% mean time spent in hospital. 
 
DSM 
PMD Mood congruent: 15.3% mean time spent in hospital. 
PMD Mood incongruent: 11.4% mean time spent in hospital. 
NPMD: 17.1% mean time spent in hospital. 
 
Catego:  
PMD: 15/16 (94%) readmitted. 
Neurotic depression: 9/20 (45%) readmitted. 
Retarded depression: 8/18 (44%) readmitted.  
RDC – time in 
hospital:  
PMD = SAD 
 
DSM – time in 
hospital:  
PMD congruent & 
PMD incongruent 








depression > PMD 
p<0.01 






4.5.1. Summary of the findings 
There are several key points to take from this review: 
1. There is very little research on SAD. 
2. Much of the research is contradictory which is likely due to the substantial 
differences in methodologies. 
3. There are only four studies based on the best sampling method – incidence 
samples.  
 
Based on these key points, an incidence study of long-term outcomes in PMD and SAD 
cases compared with schizophrenia and bipolar cases is needed to advance the literature.  
 
4.5.2. Methodological limitations in the literature 
This review highlights a number of key methodological limitations within the literature. 
There are few studies examining outcomes in PMD and SAD cases that are based on the 
best source of evidence – incidence samples. Of the papers that do use these samples, 
they are over relatively short periods of time (6 months – 4 years); therefore, knowledge 
of long-term outcomes is limited.  
 
Even the four studies which were based on first episode psychosis samples had some 
methodological flaws. Two of the papers did not report confidence intervals
78, 197
 which, 
as discussed in section 5.5.10.3, is important in the interpretation of results. One paper 
also did not appear to match controls or control for differences between cases and 





A further issue with previous literature is that in many studies it is unclear whether the 
bipolar disorder group includes psychotic bipolar disorder, non-psychotic bipolar 
disorder, or both. This makes it difficult to tell who the PMD or SAD group is actually 
being compared with and could be the reason for inconsistent findings. 
 
One issue that has not been addressed in this review so far is the issue of the influence 
of diagnostic change on other outcomes. Since diagnostic stability in PMD and SAD 
cases is relatively low, other outcomes may be influenced by this instability. For 
example, based on an initial diagnosis, PMD may have lower suicide attempt rates 
compared with schizophrenia. However, if a substantial proportion of PMD cases 
change to a different diagnosis, the results are likely to change. Therefore, accounting 
for diagnostic change is very important in examining outcomes.  
 
4.5.3. Limitations of this review 
This review is not without its limitations. Due to the heterogeneous nature of the 
studies, a meta-analysis was not possible; therefore a narrative review has been used to 
assimilate the data from the systematic searches. This is not ideal as narrative reviews 
often do not meet important criteria to help mitigate bias.
372
 However, this is the first 
systematic review of the course and outcome of PMD and SAD and as such, is thought 
to be more reliable than selective literature reviews.  
 
4.5.4. Implications for this thesis 
Based on the literature and the methodological issues mentioned above, this thesis 
aimed to use an incidence psychosis sample of PMD and SAD cases, followed up over a 
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long (at least 8 years) period and based on both the baseline and lifetime diagnoses, to 
investigate the following outcomes: 
1. Diagnostic stability including prospective and retrospective consistency; 
2. Course of illness, namely, course type (episodic, continuous and neither), 
longest remissions, number of episodes, length of remissions and percentage of 
time psychotic; 
3. Mortality and suicidality, namely, deaths from all causes, completed suicide, 
suicide attempts and self-harm; 
4. Social outcomes, namely, employment status, relationship status, close 
confidants and time in prison; 
5. Inpatient service use, namely, the proportion of hospitalisations, days 
hospitalised, percentage of follow-up as an inpatient; compulsory admissions; 
and admissions involving the police. 
 
These outcomes were compared against outcomes for schizophrenia and psychotic 
bipolar disorder cases. 
 
4.5.4.1. Hypotheses 
The following were hypothesized based on the literature discussed above: 
1. PMD and SAD cases will have a lower prospective consistency and higher 
retrospective consistency compared with schizophrenia and bipolar disorder 
cases. 
2. PMD and SAD cases will have a higher proportion of cases with an episodic 
course of illness and less with a continuous course of illness compared with 
schizophrenia cases.  
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3. PMD and SAD will have: longer remissions; more episodes; shorter episodes; 
and will spend a smaller percentage of the follow-up psychotic, all compared 
with schizophrenia cases.  
4. PMD and SAD cases will have a higher proportion of cases who die (from all 
causes) over the follow-up compared with schizophrenia and bipolar cases. 
5. PMD and SAD cases will have a higher proportion of cases who complete 
suicide over the follow-up compared with schizophrenia and bipolar cases. 
6. PMD and SAD cases will have a higher proportion of cases who attempt suicide 
over the follow-up, and a higher rate of suicide attempts for those who do 
attempt, compared with schizophrenia and bipolar cases. 
7. PMD and SAD cases will have a higher proportion of cases who self-harm over 
the follow-up, and a higher rate of self-harm events for those who do self-harm, 
compared with schizophrenia and bipolar cases. 
8. In terms of social outcomes over follow-up, PMD and SAD cases will have a 
higher proportion of cases who are: employed; in a relationship; have close 
confidants; and a lower proportion of cases who have been to prison, all 
compared with schizophrenia cases. 
9. In terms of service use, PMD and SAD cases will have: a lower proportion of 
cases admitted; less hospitalisations; less days hospitalised; a lower percentage 
of the follow-up spent as an inpatient; a lower percentage of compulsory 
admissions; a lower proportion of cases being compulsorily admitted; and a 











CHAPTER 5. Methodology 
 





5.1. Aims of the chapter 
The aim of this chapter was to provide a full account of the methods used in this thesis. 
This will include specifying the aims and hypotheses of the study, describing the full 
procedure used in this thesis and giving a background to the ÆSOP study, the study 
from which data used in this thesis were drawn. 
 
5.2. Aims of the study 
As discussed in chapter 3 and chapter 4, this PhD thesis had three main aims: 
1. To examine the role of psychosocial risk factors in PMD and SAD cases, within 
a study that overcomes the three major methodological limitations of previous 
research (separating PMD and SAD cases from other diagnoses, sampling from 
an incidence psychosis sample, and accounting for diagnostic stability). 
2. To investigate the long-term diagnostic stability, course of illness, mortality and 
suicidality, social and inpatient service use outcomes for PMD and SAD cases, 
while overcoming major limitations from previous research (by sampling from 
incidence psychosis samples). 
3. To compare the above between cases with PMD and SAD to the other major 
psychotic diagnostic groups of schizophrenia and bipolar disorder with 
psychotic features. 
 
5.3. Outline  
This thesis is based on data from the Aetiology and Ethnicity in Schizophrenia and 
Other Psychoses (ÆSOP) study. The ÆSOP study is made up of 2 parts: an 
epidemiological, case-control study of the incidence of psychosis (also referred to as 
baseline); and a cohort follow-up study (also referred to as follow-up; see figure 5-1). 
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The data from both of these sections of the study are used within this thesis. The study 








5.4. Background to the ÆSOP study 
This section aims to describe some background information about the recruitment 
locations, specifically: employment and income deprivation; population density; and 
ethnic density. 
 
The ÆSOP study was based in 3 tightly defined areas in the UK; South-east London; 
Nottingham; and Bristol (see Figure 5-2). The south-east London site had an inclusion 
area which covered the local authority boroughs of Lambeth and two-thirds of 
Southwark. This inclusion area was a portion of the Maudsley, South Western and St. 
Thomas’ hospitals catchment area within the former Bethlem and Maudsley NHS trust. 
The Nottingham site inclusion areas included the local authority boroughs of Ashfield, 
Broxtowe, Gedling, Rushcliffe and Nottingham. This inclusion area consisted of part of 
the Nottingham Healthcare NHS Trust catchment area. The Bristol site inclusion area 
was the Bristol local authority alone, which made up one of the seven local authorities 






Figure 5-1: Outline of study 
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area. Due to financial restraints, Bristol case control cases were not followed up and 
were consequently excluded from this thesis. Therefore, only information on the 
London and Nottingham sites will be described from henceforth. 
 
             
Figure 5-2: Map of recruitment sites 
 
5.4.1. Employment and Income Deprivation 
The employment deprivation and income deprivation ranks published in 2000 (around 
the time of the case control study) for both the London and Nottingham sites are 
reported in Table 5-1. The ranks are reported for each local authority in England and are 
therefore out of a total of 354. A lower rank indicated greater level of employment 
deprivation and income deprivation such that a rank of 1 signifies the most employment 
and income deprived and a rank of 354 signifies the least employment and income 
deprived. The two inner-city boroughs covered by the London site had a median rank 






 The median rank income deprivation score was 22 out of 354 (range 21-
23).
383
 The five boroughs covered by the Nottingham site had a median rank 
employment deprivation score of 128.5 out of 354 local authorities across England 
(range 14-243).
383
 The median rank income deprivation score was 146.5 out of 354 
(range 10-283).
383
 The ranges of the employment and income deprivation scores in 
Nottingham vary dramatically highlighting the differences even within this one site.  
 
Table 5-1: Employment Deprivation and Income Deprivation 2000 




London Lambeth 17 21 
Southwark 22 23 
Nottingham Ashfield 106 112 
Broxtowe 177 118 
Gedling 163 178 
Rushcliffe 243 283 
Nottingham 14 10 




The employment deprivation and income deprivation ranks published in 2007 (around 
the time of the follow-up of the cohort study) for the London and Nottingham sites are 
reported in Table 5-2.  
 
Table 5-2: Employment Deprivation and Income Deprivation 2007 




London Lambeth 16 16 
Southwark 22 18 
Nottingham Ashfield 111 124 
Broxtowe 183 217 
Gedling 175 194 
Rushcliffe 281 298 
Nottingham 12 13 
Information taken from The English Indices of Deprivation by Noble and Colleagues, 2007 
 
The two inner-city boroughs covered by the London site had a median rank employment 
deprivation score of 19 out of 354 local authorities across England (range 16-22).
384
 The  




The five boroughs covered by the Nottingham site had a median rank employment 
deprivation score of 146.5 out of 354 local authorities across England (range 12-281).
384
 
The median rank income deprivation score was 155.5 out of 354 (range 13-298).
384
 
Again, the ranges of the employment and income deprivation scores in Nottingham vary 
dramatically highlighting the differences even within this one site. 
 
5.4.2. Population Density 
Table 5-3 shows the population density for the London and Nottingham sites in 2002 
(between the case control and follow-up for the cohort study). The Median population 
density for London was 9,423 (range 8,710-10,136).
385
 The Median population density 
for Nottingham was 1,939 (range 259-3,619).  
 
Due to its high population density, participants from the London site were considered as 
coming from a high population density environment. Nottingham having a lower 
population density was therefore considered a low population density environment. 
 
Table 5-3: Population Density 2002 
Site Local Authority People per square kilometre 
London Lambeth 10,136 
Southwark 8,710 









5.4.3. Ethnic Density 
Table 5-4 shows the ethnic composition of the populations from each site by local 
authority in 2001 (between the case control and follow-up phase of the cohort study). 
The figures highlight the relatively low proportions of non-White British ethnic groups 
 174 
in Nottingham (81.0-93.9% White British inhabitants)
386-390
 compared with the London 




Table 5-4: Ethnic Composition 2001 







White British 50.0 





Other Asian 0.8 
Black Caribbean 11.9 
Black African 11.4 
Black Other 2.1 
Chinese 1.3 





White British 52.3 
White Other 10.9 




Other Asian 0.6 
Black Caribbean 7.9 
Black African 15.9 
Black Other 1.8 
Chinese 1.9 





White British 98.0 





Other Asian 0.0 
Black Caribbean 0.1 
Black African 0.0 
Black Other 0.0 
Chinese 0.1 





White British 87.7 





Other Asian 0.4 
Black Caribbean 0.6 
Black African 0.6 
Black Other 0.1 
Chinese 1.7 





White British 93.9  
White Other 2.3  




Other Asian 0.1 
Black Caribbean 0.8 
Black African 0.1 
Black Other 0.1 
Chinese 0.3 





White British 93.2 





Other Asian 0.1 
Black Caribbean 0.3 
Black African 0.1 
Black Other 0.0 
Chinese 0.3 





White British 81.0 





Other Asian 0.4 
Black Caribbean 3.4 
Black African 0.5 
Black Other 0.4 
Chinese 0.6 
Other Ethnic Group 0.5 
Information taken from the Office of National Statistics, 2001  
 
This background section has highlighted the differences in employment deprivation, 
income deprivation, population density and ethnic density between the three recruitment 
sites. It is clear that London has very high deprivation levels compared with 
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Nottingham, London has high population density compared with Nottingham, and 
London has a much higher proportion of non-white British inhabitants compared with 
Nottingham. However, it also highlights the variation within each site with Nottingham 
having large variation of all of the social context factors examined. 
 
5.5. Phase 1 – case control study      
The case control phase of the study was used to investigate the psychosocial risk factors 
associated with a diagnosis of PMD and SAD, and to test the hypotheses outlined at the 
end of Chapter 3.  
 
5.5.1. Design 
The case control study recruitment occurred in two stages: 
1. An incidence study which aimed to count the number of psychosis cases and 
collate sociodemographic and clinical data from case notes. 
2. A case control study which aimed to recruit, consent and interview as many of 




Within the specified geographical areas, all cases with a first episode of psychosis 
(codes F20–29 and F30–33 in ICD–1014) who presented to secondary services (i.e. 
inpatient units, outpatient units, community mental health teams, assertive outreach 
teams, emergency clinics and private sector clinics) were included in the incidence 
study. Table 5-5 gives details on the diagnoses included. For the purpose of this thesis, 
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cases with bipolar disorder and mania will be included into the same diagnostic group 
and referred to as bipolar disorder cases. 
 
Table 5-5: All diagnoses included in the ÆSOP study 
Code       Diagnosis    Subtypes 
 
F20   Schizophrenia    Paranoid, Hebephrenic, Catatonic, Undifferentiated 
 
F21   Schizotypal Disorder 
 
F22   Persistent Delusional Disorder  Delusional disorder, other persistent delusional disorders 
 
F23   Acute and Transient Psychotic Disorder Acute psychotic disorder without schizophrenic symptoms 
      Acute psychotic disorder with schizophrenic symptoms 
      Acute schizophrenia-like psychotic disorder 
      Other acute delusional psychotic disorder 
      Other acute transient psychotic disorder 
 
F24   Induced Delusional Disorder 
 
F25   Schizoaffective Disorder   Manic type, Depressive type, Mixed type, Unspecified 
 
F28   Other Nonorganic Psychotic Disorder 
 
F29   Unspecified Nonorganic Psychosis 
 
F30   Mania Episode    Mania with psychotic symptoms 
 
F31   Bipolar Affective Disorder  Current episode manic with psychotic symptoms  
      Current episode depressed, severe with psychotic symptoms 
 
F32   Depressive Episode   Severe depressive episode with psychotic symptoms 
 
F33   Recurrent Depressive Disorder  Current episode severe with psychotic symptoms 




Cases who presented to these services were screened for eligibility using the Screening 
Schedule for Psychosis
393
 (Appendix C). The Screening Schedule for Psychosis is a 
checklist which identifies both positive and negative symptoms of psychosis in a 
participant.  The Screening Schedule for Psychosis was completed using information 
from clinical notes and corroboration from mental health staff, or where possible, by 
interview with the participant. Every person who was screened and found to be positive 
for psychosis was included in the incidence study and then invited to participate in the 
case control section of the study. Participants were given an information sheet 
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(Appendix D) which they read and had explained to them. Once the case understood the 
study, they were asked to give written consent (Appendix E).  
 
Exclusion criteria for the study were: 
 Aged less than 16 years or over 65 years. 
 Had evidence of psychotic symptoms precipitated by an organic cause. 
 Had transient psychotic symptoms resulting from acute intoxication as defined 
by ICD– 10.14 
 Had previous contacts with mental health services for psychosis. 
 Had moderate or severe learning difficulties or an IQ of less than 50.14 
 
5.5.2.2. Controls 
The ÆSOP study also collected data from a sample of non-psychotic controls. This was 
done using a population-based selection approach. Population-based selection 
approaches have advantages over facility-based selection and family-based selection 
which “...assume that patients with the disease of the cases originate in the same source 
population as patients admitted with the disease of the controls. This assumption is not 
always realistic”.160 Population-based selection is preferred as “...the cases are 
representative of all people with new onset of the disorder (incident cases) in a defined 
population over a specified time period...”.160 However, there is an assumption that 
controls developing the same diseases as cases would present to the same services. 
Bromet et al. highlight that “such assumptions are difficult to verify”.160 The impact of 
this is discussed further in chapter 8. 
 
Control participants were recruited using the postal address file (PAF) method described 
by Jenkins and Meltzer.
394
 The PAF was used to generate a random sample of 10 target 
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addresses that was within the same postcode as each of the psychosis cases. This 
ensured matching of cases and controls in terms of geographic location. The first of the 
target addresses was visited by researchers on three separate occasions, at different 
times of day (morning, afternoon and evening) and on different days to ensure 
maximum likelihood of contact being made and to minimise the sampling bias of 
unemployed people being more likely to be at home during the day. If there were no 
responses from the address or if there was a refusal from occupants then the next target 
address was approached.  
 
An eligible resident was sought from each address. Written informed consent was 
sought from each control (Appendix F). A Kish
395
 grid was used to randomly select one 
control if more than one eligible control was selected from each household. A Kish grid 
is a list of predefined numbers which are used to select a potential participant. All 
potential participants from the same address were listed in age order and then the 
participant corresponding with the Kish grid number were selected for interview.
395
 This 
allowed all potential participants within a household to have an equal chance of 
selection. 
 
Exclusion criteria for the study were: 
 Had previous contacts with mental health services for psychosis. 
 Aged less than 16 years or over 65 years. 
 Had an insufficient level of English to complete the interviews. 
 Had moderate or severe learning difficulties or an IQ of less than 50.14 
 
Once a control had given written informed consent, they were asked to complete the 
Psychosis Screening Questionnaire (PSQ).
396
 The PSQ (Appendix G) developed by 
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Bebbington and Nayani is a schedule designed to screen for psychotic symptoms in the 
general population and is usable by lay interviewers. If a potential control screened 
positive on the PSQ, a SCAN (see section 5.5.6.2) interview was completed, and anyone 
with a psychotic disorder was excluded. Control participants were not excluded if they 
had experienced or were currently experiencing any mental illness or symptoms of 
mental illness other than psychosis. 
 
5.5.3. Timelines  
Recruitment occurred over a 3-year period. From 1
st
 September 1997 to the 31
st
 August 
1999 all eligible participants were approached for recruitment into the study. From 1
st
 
September 1999 to 31
st
 August 2000 participants of a Black Caribbean ethnic origin 
were recruited in order to increase the power for a case-control analysis (see Figure 
5-3). Only cases from the 2 year incidence sample plus the leakage cases (discussed in 
section 5.5.4) were used in this PhD thesis as the aim was to explore the risk factors and 
outcomes in an epidemiological first episode sample. 
 
 
Figure 5-3: Recruitment by site 
 
5.5.4. Leakage study 
At the end of the recruitment period a leakage study was performed to identify any 
eligible participants who had been missed by the main recruitment method. The leakage 
  All eligible participants 




September 1997 August 1999    August 2000 
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methodology described by Cooper and colleagues 
397
 was used to identify further 
participants who were missed. This involved checking with local private psychiatric 
hospitals and local private practising psychiatrist as well as checking the relevant 
psychiatric registers. These participants were included in the incidence section of the 
study but were not approached to be recruited into the case control study. As for all 
incidence cases, case notes were used to gain sociodemographic and clinical data. 
   
5.5.5. Data collection 
Cases for the incidence study were identified by members of the research team regularly 
checking all points of contact with mental health services within the catchment areas. 
Case notes were then accessed to compile information about sociodemographics and 
clinical picture. 
 
Cases who consented to participate in the case control study were asked to complete a 
battery of schedules over an average of 4 interviews. The assessments took an average 
of 6 hours to complete. Participants were also asked for their permission for the team to 




The literature review in Chapter 3 drew out key psychosocial factors to investigate in 
this thesis. These were age, gender, ethnicity, place of birth, employment, education, 
social isolation, life events and childhood adversity. Within this thesis, social isolation 
was indicated using a number of proxy variables. These were relationship status, living 
circumstances, contact with friends, contact with family and close confidants. Data on 
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Although a battery of schedules was conducted with each of the participants and 
controls for the larger AESOP study, only a small number of them were relevant for this 
thesis. Table 5-6 shows the schedules that were used in this thesis and the source of 
information for each schedule. These were the Medical Research Council Socio-
demographic Schedule (MRC-SDS),
398
 the Schedules for Clinical Assessment in 
Neuropsychiatry (SCAN),
399
 the Personal and Psychiatric History Schedule (PPHS),
400
 
the Childhood Experiences of Care and Abuse Questionnaire (CECA-Q)
401
 and the Life 
Events and Difficulties Schedule (LEDS).
402, 403







Table 5-6: Baseline assessments 
Type of data  Schedule     Source of data 
 
Clinical   Schedules for Clinical Assessment in  Patient  
   Neuropsychiatry (SCAN)
399
      Case notes 
         Staff informant 
         Relative
 
 
   Personal and Psychiatric History   Patient 
   Schedule (PPHS)
400
                 Case notes 
         Staff informant 
         Relative 
 
Social   MRC Sociodemographic Schedule    Patient 
   (MRC-SDS)
398
     Case notes 
         Staff informant 
         Relative 
 
Psychosocial  Childhood Experiences of Care and Abuse  Patient  
   Questionnaire (CECA-Q)
401
   Case notes 
 
   Life Events and Difficulties Schedule (LEDS)
402, 403
 Patient   
         Case notes 
 
Biological   Family Interview for Genetics (FIGS)
406
  Patient   
         Relative 





5.5.6.1. Medical Research Council Socio-demographic Schedule  
The Medical Research Council Socio-demographic Schedule (MRC-SDS)
398
 was used 
to collect data on: centre; age; ethnicity; gender; highest educational level achieved; 
place of birth; current and historical employment status; current and living 
circumstances; and current and historical relationship status (Appendix H). For those 
participants who declined to be interviewed, the MRC-SDS was completed as far as 
possible using the patient’s case notes. 
 
Participants self-ascribed their own ethnicity from the Census categories.
407
 For those 
participants who were not interviewed, place of birth and place of parent’s birth was 
used to assign ethnicity by consensus within the team. The ethnic groups were then 
reorganised from the 9 original categories into 6 new categories: White British 
(previously White); African Caribbean (Black Caribbean and Black other); Black 
African; White Other (previously White); Asian (Indian, Pakistani and Bangladeshi) 
and Other (Chinese and other). 
 
5.5.6.2. Schedules for Clinical Assessment in Neuropsychiatry  
The Schedules for Clinical Assessment in Neuropsychiatry , Version 2 (SCAN, V2)
399
 
incorporates the Present State Examination Version 10, to determine whether a range of 
symptoms are present, and how severe they are. 
408
 These symptoms are part of a 
comprehensive and defined list. The SCAN was used to determine the present mental 
state at baseline, i.e. the one month around the time of first presentation. The SCAN is 
comprised of two sections. Part 1 examines non-psychotic symptoms and part 2 
examines psychotic and cognitive disorders.
409
 A shortened version of the SCAN was 
used to focus solely on symptoms of depression, mania and psychosis.  
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Where an interview with the patient was not possible, case notes, clinicians and other 
informants were used to gain information to complete the Item Group Checklist (IGC) 




5.5.6.3. Personal and Psychiatric History Schedule  
The Personal and Psychiatric History Schedule (PPHS)
400
 is a semi-structured interview 
about a patient’s psychiatric history and the circumstances surrounding the patient’s 
current episode (Appendix I). The PPHS was used for a number of purposes.  
 
Firstly, it was used to gather clinical information about the first episode of illness and 
initial modes of treatment. The PPHS collates information on the details and 
circumstances of current outpatient treatment, details and circumstances of current 
inpatient treatment, reasons for current treatment and general psychiatry history. This 
provides a detailed psychiatric history. 
 
Secondly, the PPHS was used to gather data on pathways to care and mode of contact 
with services. Pathways to care were defined as contacts initiated by or on behalf of the 
cases in the period immediately before their presentation to secondary mental health 
services with a first episode of psychosis. These contacts included NHS and Criminal 
Justice System contacts as well as alternative contacts such as traditional healers and 
church leaders. The PPHS section on pathways to care was extended to include two 
extra items. These were who initiated help-seeking and a space for a detailed narrative 
description of the pathway to care.  
 
Finally, the PPHS was used to collect information on the duration of untreated 
psychosis. Duration of untreated psychosis was defined very similarly to that described 
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by Craig and colleagues as the period from onset to the point of contact with secondary 
mental health services (i.e. receipt of either an inpatient admission or treatment 
in/contact with an outpatient facility for a psychotic disorder).
410
 Onset was defined in 
line with previous research as the presence for one week or more of: delusions; 
hallucinations; formal thought disorder; marked psychomotor disorder; bizarre grossly 





5.5.6.4. Childhood Experiences of Care and Abuse Questionnaire 
The Childhood Experience of Care and Abuse Questionnaire or CECA-Q
401
 is a 
questionnaire based on a semi structured interview: the Childhood Experience of Care 
and Abuse (CECA).
411
 The CECA interview is designed to measure childhood 
experiences of neglect, antipathy, physical abuse and sexual abuse reported 
retrospectively.  
 
The CECA-Q is a self-report tool based on the CECA interview. It has been found to 
have high reliability and validity.
401
 It consists of six sections: parental loss; parental 
neglect; parental antipathy; support; physical punishment; and unwanted sexual 
experiences (Appendix J). A cumulative score for each section is obtained by adding a 
point for each item marked positive for adversity (some items are reversed). The CECA-
Q has published cut-off scores to ensure that minor levels of adversity are not 
included.
412
 These scores are then used to indicate the presence of childhood adversity. 
This is then used in the analyses to indicate: i) the presence or absence or childhood 
adversity and; ii) the number of different types of abuse (e.g. if neglect and physical 
abuse are both present, this would count as two types of abuse). 
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Due to the sensitive nature of the information needed for the completion of the CECA-
Q, special measures were taken in the collection of this data. Participants were reminded 
of the confidential nature of the interview, were reminded that they were able to decline 
to answer any questions they felt uncomfortable with and were able to stop the 
interview at any point. If participants became distressed during the interview, they were 
offered tissues and the interviewer remained silent to give the participant time to 
compose themselves. Interviewers then clarified whether the participant wanted to 
continue before doing so. If participants were particularly distressed during the 
interview, they were advised to contact their GP or care coordinator.  
 
5.5.6.5. Life Events and Difficulties Schedule 
The Life Events and Difficulties Schedule (LEDS)
402, 403
 is a semi-structured interview 
which is used to gather information on the presence or absence of a range of stressful 




The LEDS is based on detailed definitions of what should and should not be included as 
an event or difficulty. This helps to ensure consistency between different studies but 
also guards against investigator bias that might arise were the inclusion of incidents 
determined retrospectively by the investigator. The LEDS events included are defined 
as incidents which would be followed by a negative or positive emotional response in 
most people, and are restricted to the participant and the participant’s ‘close ties’ 




The LEDS list contains 40 types of event that fit into eight groups: changes in role for 
the participant; major changes in role for close ties; major changes in participants 
health; major changes in health for close ties; residence changes or marked change in 
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amount of contact with close ties; forecasts of change; fulfilments or disappointments of 
a valued goal; and other dramatic event involving the participant or close tie.
414
 There 
are detailed manuals explaining the inclusion rules and glossaries of several hundreds of 
events and difficulties with their ratings. 
 
Participants are first asked about the presence and timing of an event or difficulty.
413
 In 
order to establish when the event had occurred, an anchor is provided to participants 
(e.g., bank holidays, birthdays etc.) to help them pinpoint the event more accurately.
414
 
The questioning is standardised only in that there are a list of topics to be discussed and 
a number of suggested probes. Once the presence or absence of an event or difficulty 




Once the information has been collected from the participant, a LEDS rating meeting is 
held.
414
 During this, the participant interviewer reads an account of the event/difficulty 
and its surrounding circumstances (the ‘context’ of the event) to the rest of the research 
team. Care is taken to omit any mention of the participant’s reaction to the 
event/difficulty and to omit any information on the subsequent incidence of illness.
414
 A 
rating of contextual threat is then made independently by each member of the team 
without discussion. This threat rating is based on what most people would be likely to 
feel in response to the event given the particular  circumstances (i.e. context) in which it 
occurred.
414
 Ratings by members of the team are compared and any disagreements are 
discussed until a consensus rating is reached.  
 
Short term threat for an event is defined as on the day of the event.
414
 Long term threat 
for an event is a week after the occurrence. Long term difficulties are defined as 
difficulties of at least four weeks.
414
 The rating of degree of threat for events is: marked; 
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moderate; some; and little or none. The rating of degree of threat for difficulties is on a 
scale of one to seven of unpleasantness with one indicating the highest degree of 
threat.
413
 A severe event is one with marked or moderate long-term threat that is 
focussed on the participant only or jointly on the participant and one of the restricted list 
of close family/friends. A severe difficulty is one rated on the top three levels on the 7-
point difficulty scale. Within this thesis, only severe events and difficulties were 
included.  
 
Independence of an event or difficulty is also important. An independent event is when 
the event is independent of the case’s mental state and unlikely to be the results of a 
behavioural change that might be linked to the onset of disorder. Within this thesis, only 
independent events and difficulties were used. 
 
The LEDS was chosen for this study due to its advantages over other life events data 
collection methods. These are that the LEDS has greatly reduced ‘false positives’ (i.e., 
the number cases who claim to have life events but these events are not seen as 
significant from an objective point of view), it can overcome lack of awareness in cases 
(cases may underplay certain events which could be seen as significant from an 
objective point of view), it does not rule out using the person’s view of the significance 
of the event, and checklist-dictionary approaches have been shown to have low validity 
and reliability.
414
 Dohrenwend et al.
415
 claim that the contextual approach adopted by 
the LEDS is more precise than the commonly used checklist methods. Brown and 
Harris
414
 point out that there are no satisfactory alternatives. 
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5.5.6.6. Family Interview for Genetic Studies 
Data on family history of mental illness was collected using the Family Interview for 
Genetic Studies (FIGS; see Appendix L).
416
 The FIGS is a schedule for gathering 
diagnostic information about relatives of a proband within a study.
417
 It can be 
conducted with the proband or a relative of the proband. The FIGS is made up of three 
parts: the family tree; general screening questions, and the symptom checklists. As a 
minimum, the family tree must include the proband’s parents, grandparents, siblings, 
aunts, uncles, cousins, offspring and spouse.
418
 The screening questions are then used to 
gather information on possible mental illness in first degree relatives. The symptom 
checklists are then used to elicit specific information about relatives that have an 
indication of mental illness from the screening questions. Within this study, a shortened 
version of the FIGS was used including the family tree, the general screening questions, 
and only the depression, mania and psychosis symptom checklists.  
 
The information gathered using the FIGS was presented in consensus meetings (as 
described in section 5.5.7) to determine presence of mental illness and psychosis in 
parents and family members. 
 
5.5.6.7. Control Measures 
Control participants were asked to complete the same battery of assessments as the 
psychosis cases with the exception of the illness related questionnaires; Schedules for 
Clinical Assessment in Neuropsychiatry (SCAN)
399







To ensure a high level of interrater reliability for the SCAN, all members of the research 
team who utilised the SCAN had to attend a one week formal World Health 
Organisation (WHO) training course. This ensured all raters were conducting and rating 
the SCAN in a standardised way. Interrater reliability of the SCAN was assessed using 
taped SCAN interviews with a Cohen’s kappa coefficient ranging between 0.727 and 
0.743. 
 
Using information obtained via the SCAN, case notes and informant information, an 
ICD-10
14
 diagnosis was determined by consensus using the following procedure. The 
researcher who completed the SCAN presented the information from the SCAN during 
a consensus meeting that was attended by at least 3 members of the research team, 
including at least one of the principal investigators. The presenter was very careful not 
to reveal information about the diagnosis given by the clinical team, or about the 
patient’s ethnicity (as far as possible). Diagnosis was determined by consensus and any 
disagreement was resolved by discussion among the team. Interrater reliability between 
the London and Nottingham teams was estimated using 20 cases and was judged 
satisfactory by the research team, with Cohen’s kappa coefficients ranging between 0.63 
and 0.75 (p<0.001). 
 
For all other schedules used within the study, formal standardised training was provided 
to each research team member before they began collecting data. 
 
5.5.8. Ethical Issues 
Ethical approval was granted for the baseline study by the Institute of Psychiatry and 
South London and Maudsley (SLaM) Research Ethics Committee for the London site, 
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by the City Hospital Research Ethics Committee for the Nottingham site and by the 
Bristol NHS Research Ethics Committee for the Bristol site. 
 
As discussed in section 5.5.2.1, informed consent was sought from all participants. If a 
participant was judged not to have capacity to consent, they were not interviewed but 
still included in the study. This was made possible by the use of clinical notes which 
was authorised by the relevant ethics committees.  
 
Confidentiality of data was strictly maintained by the use of participant identification 
numbers instead of names on paper copies of data and in databases. All databases were 
password protected and encrypted. Confidentiality was only broken in cases where there 
was a risk to the participant or others. In this case, a principle investigator was consulted 
and a clinician relevant to the participant (i.e. consultant psychiatrist, care coordinator, 
or GP) was contacted.  
 
5.5.9. Data Management 
All data were entered into Microsoft Access 2003
419
 and a number of cleaning checks 
were run on the data. Any discrepancies were checked against the paper copies of the 
relevant measure and where necessary (and appropriate), corrected.  
 
5.5.10. Statistical analyses 
Mills
373
 highlights the issues surrounding data analysis in terms of ‘data torturing’. This 
means that if manipulated in enough different ways, the data can show anything the 
analyser wishes it to and can be used as evidence of whatever the investigator wants to 
prove. Thus, it is important to have a detailed analysis plan before attempting to analyse 
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data. This can aid the analyser to resist the urge to ‘mine the data’ for significant 
findings. 
 





The descriptive section took the following form: an account of the numbers of cases and 
controls recruited in to the study; a description of the demographic and clinical 
characteristics of the whole sample, and of the individual diagnostic groups of interest; a 
statistical comparison of demographic and clinical characteristics between cases and 
controls, and each of the individual diagnostic groups of interest. A comparison between 
cases and controls, and between the individual diagnostic groups of interest, on missing 
data was also conducted.  
 
Description of demographic and clinical characteristics took the form of: means and 
standard deviations for variables which were interval/ratio, continuous and normally 
distributed;
421
 medians and interquartile ranges for variables which were interval/ratio, 
continuous but not normally distributed;
421





Statistical comparison tests between two groups (cases and controls) took the form of: 
independent sample t-tests for variables which were interval/ratio, continuous and 
normally distributed; Mann Whitney-U tests for variables which were interval/ratio, 
continuous and not normally distributed; and chi-squared tests for data which was 
categorical (including the use of the fisher’s exact test for variables which had expected 




Statistical comparisons between more than two groups (between the diagnostic groups) 
took the form of: ANOVAs for variables which were interval/ratio, continuous and 
normally distributed; Kruskal-Wallis tests for variables which were interval/ratio, 
continuous and not normally distributed; and chi-squared tests for data which was 
proportional in nature (including the use of the fisher’s exact test for variables which 




5.5.10.2. Analysis of risk factors 
The analysis of risk factors has been broken down into two parts: unadjusted and 
adjusted analyses. 
 
5.5.10.2.1. Unadjusted analyses 
As it is not possible to calculate risk ratios in case control studies (as the controls form 
an unknown proportion of the total population at risk), odds ratios are the preferred 
measure of effect. As the outcome variable had more than 2 levels (categories),
423
 
multinomial logistic regressions were used. This allows for the comparison of each 
group to the control group to be conducted within a single regression model.  
 
Within the multinomial regression analyses, data were weighted. If a random sample of 
the population is recruited, as was done for the controls, there are rarely enough ethnic 
minority individuals and for this study, there were not enough Black Caribbean 
participants. Therefore, Black Caribbean controls were oversampled. Analyses were 




5.5.10.2.2. Adjusted analyses 
Hennekens and Buring argue that “... age and sex are associated with virtually all 
diseases and are related to the presence or level of many exposures... This means that 
there must be an association between the confounder and disease even among non-
exposed individuals.”424 Therefore, it is important to control for these within studies of 
risk factors. As well as age and gender, the analyses control for centre and ethnicity. 
 
The possible ways to control for confounding are restriction, matching and analytical 
adjustments.
424
 Restriction and matching both have limitations
424
 and are only 
applicable at the design stage of the study. As the data had already been collected at the 
start of this thesis, I was limited to analytical adjustments. The analytical adjustment 
options are stratification and multivariate analyses. “A fundamental problem with 
stratified analysis, however, is its inability to control simultaneously for even a 
moderate number of potential confounders”, thus multivariable analyses have been used 




5.5.10.3. General statistical issues 
Kirkwood and Sterne state that the questions that are trying to be answered in 
epidemiology are: ‘what is the effect size?’; ‘what does the effect in the study tell us 
about the size of the effect more generally in the population?; and ‘do the data provide 
evidence that the observed difference may have arisen by chance?’. Researchers are 
aided in answering each of these questions through the use of measures of effect size 
(odds ratios, relative risk, incidence rate ratios), measures of precision (confidence 
intervals), and measures of chance (p-values).
425
 Only with all three of these pieces of 
information can a researcher interpret the study findings. Therefore, the risk results 
chapter reported on all three of these components for each analysis: effect size; 
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confidence intervals; and p-values. Within the analyses and interpretation of the results, 
a p-value of less than 0.1 was taken to be indicative of weak evidence of an effect, a p-
value of less than 0.05 was taken to be an indication of moderate evidence of an effect, 
and a p-value of less than 0.01 was taken to be an indication of strong evidence of an 
effect.  
 
The recommendation that two-sided p values are used in epidemiological analyses 
because they cater for the uncertainty about the direction of effects
424
 was adopted. 
 
As stated in Chapter 3, diagnoses received at the time of onset are often inaccurate. 
Therefore analyses of risk factors based on initial diagnosis are likely to be 
misleading.
160
 For this reason, all risk factor analyses were conducted on the baseline 
diagnoses, and then reanalysed using the lifetime diagnoses. 
 
Within the analyses of risk factors, variables were simplified into binary factors where 
appropriate to simplify the analyses and increase power. 
 
5.5.10.4. Power calculations 
The data for this section of the thesis was collected prior to the thesis starting and thus 
numbers of cases and controls were not adjustable. However, a power calculation was 
conducted using NQuery Advisor
426
 to determine what size of effects could be detected 
by the data. As there were many statistical tests, the power calculation was based on one 
of the comparisons: a comparison of PMD cases versus controls on the risk factor of 
relationship status (single versus not). A two group chi-square test with a 0.05 two-sided 
significance level was found to have 87% power to detect a difference between Group 1 
(controls) with a proportion of 0.400 (40% single) and Group 2 (PMD cases) with a 
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proportion of 0.600 (60% single; odds ratio of 2.250) when the sample sizes are 381 and 
69, respectively (a total sample size of 451).  
 
5.6. Phase 2 – cohort study 
The purpose of the cohort study was to enable an investigation of the course and 




The cohort study aimed to follow-up all incidence cases identified in the case control 




All cases identified in the incidence study were traced. Information from case notes and 
informants (psychiatrists and care coordinators) was gathered to complete the WHO 
Life Chart (see section 5.6.4.2). Once this had been completed, all traced cases were 
approached and invited to complete a battery of follow-up assessments including 
providing corroborative information for the life chart. Prior to participation, all 
participants were given a consent form (Appendix L). This was read to all cases and 
they had the opportunity to ask questions. All interviewed participants gave written 




Recruitment happened in three chronological stages: 
1. SLaM services were approached to find out which cases were in contact with 
services. If a case was found to be in contact with services we approached that 
participant though their clinical team. If a case had been transferred to an out of 
area mental health service, we approached the participant through the relevant 
clinical team. 
2. At baseline contact details were collated for each case. This information was 
used to write to the last known address. If no response was received after 
sending 2 letters, we visited the address. If this was unsuccessful, we contacted 
the last known GP in order to get a letter forwarded to the current address. 
3. The details of all cases were run through ONS to gather information on who had 
died during follow-up. 
 
5.6.4. Measures 
As reported in section 5.6.2.1, data was collected using a combination of self-reported 
information, clinical notes and information from informants. Clinical notes were used to 
collect information on core items such as course of illness, months of remission, suicide 
attempts, social outcomes and service use among many others. Cases who consented to 
be interviewed were then asked to complete a battery of assessments. Table 5-7 lists the 
assessments that were used in this thesis. Within this thesis, the only measures which 
were used were the Schedules for Clinical Assessment in Neuropsychiatry, Version 2 
(SCAN, V2)
399





5.6.4.1. Schedules for Clinical Assessment in Neuropsychiatry  
Details on the SCAN have already been given in section 5.5.6.2. The SCAN
399
 was used 
to determine the present mental state at follow-up, i.e. the one month prior to the 
interview.  
 
As at baseline, information obtained from the SCAN, case notes, informant information 
and the Life Chart were presented at consensus meetings (see section 5.5.7) to 
determine a lifetime diagnosis. These consensus meetings involved at least 3 members 
of the research team including at least one who was a consultant psychiatrist. The 
lifetime diagnosis was made according to the ICD-10
14
 and as far as possible, blind to 
baseline diagnosis and ethnicity. 
 
Table 5-7: Follow-up assessments 
Type of data  Schedule     Source of data
 
Clinical   Schedules for Clinical Assessment in   Patient 
Neuropsychiatry Version 2 (SCAN, V2)
399
   
 
Clinical   WHO Life Chart
429, 430
    Patient 
Social         Case notes 
Service use        Other informants 
 




5.6.4.2. WHO Life Chart Schedule 
The WHO Life Chart Schedule
429, 430
 was designed to assess the long-term course of 
schizophrenia.
430
 It includes four main areas; symptoms; treatment; residence; and 
work. The Life Chart in this study was adapted to include more information on service 
use (relevant parts of the Life Chart are included in Appendix N). 
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Information was derived for the life chart from a combination of sources: case notes 
and, when possible, interviews with cases and informant information (carers, relatives, 
friends, GPs, treating consultants).  
 
From the Life Chart, the following information was gathered for this thesis: course of 
illness (episodic (defined as no episode lasting over 6 months), continuous (defined as 
no remission lasting over 6 months) or ‘neither episodic nor continuous’ (episodes 
lasted over 6 months and remission lasted over 6 months); longest period of remission; 
average number of episodes; months of longest episode; percentage of time psychotic 
during follow-up; deaths; completed suicide; attempted suicide; self-harm; time in 
prison; relationship status; employment status; close confidants; binary hospitalisations; 
total number of hospitalisations; total number of days hospitalised; proportion of the 
follow-up spent as an inpatient; percentage of admissions which were compulsory; 
having ever been admitted compulsorily; and percentage of hospitalisations involving 
the police. As well as being used to inform decisions about lifetime diagnoses (see 
section 5.6.5), the Life Chart was also presented at consensus meetings along with case 
note information so decisions about all aspects of the Life Charts could be decided upon 
in a consensus fashion. 
 
5.6.5. Reliability 
As with the case control study, to ensure a high level of interrater reliability in the 
SCAN, all members of the cohort research team who used the SCAN attended a one 
week formal WHO training course to ensure all raters were conducting and rating the 
SCAN in a standardised way. On all other schedules used within the study, formal 
standardised training was provided to each research team member before they began 
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collecting data. As mentioned above, completion of the Life Chart and decisions about 
diagnosis were made by the team in consensus meetings to improve reliability.  
 
5.6.6. Ethical Issues 
Ethical approval was granted by the Institute of Psychiatry and SLaM Research Ethics 
Committee (reference 321/02) for the London site and by the North Nottinghamshire 
Local Research Ethics Committee (reference 04/Q2402/35) for the Nottingham site. 
Informed consent was sought from all participants. If a participant was judged not to 
have capacity to consent, they were not interviewed.  
 
As with the case control study, confidentiality of data was strictly maintained by the use 
of participant identification numbers instead of names on paper copies of data and in 
databases. All databases were password protected and encrypted. Confidentiality was 
only broken in cases where there was a risk to the participant or others. In any such 
case, a principle investigator was consulted and a clinician relevant to the participant 
(i.e. consultant psychiatrist, care coordinator, or GP) was contacted, and a relevant 
report was made to the local ethics committee.  
 
5.6.7. Data Management 
All life chart data was double entered. A number of cleaning checks were also run on 




5.6.8. Statistical analyses 
All data was analysed in STATA 10.
431
 Outcome variables were described using means 
and standard deviations where variables were interval/ratio, continuous and normally 
distributed,
421
 medians and interquartile ranges where variables were interval/ratio, 
continuous but not normally distributed,
421
 and numbers and percentages for categorical 
variables.
421
 Categorical variables with more than two levels were transformed into 
binary variables (where appropriate) to simplify analyses and their interpretation (e.g. 
married and cohabiting were combined into an ‘in a relationship’ group and single, 
divorced, separated and widowed were all combined into a ‘single’ group). 
As the focus of the outcomes analyses was to investigate the course and outcomes of 
PMD and SAD cases compared with bipolar disorder and schizophrenia cases, the 
following comparisons were made: PMD versus schizophrenia; PMD versus bipolar 
disorder; PMD versus SAD; SAD versus schizophrenia; SAD versus bipolar 
disorder. To conduct comparisons in binary categorical outcome variables, logistic 
regression was employed, using the ‘or’ option to create odds ratios (ORs).421 ORs are 
almost always reported in medical literature when analysing binary variables.
425
 This is 
for the three key reasons: when the outcome is rare, the odds ratio is the same as the risk 
ratio; when the outcome is common, risk ratios are constrained but the odds ratio are 
not; and for odds ratios, the conclusions are identical whether we consider our outcome 
as the occurrence of an event, or the absence of the event.
425
 For these reasons, odds 
ratios are being used to measure the effect sizes in the cohort study. 
 
For continuous interval and ratio data which were normally distributed, linear regression 
was used.
421
 However, post regression, residuals were examined using the graph box, 
‘kdensity’, ‘pnorm’ and ‘qnorm’ commands in STATA to examine the normality of the 
residuals.
432
 These outputs were judged by visually analysing the outputs. For variables 
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where the residuals were normal, the linear regression was used. For interval/ratio, 
continuous, normally distributed outcomes for which the residuals were not normal, or 
for outcome variables which were non-normally distributed, the ‘Ladder’ function was 
used to indicate which transformation would produce the most normal distribution.
432
 
Once the variable was transformed, a linear regression was used plus the checking for 
normality process mentioned above was again adopted. If transformation did not correct 
normality problems, then a bootstrap regression (using 1000 replications) was 
implemented.
423
 Bootstrapping is a non-parametric statistical method which accounts 
for the skewedness of the data.
433
 It is, therefore, suitable for use when the normality 
assumption is violated. Bootstrapping is primarily used when distributions are skewed 




For outcome variables which were count data, poisson regression was used.
423
 A 
calculation of incidence-rate ratios was conducted using the ‘irr’ option in STATA. 
Since the poisson command assumes all subjects had the same follow-up time, the 
‘exposure’ option was used to indicate the length of time an individual was followed for 
to adjust the poisson regression estimates.
434
 The ‘vce(robust)’ option was also used to 
obtain robust standard errors for the parameter estimates in order to control for mild 
violation of underlying assumptions.
435
 However, where count data was not normally 
distributed, the dispersion of the data was tested by examining the mean and variance.
436
 
Where the variance was similar to or the same as the mean, this indicated over 
dispersion was not present and poisson regression was used. Where the variance was 
greater than the mean, this indicated over dispersion and therefore, negative binomial 
regression was used.
437
 As with the poisson regression, incident rate ratios were 
calculated and the ‘exposure’ option was used to adjust regression estimates according 
to follow-up time. 
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As with the analysis of the risk factors in the case control study, results were presented 
in the following way: effect size; confidence intervals; p-values. In addition, as with the 
case control analyses, a more liberal p value of <0.1 has been employed, two-tailed tests 
have been utilised and analyses were run first based on the baseline diagnoses and then 
on the lifetime diagnoses. 
 
5.6.8.1. Power calculations 
The data for this section of the thesis was dictated by the number of cases collected in 
the case control section of the study and thus the numbers of cases, and numbers of 
specific diagnoses were not adjustable. However, a power calculation was conducted 
using NQuery Advisor
426
 to determine what size of effects could be detected by the 
data. As there were many statistical tests, the power calculation was based on one of the 
comparisons: a comparison of PMD cases and schizophrenia cases in the outcome of 
episodic versus other illness course type. A two group chi-square test with a 0.050 two-
sided significance level would have 80% power to detect a difference between Group 1 
(schizophrenia cases) with a proportion of 0.200 (20% of cases episodic) and Group 2 
(PMD cases) with a proportion of 0.400 (40% of cases episodic; odds ratio of 2.667) 













CHAPTER 6. Results of social adversity risk factors for PMD and SAD 
 
“... differential exposure to stressful life events is substantially less important than 
differential vulnerability to stress in determining the relationships between mental 
health and social class, gender, and marital status.”70 
Turner, Wheaton and Lloyd (1995) 
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6.1. Aims of the chapter 
The aim of this chapter was to describe the baseline characteristics of the sample under 
examination in this thesis and to examine the social adversity risk factors described in 
chapter 3. As this thesis aimed to improve on previous research by examining risk 
factors by both baseline and lifetime diagnosis, diagnostic change will be briefly 
described in this chapter, but fully explored in chapter 7. A comparison of differences in 
findings by baseline and lifetime diagnosis will be discussed in chapter 8. 
 
6.2. Baseline sample characteristics 
6.2.1. Numbers 
A total of 511 first episode psychosis cases were identified at baseline. During the 
follow-up phase of the study, it came to light that six cases did not meet the inclusion 
criteria at baseline as they were either not first episode at baseline or had an organic 
psychosis at baseline. These six cases were therefore excluded from the baseline 
analyses which led to a total number of 505 cases. These 505 cases consisted of 304 
from the London site and 201 from the Nottingham site. Over, the 2-year period from 
1st September 1997 to the 31st August 1999 in which all eligible cases were included in 
the study, a total of 444 were identified. A further 61 participants were identified during 
the leakage phase of the study. A total of 391 controls were recruited, 183 from London 
and 208 from Nottingham. 
 
6.2.2. Demographic and clinical variables for the total sample 
A description of the baseline demographic characteristics for cases compared with 
controls is shown in Table 6-1. From this table it can be seen that there was evidence 
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that cases were different from the controls on all demographic variables except place of 
birth (Table 6-1). This is to be expected as sociodemographic variables are often 
associated with disease.
424
 This is not further explored here as these variables are 
included in the risk factors analysis and so are further explored in section 6.3. 
 
Table 6-1: Overall demographic variables for cases versus controls at baseline 
 Cases (n=505) Controls (n=391)   
 Median (IQR) Median (IQR) Mann-Whitney U P-value 
Age 29.00 (22-36) 35.00 (28-47) 8.295 <0.001 
 N (%) N (%) Chi2, df P-value 























































































































Some variables have missing cases (see Table 6-5).  IQR = Interquartile range.  
 
 
Table 6-2 presents the clinical variables for the cases. From this table, it can be seen that 
the most common baseline ICD-10 diagnosis was schizophrenia. There were 72 PMD 
cases and 21 SAD cases.  
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Table 6-2: Overall clinical variables for all cases at baseline 
 Cases (n505) 
 Median (IQR) 
DUP in days 
 
59 (15-231) 
Age of onset  27.50 (21-35) 
 N (%) 






Other / Unspecified nonorganic disorder 
Acute and transient psychosis  














Mode of Onset: 
Sudden 
Precipitous 
Acute, no previous symptoms 
Acute, with previous symptoms 
Insidious 


















































Some variables have missing cases (see Table 6-6). IQR = Interquartile range. 
 
The groups of interest, PMD and SAD, were compared with the other major diagnostic 
groups, schizophrenia and bipolar disorder. Cases with a diagnosis of a manic episode 
with psychotic symptoms (F30) or bipolar affective disorder with psychotic symptoms 
(F31) were both included as bipolar disorder. The remaining diagnoses were not used in 
the risk factor analysis as they were not the focus of this thesis and the low numbers 
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were considered a power problem. Therefore, they are not included in the rest of this 
chapter. Removal of these cases resulted in a total number of cases in the four key 
diagnostic groups of 381. 
 
A description of the baseline demographic characteristics comparing the four key 
diagnostic groups is presented in Table 6-3. From this table, it can be seen that there 
was evidence that the diagnostic groups were different from each other in terms of age, 
centre, gender, ethnicity, relationship status and education level. A post hoc analysis has 
not been conducted to examine between which diagnostic groups the differences in 
these variables exist as the focus of the risk factors analysis is on whether the risk 
factors for each diagnostic group compared with controls, and this is explored in section 
6.3.  
 
Table 6-4 shows the clinical variables by different diagnoses. It shows that there was 
evidence of a difference between the diagnostic groups for all the clinical variables. A 
post hoc analysis has not been conducted to examine where the differences in these 
variables between the diagnostic groups exist in clinical variables as this was beyond 
the scope of what was feasible in this thesis. 
 
The demographic and clinical variables above were intended to characterise the sample 
and as such are as detailed as possible. A number of these variables were modified in 
order to simplify the analyses and increase power. These modified variables are used 





Table 6-3: Overall demographic variables for cases divided by baseline diagnoses 
 PMD (n72) SAD (n21) Schizophrenia (n218) Bipolar (n70)   
 Median (IQR) Median (IQR) Median (IQR) Median (IQR) Kruskal Wallis, df P value 








7.938, 3 0.047 













































































0.010 (Fisher’s exact) 






































































































Some variables have missing cases (see Table 6-5).  IQR = Interquartile range.  
 209 
Table 6-4: Overall clinical variables for cases divided by baseline diagnoses 
 PMD (n72) SAD (n21) Schizophrenia (n218) Bipolar (n70)   
 Median (IQR) Median (IQR) Median (IQR) Median (IQR) Kruskal Wallis, df P value 
DUP in days 41.50 (15.00-123.00) 51.00 (17.00-92.00) 123.50 (31.00-443.00) 21.00 (7.00-66.00) 48.829, 3 <0.001 










10.436, 3 0.015 
 N (%) N (%) N (%) N (%) Chi2, df P value 
Mode of Onset: 
Sudden 
Precipitous 
Acute, no previous symptoms 
Acute, with previous symptoms 
Insidious 

























































































































































Some variables have missing cases (see Table 6-6). IQR = Interquartile range. 
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6.2.3. Missing data 
Table 6-5 and Table 6-6 show the differences in missing data for each risk factor 
variable used in the adjusted and unadjusted analyses comparing cases and controls and 
diagnostic groups respectively. Table 6-5 shows evidence that there was a difference 
between the cases and controls in terms of missing data in most of the risk factor 
variables. This difference in missing data is to be expected due to the fact that controls 
volunteered themselves to be in the study and a replacement control was found when a 
control refused participation. Cases on the other hand were selected due to their being a 
case and an alternative could not be obtained. The potential bias resulting from missing 
data is discussed in chapter 8. 
 
Table 6-6 shows that there are no differences in missing data between the diagnostic 
groups in most of the variables examined. However, there was evidence of differences 
between different diagnostic groups in lifetime relationship and employment statuses, 
family contacts, family mental health history and childhood adversity data. This has 
implications for the possibility of bias which are considered in chapter 8.  
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 N (%) N (%) N (%) N (%) Chi2, df P value 





























































































































6.3. Social adversity risk factors by baseline diagnosis 
6.3.1. Unadjusted analyses  
To test the hypothesis that psychosocial risk factors are associated with PMD and SAD, 
comparisons were made for each baseline diagnostic group (PMD and SAD plus the 
comparison groups of schizophrenia and bipolar disorder) compared with controls. This 
is shown in Table 6-7 and Table 6-8.  
 


















Age 35 (28-47) 32.5 (25-
41) 
28 (24-38) 29 (22-35) 27 (23-33) 
 N (%) N (%) N (%) N (%) N (%) 






















































































































































































Employment Status:  



































Contact with friends: 
Daily – monthly 

















Contact with family: 
Daily – monthly 





































































































































































































IQR = Interquartile range. Numbers in each group available in Table 6-5 and Table 6-6.
 216 
Table 6-8: Unadjusted odds ratios and 95% CIs for each baseline diagnosis compared with controls  


















Age 0.97 0.95-1.00 0.022 0.97 0.92-1.01 0.141 0.94 0.93-0.96 <0.001 0.93 0.91-0.96 <0.001 














































































































































































































































































































































































































































































































































Contact with friends: 
Daily – 
monthly 


















































Contact with family: 
Daily – 
monthly 











































































































































































































































































































































































































































































uOR = unadjusted odds ratio; CI = confidence intervals; OR calculated using weighted data. 
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The unadjusted analyses showed strong evidence that the following factors were 
associated with an increased odds of receiving a baseline diagnosis of PMD compared 
with being a control: being Asian (OR 5.70, 95% CI 1.95-16.66, p=0.001) or ‘other’ 
ethnicity (OR 11.72, 95% CI 3.72-36.92, p<0.001); being single (OR 2.49, 95% CI 
1.47-4.22, p=0.001); never having had a long term relationship (OR 2.21, 95% CI 1.23-
3.97, p=0.008); having contact with friends less than monthly (OR 4.60, 95% CI 1.98-
10.69, p<0.001); having no close confidants (OR 4.73, 95% CI 2.32-9.67, p<0.001); 
having a family history of mental illness (OR 5.14, 95% CI 2.58-10.22, p<0.001), 
family history of psychosis (OR 5.70, 95% CI 2.37-13.71, p<0.001), parental history of 
mental illness (OR 6.61, 95% CI 2.54-17.20, p<0.001), or parental history of psychosis 
(OR 7.34, 95% CI 2.24-23.99, p=0.001);  having a severe life event during the year 
before onset of illness (OR 4.57, 95% CI 1.75-11.92, p=0.002); or having a severe life 
difficulty in the year before onset of illness (OR 4.49, 95% CI 1.65-12.20, p=0.003). 
There was moderate evidence that the following factors were associated with an 
increased odds of receiving a baseline diagnosis of PMD compared with being a 
control: lower age (OR 0.97, 95% CI 0.95-1.00, p=0.022); not having been born in the 
UK (OR 1.76, 95% CI 1.00-3.09, p=0.049); having school as the highest education level 
(OR 2.40, 95% CI 1.18-4.85, p=0.015). There was some weak evidence that the 
following factors were associated with an increased odds of receiving a baseline 
diagnosis of PMD compared with being a control: being unemployed (OR 1.58, 95% CI 
0.94-2.64, p=0.081); and having contact with family less than monthly (OR 2.99, 95% 
CI 0.88-10.14, p=0.079). Interestingly, there was no evidence that childhood adversity 
was associated with an increased odds of receiving a baseline diagnosis of PMD (OR 
1.31, 95% CI 0.61-2.79, p=0.489).  
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The unadjusted analyses showed strong evidence that the following factors were 
associated with an increased odds of receiving a baseline diagnosis of SAD compared 
with being a control: being single (OR 5.45, 95% CI 1.95-15.21, p=0.001); living alone 
(OR 3.34, 95% CI 1.37-8.17, p=0.008); having contact with family less than monthly 
(OR 9.34, 95% CI 2.23-39.17, p=0.002); having no close confidants (OR 5.55, 95% CI 
1.62-19.00, p=0.006); and a having a family history of mental illness (OR 8.67, 95% CI 
3.06-24.60, p<0.001), family history of psychosis (OR 11.41, 95% CI 3.50-37.15, 
p<0.001), parental history of mental illness (OR 7.71, 95% CI 1.90-31.33, p=0.004), 
parental history of psychosis (OR 8.48, 95% CI 1.56-46.12, p=0.013). There was 
moderate evidence that the being unemployed was associated with an increased odds of 
receiving a baseline diagnosis of SAD compared with being a control (OR 2.77, 95% CI 
1.08-7.11, p=0.034). There was some weak evidence that the following factors were 
associated with increased odds of receiving a baseline diagnosis of SAD: being male 
(OR 2.35, 95% CI 0.95-5.80, p=0.065); being Black African (OR 3.28, 95% CI 0.99-
10.87, p=0.052); and never having had a long term relationship (OR 2.53, 95% CI 0.93-
6.87, p=0.068). Table 6-8 also indicates that having experienced more types of 
childhood adversity was associated with a reduced odds of SAD (OR 0.58, 95% CI 
0.36-0.93, p=0.024). However, this is highly likely to be a spurious finding due to the 
very small number of cases (n7) available for the analysis due to missing data. The 
small numbers included in the analysis (and therefore low power) are  also the likely 
cause for the finding that several factors which were not statistically significant at p < 
0.1 but had ORs which were comparable or more extreme than in other diagnostic 
groups which did achieve statistical significance at the p<0.1 level. These factors were: 
lower age; never having worked; contact with friends less than monthly; and 
experiencing a life event during the year before onset of illness.  
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There was evidence (to varying degrees) that all factors investigated were associated 
with an increased odds of receiving a baseline diagnosis of schizophrenia except being 
white non-British and experiencing a life event during the year before onset of illness. 
Similarly, for cases with bipolar disorder, most factors were associated with an 
increased odds of receiving a diagnosis of bipolar disorder except gender, being white 
non-British, place of birth, level of education, contact with family, childhood adversity 
and experiencing a life event or life difficulty during the year before onset of illness. 
 
6.3.2. Adjusted analyses 
As might be expected, the numbers for the SAD group were very low. Therefore, it was 
not appropriate to use the data from this group in an adjusted model. For the other three 
diagnostic groups, the above regression analyses were run again but this time adjusting 
for four key variables; age, gender, centre and ethnicity (see Appendix O for adjusted 
results).  
 
The differences that arise once gender, age, centre and ethnicity are controlled for is that 
there is now evidence that being single is associated with an increased odds of receiving 
a baseline diagnosis of PMD compared with being a control (OR 2.05, 95% CI 1.19-
3.53, p=0.009), and the following factors are no longer associated with an increased 
odds of receiving a baseline diagnosis of PMD compared with being a control: never 
having had a long term relationship (OR 0.79, 95% CI 0.13-4.94, p=0.799); and not 
having been born in the UK (OR 1.20, 95% CI 0.53-2.72, p=0.667). 
 
Once gender, age, centre and ethnicity had been controlled for, there was evidence (to 
varying degrees) that all risk factors except place of birth, ever worked, and life events 
were associated with an increased odd of receiving a diagnosis of schizophrenia 
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compared with being a control. For cases with bipolar disorder, the same factors that 
were associated with increased odds in the unadjusted analysis were significantly 
associated in the adjusted analyses: being single, never having had a long term 
relationship, living alone, being unemployed, having contact with friends less than 
monthly, having no close confidants and family or parental history of mental illness or 
psychosis. However, never having worked was no longer associated with a diagnosis of 
bipolar disorder, and having a life event in the year prior to onset became significantly 
associated with increased odds of bipolar disorder.  
 
Both the adjusted and unadjusted analyses provided evidence that more of the 
psychosocial risk factors investigated in this thesis were associated with schizophrenia 
and bipolar disorder than PMD (and SAD within the unadjusted analyses only).  
 
6.3.3. Exploratory analysis of life events based on baseline diagnosis 
Exploratory analyses were conducted to investigate life events and difficulties. Results 
are presented in Table 6-9 and Table 6-10. Table 6-10 indicates that the odds of PMD 
cases having experienced both a life event and a life difficulty during the year prior to 
illness onset was around 5 times higher than for controls (OR 5.35, 95% CI 2.04-14.03, 
p=0.001), compared with only around 50% higher (OR 1.56, 95% CI 0.63-3.87, 
p=0.342) for schizophrenia cases and around 2 times higher (OR 1.94, 95% CI 0.56-
6.74, p=0.294) for bipolar disorder cases. In contrast, the odds of schizophrenia cases 
having experienced either a life event OR a life difficulty during the year prior to illness 
onset was around 8 times higher than for controls (OR 8.54, 95% CI 2.85-25.56, 
p<0.001), compared with around 6 times higher (OR 6.83, 95% CI 1.92-24.29, p=0.003) 
for PMD cases and 2 times higher (OR 2.28, 95% CI 0.74-7.01, p=0.152) for bipolar 
disorder cases. However, these analyses are based on small sample sizes and must 
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therefore be interpreted with caution. The results based on the SAD group are based on 
a total of 3 cases and therefore no conclusions can be drawn from these findings.  
 
As previous research has found that the humiliation/entrapment component of the LEDs 
is more highly associated with depression than other key components such as loss or 
danger,
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 an exploratory analysis examining humiliation and odds for PMD was 
performed. Table 6-11 contains the numbers for each diagnostic group for 
humiliation/entrapment events at different time points. Table 6-12 shows that there was 
evidence that independent humiliation difficulties of any type in the year pre onset were 
associated with an increased odds of a baseline diagnosis of PMD (OR 12.85, 95% CI 
3.62-45.67, p<0.001), schizophrenia (OR 6.68, 95% CI 2.04-21.78, p=0.002) and 
bipolar disorder (OR 6.36, 95% CI 1.36-29.75, p=0.019), but PMD had the highest odds 
ratio (although there is a large amount of overlap and some of these confidence intervals 
are very wide indicating imprecise estimates of effects). There was strong evidence that 
PMD was associated with an increased odds of having experienced an independent 
humiliation or entrapment event at 4 weeks (OR 21.74, 95% CI 2.14-220.90, p=0.009), 
3 months (OR 13.30, 95% CI 2.91-60.88, p=0.001), 6 months (OR 10.70, 95% CI 2.90-
39.41, p<0.001) and 1 year (OR 5.81, 95% CI 1.81-18.63, p=0.003) prior to onset. 
There was no evidence for this association in bipolar disorder cases and only very weak 
evidence for this association at 3 and 6 months in schizophrenia cases. There was also 
evidence of a temporal relationship in the PMD cases, with higher odds ratios at time 
periods closer to onset. The results based on the SAD group are based on a total of 3 
cases and therefore no conclusions can be drawn from these findings although they do 
follow the exact same pattern as the PMD group. Independent humiliation or 
entrapment severe events during the 1 week prior to onset were unable to be computed 
as no controls had this type of event in this time period. 
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Table 6-9: Life events and difficulties exploratory analysis based on baseline diagnosis 
 Control PMD SAD Schizophrenia Bipolar 
 N (%) N (%) N (%) N (%) N (%) 










































































Table 6-10: Unadjusted odds ratios and 95% CIs for the life events and difficulties exploratory analysis based on baseline diagnosis 














































































































































































uOR = unadjusted odds ratio; CI = confidence intervals; OR calculated using weighted data. 
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Table 6-11: Humiliation exploratory analysis based on baseline diagnosis 
 Control PMD SAD Schizophrenia Bipolar 
 N (%) N (%) N (%) N (%) N (%) 













































































































Table 6-12: Unadjusted odds ratios and 95% CIs for the humiliation exploratory analysis based on baseline diagnosis 
 PMD (n72) vs. controls SAD (n20) vs. controls Schizophrenia (n214) vs. 
controls 



















difficulty of any type in the 
year pre onset 
 
12.85 3.62-45.67 <0.001 27.54 3.18-238.34 0.003 6.68 2.04-21.78 0.002 6.36 1.36-29.75 0.019 
Any independent humiliation 
or entrapment severe event 1 
week pre onset 
 
Unable to compute as no controls had this type of event in this time period 
Any independent humiliation 
or entrapment severe event 4 
weeks pre onset 
21.74 2.14-220.90 0.009 45.9 2.27-926.66 0.013 3.72 0.23-61.30 0.358 8.61 0.51-145.24 0.135 
Any independent humiliation 
or entrapment severe event 3 
months pre onset 
13.30 2.91-60.88 0.001 22.62 1.57-324.96 0.022 4.11 0.79-21.38 0.093 2.83 0.28-28.94 0.381 
Any independent humiliation 
or entrapment severe event 6 
months pre onset 
10.70 2.90-39.41 <0.001 13.37 1.03-174.13 0.048 3.34 0.85-13.20 0.085 3.82 0.67-21.62 0.130 
Any independent humiliation 
or entrapment severe event 12 
months pre onset 
5.81 1.81-18.63 0.003 7.26 0.60-88.40 0.120 2.59 0.81-8.35 0.110 2.23 0.43-11.50 0.336 
uOR = unadjusted odds ratio; OR calculated using weighted data. 
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6.4. Diagnostic change 
For the purpose of being able to examine social adversity risk factors based on lifetime 
diagnosis, diagnostic change will be described briefly here but is further detailed in 
chapter 7. 
 
Table 6-13 shows the number of cases with each diagnosis at baseline and follow-up. 
As can be seen in the table, there are 21 less cases with PMD at follow-up compared 
with baseline and 2 less cases of SAD. Twenty-eight cases were unable to be given a 
lifetime diagnosis due to lack of information. 
 
Table 6-13: Number of cases with each baseline and follow-up diagnosis 
Diagnosis Baseline n (%) Follow-up n (%) 
Schizophrenia 218 (43.17) 225 (47.17) 
PMD 72 (14.26) 51 (10.69) 
Bipolar disorder/mania 70 (13.86) 73 (15.30) 
SAD 21 (4.16) 19 (3.98) 
SABP/SAM 10 (1.98) 20 (4.19) 
Other / Unspecified nonorganic disorder 36 (7.13) 29 (6.08) 
Acute and transient psychosis 29 (5.74) 16 (3.35) 
Drug / alcohol induced psychosis  26 (5.15) 34 (7.13) 
Delusional disorder 22 (4.36) 8 (1.68) 
Schizotypal disorder 1 (0.20) 1 (0.21) 
Other disorder - 1 (0.21) 
No follow-up - 28 (5.54) 
 
6.5. Social adversity risk factors by lifetime diagnosis 
6.5.1. Missing Data 
Table 6-14 shows that there are no differences in missing data between the diagnostic 
groups in many of the variables examined. However, there was evidence of differences 
between different diagnostic groups in missing data in the following variables: lifetime 
relationship, contact with friends, contact with family, family mental health history, life 
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events and childhood adversity data (possible bias associated with this is considered in 
chapter 8).  
 
















































































































































































































































































































 N (%) N (%) N (%) N (%) Chi2, df P value 































































































































































































*: p<0.05; **: p<0.01; ***: p<0.001*** 
 
6.5.2. Unadjusted analyses  
To test the hypothesis that psychosocial risk factors are associated with PMD and SAD, 
comparisons were made for each lifetime diagnostic group (PMD and SAD plus the 
comparison groups of schizophrenia and bipolar disorder) compared with controls. This 
is shown in Table 6-15 & Table 6-16.  
 230 


















Age 35 (28-47) 36 (30-46) 29 (22-41) 28 (22-35) 27 (23-33) 
 N (%) N (%) N (%) N (%) N (%) 




















































































































































































Employment Status:  



































Contact with friends: 
Daily – monthly 

















Contact with family: 
Daily – monthly 














































































Yes 16 (4.09) 13 (30.95) 5 (38.46) 46 (30.67) 14 (24.14) 






















































































































IQR=Interquartile range. Numbers in each group reported in Table 6-14. 
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Table 6-16: Unadjusted odds ratios and 95% CIs for each lifetime diagnosis compared with controls  
 PMD (n51) vs. controls SAD (n19) vs. controls Schizophrenia (n225) vs. 
controls 


















Age 1.00 0.98-1.03 0.693 0.95 0.91-0.99 0.011 0.94 0.92-0.95 <0.001 0.93 0.91-0.96 <0.001 


























































































































































































































































































































































































 PMD (n51) vs. controls SAD (n19) vs. controls Schizophrenia (n225) vs. 
controls 


















School 3.15 1.27-7.81 0.013 1.91 0.51-7.12 0.335 3.65 2.17-6.12 <0.001 1.01 0.53-1.93 0.973 














































































Contact with friends: 
Daily – monthly 


















































Contact with family: 
Daily – monthly 














Unable to compute as no SAD 
cases reported no contact / less 










































































































































































































































 PMD (n51) vs. controls SAD (n19) vs. controls Schizophrenia (n225) vs. 
controls 


















Yes 12.72 3.98-40.61 <0.001 19.07 4.11-88.53 <0.001 12.72 4.99-32.38 <0.001 13.25 4.52-38.78 <0.001 












Unable to compute as no SAD 































Unable to compute as no SAD 


























































Number of Childhood 
Adversity Factors 
1.28 1.03-1.60 0.028 0.98 0.76-1.26 0.873 1.24 1.07-1.43 0.004 1.20 0.97-1.47 0.087 
uOR = unadjusted odds ratio; CI = confidence intervals; OR calculated using weighted data. 
 235 
The unadjusted analyses showed strong evidence that the following factors were 
associated with an increased odds of receiving a lifetime diagnosis of PMD compared 
with being a control: being of ‘other’ ethnicity (OR 6.22, 95% CI 1.58-24.43, p=0.009); 
living alone (OR 2.23, 95% CI 1.23-4.04, p=0.008); having contact with friends less 
than monthly (OR 4.87, 95% CI 1.99-12.46, p=0.001); having no close confidants (OR 
5.09, 95% CI 2.28-11.36, p<0.001); and having a family history of mental illness (OR 
10.23, 95% CI 4.96-21.08, p<0.001), family history of psychosis (OR 12.27, 95% CI 
5.21-28.89, p<0.001), parental history of mental illness (OR 11.24, 95% CI 4.32-29.25, 
p<0.001), or parental history of psychosis (OR 12.72, 95% CI 3.98-40.61, p<0.001). 
There was strong evidence that having ever worked was associated with a reduced odds 
of PMD (OR >0.01, 95% CI >0.01 to >0.01, p<0.001). There was moderate evidence 
that the following factors were associated with an increased odds of receiving a lifetime 
diagnosis of PMD compared with being a control: being Asian (OR 3.89, 95% CI 1.10-
13.67, p=0.034); being single (OR 1.48, 95% CI 1.02-3.34, p=0.044); having school as 
the highest education level (OR 3.15, 95% CI 1.27-7.81, p=0.013); being unemployed 
(OR 2.06, 95% CI 1.13-3.75, p=0.018); having a severe life event during the year before 
onset of illness (OR 3.28, 95% CI 1.03-10.42, p=0.044); having a severe life difficulty 
in the year before onset of illness (OR 3.79, 95% CI 1.11-12.93, p=0.034); and having 
experienced childhood adversity (OR 2.61, 95% CI 1.01-6.73, p=0.047). There was also 
moderate evidence that increasing numbers of types of childhood adversity was 
associated with increasing odds of PMD (OR 1.28, 95% CI 1.03-1.60, p=0.028). 
 
The unadjusted analyses showed evidence that very few factors were associated with 
increased odds of receiving a lifetime diagnosis of SAD. However, there was strong 
evidence that the following were associated with a lifetime diagnosis of SAD: having a 
family history of mental illness (OR 14.45, 95% CI 4.53-46.06, p<0.001), family history 
 236 
of psychosis (OR 17.11, 95% CI 4.92-59.53, p<0.001), parental history of mental illness 
(OR 10.79, 95% CI 2.56-45.60, p=0.001), or parental history of psychosis (OR 19.07, 
95% CI 4.11-88.53, p<0.001). There was moderate evidence that the following were 
associated with increased odds of receiving a lifetime diagnosis of SAD: being younger 
(OR 0.95, 95% CI 0.91-0.99, p=0.011); and having no close confidants (OR 4.63, 95% 
CI 1.18-18.20, p=0.028). There was some weak evidence that being African Caribbean 
(OR 2.76, 95% CI 0.86-8.84, p=0.088) and being single (OR 2.34, 95% CI 0.92-5.97, 
p=0.075) was associated with an increased odds of receiving a lifetime diagnosis of 
SAD. 
 
Within the analyses of SAD cases, there were several factors which were not 
statistically significant but for which ORs which were comparable or more extreme than 
in other diagnostic groups which were statistically significant. This is likely due to a 
power issue. These factors were: never having had a long term relationship; never 
having worked; contact with friends less than monthly; and having experienced 
childhood adversity. Contact with family, life events and life difficulties could not be 
calculated as no SAD cases reported less than monthly contacts with family, and none 
reported any life events or difficulties. The data on SAD cases is also based on 
extremely low numbers and therefore need to be interpreted with extreme caution. 
 
There was evidence (to varying degrees) that all factors investigated were associated 
with an increased odds of receiving a lifetime diagnosis of schizophrenia being white 
non-British and experiencing a life event during the year before onset of illness. There 
was evidence (to varying degrees) that the following factors were associated with an 
increased odds of receiving a lifetime diagnosis of bipolar disorder: being younger; 
being from London; being Black African, African Caribbean, Asian or ‘other’ ethnicity; 
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being single; never having had a long term relationship; having no close confidants; 
having a family history or a parental history of mental illness or psychosis; having a 
severe life event during the year before onset of illness; having a severe life difficulty in 
the year before onset of illness; having experience childhood adversity; and an 
increasing number of types of childhood adversity. 
 
Important differences but also important similarities were picked up between the 
baseline and lifetime unadjusted analyses. Both the analyses based on the baseline and 
based on the life time diagnoses found evidence (to varying degrees) that the following 
risk factors were associated with an increased odds of PMD compared with controls: 
being Asian or ‘other’ ethnicity; being single; having school as the highest level of 
education; being unemployed; having contact with friends less than monthly; having no 
close confidants; having a family or parental history of mental illness or psychosis; 
having experienced a life event in the year prior to onset; and having experienced a life 
difficulty. Differences between the analyses were that baseline analyses showed 
evidence that the following risk factors were associated with an increased odds of PMD 
compared with controls, but this was not supported by the life time diagnoses (i.e. the 
odds ratio moved closer to one and the p-value increased to over 0.1): being younger 
(OR 0.97 versus OR 1.00); having not been born in the UK (OR 1.76 versus OR 1.37); 
never having had a long term relationship (OR 2.21 versus OR 1.62); and having 
contact with family less than monthly (OR 2.99 versus OR 1.97). There were also 
differences between the analyses in that life time analyses showed evidence that the 
following risk factors were associated with an increased odds of PMD compared with 
controls, but this was not supported by the baseline diagnoses (i.e. in the baseline 
analyses, the odds ratio was closer to one and the p-value was over 0.1): living alone 
(OR 2.23 versus OR 1.39); having worked (never having worked OR >0.01 versus OR 
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1.70); having experienced childhood adversity (OR 2.61 versus OR 1.31); and having 
experienced an increasing number of different types of childhood adversity (OR 1.28 
versus OR 1.08). 
 
Both the unadjusted analyses based on the baseline and based on the lifetime diagnoses 
found evidence (to varying degrees) that the following risk factors were associated with 
an increased odds of SAD compared with controls: being single; having no close 
confidants; and having a family or parental history of mental illness or psychosis. 
Differences between the analyses were that baseline analyses showed evidence that the 
following risk factors were associated with an increased odds of SAD compared with 
controls, but this was not supported by the lifetime diagnoses (i.e. the odds ratio moved 
closer to one and the p-value increased to over 0.1): being male (OR 2.35 versus OR 
1.60); being Black African (OR 3.28 versus OR 1.91); never having had a long term 
relationship (OR 2.52 versus OR 2.26); living alone (OR 3.34 versus OR 1.46); being 
unemployed (OR 2.77 versus OR 0.87). Differences between the analyses were that 
lifetime analyses showed evidence that the following risk factors were associated with 
an increased odds of SAD compared with controls, but this was not supported by the 
baseline diagnoses (i.e. in the baseline analyses, the odds ratio was closer to one and the 
p-value was over 0.1): being younger (OR 0.95 versus OR 0.97) and being African-
Caribbean (OR 2.76 versus OR1.18).  
 
6.5.3. Adjusted analyses  
As in adjusted analyses based on the baseline diagnoses, the numbers in the SAD group 
were very low. Therefore, it is not appropriate to use the data from this group into an 
adjusted model. For the other three diagnostic groups, the above regression analyses 
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were run again but this time adjusting for four key variables; age, gender, centre and 
ethnicity (see Appendix O for adjusted analyses).   
 
The only differences which arose between the adjusted and unadjusted analyses of risk 
factors in PMD cases was the degree of evidence that was detected, i.e. the evidence for 
some variables got slightly less and for others slightly more. 
 
Once gender, age, centre and ethnicity were controlled for, there was evidence (to 
varying degrees) that all risk factors except place of birth and ever worked were 
significantly associated with an increased odds of receiving a lifetime diagnosis of 
schizophrenia. The confidence interval and p-values were not able to be calculated for 
life difficulties data due to the numbers being so low so although the odds ratio is fairly 
high (3.36), no conclusions can be reached about this data. For cases with bipolar 
disorder, there was evidence that mostly the same factors that were associated with an 
increased odds in the unadjusted analysis were significantly associated in the adjusted 
analyses: being single, never having had a long term relationship, having no close 
confidants and family or parental history of mental illness or psychosis and 
experiencing a life event in the year pre onset. As with the other diagnoses, it was not 
possible to calculate the confidence intervals and p-values for life difficulties data due 
to the numbers being so low so although the odds ratio is fairly high (3.61), no 
conclusions can be reached about this data. After adjusting for gender, age, centre and 
ethnicity, evidence became stronger for an association with employment status (OR 
1.58, 95% CI 0.94-2.64, p=0.082), but weaker for childhood adversity (OR 1.55, 95% 
CI 0.65-3.71, p=0.323) and the number of different types of childhood adversities (OR 
1.15, 95% CI 0.91-1.46, p=0.241).  
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As with the baseline diagnosis analyses, both the adjusted and unadjusted analyses 
provided evidence that more of the psychosocial risk factors investigated in this thesis 
were associated with schizophrenia and bipolar disorder than PMD (and SAD within the 
unadjusted analyses only).  
 
Important differences but also important similarities were picked up between the 
baseline and lifetime adjusted analyses. Both the adjusted analyses based on the 
baseline and based on the life time diagnoses found evidence (to varying degrees) that 
the following risk factors were associated with an increased odds of PMD compared 
with controls: being single; having school as the highest level of education; being 
unemployed; having contact with friends less than monthly; having no close confidants; 
having a family or parental history of mental illness or psychosis; and having 
experienced a life event in the year prior to onset. In both the baseline diagnosis and 
lifetime diagnosis analyses, the effect size of the association between PMD and life 
difficulties was 2.71 or over. However, in the lifetime diagnosis analyses, the 
uncertainty surrounding the estimate was unable to be calculated. There were some 
differences between the baseline and lifetime diagnosis analyses. The baseline analyses 
showed evidence that the following risk factors were associated with an increased odds 
of PMD compared with controls, but this was not supported by the life time diagnoses 
(i.e. the odds ratio moved closer to one and the p-value increased to over 0.1): having 
contact with family less than monthly (OR 3.15 versus OR 1.83). There were also 
differences between the analyses in that life time analyses showed evidence that the 
following risk factors were associated with an increased odds of PMD compared with 
controls, but this was not supported by the baseline diagnoses (i.e. in the baseline 
analyses, the odds ratio was closer to one and the p-value was over 0.1): living alone 
(OR 2.26 versus OR 1.41); having worked (never having worked OR <0.01versus OR 
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0.79); having experienced childhood adversity (OR 2.57 versus OR 1.30); and having 
experienced an increasing number of different types of childhood adversity (OR 1.26 
versus OR 1.07). 
 
6.5.4. Exploratory analysis of life events based on lifetime diagnosis 
Exploratory analyses based on lifetime diagnoses were conducted to investigate life 
events and life difficulties. Results are presented in Table 6-17 and Table 6-18. Table 
6-18 reveals that the odds of PMD cases having experienced both a life event and a life 
difficulty during the year prior to illness onset was 4.17 (95% CI 1.28-13.54, p=0.018) 
times the odds of controls, compared with only 2.11 (95% CI 0.89-5.02, p=0.09) for 
schizophrenia cases and 3.98 (95% CI 1.48-10.67, p=0.006) for bipolar disorder cases. 
On the other hand, the odds of schizophrenia cases having experienced either a life 
event or a life difficulty was 11.76 (95% CI 3.43-40.35, p<0.001) the odds of controls, 
compared with 3.79 (95% CI 1.00-14.41, p=0.050) for PMD cases and 4.84 (95% CI 
1.55-15.13, p=0.007) for bipolar disorder cases. The results for the SAD group were 
based on a total of 2 cases neither of whom experienced a life event or difficulty and so 
the ORs could not be calculated. Therefore no conclusions can be drawn on the SAD 
cases.  
 
An exploratory analysis examining humiliation/entrapment and odds for PMD using 
lifetime diagnosis was performed. Table 6-19 contains the numbers for each diagnostic 
group for humiliation/entrapment events at different time points.  
 242 
 
Table 6-20 shows that independent humiliation difficulties of any type in the year pre 
onset were significantly associated with a diagnosis of PMD (OR 12.24, 95% CI 2.78-
53.80, p=0.001), schizophrenia (OR 6.48, 95% CI 1.99-21.10, p=0.002) and bipolar 
disorder (OR 8.61, 95% CI 2.24-33.07, p=0.002), with PMD having the highest OR. 
There was strong evidence that having experienced an independent humiliation or 
entrapment event at 4 weeks (OR 25.00, 95% CI 2.09-299.00, p=0.011), 3 months (OR 
20.10, 95% CI 3.88-104.24, p<0.001), 6 months (OR 11.88, 95% CI 2.70-52.27, 
p=0.001) and 1 year prior to onset (OR 6.45, 95% CI 1.65-25.16, p=0.007) was 
associated with an increased odds of PMD compared with controls.  
 
Within the exploratory analysis of life events and difficulties, plus in the humiliation 
events exploratory analyses, there are also some interesting similarities and differences 
in the baseline and lifetime diagnosis analyses. Schizophrenia has the highest odds ratio 
for having experienced a life event OR difficulty in both analyses but the effect is still 
present in PMD cases. However, this difference is magnified in the lifetime diagnoses 
with the effect size getting larger for schizophrenia cases and lower for PMD cases in 
the life time diagnoses. PMD cases have the highest odds ratio for having experienced a 
life event AND difficulty in both analyse. Although this is non-significant in 
schizophrenia cases in the baseline analyses, it does reach significance in the life time 
diagnoses. For bipolar cases, there is no evidence of an increased odds ratio of having 
experienced a life event OR a life difficulty, or a life event AND life difficulty when 
based on the baseline diagnoses, but there is evidence of an increased odds ratio for both 
these items when based on the lifetime diagnoses. 
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As for the analyses on humiliation life events and life difficulties, the baseline and 
lifetime analyses both find evidence that independent humiliation difficulties are 
associated with an increased odds ratio for all the diagnoses (except SAD cannot be 
estimated in the lifetime analyses due to low numbers). Both the baseline and lifetime 
analyses find evidence that independent humiliation or entrapment events at 4 weeks, 3 
months, 6 months and 12 months are associated with an increased odds of PMD 
compared with controls, and there is evidence of a temporal effect in both analyses with 
the effect getting stronger, the closer to onset. Both the baseline and the lifetime 
diagnosis analyses find some weak evidence that independent humiliation or entrapment 
events at certain points are associated with an increased odds of schizophrenia 
compared with controls. The baseline analyses reveal no association between 
independent humiliation or entrapment events and bipolar disorder. However, the 
lifetime diagnosis analyses reveal evidence that independent humiliation or entrapment 
events at 4 weeks, 3 months, 6 months and 12 months are associated with an increased 
odds of bipolar disorder, although with lesser effect sizes compared with PMD and 
without as strong evidence of a temporal effect. 
 
There was moderate to strong evidence of the same in the bipolar disorder group (4 
weeks: OR 13.75, 95% CI 1.19-159.27, p=0.036, 3 months: OR 7.14, 95% CI 1.34-
38.12, p=0.021, 6 months: OR 10.03, 95% CI 2.74-36.72, p<0.001 and 1 year: OR 5.81, 
95% CI 1.81-18.63, p=0.003). There was only moderate to weak evidence in the 
schizophrenia group that having experienced an independent humiliation or entrapment 
event at 4 weeks (OR 11.46, 95% CI 1.15-113.82, p=0.037), 3 months (OR 4.11, 95% 
CI 0.79-21.39, p=0.093), and 6 months (OR 3.45, 95% CI 0.87-13.64, p=0.077).  
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There was also evidence of a temporal relationship in having experienced an 
independent humiliation or entrapment event in PMD cases, with a higher OR at time 
periods closer to onset. It was not possible to compute the OR for the SAD group as no 
SAD cases experienced life events or difficulties.  
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Table 6-17: Life events and difficulties exploratory analysis based on lifetime diagnosis 
 Control PMD SAD Schizophrenia Bipolar 
 N (%) N (%) N (%) N (%) N (%) 









































































Table 6-18: Unadjusted odds ratios and 95% CIs for the life events and difficulties exploratory analysis based on lifetime diagnosis 
 PMD (n51) vs. controls SAD (n19) vs. controls Schizophrenia (n225) vs. 
controls 
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uOR = unadjusted odds ratio; CI = confidence intervals; OR calculated using weighted data.
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Table 6-19: Humiliation exploratory analysis based on lifetime diagnosis 
 Control PMD SAD Schizophrenia Bipolar 
 N (%) N (%) N (%) N (%) N (%) 















































































































Table 6-20: Unadjusted odds ratios and 95% CIs for the humiliation exploratory analysis based on lifetime diagnosis 



















difficulty of any type in the 
year pre onset 
 
12.24 2.78-53.80 0.001  
Unable to compute as no SAD 
cases experienced life events 
or difficulties 
6.48 1.99-21.10 0.002 8.61 2.24-33.07 0.002 
Any independent humiliation or 
entrapment severe event 1 week 
pre onset 
 
Unable to compute as no controls had this type of event in this time period 
Any independent humiliation or 
entrapment severe event 4 
weeks pre onset 
25.00 2.09-299.00 0.011  
Unable to compute as no SAD 
cases experienced life events 
or difficulties 
11.46 1.15-113.82 0.037 13.75 1.19-159.27 0.036 
Any independent humiliation or 
entrapment severe event 3 
months pre onset 
20.10 3.88-104.24 <0.001  
Unable to compute as no SAD 
cases experienced life events 
or difficulties 
4.11 0.79-21.39 0.093 7.14 1.34-38.12 0.021 
Any independent humiliation or 
entrapment severe event 6 
months pre onset 
11.88 2.70-52.27 0.001  
Unable to compute as no SAD 
cases experienced life events 
or difficulties 
3.45 0.87-13.64 0.077 10.03 2.74-36.72 <0.001 
Any independent humiliation or 
entrapment severe event 12 
months pre onset 
6.45 1.65-25.16 0.007  
Unable to compute as no SAD 
cases experienced life events 
or difficulties 
2.59 0.80-8.35 0.111 5.81 1.81-18.63 0.003 










CHAPTER 7. Results of clinical, social and service use outcomes 10 years after 
first episode of psychosis 
 
“A person with psychotic depression suffers a dangerous combination of 





7.1. Aims of the chapter 
This chapter aimed to describe and summarise the follow-up success for the entire 
incidence sample and to explore the clinical, social and service use outcomes of PMD 
and SAD cases compared with the other major psychotic diagnostic groups, 
schizophrenia and bipolar disorder. The importance of examining course of illness and 
outcome based on both baseline and lifetime diagnosis has already been discussed in 
chapter 4. Therefore, outcomes based on both baseline and lifetime diagnosis will be 
examined in section.  
 
7.2. Sample 
In the follow-up phase of the study, an attempt was made to trace all incidence cases 
identified in the case control study. As mentioned in Chapter 6, of the 511 cases 
included in the baseline analyses, six (1.2%) were excluded due to information that 
came to light after baseline that these patients either had an organic psychosis or were 
not first episode cases at baseline. Therefore, a total of 505 cases were included in the 
follow-up.  
 
7.3. Follow-up description and exploration 
7.3.1. Follow-up success 
As well as using case notes to determine outcomes, every effort was made to follow 
cases up with an interview to ensure the maximum amount of information was gained. 
This is reflected in the fact that patients were located, contacted and interviewed all over 
the UK. There were also several patients who were traced to outside the UK and had 
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telephone interviews conducted. This included one case in Ireland, one in Norway and 
one in New Zealand. 
 
7.3.2. Participant follow-up and functional outcomes 
Follow-up data covering a ten year period (minimum 8 years, range of 8-13 years) was 
available for 379 (75.1%) cases. A further 33 (6.5%) cases were dead at follow-up and 
26 (5.2%) were uncontactable as they had gone abroad (three cases had sufficient 
information at 8+ years although they were abroad when followed up at 10 years and 
are counted as followed up here). This left 67 cases (13.3%) who did not have a 10 year 
follow-up. As stated in the methods, cases were followed up using case notes which 
were supplemented with patient interview where possible. Table 7-1 gives the 
information on interview status. Twenty-one cases were traced to a current address but 
no contact with the participant was ever made and a further four were traced but they 
did not have sufficient capacity to consent to interview. 
 
Table 7-1: Interview status at follow-up 
Interview status N (%) 
Interviewed 208 (41.2) 
Dead 33 (6.5) 
Abroad 26 (5.2) 
Refused interview 167 (33.1) 
Traced, but no contact made 21 (4.2) 
Traced, but no capacity 4 (0.8) 
Not traced 46 (9.1) 
*Cases who were abroad but were interviewed were counted as interviewed here 
 
Table 7-2 presents the follow-up status of cases by baseline ICD-10 diagnosis. A chi-
squared test showed that there was no difference in the follow-up status by diagnosis 




Table 7-2: Follow-up status by baseline ICD-10 diagnosis 




Dead Aboard   





PMD  54 (75.0) 13 (18.1) 3 (4.2) 2 (2.8) 10.70 (2) 0.690 
(fisher’s 
exact) 
SAD  18 (85.7) 3 (14.3) 0 (0) 0 (0) 
Schizophrenia  163 (74.8) 24 (11.0) 18 (8.3) 13 (6.0) 
Bipolar 53 (75.7) 8 (11.4) 3 (4.3) 6 (8.6) 
Other diagnoses 91 (73.4)  19 (15.3)  9 (7.3)  5 (4.0)  
df = degrees of freedom. 
 
The median follow-up time for the cases who had 8+ years follow-up was 10.59 years 
(9.92-11.47 inter-quartile range). Table 7-3 presents the median follow-up time in years 
by diagnostic group for those with 8+ years follow-up. A Kruskal Wallis test revealed 
no significant differences between the groups (Chi2=4.765, df4, p=0.312). 
 
Table 7-3: Follow-up time by diagnosis for those with 8+ years follow-up 
Diagnosis Median years follow-up time (IQR) Range 
PMD (n54) 10.59 (9.92-11.63) 8.08-13.13 
SAD (n18) 10.66 (9.52-11.40) 8.42-13.62 
Schizophrenia (n163) 10.52 (9.91 – 11.31) 8.32-13.38 
Bipolar (n53) 10.55 (9.86-11.10) 8.35-13.37 
Other diagnoses (n91) 10.89 (10.01-11.73) 8.18-13.70 
IQR = Interquartile range. 
  
7.3.3. Comparison of baseline variables for cases with follow-up data compared 
with those without follow-up data  
Table 7-4 and Table 7-5 present the baseline demographic and clinical variables broken 
down by those with follow-up data compared with those without follow-up data; cases 
abroad and deceased cases are not included in these analyses.  
 
Table 7-4 shows that there were no significant differences between those with and those 
without follow-up data at 8-12 years in terms of demographic variables (although level 
of qualification was on the cusp of being statistically significant at the traditional 










Table 7-4: Comparison of baseline demographic variables of those with and those 
without follow-up data at 8 years+ 





   
 Median (IQR) Median (IQR) Wilcoxin z df P value 
Age 27.00 (20-33) 29.00 (22-36) -1.842 - 0.066 






















































































































































Table 7-5: Comparison of baseline clinical variables of those with and those 
without follow-up data 





   
 Median (IQR) Median (IQR) Kruskal 
Wallis 
df P value 




-0.224 - 0.823 




-1.639 - 0.101 



























Mode of Onset: 
Sudden 
Precipitous 
Acute, no previous symptoms 
Acute, with previous symptoms 
Insidious 

































































IQR = Interquartile range.  
 
Table 7-5 shows that those not followed up were no different clinically compared with 
those who were followed up including by diagnosis. 
 
7.3.4. Core analytic sample 
As stated in chapter 4, the purpose of this chapter was to compare outcomes in PMD 
and SAD cases to schizophrenia and bipolar cases. Hence, cases with other diagnoses 
were excluded from the analyses. Therefore, the analyses based on baseline diagnoses 
were based on a core analytic sample of the 381 cases (PMD, SAD, schizophrenia and 
bipolar cases only).  Although 288 cases in this core analytic sample had 8-12 year 
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follow-up information, some cases who had died or were abroad had relevant 
information and could be included in some analyses. Furthermore, some cases who had 
8-12 year follow-up information had some missing data. Therefore, each section will 
have a note about the number of cases in each particular analysis.  
 
The analyses based on lifetime diagnoses were based on a core analytic sample of 368 
cases (PMD, SAD, schizophrenia and bipolar cases only). As with the baseline core 
analytic sample, although 298 cases in this core analytic sample had 8-12 year follow-
up information, some cases have some missing variables within this, and some cases 
who had died or were abroad were able to be included in some analyses. Therefore, 
each section will have a note about the number of cases in each particular analysis.  
 
7.4. Diagnostic change 
Although PMD, SAD, schizophrenia and bipolar disorder cases are the main diagnoses 
of interest in this thesis, all diagnoses will be included in this section on diagnostic 
change as change can involve all diagnoses. This section aimed to test the hypothesis 
that PMD and SAD cases would have a lower prospective consistency and higher 
retrospective consistency compared with schizophrenia and bipolar disorder. 
 
7.4.1. Description 
A lifetime diagnosis was made for each case if there was sufficient information to do so 
regardless of follow-up status (i.e. even if cases were deceased). A lifetime diagnosis 
was available for 477 out of 511 baseline cases. Twenty-eight cases had insufficient 
information to make a follow-up diagnosis. There was insufficient information to give a 
follow-up diagnosis for 5 (7.5%) baseline PMD cases, 3 (16.7%) SAD cases, 11 (5.3%) 
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schizophrenia cases, 4 (6.1%) bipolar disorder cases and 5 (4.2%) other diagnosis cases. 
Of the 6 excluded cases, 3 had a baseline diagnosis of schizophrenia and 3 had an 
‘other’ diagnosis. A chi-squared analysis to test whether there was a difference between 
the diagnostic groups in those missing follow-up diagnosis showed that there was no 
evidence of a difference (chi2=3.982, df4, p=0.367 (fisher’s exact)).  
 
Table 7-6 presents a diagnosis movement matrix (baseline diagnosis by follow-up 
diagnosis) for those with a lifetime diagnosis.  
  
Table 7-6: Baseline diagnosis by lifetime diagnosis 
















PMD (n67) 33 2 16 7 9 
SAD (n18) 1 7 7 1 2 
Schizophrenia (n207) 8 6 157 8 28 
Bipolar (n66) 2 0 3 51 10 
Other (n119) 7 4 42 6 60 
 
Table 7-6 shows that only 33/67 (49%) of PMD patients had the same lifetime diagnosis 
that they had at baseline. The majority of changers moved to schizophrenia (n16, 47%) 
with smaller numbers moving to ‘other’ diagnoses (psychosis not otherwise specified 
(n3, 9%), delusional disorder (n2, 6%), acute and transient psychoses (n1, 3%), drug 
induced psychosis (n1, 3%), schizoaffective bipolar disorder (n1, 3%)); and other 
disorder (n1, 3%), bipolar disorder (n7, 21%) and SAD (n2, 6%). Only 7/18 (39%) of 
SAD cases had the same lifetime diagnosis that they had at baseline, with a higher 
percentage of changers moving to a diagnosis of schizophrenia (n7, 64%) and the rest 
moving to PMD (n1, 9%), bipolar disorder (n1, 9%) and other diagnoses (psychosis not 
otherwise specified (n2, 18%)).  
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In terms of movement to a particular diagnosis, 18 cases moved from a non-PMD 
diagnosis at baseline to a lifetime diagnosis of PMD. Twelve cases moved from a non-
SAD diagnosis at baseline to a lifetime diagnosis of SAD.  
 
7.4.2. Calculation of prospective consistency for all groups 
Prospective consistency is defined as the proportion of cases who have the same 
diagnosis at follow-up as they did at baseline. Table 7-7 presents the prospective 
consistency for each diagnostic group and shows that PMD and SAD both had low 
prospective consistencies of less than 50%. This is compared with a prospective 
consistency of 76% and 77% for schizophrenia and bipolar disorder respectively. 
 
Table 7-7: Prospective consistency by diagnosis 







Table 7-8 shows the odds ratios, confidence intervals and p values for the proportion of 
cases who have the same diagnosis at follow-up as they did at baseline (prospective 
validity). The table shows strong evidence that PMD cases were less likely to have the 
same diagnosis at follow-up as they did at baseline compared with schizophrenia cases 
(OR 0.31, 95% CI 0.17-0.55, p<0.001) and compared with bipolar cases (OR 0.29, 95% 
CI 0.13-0.60, p=0.001). There was evidence that SAD cases were less likely to have the 
same diagnosis at follow-up as they did at baseline compared with schizophrenia cases 
(OR 0.20, 95% CI 0.07-0.55, p=0.002) and compared with bipolar cases (OR 0.19, 95% 
CI 0.06-0.57, p=0.003). 
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Table 7-8: Odds ratios, confidence intervals and p values for the proportion of 
cases who have the same diagnosis at follow-up as they did at baseline (prospective 
consistency) 
 PMD vs. SZ 
(n274) 
PMD vs. BP 
(n133) 
PMD vs. SAD 
(n85) 
SAD vs. SZ 
(n225) 
SAD vs. BP  
(n84) 













* p<0.1; ** p<0.05; *** p<0.01; CI = 95% confidence interval. 
 
7.4.3. Calculation of retrospective consistency for all groups 
Retrospective consistently is defined as the proportion of cases who have the same 
diagnosis at baseline as they do at follow-up. Table 7-9 presents the retrospective 
consistency for each diagnostic group and shows that the retrospective consistency of 
PMD was similar to that of schizophrenia and bipolar disorder, 65-70%. The 
retrospective consistency for SAD was very low at 37%. 
 
Table 7-9: Retrospective consistency by diagnosis 







Table 7-10 shows the odds ratios, confidence intervals and p values for the proportion 
of cases who have the same diagnosis at baseline as they did at follow-up (retrospective 
validity). The table shows strong evidence that SAD cases were less likely to have the 
same diagnosis at follow-up as they did at baseline compared with schizophrenia cases 
(OR 0.25, 95% CI 0.10-0.67, p=0.006). There was evidence that SAD cases were less 
likely to have the same diagnosis at follow-up as they did at baseline compared with 
bipolar cases (OR 0.25, 95% CI 0.09-0.72, p=0.011). There was evidence that PMD 
cases were more likely to have the same diagnosis at follow-up as they did at baseline 
compared with SAD cases (OR 3.14, 95% CI 1.05-9.39, p=0.040). 
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Table 7-10: Odds ratios, confidence intervals and p values for the proportion of 
cases who have the same diagnosis at baseline as they did at follow-up 
(retrospective validity) 
 PMD vs. SZ 
(n276) 
PMD vs. BP 
(n124) 
PMD vs. SAD 
(n70) 
SAD vs. SZ 
(n244) 
SAD vs. BP  
(n92) 













* p<0.1; ** p<0.05; *** p<0.01; CI = 95% confidence interval. 
 
7.4.4. Predictors of diagnostic change  
Baseline demographic and clinical variables were examined to see if any of these 
variables predicted diagnostic change in PMD and SAD (Table 7-11). The analysis of 
predictors of diagnostic change in SAD was limited by the fact that the numbers of 
cases included in the analysis were low (n12-18). This resulted in some predictors being 
incalculable and other variables having very large confidence intervals, therefore it was 
very difficult to make any conclusions about predictors of change in SAD cases.  
 
The following variables were found to be statistically significantly (at the traditional 
p<0.05 threshold) associated with diagnostic change in PMD: being younger at first 
contact (Age: OR 0.91, 95% CI 0.86-0.96, p<0.001; Aged 16-29: OR 6.43, 95% CI 
2.10-19.65, p=0.001); being younger at onset (OR 0.90, 95% CI 0.84-0.95, p<0.001) 
and being single (OR 2.90, 95% CI 1.03-8.17, p=0.044). There are other predictors 
which have large odds ratios but do not reach statistical significance. This was possibly 
due to low numbers in the PMD cases in these analyses. These predictors are: being 
black African (OR 9.0, 95% CI 0.98-83.06) or of other white ethnicity (OR 4.5, 95% CI 
0.42-47.76); being born outside the UK (OR 1.93, 95% CI 0.67-5.55,  p=0.220); being 
referred to services via A&E (OR 2.35, 95% CI 0.38-14.47), police or court (OR 2.35, 
95% CI 0.38-14.47); and having no family history of psychosis (OR 1.96, 95% CI 0.59-
6.52, p=0.272), no family history of general mental illness (OR 2.68, 95% CI 0.61-
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11.78, p=0.191), no parental history of psychosis (OR 1.74, 95% CI 0.37-8.18, 
p=0.481), and no parental history of general mental illness (OR 2.09, 95% CI 0.35-
12.51, p=0.421). 
 
Some clinicians have argued that “...early-onset PMD should be considered an initial 
episode of bipolar disorder until proven otherwise...”161 Therefore, Table 7-12 presents 
the predictors of change recalculated without the cases who move from PMD to bipolar 
disorder. There was no difference in the results with the exception of Black African 
cases now being 14 times more likely to change from a diagnosis of PMD to another 
diagnosis at follow-up (OR 14, 95% CI 1.47-133.68, p<0.05). 
 
7.4.5. Summary of diagnostic change 
In summary, there was evidence that PMD and SAD have lower prospective 
consistency compared with schizophrenia and bipolar disorder, and that SAD has lower 
retrospective consistency compared with schizophrenia, bipolar disorder and PMD. The 
majority of PMD and SAD cases who change diagnosis, change to a diagnosis of 
schizophrenia as their lifetime diagnosis. Predictors of diagnostic change in PMD are 
being single, being younger at illness onset and being younger at first contact with 
services. 
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Table 7-11: Baseline demographic and clinical predictors of diagnostic change in 
PMD and SAD cases 
 PMD SAD 
Demographics OR (CI) OR (CI) 









































Place of birth: 
UK born 

























Clinical variables OR (CI) OR (CI) 





































DUP in days 1.00 (1.00-1.01) 1.00 (1.00-1.00) 




































*p<0.05; OR=odds ratio; CI=95% confidence interval; $=STATA unable to calculate due to low numbers 
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Table 7-12: Baseline demographic and clinical predictors of diagnostic change in 
PMD without cases who moved to bipolar disorder 
 PMD 
Demographics OR (CI) 




























Place of birth: 
UK born 
















Clinical variables OR (CI) 
























DUP in days 1.00 (1.00-1.01) 
























*p<0.05; OR = odds ratio; CI = 95% confidence interval. 
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7.5. Course and outcome by baseline diagnosis 
Course of illness and outcome by baseline diagnosis will now be examined. 
 
7.5.1. Course of illness over 10 years by baseline diagnosis 
7.5.1.1. Course of illness type by baseline diagnosis 
Table 7-13 shows that the bipolar group had the highest proportion of cases with an 
episodic course of illness and the lowest proportion with a continuous course of illness 
(number in analyses: 283). The schizophrenia group had the opposite with the lowest 
proportion of episodic and highest proportion of continuous course of illness. The PMD 
and SAD groups were between these two. The PMD and SAD group had approximately 
50% of cases who had a ‘neither episodic nor continuous course’ (i.e. episodes lasted 
over 6 months and remission lasted over 6 months), with around 30-35% having an 
episodic course and only around 15% having a continuous course. 
 
Table 7-13: Comparison of course of illness variables by baseline diagnosis 
 PMD (n51) SAD (n17) SZ (n167) BP (n48) 























The hypothesis that PMD and SAD groups have a higher proportion of cases with an 
episodic course of illness and less with a continuous course of illness compared with 
schizophrenia cases was tested. There was strong evidence that PMD cases were more 
likely to have an episodic course of illness (OR 2.71, 95% CI 1.36-5.41, p=0.005) and 
less likely to have a continuous course of illness (OR 0.32, 95% CI 0.13-0.75, p=0.009) 
compared with schizophrenia cases (Table 7-14). There was no evidence of any 
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differences in the course of illness between SAD and schizophrenia cases (episodic: OR 
1.90, 95% CI 0.62-5.81, p=0.258; continuous: OR 0.42, 95% CI 0.12-1.54, p=0.192). 
  
There was also strong evidence that PMD cases were less likely to have an episodic 
course of illness (OR 0.18, 95% CI 0.07-0.43, p<0.001) and more likely to have a 
‘neither episodic nor continuous’ course of illness (OR 4.17, 95% CI 1.68-10.34, 
p=0.002) compared with bipolar cases. There was strong evidence that SAD cases were 
less likely to have an episodic course of illness (OR 0.12, CI .04-0.43, p=0.001) and 
more likely to have a ‘neither’ course of illness (OR 4.88, 95% CI 1.47-16.13, p=0.009) 
compared with bipolar cases. There was some evidence that SAD cases were more 
likely to have a continuous course of illness (OR 4.93, 95% CI 0.75-32.51, p=0.097) 
compared with bipolar cases. The OR for this finding is high and the fact that the p 
value is not significant at the traditional p value of 0.05 is possibly due to the lower 
numbers in this comparison. There was no evidence of any differences in the course of 
illness between SAD and PMD cases (see Table 7-14). 
 
Table 7-14: OR, CI and p value for comparisons between the groups in the course 
of illness variable 
 PMD vs. SZ 
(n218) 






SAD vs. BP  
(n65) 





































*p<0.1; **p<0.05; ***p<0.01; OR = odds ratio; CI = 95% confidence interval. 
 
7.5.1.2. Longest period of remission by baseline diagnosis 
Figure 7-1 is a histogram of the longest weeks of remission and shows that the data is 
not normally distributed. Therefore, medians and interquartile ranges have been used to 
describe the data. Attempts to transform the data and make it and its residuals normal 
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were unsuccessful so bootstrap regressions were applied. Table 7-15 shows that the 
bipolar group had the longest median weeks of remission and schizophrenia had the 
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Figure 7-1: Histogram of longest weeks of remission for the core analytic sample 
with valid data 
 
The hypothesis that PMD and SAD cases would have longer remissions compared with 
schizophrenia cases was tested. There was strong evidence that PMD cases (beta 
coefficient 134.17, 95% CI 62.55 to 205.79, p<0.001; Table 7-16), but not SAD cases 
(beta coefficient 68.94, 95% CI -31.22 to 169.10, p=0.177), had on average a longer 
period of remission compared with schizophrenia cases. There was evidence that SAD 
cases had a shorter longest period of remission compared with bipolar cases (beta 




Table 7-15: Comparison of longest weeks of remission by baseline diagnosis 
 PMD (n41) SAD (n13) SZ (n136) BP (n40) 
 Median (IQR) Median (IQR) Median (IQR) Median (IQR) 
Longest weeks of remission 337 (101-468) 210 (120-334) 106 (0-299) 377 (221-469) 
IQR = Interquartile range 
 
Table 7-16: Coefficients, CI and p value for comparisons between the groups in the 
longest weeks of remission variable 
 PMD vs. SZ 
(n177) 
PMD vs. BP 
(n81) 
PMD vs. SAD 
(n54) 
SAD vs. SZ 
(n149) 


































*p<0.1; **p<0.05; ***p<0.01; CI = 95% confidence interval. 
 
7.5.1.3. Number of episodes by baseline diagnosis 
The data on the number of episodes was not normally distributed, therefore, medians 
and interquartile ranges have been used to describe the data. Number of episodes is 
count data and as the mean and variance of this outcome indicated that over dispersion 
was present, a negative binomial regression has been used. Table 7-17 shows that the 
median number of episodes excluding the first was very similar in all the groups but 
PMD had the lowest with a median of 0.5 episodes and SAD had the highest with a 
median of 2 episodes (number in analyses: 177 of the 237 who had a non-continuous 
course). 
 
The hypothesis that PMD and SAD cases would have more episodes compared with 
schizophrenia cases was tested. There was strong evidence that the rate at which 
episodes occurred was 49% less in the PMD group compared with the schizophrenia 
group (IRR=0.49, 95% CI 0.31-0.76, p=0.001). There was no difference between SAD 
and schizophrenia cases (IRR=0.80, 95% CI 0.46-1.37, p=0.414). There was also 
evidence that the rate at which episodes occurred was 55% less in PMD cases compared 
with bipolar cases (IRR=0.55, 95% CI 0.31-0.99, p=0.046; Table 7-18).  
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Table 7-17: Comparison of number of episodes by baseline diagnosis 









Number of episodes 0.5 (0-1) 2 (0-3) 1 (0.5-3) 1 (0-2) 
IQR = Interquartile range 
 
Table 7-18: IRR, CI and p value for comparisons between the groups in the 
number of episodes 
 PMD vs. SZ 
(n124) 






SAD vs. BP 
(n53) 
 IRR (CI) IRR (CI) IRR (CI) IRR (CI) IRR (CI) 










*p<0.1; **p<0.05; ***p<0.01; IRR = incidence rate ratio; CI = 95% confidence interval. 
 
7.5.1.4. Months of longest episode by baseline diagnosis 
Figure 7-2 is a histogram of the months of longest episode and shows that the data is not 
normally distributed. Therefore, medians and interquartile ranges have been used to 
describe the data. Attempts to transform the data and make it and its residuals normal 
were unsuccessful so bootstrap regressions were applied. Table 7-19 shows that the 
bipolar group had the lowest median longest episode with three months while the SAD 
group had the longest with 10 months (number in analyses: 144 of the 237 who had a 
non-continuous course). The PMD and schizophrenia groups lay in between with a 
median of seven months for the longest episode. 
 
The hypothesis that PMD and SAD cases would have shorter episodes compared with 
schizophrenia cases was not supported by the data (Table 7-20). However, there was 
evidence that compared with bipolar cases, PMD cases (beta coefficient = 15.17, 95% 
CI 0.19-30.14, p=0.047) and SAD cases (beta coefficient = 10.29, 95% CI 0.67 to 
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Figure 7-2: Histogram of months of longest episode for the core analytic sample 
with valid data 
 
 
Table 7-19: Comparison of longest episode in months by baseline diagnosis 









Longest episode in months (including 
first episode) 
7 (2-21) 10 (3.5-17) 7 (3-35) 3 (1-4) 
IQR = Interquartile range 
 
 
Table 7-20: Coefficient, CI and p value for comparisons between the groups in the 
longest episode in months 
 PMD vs. SZ 
(n82) 




SAD vs. SZ 
(n74) 



































*p<0.1; **p<0.05; ***p<0.01; CI = 95% confidence interval. 
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7.5.1.5. Percentage of time psychotic during follow-up by baseline diagnosis 
Figure 7-3 is a histogram of the percentage of time psychotic during follow-up and 
shows that the data is not normally distributed. Therefore, medians and interquartile 
ranges were used to describe the data. Attempts to transform the data and make it and its 
residuals normal were unsuccessful so bootstrap regressions have been applied. Table 
7-21 shows wide variation in the median percentage of time psychotic over the follow-
up from 4.39% in the bipolar group to 48.53% in the schizophrenia group, with the 
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Figure 7-3: Histogram of percentage of time psychotic over follow-up for the core 
analytic sample with valid data 
 
The hypothesis that PMD and SAD cases would spend a smaller percentage of the 
follow-up psychotic compared with schizophrenia cases was tested. There was evidence 
that PMD cases (beta coefficient -17.09, 95% CI -33.35 to -0.82, p=0.039), but not SAD 
cases (beta coefficient -10.00, 95% CI -34.19 to 20.02, p=0.436), spent less of the 
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follow-up in a psychotic episode compared with schizophrenia cases. There was also 
evidence that PMD cases spent more of the follow-up in a psychotic episode compared 
with bipolar cases (beta coefficient 21.70, 95% CI 5.83 to 37.92, p=0.007; Table 7-22), 
and that SAD cases spent more time in a psychotic episode compared with bipolar cases 
(beta coefficient 28.78, 95% CI 3.97 to 53.59, p=0.023). 
 
Table 7-21: Percentage of time psychotic during follow-up by baseline diagnosis 



















IQR = Interquartile range 
 
Table 7-22: Coefficient, CI and p value for comparisons between the groups in the 
percentage of time psychotic during follow-up 
 PMD vs. SZ 
(n143) 




SAD vs. SZ 
(n123) 




























28.78 (3.97 to 
53.59)** 
*p<0.1; **p<0.05; ***p<0.01; CI = 95% confidence interval. 
 
7.5.1.6. Course of illness summary by baseline diagnosis 
In summary, of those with a baseline diagnosis of PMD, 37.3% had an episodic course 
type, 13.7% had a continuous course type and 49% had neither course type. The median 
longest remission was 337 weeks (101-468 IQR), median number of episodes excluding 
the first was 0.5 (0-1 IQR), median longest episode was seven months (2-21 IQR) and 
the median percentage of time in a psychotic episode was 15.78% (4.36-70.83% IQR).  
For cases with a baseline diagnosis of SAD, 29.4% had an episodic course type, 17.7% 
had a continuous course type and 52.9% had neither course type. The median longest 
remission was 210 weeks (120-334 IQR), median number of episodes including the first 
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was 2 (0-3 IQR), median longest episode was 10 months (3.5-17 IQR) and the median 
percentage of time in a psychotic episode was 20.66% (6.11-89.62% IQR). 
 
The comparisons revealed evidence that PMD and schizophrenia cases differed from 
each other on almost every variable on course of outcome. PMD cases: were more 
episodic and less continuous in course type; had longer remissions; had less episodes; 
and spent a lower percentage of the follow-up in a psychotic episode, all compared with 
schizophrenia. There was also some evidence of differences between PMD and bipolar 
cases. PMD cases: were less episodic in course type and more neither episodic nor 
continuous; had fewer episodes; had longer longest episodes; and had a higher 
percentage of time psychotic compared with bipolar cases. There was evidence of 
differences between SAD and bipolar cases in most of the course of illness variables. 
SAD cases: were less episodic course type, more continuous course type and more 
neither continuous nor episodic; had lower longest periods of remission; had longer 
longest episodes; and had a higher percentage of time psychotic over the follow-up, 
compared with bipolar cases. Interestingly, no evidence of differences in course type 
were found between PMD and SAD cases. The results based on the SAD cases must be 
interpreted with caution due to the low numbers in the SAD group (n8 in some 
analyses).  
 
7.5.2. Mortality, suicidality and social outcomes at 10 years by baseline diagnosis 
7.5.2.1. Mortality and suicidality by diagnosis by baseline diagnosis 
7.5.2.1.1. Mortality by baseline diagnosis 
Overall, 24 cases (7.7%) died over the follow-up (of the core analytic sample). Table 
7-23 shows the percentages of cases who died over follow-up varied from 0% in the 
 271 
SAD group to 9.9% in the schizophrenia group. The number of deaths in the PMD and 
bipolar groups fell between these with 5.3% and 5.4% respectively (number in analyses: 
312).  
 
Table 7-23: Comparison of numbers and percentages of cases who died by baseline 
diagnosis 
 PMD (n57) SAD (n18) SZ (n181) BP (n56) 
 n/N (%) n/N (%) n/N (%) n/N (%) 
Dead 3/57 (5.3) 0/18 (0.0) 18/181 (9.9) 3/56 (5.4) 
 
Table 7-24: OR, CI and p value for comparisons between the groups in the 
proportion of cases who died over follow-up 
 PMD vs. SZ 
(n238) 
PMD vs. BP 
(n113) 
PMD vs. SAD 
(n57) 
SAD vs. SZ 
(n181) 
SAD vs. BP 
(n56) 
 OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) 
Death 0.50  
(0.14-1.77) 
0.98   
(0.19-5.08) 
$ $ $ 
*p<0.1; **p<0.05; ***p<0.01; OR = odds ratio; CI = 95% confidence interval; $ Unable to calculate odds 
ratios as no SAD cases died over follow-up. 
 
The hypothesis that PMD and SAD cases would have a higher proportion of cases who 
died over follow-up compared with schizophrenia and bipolar cases was tested. There 
was no evidence that any of the groups differed in those who died over the follow-up 
period (Table 7-24). The comparison of each group to the SAD group was not possible 
as there were no deaths in the SAD group. However, the chi squared analysis of the 
whole core analytic sample indicated that there were no differences between the groups 
in terms of the number of cases who died (chi2=3.70, df3, p=0.443 (fisher’s exact)).  
 
7.5.2.1.2. Completed suicide by baseline diagnosis 
Data on cause of death was only available for 16 out of the 24 cases who died. Eight of 
these cases had committed suicide. Due to the very low numbers, there was not enough 
information to test the hypothesis that PMD and SAD cases would have a higher 
frequency of completed suicides compared with schizophrenia and bipolar cases.  
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7.5.2.1.3. Attempted suicide by baseline diagnosis 
The data on number of suicide attempts was count data and an examination of the mean 
and variance indicated over dispersion, therefore, a negative binomial regression has 
been used. Table 7-25 shows that similar proportions from each group attempted suicide 
and that the median number of suicide attempts was similar between the groups both 
when all cases are included and when only those who attempted were included (number 
in analyses: 270). 
 
Table 7-25: Comparison of the occurrence of suicide attempts and the number of 
suicide attempts by baseline diagnosis 
 PMD (n47) SAD (n18) SZ (n159) BP (n46) 
























Number of suicide attempts (for all 
cases not just attempters) 
0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Mean number of suicide attempts (for 
suicide attempters only) 
2 (1-4) 1 (1-1) 1 (1-3) 1 (1-2) 
SZ=schizophrenia; BP=bipolar; IQR = Interquartile range. 
 
Table 7-26: OR, CI and p value for comparisons between the groups in the 
occurrence of suicide attempts and the IRR, CI and p value for comparisons 
between the groups in the number of suicide attempts 
 PMD vs. SZ 
(n206) 
PMD vs. BP 
(n93) 
PMD vs. SAD 
(n65) 
SAD vs. SZ 
(n177) 
SAD vs. BP 
(n64) 













 IRR (CI) IRR (CI) IRR (CI) IRR (CI) IRR (CI) 
Suicide 


























*p<0.1; **p<0.05; ***p<0.01; OR = Odds ratio; IRR = incidence rate ratio; CI = 95% confidence 
interval. 
 
The hypothesis that PMD and SAD cases would have a higher proportion of cases who 
attempted suicide over the follow-up, and a higher rate of suicide attempts for those 
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who do attempt, compared with schizophrenia and bipolar cases was tested. There was 
no evidence that PMD or SAD differed from bipolar or schizophrenia, or each other, in 
the occurrence of suicide attempts, or in the number of suicide attempts (Table 7-26). 
 
7.5.2.1.4. Self-harm by baseline diagnosis 
Of the 381 included in the core analytic sample, 157 had data on self-harm and therefore 
form the participants included in this section (the number of self-harm occurrences was 
missing for one case although self-harm was confirmed therefore the numbers are 
slightly different in the table (see Table 7-27)). The data on number of events is count 
data and an examination of the mean and variance indicated over dispersion, therefore, a 
negative binomial regression has been used. 
 
Table 7-27 shows the occurrence of self-harm by each baseline diagnosis. It shows that 
the frequency of self-harm varied from 10.9% in the bipolar group to 27.8% in the SAD 
group with the PMD and schizophrenia group falling between these two at 20.8% and 
14.7% respectively. It also shows that the median number of self-harm occurrences was 
similar between the groups both when all cases are included and when only those who 
self-harmed were included.  
 
Table 7-27: Comparison of the occurrence of self-harm data by baseline diagnosis 
 PMD (n48) SAD (n18) SZ (n157) BP (n46) 

























Mean number of self-harm episodes for 
all cases not just self-harmers) 
0 (0-0) 0 (0-1) 0 (0-0) 0 (0-0) 
Mean number of self-harm episodes for 
self-harmers only) 
1 (1-2) 1 (1-1) 1 (1-3) 1 (1-1) 
SZ=schizophrenia; BP=bipolar; IQR = Interquartile range. 
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Table 7-28: OR, IRR, CI and p value for comparisons between the groups in the 
occurrence of self-harm 
 PMD vs. SZ 
(n205) 
PMD vs. BP 
(n94) 
PMD vs. SAD 
(n66) 
SAD vs. SZ 
(n175) 
SAD vs. BP 
(n64) 
 OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) 










 PMD vs. SZ 
(n204) 
PMD vs. BP 
(n94) 
PMD vs. SAD 
(n66) 
SAD vs. SZ 
(n174) 
SAD vs. BP 
(n64) 




























*p<0.1; **p<0.05; ***p<0.01; OR = odds ratio; IRR = incidence rate ratios; CI = 95% confidence 
interval. 
 
The hypothesis that PMD and SAD cases would have a higher proportion of cases who 
self-harmed over the follow-up, and a higher rate of self-harm events for those who do 
self-harm, compared with schizophrenia and bipolar cases was tested. There was no 
evidence that PMD and SAD differed from each other or from bipolar or schizophrenia 
in terms of the occurrence of self-harm (Table 7-28). There was no evidence that the 
rate at which self-harm events occur differed between PMD and SAD compared with 
bipolar and schizophrenia, except for one comparison for which there was weak 
evidence that PMD cases have a higher rate of self-harm events compared with bipolar 
cases (IRR=3.15, 95% CI 0.88-11.27, p=0.077). 
 
7.5.2.1.5. Mortality and suicidality summary by baseline diagnosis 
In summary, of those with a baseline diagnosis of PMD: 5.3% died over follow-up; 
23.4% attempted suicide; and 20.8% self-harmed at some point over the follow-up 
period. For SAD cases: there were no deaths over the follow-up; 22.22% attempted 
suicide; and 27.8% self-harmed at some point over the follow-up period. 
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Based on the regression analyses comparing PMD and SAD to each other and to 
schizophrenia and bipolar, there was no evidence that there were any differences 
between any of the groups in terms of death, attempted suicide or self-harm, except 
there was some weak evidence of a difference between PMD cases and bipolar cases in 
the number of self-harm events. 
 
7.5.2.2. Social outcomes by baseline diagnosis 
7.5.2.2.1. Employment status by baseline diagnosis 
Table 7-29 shows that the large majority (approximately 75-85%) of SAD and 
schizophrenia cases were employed for less than 25% of the follow-up (number in 
analyses: 245). This was lower for PMD and bipolar cases with approximately a half 
having been employed for less than 25% of the follow-up. 
 
Table 7-29: Comparison of employment outcomes by baseline diagnosis 
 PMD (n42) SAD (n15) SZ (n150) BP (n38) 
 N (%) N (%) N (%) N (%) 



























Table 7-30: OR, CI and p value for comparisons between the groups of the 
employment status over the follow-up period 
 PMD vs. SZ 
(n192) 
PMD vs. BP 
(n80) 
PMD vs. SAD 
(n57) 
SAD vs. SZ 
(n165) 
SAD vs. BP 
(n53) 



















$ $ $ 
*p<0.1; **p<0.05; ***p<0.01; OR = odds ratio; CI = 95% confidence interval; $ STATA unable to 
calculate as 0 in the SAD group were employed 75-100% of the time. 
 
The hypothesis that PMD and SAD cases would have a higher proportion of cases who 
were employed over follow-up compared with schizophrenia cases was tested. There 
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was strong evidence that compared with schizophrenia cases, PMD cases were less 
likely to have been employed for 25% or less of the follow-up (OR 0.34, 95% CI 0.17-
0.69, p=0.003) and more likely to have been employed for 75% or more of the follow-
up (OR 3.13, 95% CI 1.35-7.24, p=0.008; Table 7-30). The finding that SAD cases were 
over two times more likely than schizophrenia cases to be employed only 0-25% of the 
follow-up did not reach statistical significance (OR 2.21, 95% CI 0.48-10.22, p=0.312). 
There was evidence that PMD cases were less likely to have been employed for 25% of 
less or the follow-up compared with SAD cases (OR 0.15, 95% CI 0.03-0.77, p=0.022), 
and there was evidence that SAD cases were more likely to have been employed for 
25% or less of the follow-up compared with bipolar cases (OR 5.85, 95% CI 16-29.54, 
p=0.032). 
 
7.5.2.2.2. Relationship status by baseline diagnosis 
Table 7-31 shows that both SAD and schizophrenia had the highest percentages (both 
around 80%) of cases who were mainly single, divorced or separated over the follow-
up, with PMD having the lowest at 48.8% (number in analyses: 255). 
 
Table 7-31: Comparison of main relationship status over the follow-up period by 
baseline diagnosis 
 PMD (n41) SAD (n15) SZ (n155) BP (n44) 
 N (%) N (%) N (%) N (%) 
Main relationship status: 
Single/divorced/separated 















The hypothesis that PMD and SAD cases would have a higher proportion of cases who 
were in a relationship over the follow-up compared with schizophrenia cases was tested. 
There was evidence that PMD cases (OR 4.04, 95% CI 1.95-8.34, p<0.001), but not 
SAD cases (OR 0.96, 95% CI 0.26-3.61, p=0.953), were more likely to be in a 
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relationship over the follow-up compared with schizophrenia (Table 7-32).  There was 
also evidence that PMD cases were more likely to be in a relationship over the follow-
up compared with SAD cases (OR 4.20, 95% CI 1.03-17.13, p=0.045). There was 
weaker evidence that SAD was less likely to be in a relationship compared with bipolar 
cases (OR 0.3, 95% CI 0.07-1.21, p=0.091).  
 
Table 7-32: OR, CI and p value for comparisons between the groups of the main 
relationship status over the follow-up period 
 PMD vs. SZ 
(n196) 
PMD vs. BP 
(n85) 
PMD vs. SAD 
(n56) 
SAD vs. SZ 
(n170) 
SAD vs. BP 
(n59) 
 OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) 
Relationship 












*p<0.1; **p<0.05; ***p<0.01; OR = odds ratio; CI = 95% confidence interval. 
 
7.5.2.2.3. Close confidants by baseline diagnosis 
Table 7-33 shows that the percentage of cases without a close confidant at follow-up 
was lowest in bipolar cases with 25% and highest in schizophrenia cases with 46.3% 
(number in analyses: 137). PMD cases and SAD cases came in between these with 
28.6% and 40.0% respectively. 
 
Table 7-33: Comparison of those with close confidants by baseline diagnosis 
 PMD (n28) SAD (n5) SZ (n80) BP (n24) 


















Table 7-34: OR, CI and p value for comparisons between the groups of the close 
confidants variable over the follow-up period 
 PMD vs. SZ 
(n108) 
PMD vs. BP 
(n52) 
PMD vs. SAD 
(n33) 
SAD vs. SZ 
(n85) 
SAD vs. BP 
(n29) 













*p<0.1; **p<0.05; ***p<0.01; OR = odds ratio; CI = 95% confidence interval. 
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There was no evidence to support the hypothesis that PMD or SAD cases would have a 
higher proportion of cases with a close confidant over follow-up compared with 
schizophrenia cases. In fact, there were no differences between any of the groups in 
those with close confidants (Table 7-34). 
 
7.5.2.2.4. Time in prison by baseline diagnosis 
The data on number of months in prison was not normally distributed, therefore, 
medians and interquartile ranges have been used to describe the data. Attempts to 
transform the data and make it and its residuals normal were unsuccessful so bootstrap 
regressions have been applied. 
 
Table 7-35: Comparison of prison contacts by baseline diagnosis 
 PMD (n47) SAD (n16) SZ (n154) BP (n46) 
 n (%) n (%) n (%) n (%) 























Months in prison (for all cases) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Months in prison (for incarcerated 
cases only) 
3.5 (2-5) 60 (60-60) 5 (2-12) 3 (2-4) 
SZ=schizophrenia; BP=bipolar; IQR = Interquartile range. 
 
Table 7-35 shows that more schizophrenia cases spent time in prison (16.9%) compared 
with the other three groups, with the PMD group having the lowest proportion of cases 
having been to prison (4.3%). The median months spent in prison was similar for all 
groups when including all cases, but when only including those cases who had been to 
prison, the SAD group had a much higher median (60 months) compared with the other 
groups (number in analyses: 263). This is likely due to the low numbers of SAD cases 
who had been to prison (only one).  
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Table 7-36: OR, CI and p value for comparisons between the groups for time in 
prison 
 PMD vs. SZ 
(n201) 
PMD vs. BP 
(n93) 
PMD vs. SAD 
(n63) 
SAD vs. SZ 
(n170) 
SAD vs. BP 
(n62) 

































(-0.36 to 0.27) 
-3.60 
(-10.83 to 3.63) 
2.15  






















*p<0.1; **p<0.05; ***p<0.01; OR = odds ratio; CI = 95% confidence interval. 
 
The hypothesis that PMD and SAD cases would have a lower proportion of cases who 
had been in prison over the follow-up compared with schizophrenia cases was tested. 
There was evidence that compared with schizophrenia cases, PMD cases were both less 
likely to go to prison (OR = 0.22, 95% CI 0.05-0.96, p=0.044) and spent less time in 
prison over the follow-up period both for those who went to prison (beta coefficient = -
6.00, 95% CI -11.52 to -0.48, p=0.033) and for the whole sample (beta coefficient = -
1.45, 95% CI -2.48 to -0.43, p=0.005; Table 7-36). There was strong evidence that SAD 
cases who went to prison over the follow-up spent more time in prison compared with 
schizophrenia cases (beta coefficient = 50.5, 95% CI 45.53 to 55.47, p<0.001). There 
was also strong evidence that SAD cases who went to prison over the follow-up spent 
more time in prison compared with PMD cases (beta coefficient = -56.50, 95% CI -
58.89 to -54.11, p<0.001) and bipolar cases (beta coefficient = 57.00, 95% CI 55.93 to 
58.07, p<0.001).  
 
7.5.2.2.5. Social outcomes summary by baseline diagnosis 
In summary, of those with a baseline diagnosis of PMD, 4.3% had been to prison during 
some point over the follow-up period, 48.8% were mainly single, divorced or separated 
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over the follow-up period, and 28.6% had no close confidants. In terms of employment, 
28.6% of PMD cases worked for 75-100% of the follow-up period and 50% worked for 
0-25% of the follow-up. 
 
Of the cases with a baseline diagnosis of SAD, 6.3% had been to prison during some 
point over the follow-up period, 80.0% were mainly single, divorced or separated over 
the follow-up period and 40.0% had no close confidants. In terms of employment, no 
SAD cases worked for 75-100% of the follow-up period and 86.7% worked for 0-25% 
of the follow-up. 
 
The comparisons between the groups showed evidence that PMD cases had better 
outcomes compared with schizophrenia cases on many social outcomes. Compared with 
schizophrenia cases, PMD cases: were less likely to go to prison; spent less time in 
prison; were more likely to be in a relationship; and had more time in employment. 
 
There was evidence that PMD cases had better outcomes compared with SAD cases on 
a number of social outcomes. PMD cases were more likely to be in a relationship, spent 
more time employed and when examining only those who were incarcerated, PMD 
cases spent less time in prison. There was also evidence on a few social outcomes that 
SAD cases had worse outcomes compared with schizophrenia and bipolar cases; when 
examining only those who were incarcerated, SAD cases spent longer in prison 
compared with both schizophrenia and bipolar cases; more SAD cases were 
single/separated/divorced compared with bipolar cases; and SAD cases worked for less 
time compared with bipolar cases. However, as with the majority of analyses in this 
chapter, the findings based on SAD cases must be interpreted with caution due to the 
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low number of cases. For example, when examining months in prison, there was only 
one case who had been to prison on which to base the analysis. 
 
7.5.3. Service use over 10 years by baseline diagnosis 
7.5.3.1. Binary hospitalisation by baseline diagnosis 
Table 7-37 shows that the PMD and SAD group have the lowest percentage of cases 
who were admitted with 84.2% and 88.2% respectively (number in analyses: 308). 
 
Table 7-37: Comparison of hospitalisation data by baseline diagnosis 
 PMD (n57) SAD (n17) SZ (n180) BP (n54) 


















There was no evidence to support the hypothesis that PMD and SAD cases would have 
a lower proportion of cases admitted compared with schizophrenia cases (see Table 
7-38). There was some weak evidence that PMD cases were less likely to be 
hospitalised over the follow-up compared with bipolar cases (OR 0.21, 95% CI 0.04-
1.00, p=0.05; Table 7-38). 
 
Table 7-38: OR, CI and p value for comparisons between the groups on 
hospitalisation 
 PMD vs. SZ 
(n237) 
PMD vs. BP 
(n111) 
PMD vs. SAD 
(n74) 
SAD vs. SZ 
(n197) 
SAD vs. BP 
(n71) 
 OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) 










*p<0.1; **p<0.05; ***p<0.01; OR = odds ratio; CI = 95% confidence interval. 
 
7.5.3.2. Total number of hospitalisations by baseline diagnosis 
The data on total number of admissions was not normally distributed so medians and 
IQRs are presented. The data on total number of hospitalisations is count data and an 
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examination of the mean and variance indicated over dispersion. Therefore, a negative 
binomial regression has been used. Table 7-39 shows that the medians and IQRs were 
all very similar, with PMD cases having a slightly lower median of 1 (number in 
analyses: 276). 
 
Table 7-39: Comparison of total hospitalisations by baseline diagnosis 
 PMD (n50) SAD (n17) SZ (n162) BP (n47) 
 Median (IQR) Median (IQR) Median (IQR) Median (IQR) 
Total number of 
hospitalisations 
1 (1-3) 2 (1-4) 2 (1-5) 2 (1-4) 
SZ=schizophrenia; BP=bipolar; IQR = Interquartile range. 
 
Table 7-40: IRR, CI and p value for comparisons between the groups of the total 
hospitalisations over the follow-up period 
 PMD vs. SZ 
(n212) 
PMD vs. BP 
(n97) 
PMD vs. SAD 
(n67) 
SAD vs. SZ 
(n179) 
SAD vs. BP 
(n64) 
 IRR (CI) IRR (CI) IRR (CI) IRR (CI) IRR (CI) 












*p<0.1; **p<0.05; ***p<0.01; IRR = incidence rate ratio; CI = 95% confidence interval. 
 
The hypothesis that PMD and SAD cases would have less hospitalisations compared 
with schizophrenia cases was tested. There was strong evidence that the rate at which 
hospitalisations occur was lower in PMD cases compared with schizophrenia cases 
(IRR 0.63, 95% CI 0.46-0.88, p=0.006; Table 7-40). There was some weak evidence 
that the rate at which hospitalisations occur were lower in SAD cases compared with 
schizophrenia cases (IRR 0.72, 95% CI 0.46-1.12, p=0.095). There was also strong 
evidence that the rate at which hospitalisations occur was lower in PMD cases 
compared with bipolar cases (IRR 0.68, 95% CI 0.47-0.98, p=0.041). 
 
7.5.3.3. Total number of days hospitalised by baseline diagnosis 
The data on the number of days hospitalised was not normally distributed, thus, medians 
and IQRs were calculated. Attempts to transform the data and make it and its residuals 
normal were unsuccessful so bootstrap regressions have been applied. Table 7-41 shows 
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that the median days were highest for schizophrenia cases at 111.5 days and lowest for 
PMD cases at 54 days (number in analyses: 235). 
 
Table 7-41: Comparison of days hospitalised by baseline diagnosis 
 PMD (n47) SAD (n15) SZ (n132) BP (n41) 
 Median (IQR) Median (IQR) Median (IQR) Median (IQR) 
Total number of days 
hospitalised 
54 (13-186) 80 (24-191) 115.5 (33-287.7) 73 (27-165) 
SZ=schizophrenia; BP=bipolar; IQR = Interquartile range. 
 
The hypothesis that PMD and SAD cases would have less days hospitalised compared 
with schizophrenia cases was tested. There was strong evidence that PMD cases had 
less total hospitalisation days over the follow-up compared with schizophrenia cases 
(beta coefficient -163.62, 95% CI -270.52 to -56.72, p=0.003; Table 7-42). There was 
no evidence that SAD cases had less total hospitalisation days over the follow-up 
compared with schizophrenia cases (beta coefficient -50.41, 95% CI -290.07 to 189.26, 
p=0.686) and there was no evidence of any other differences between the groups.  
 
Table 7-42: Coefficient, CI and p value for comparisons between the groups of the 
hospitalisation days over the follow-up period 
 PMD vs. SZ 
(n179) 
PMD vs. BP 
(n88) 
PMD vs. SAD 
(n62) 
SAD vs. SZ 
(n147) 

































*p<0.1; **p<0.05; ***p<0.01; CI = 95% confidence interval. 
 
Figure 7-4 shows the histograms of the number of inpatient days per year by diagnosis. 
The figure demonstrates that the total number of inpatient days in the first year was 
similarly high for all diagnoses. Following the first year, the total number of days in 
each year for PMD was very small in comparison to SAD and schizophrenia. This 
indicates that the majority of inpatient days are accrued for PMD cases in the first year 
following first episode of psychosis, but this was not the case for schizophrenia and 
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SAD cases who have a more even distribution of inpatient days usage. This has 





7.5.3.4. Percentage of the follow-up spent as an inpatient by baseline diagnosis 
The data on the percentage of follow-up hospitalised was not normally distributed, thus, 
medians and IQRs were calculated. Attempts to transform the data and make it and its 
residuals normal were unsuccessful so bootstrap regressions have been applied. Table 
7-43 shows that the percentage of the follow-up spent as in inpatient was highest for 















mean of Year1days mean of Year2days 
mean of Year3days mean of Year4days 
mean of Year5days mean of Year6days 
mean of Year7days mean of Year8days 
Figure 7-4: Histograms of the number of inpatient days per year by diagnosis 
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Table 7-43: Comparison of percentage of the follow-up as inpatient data by 
baseline diagnosis 
 PMD (n47) SAD (n15) SZ (n132) BP (n41) 
 Median (IQR) Median (IQR) Median (IQR) Median (IQR) 
Percentage of follow-up as 









SZ=schizophrenia; BP=bipolar; IQR = Interquartile range. 
 
The hypothesis that PMD and SAD cases would have a lower a lower percentage of the 
follow-up spent as an inpatient compared with schizophrenia cases was tested. There 
was evidence that PMD cases spent less of the follow-up as an inpatient compared with 
schizophrenia cases (beta coefficient -4.63, 95% CI -8.38 to -0.88, p=0.015; Table 
7-44). There was no evidence that SAD cases (beta coefficient -2.12, 95% CI -9.45 to 
5.20, p=0.562) spent less of the follow-up as an inpatient compared with schizophrenia 
cases and there was no evidence of any other differences. 
 
Table 7-44: Coefficient, CI and p value for comparisons between the groups of the 
percentage as an inpatient over the follow-up period 
 PMD vs. SZ 
(n179) 
PMD vs. BP 
(n88) 
PMD vs. SAD 
(n62) 
SAD vs. SZ 
(n147) 
























(-6.41 to 2.98) 
-2.51  
(-9.67 to 4.66) 
-2.12  
(-9.45 to 5.20) 
0.79  
(-6.85 to 8.44) 
*p<0.1; **p<0.05; ***p<0.01; CI = 95% confidence interval. 
 
7.5.3.5. Percentage of admissions which were compulsory by baseline diagnosis 
The data on the percentage of admission compulsory was not normally distributed, thus, 
medians and IQRs were calculated. Attempts to transform the data and make it and its 
residuals normal were unsuccessful so bootstrap regressions have been applied. Table 
7-45 shows that the median percentage for schizophrenia cases was very high at 80% 
and lowest in the PMD (20%) and SAD (33.3%) cases (number in analyses: 192). 
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Table 7-45: Comparison of percentage of hospitalisations which were compulsory 
data by baseline diagnosis 
 PMD (n35) SAD (n11) SZ (n109) BP (n37) 
 Median (IQR) Median (IQR) Median (IQR) Median (IQR) 










SZ=schizophrenia; BP=bipolar; IQR = Interquartile range. 
 
Table 7-46: Coefficient, CI and p value for comparisons between the groups of the 
percentage of hospitalisations which were compulsory over the follow-up period 
 PMD vs. SZ 
(n144) 
PMD vs. BP 
(n72) 
PMD vs. SAD 
(n46) 
SAD vs. SZ 
(n120) 





























*p<0.1; **p<0.05; ***p<0.01; CI = 95% confidence interval. 
 
The hypothesis that PMD and SAD cases would have a lower proportion of cases being 
compulsorily admitted compared with schizophrenia cases was tested. There was strong 
evidence that PMD cases had a lower percentage of compulsory admissions compared 
with schizophrenia cases (beta coefficient -23.29, 95% CI -23.29 to -8.89, p=0.009). 
There was some weak evidence that SAD cases had a lower percentage of compulsory 
admissions compared with schizophrenia cases (beta coefficient -24.32, 95% CI -51.28 
to 2.65, p=0.077). There was also some evidence that PMD cases had a lower 
percentage of compulsory admissions compared with bipolar cases (beta coefficient -
23.24, 95% CI -42.01 to -4.47, p=0.015; Table 7-46) and some weak evidence that SAD 
cases had a lower percentage of compulsory admissions compared with bipolar cases 
(beta coefficient -24.27, 95% CI -52.54 to 4.00, p=0.092).  
 
7.5.3.6. Having ever been admitted compulsorily by baseline diagnosis  
Table 7-47 presents data on whether cases were ever compulsorily admitted by baseline 
diagnoses (number in analyses: 232). PMD (44.4%) and SAD (50.0%) cases had the 
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lowest percentage of cases who were compulsorily admitted with bipolar cases having 
the highest percentage (80.5%) being compulsorily admitted. 
 
Table 7-47: Comparison of compulsory hospitalisation data by baseline diagnosis 
 PMD (n45) SAD (n14) SZ (n132) BP (n41) 
 N (%) N (%) N (%) N (%) 

















The hypothesis that PMD and SAD cases would have a lower proportion of cases being 
compulsorily admitted compared with schizophrenia cases was tested. There was strong 
evidence that PMD cases were less likely to be compulsorily admitted compared with 
schizophrenia cases (OR 0.35, 95% CI 0.17-0.70, p=0.003). This was not supported for 
SAD cases (OR 0.43, 95% CI 0.14-1.32, p=0.142). There was also evidence that PMD 
cases (OR 0.19, 95% CI 0.07-0.51, p=0.001; Table 7-48) and SAD cases were less 
likely to be compulsorily admitted compared with bipolar cases (OR 0.24, 95% CI 0.07-
0.89, p=0.033). 
 
Table 7-48: OR, CI and p value for comparisons between the groups of 
compulsory admissions 
 PMD vs. SZ 
(n177) 
PMD vs. BP 
(n86) 
PMD vs. SAD 
(n59) 
SAD vs. SZ 
(n146) 
SAD vs. BP 
(n55) 













*p<0.1; **p<0.05; ***p<0.01; OR = odds ratio; CI = 95% confidence interval. 
 
7.5.3.7. Percentage of hospitalisations involving the police by baseline diagnosis 
The data on the percentage of admissions involving the police was not normally 
distributed, thus, medians and IQRs were calculated. Attempts to transform the data and 
make it and its residuals normal were unsuccessful so bootstrap regressions have been 
applied. Table 7-49 shows that the median percentage for each group was zero except 
the bipolar group which had a median of 27.8% (number in analyses: 207). 
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Table 7-49: Comparison of police involvement in hospitalisation data by baseline 
diagnosis 



















SZ=schizophrenia; BP=bipolar; IQR = Interquartile range. 
 
Table 7-50: Coefficient, CI and p value for comparisons between the groups of 
police involvement in hospitalisations over the follow-up period 
 PMD vs. SZ 
(n160) 
PMD vs. BP 
(n79) 
PMD vs. SAD 
(n54) 
SAD vs. SZ 
(n128) 



































*p<0.1; **p<0.05; ***p<0.01; CI = 95% confidence interval. 
 
The hypothesis that PMD and SAD cases would have a lower percentage of 
hospitalisations involving the police compared with schizophrenia cases was tested. 
There was evidence that the PMD group had a lower percentage of hospitalisations 
involving the police that schizophrenia cases (beta coefficient -17.23, -29.35 to -5.10, 
p=0.005). There was some weak evidence that the SAD group had a lower percentage 
of hospitalisations involving the police than schizophrenia cases (beta coefficient -
20.34, 95% CI -41.00 to 0.33, p=0.054). There was evidence that PMD cases had a 
lower percentage of hospitalisations involving the police compared with bipolar cases 
(beta coefficient -19.79, -35.61 to -3.96, p=0.014; Table 7-50) and some weak evidence 
for the same in SAD cases (beta coefficient -22.89, 95% CI -46.43 to 0.64, p=0.057). 
 
7.5.3.8. Summary of service use by baseline diagnosis 
In summary, of those with a baseline diagnosis of PMD, 84.2% had an admission over 
the follow-up, the median number of admissions was 1 (1-3 IQR), the median number 
of days hospitalised was 54 (13-186 IQR), the median percentage of the follow-up spent 
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as an inpatient was 1.66% (0.46-4.75% IQR), the median percentage of admissions 
which were compulsory was 20.0% (0-100% IQR), 55.6% were never admitted 
compulsorily and the median percentage of hospitalisations involving the police was 0% 
(0-20% IQR). 
 
Of those with a baseline diagnosis of SAD, 88.2% had an admission over the follow-up, 
the median number of admissions was 2 (1-4 IQR), the median number of days 
hospitalised was 80 (24-191 IQR), the median percentage of days spent as an inpatient 
was 2.28% (0.63-5.49% IQR), the median percentage of admissions which were 
compulsory was 33.3% (0-100% IQR), 50.0% were never admitted compulsorily and 
the median percentage of hospitalisations involving the police was 0% (0-0% IQR). 
 
The comparisons between the groups showed that there was evidence that PMD cases 
had better outcomes on most of the service use outcomes compared with schizophrenia 
cases and bipolar cases. Compared with schizophrenia cases, PMD cases had: less total 
hospitalisations; less total days hospitalised; a lower percentage of the follow-up as an 
inpatient; less compulsory admissions; and had fewer admissions involving the police. 
Compared with bipolar cases, PMD cases: were less likely to be admitted; had less total 
hospitalisations; had less compulsory admissions; and had fewer admissions involving 
the police. 
 
There was only some weak evidence of differences between SAD, schizophrenia and 
bipolar cases on a few service use outcomes. There was no evidence of any differences 
between PMD and SAD cases on service use outcomes. 
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7.6. Course and outcome by lifetime diagnosis 
7.6.1. Course of illness over 10 years by lifetime diagnosis 
7.6.1.1. Basic comparison of course type by lifetime diagnosis 
There were some small differences in the findings between the analyses based on 
baseline and lifetime diagnoses. Table 7-51 shows that PMD and bipolar cases were 
mostly episodic or ‘neither episodic nor continuous’ in course type (number in analyses: 
298). SAD and schizophrenia cases had mostly neither episodic nor continuous course 
type. 
 
Table 7-51: Comparison of course of illness variables by lifetime diagnosis  
 PMD (n39) SAD (n15) SZ (n184) BP (n60) 























The hypothesis that PMD and SAD cases would have a higher proportion of cases with 
an episodic course of illness and less with a continuous course of illness compared with 
schizophrenia cases was tested. There was evidence that PMD cases were more likely to 
be episodic in course type (OR 6.78, 95% CI 3.20-14.37, p<0.001) and less likely to be 
continuous (OR 0.09, 95% CI 0.02-0.39, p=0.001) in comparison to schizophrenia cases 
(Table 7-52). There was no evidence of any differences in course type between SAD 
and schizophrenia cases (episodic: OR 0.43, 95% CI 0.12-1.56, p=0.199; continuous: 
OR 1.22, 95% CI 0.42-3.50, p=0.712). There was some weak evidence that PMD cases 
were more likely to have an episodic course type compared with SAD cases (OR 3.21, 
95% CI 0.87-11.84, p=0.08). There was evidence that SAD cases were less likely to 
have an episodic course type compared with bipolar cases (OR 0.13, 95% CI 0.04-0.48, 
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p=0.002) and there was weak evidence that they were more likely to have a course type 
of neither episodic nor continuous (OR 3.14, 95% CI 0.98-10.07, p=0.054). 
 
Table 7-52: OR, CI and p value for comparisons between the groups in the course 
of illness variable 
 PMD vs. SZ 
(n223) 
PMD vs. BP 
(n99) 




SAD vs. BP 
(n75) 



































*p<0.1; **p<0.05; ***p<0.01; OR = Odds ratio; CI = 95% confidence interval; $ STATA unable to 
calculate as one group with zero cases. 
 
The findings which differ from the baseline analyses were that there was no longer 
evidence of a difference between PMD and bipolar cases in the occurrence of neither 
episodic nor continuous life course. There was also evidence of a difference between 
PMD and SAD in the occurrence of episodic course types that did not exist based on the 
baseline diagnoses. 
 
7.6.1.2. Longest period of remission by lifetime diagnosis 
There was a difference in the findings between the analyses based on baseline and 
lifetime diagnoses. Table 7-53 shows that PMD cases had the greatest median longest 
period of remission at 372 weeks with schizophrenia cases having the lowest at 83.5 
weeks (number in analyses: 249). SAD and bipolar cases had a median between these at 
178 weeks and 360 weeks respectively. 
 
Table 7-53: Comparison of longest weeks of remission by lifetime diagnosis 
 PMD (n31) SAD (n12) SZ (n154) BP (n52) 
 Median (IQR) Median (IQR) Median (IQR) Median (IQR) 
Longest period of 
remission in weeks 
372 (255-533) 178 (39-293) 83.5 (0-230) 360 (213.5-475.5) 
IQR = Interquartile range 
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The hypothesis that PMD and SAD would have longer remissions compared with 
schizophrenia cases was tested. There was strong evidence that PMD cases had higher 
longest weeks of remission compared with schizophrenia cases (beta coefficient 228.59, 
95% CI 157.85-299.33, p<0.001). There was no evidence for such a difference between 
SAD and schizophrenia cases (beta coefficient 46.76, 95% CI -46.95 to 146.46, 
p=0.313). There was also strong evidence that PMD cases had higher longest weeks of 
remission compared with SAD cases (beta coefficient 178.83, 95% CI 62.04 to 286.31, 
p=0.003; Table 7-54) and there was strong evidence that SAD cases had lower longest 
weeks of remission compared with bipolar cases (beta coefficient -154.12, 95% CI -
258.55 to -49.68, p=0.004). 
 
Table 7-54: Coefficients, CI and p value for comparisons between the groups in the 
longest weeks of remission variable 
 PMD vs. SZ 
(n185) 
PMD vs. BP 
(n83) 
PMD vs. SAD 
(n43) 
SAD vs. SZ 
(n166) 






























*p<0.1; **p<0.05; ***p<0.01; CI = 95% confidence interval. 
 
The finding that PMD cases had higher longest weeks of remission compared with SAD 
cases was not evident in the analyses based on baseline diagnoses; however, the other 
two significant findings were identified by the baseline diagnosis analyses. 
 
7.6.1.3. Number of episodes by lifetime diagnosis 
There was a difference in the findings between the analyses based on baseline and 
lifetime diagnoses. Of the 368 included in the core analytic sample, 248 cases had a 
non-continuous course of illness. Of those, 185 had data on number of episodes and 
therefore form the participants included in this section. Table 7-55 shows that the 
median number of episodes excluding the first was lowest in the PMD group at zero 
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episodes and highest in the SAD group at three episodes (number in analyses: 185 (248 
had a non-continuous course). 
 
Table 7-55: Comparison of number of episodes by lifetime diagnosis 
 PMD (n31) SAD (n11) SZ (n90) BP (n53) 
 Median (IQR) Median (IQR) Median (IQR) Median (IQR) 
Number of episodes 0 (0-1) 3 (1-3) 2 (1-3) 1 (0-2) 
IQR = Interquartile range 
 
The hypothesis that PMD and SAD cases would have more episodes compared with 
schizophrenia cases was tested. There was strong evidence that the rate at which 
episodes occurred were 40% less in the PMD group compared with the schizophrenia 
group (IRR 0.40, 95% CI 0.25 – 0.65, p<0.001) but not in SAD compared with 
schizophrenia cases (IRR 1.01, 95% CI 0.60-1.70, p=0.976). There was strong evidence 
that the rate at which episodes occurred were 53% less in PMD cases compared with 
bipolar (IRR 0.53, 95% CI 0.29-0.96, p=0.037; Table 7-56). There was also evidence 
that the rate at which episodes occurred were 40% less in the PMD group compared 
with the SAD group (IRR 0.40, 95% CI 0.19-0.85, p=0.017). 
 
The finding that PMD cases experienced episodes at a rate of 40% less than SAD cases 
was not evidenced in the analyses based on the baseline diagnoses; however, the other 
two significant findings were identified by the baseline diagnosis analyses. 
 
Table 7-56: IRR, CI and p value for comparisons between the groups in the 
average number of episodes 
 PMD vs. SZ 
(n121) 
PMD vs. BP 
(n84) 
PMD vs. SAD 
(n42) 
SAD vs. SZ 
(n101) 
SAD vs. BP 
(n64) 













*p<0.1; **p<0.05; ***p<0.01; IRR = incidence rate ratio; CI = 95% confidence interval. 
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7.6.1.4. Months of longest episode by lifetime diagnosis 
There was a difference in the findings between the analyses based on baseline and 
lifetime diagnoses. Table 7-57 shows that the bipolar group had the lowest median 
length of longest episode at 2 months and schizophrenia cases had the highest at 11 
months. PMD and SAD cases came between these: both had a median of 5 months 
(number in analyses: 124 (248 had a non-continuous course). 
 
Table 7-57: Comparison of average length of longest episode by lifetime diagnosis 









Length of longest episode in months 
(including first episode) 
5 (1-12) 5 (2-26) 11 (5-43) 2 (1-4) 
IQR = Interquartile range 
 
The hypothesis that PMD and SAD would have shorter episodes compared with 
schizophrenia cases was tested. There was strong evidence that PMD cases had lower 
longest episodes compared with schizophrenia cases (beta coefficient -17.84, 95% CI -
28.33 to -7.36, p=0.001; Table 7-58) but there was no evidence for this difference 
between SAD and schizophrenia cases (beta coefficient -7.64, 95% CI -25.90 to 10.63, 
p=0.412).  
 
Table 7-58: Coefficients, CI and p value for comparisons between the groups in the 
longest episode in months 
 PMD vs. SZ 
(n82) 




SAD vs. SZ 
(n78) 




































*p<0.1; **p<0.05; ***p<0.01; CI = 95% confidence interval. 
 
The finding from these lifetime diagnosis analyses that PMD cases had lower longest 
episodes compared with schizophrenia cases was not found in the baseline diagnosis 
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analyses. The baseline diagnosis analyses reported that PMD cases and SAD cases had 
longer longest episodes of illness compared with bipolar cases: this was not supported 
by the lifetime diagnosis analyses. 
 
7.6.1.5. Percentage of time psychotic during follow-up by lifetime diagnosis 
There were differences in the findings between the analyses based on baseline and 
lifetime diagnoses. Table 7-59 shows that the percentage of time psychotic was very 
low for PMD and bipolar cases; 5.1% and 3.8% respectively. Comparatively, the 
percentage of time psychotic was very high for SAD and schizophrenia cases; 52.9% 
and 76.7% respectively (number in analyses: 189). 
 
The hypothesis that PMD and SAD would spend a smaller percentage of the follow-up 
psychotic compared with schizophrenia cases was tested. There was strong evidence 
that PMD cases spent a lower percentage of time psychotic over follow-up compared 
with schizophrenia cases (beta coefficient -41.53, 95% CI -53.77 to -29.28, p<0.001) 
but there was no evidence for this in SAD compared with schizophrenia cases (beta 
coefficient -6.64, 95% CI -38.06 to 24.78, p=0.675). There was strong evidence that 
PMD cases spent a lower percentage of time psychotic over follow-up compared with 
SAD cases (beta coefficient -34.89, 95% CI -67.19 to -2.60, p=0.034; Table 7-60). 
There was strong evidence that SAD cases spent a higher percentage of time psychotic 
over follow-up compared with bipolar cases (beta coefficient 43.14, 95% CI 10.99 to 
75.29, p=0.009). 
 
Table 7-59: Comparison of percentage of time in psychotic episode over follow-up 
by lifetime diagnosis 
 PMD (n25) SAD (n8) SZ (n124) BP (n32) 
 Median (IQR) Median (IQR) Median (IQR) Median (IQR) 
Percentage of time in 









IQR = Interquartile range 
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Table 7-60: Coefficients, CI and p value for comparisons between the groups in the 
percentage of time psychotic during follow-up 
 PMD vs. SZ 
(n149) 




SAD vs. SZ 
(n132) 






























*p<0.1; **p<0.05; ***p<0.01; CI = 95% confidence interval. 
 
The findings that schizophrenia cases and SAD cases spent a higher percentage of time 
psychotic over follow-up compared with PMD cases and bipolar cases consecutively 
was also found in the baseline diagnosis analyses. However, the finding from the 
lifetime diagnosis analyses that SAD cases had a higher percentage of time psychotic 
compared with PMD cases was not found in the baseline diagnosis analyses. The 
finding from the baseline diagnosis analyses that PMD cases spend more time psychotic 
compared with bipolar cases was not supported by the lifetime diagnosis analyses. 
 
7.6.1.6. Course of illness summary by lifetime diagnosis 
The course of illness analyses based on lifetime diagnoses found some noteworthy 
differences from the baseline diagnosis analyses. Firstly, there was evidence of some 
differences between PMD and SAD cases. There was evidence that compared with SAD 
cases, PMD cases: were more likely to have an episodic course type (albeit weak 
evidence); had higher longest weeks of remission; had fewer episodes; and spent less 
time psychotic over the follow-up.  
 
Other findings which differed were: there was no longer evidence of a difference 
between PMD and bipolar cases in the occurrence of the ‘neither episodic or 
continuous’ course of illness; there was new evidence that PMD cases had lower longest 
episodes compared with schizophrenia cases; there was no longer evidence that PMD 
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cases and SAD cases had longer longest episodes of illness compared with bipolar 
cases; and there was no longer evidence that PMD cases spent more time psychotic 
compared with bipolar cases. 
 
7.6.2. Mortality, suicidality and social outcomes at 10 years by lifetime diagnosis 
7.6.2.1. Mortality and suicidality by lifetime diagnosis 
The analyses on death based on lifetime diagnoses had the same findings as those based 
on the baseline diagnoses (see Appendix A; any results based on lifetime diagnoses that 
show the same findings as the baseline analyses will be placed in the appendices). 
However, there were some differences in the findings on attempted suicide and self-
harm. 
 
7.6.2.1.1. Attempted suicide by lifetime diagnosis 
Table 7-61 shows the highest percentage of suicide attempters were in the PMD group 
(37.1%), followed by the SAD group (29.4%). The number of suicide attempts for those 
who did attempt suicide was highest in the PMD (median 2) and SAD (median 3) 
groups (number in analyses: 248). 
 
The hypothesis that PMD and SAD cases would have a higher proportion of cases who 
attempted suicide over the follow-up, and a higher rate of suicide attempts for those 
who do attempt, compared with schizophrenia and bipolar cases was tested. There was 
strong evidence that cases with a lifetime diagnosis of PMD were 2.86 times more 
likely to attempt suicide compared with schizophrenia cases (OR 2.86, 95% CI 1.30-
6.30, p=0.009; Table 7-62). There was some weak evidence that PMD cases were 2.22 
times more likely to attempt suicide compared with bipolar cases (OR 2.22, 95% CI 
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0.87-5.65, p=0.096). There was no evidence that SAD cases were more likely to attempt 
suicide compared with schizophrenia (OR 2.01, 95% CI 0.66-6.14, p=0.218) and bipolar 
cases (OR 1.56, 95% CI 0.46-5.30, p=0.474). In terms of number of attempts for the 
whole sample, there was evidence that PMD cases had a greater rate of suicide attempts 
compared with schizophrenia cases (IRR 3.55, 95% CI 1.38-9.12, p=0.008) and bipolar 
cases (IRR 3.17, 95% CI 1.14-8.83, p=0.028). There was some weak evidence that SAD 
cases had a greater rate of suicide attempts compared with schizophrenia cases (IRR 
2.93, 95% CI 0.85-10.16, p=0.090). When only those cases who attempted suicide were 
included, there was evidence that SAD cases had a greater rate of suicide attempts 
compared with schizophrenia cases (IRR 1.78, 95% CI 1.03-3.06, p=0.038) and bipolar 
cases (IRR 2.13, 95% CI 1.09-4.16, p=0.028). When only those cases who attempted 
suicide were included, there was no evidence that PMD cases had a greater rate of 
suicide attempts compared with schizophrenia cases (IRR 1.28, 95% CI 0.81-2.04, 
p=0.293) and bipolar cases (IRR 1.54, 95% CI 0.83-2.83, p=0.169). 
 
Table 7-61: Comparison of suicide attempts by lifetime diagnosis 
 PMD (n35) SAD (n17) SZ (n175) BP (n57) 
















 Median (IQR) Median (IQR) Median (IQR) Median (IQR) 
Number of suicide attempts 
(for all cases not just 
attempters) 
0 (0-1) 0 (0-1) 0 (0-0) 0 (0-0) 
Number of suicide attempts 
(for suicide attempters only) 
2 (1-3) 3 (2-4) 1 (1-2) 1 (1-1.5) 
SZ=schizophrenia; BP=bipolar; IQR = Interquartile range. 
 
These findings are very different from the findings based on the baseline diagnoses 
which found no differences in the occurrence of self-harm between the groups, or in the 
number of attempts. 
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Table 7-62: OR, CI and p value for comparisons between the groups in the 
occurrence of suicide attempts and the IRR, CI and p value for comparisons 
between the groups in the number of suicide attempts 
 PMD vs. SZ 
(n210) 
PMD vs. BP 
(n92) 
PMD vs. SAD 
(n52) 
SAD vs. SZ 
(n192) 
SAD vs. BP 
(n74) 











 IRR (CI) IRR (CI) IRR (CI) IRR (CI) IRR (CI) 
Suicide 






















*p<0.1; **p<0.05; ***p<0.01; OR = odds ratio; IRR = incidence rate ratio; CI = 95% confidence interval. 
 
7.6.2.1.2. Self-harm by lifetime diagnosis 
Table 7-63 that SAD cases had the highest percentage of self-harmers with 35.3%, 
followed by PMD cases with 27%. It also shows that PMD cases had the highest 
median number of self-harm occurrences for those who did self-harm (number in 
analyses: 283). 
 
The hypothesis that PMD and SAD cases would have a higher proportion of cases who 
self-harmed over the follow-up, and a higher rate of self-harm events for those who do 
self-harm, compared with schizophrenia and bipolar cases was tested. There was some 
evidence that the SAD cases were 3.41 times more likely to self-harm compared with 
the schizophrenia group (OR 3.41, 95% CI 1.15-10.08, p=0.027; Table 7-64). There was 
some weak evidence that the PMD group was more likely to self-harm compared with 
the schizophrenia cases (OR 2.31, 95% CI 1.00-5.38, p=0.051). There was also some 
weak evidence that the SAD group were more likely to self-harm compared with the 
bipolar group (OR 3.20, 95% CI 0.92-11.14, p=0.067) but not for PMD cases (OR 2.18, 
95% CI 0.77-6.18, p=0.144). In terms of number of self-harm events for the whole 
sample, there was evidence that PMD (IRR 6.16, 95% CI 1.80-21.03, p=0.004) and 
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SAD (IRR 5.87, 95% CI 0.77-6.18, p=0.004) cases had a greater rate of self-harm 
events compared with bipolar cases but not compared to schizophrenia cases. When 
only those who self-harmed were included, there was evidence that PMD had a greater 
rate of self-harm events compared with bipolar cases (IRR 3.47, 95% CI 1.52-7.93, 
p=0.003) and weak evidence that SAD cases had a greater rate of self-harm events 
compared with bipolar cases (IRR 2.51, 95% CI 0.98-6.43, p=0.054), but again there 
were no differences compared to the schizophrenia group (PMD: IRR 1.43, 95% CI 
0.63-3.24, p=0.394; SAD: IRR 0.97, 95% CI 0.36-2.59, p=0.948). 
 
Table 7-63: Comparison of self-harm data by lifetime diagnosis 
 PMD (n37) SAD (n17) SZ (n174) BP (n55) 
















 PMD (n36) SAD (n17) SZ (n174) BP (n55) 
 Median (IQR) Median (IQR) Median (IQR) Median (IQR) 
Number of self-harm 
episodes for all cases not just 
self-harmers) 
0 (0-0.5) 0 (0-1) 0 (0-0) 0 (0-0) 
Number of self-harm 
episodes for self-harmers 
only) 
3 (1-5) 1.5 (1-3) 1 (1-2) 1 (1-1) 
SZ=schizophrenia; BP=bipolar; IQR = Interquartile range. 
 
Table 7-64: OR, CI and p value for comparisons between the groups in the 
occurrence of self-harm and the IRR, CI and p value for comparisons between the 
groups in the number of self-harm events 
 PMD vs. SZ 
(n211) 
PMD vs. BP 
(n92) 
PMD vs. SAD 
(n54) 
SAD vs. SZ 
(n191) 
SAD vs. BP 
(n72) 











 PMD vs. SZ 
(n210) 
PMD vs. BP 
(n91) 
PMD vs. SAD 
(n53) 
SAD vs. SZ 
(n191) 
SAD vs. BP 
(n72) 
























*p<0.1; **p<0.05; ***p<0.01; OR = odds ratio; IRR = incidence rate ratio; CI = 95% confidence interval. 
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Like the lifetime diagnosis analyses on suicide attempts, the results on self-harm are 
very different from those based on the baseline diagnosis analyses which found weak 
evidence of only one difference between PMD and bipolar cases.  
 
7.6.2.1.3. Mortality and suicidality summary by lifetime diagnosis 
The baseline diagnosis analyses found no differences between any of the groups in 
death, suicide attempts and self-harm. In contrast, the analyses based on the lifetime 
diagnoses found evidence of many differences between the groups in suicide attempts 
and self-harm. There was evidence to varying degrees that PMD cases had worse 
outcomes compared with schizophrenia and bipolar cases in attempted suicide and self-
harm outcomes. There was also evidence to varying degrees that SAD cases had worse 
outcomes compared with schizophrenia and bipolar cases in attempted suicide and self-
harm outcomes. There was no evidence of any differences between PMD and SAD 
cases in attempted suicide and self-harm outcomes. 
 
7.6.2.2. Social outcomes by diagnosis by lifetime diagnosis 
7.6.2.2.1. Employment status by lifetime diagnosis 
There were no differences in the findings on employment status in the baseline and 
lifetime diagnosis analyses (Appendix A). 
 
7.6.2.2.2. Relationship status by lifetime diagnosis 
Table 7-65 shows that PMD and bipolar cases had the highest percentage of cases who 
were in a relationship (approximately 52% for both). This was followed by SAD cases 
of whom 43.8% were in a relationship and finally schizophrenia cases, only 19.2% of 
whom were in a relationship (number in analyses: 273). 
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Table 7-65: Comparison of relationship status by lifetime diagnosis 
 PMD (n33) SAD (n16) SZ (n172) BP (n52) 
 n (%) n (%) n (%) n (%) 
Main relationship status – dichotomised: 
Single/divorced/separated 















The hypothesis that PMD and SAD cases would have a higher proportion of cases who 
were in a relationship over the follow-up compared with schizophrenia cases was tested. 
There was evidence that PMD cases were more likely to be in a relationship compared 
with schizophrenia cases (OR 4.48, 95% CI 2.05-9.77, p<0.001) and that SAD cases 
were more likely to be in a relationship compared with schizophrenia cases (OR 3.28, 
95% CI 1.14-9.44, p=0.028; Table 7-66). 
 
Table 7-66: OR, CI and p value for comparisons between the groups of the main 
relationship status over the follow-up period 
 PMD vs. SZ 
(n205) 




SAD vs. SZ 
(n188) 
SAD vs. BP 
(n68) 
 OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) 
Relationship 












*p<0.1; **p<0.05; ***p<0.01; OR = odds ratio; CI = 95% confidence interval. 
 
There were some differences in the findings based on the baseline diagnosis analyses 
and lifetime diagnosis analyses. The baseline analyses found evidence that PMD cases 
were more likely to be in a relationship compared with schizophrenia cases and SAD 
cases whereas only the PMD group compared with the schizophrenia group not PMD 
compared with SAD was supported by the lifetime analyses. The baseline analyses 
supported bipolar cases being more likely to be in a relationship compared with SAD 
cases whereas the lifetime analyses did not support this. The lifetime diagnosis analyses 
reveal evidence that SAD cases were more likely to be in a relationship compared with 
schizophrenia which was not found in the baseline analyses. 
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7.6.2.2.3. Close confidants by lifetime diagnosis 
Table 7-67 shows that PMD cases had the highest percentage of cases with a close 
confidant at 90%. This was followed by bipolar cases with 70%, SAD cases at 62.5% 
and schizophrenia cases had the lowest at 50% (number in analyses: 144). 
 
Table 7-67: Comparison of close confidants over follow-up by lifetime diagnosis 
 PMD (n20) SAD (n8) SZ (n86) BP (n30) 


















The hypothesis that PMD or SAD cases would have a higher proportion of cases with a 
close confidant over follow-up compared with schizophrenia cases was tested. There 
was strong evidence that PMD cases were more likely to have a close confidant over the 
follow-up period compared with schizophrenia cases (OR 9.00, 95% CI 1.97-41.18, 
p=0.005; Table 7-68). There was no evidence of a difference between SAD and 
schizophrenia cases (OR 1.67, 95% CI 0.37-7.41, p=0.502), and there was no evidence 
of any other differences. 
 
The baseline analyses found no difference between any of the groups in terms of close 
confidants whereas these lifetime analyses found that PMD cases were more likely to 
have close confidants compared with schizophrenia cases. 
 
Table 7-68: OR, CI and p value for comparisons between the groups of the close 
confidants variable over the follow-up period 
 PMD vs. SZ 
(n106) 
PMD vs. BP 
(n50) 
PMD vs. SAD 
(n28) 
SAD vs. SZ 
(n94) 
SAD vs. BP 
(n38) 













*p<0.1; **p<0.05; ***p<0.01; OR = odds ratio; CI = 95% confidence interval. 
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7.6.2.2.4. Time in prison by lifetime diagnosis 
Table 7-69 shows that schizophrenia cases had the highest percentage of cases who had 
been to prison over the follow-up (15.3%) and bipolar cases had the lowest (3.7%). 
PMD and SAD cases were between these with 5.7% and 6.7% respectively. The median 
number of months in prison was the same for all groups (zero) when all cases were 
included. However, when only incarcerated cases were included, PMD cases spent 
longer in prison at 11.5 months. This was followed by the SAD group with five months 
and finally schizophrenia and bipolar cases both with three months (number in analyses: 
274). 
 
The hypothesis that PMD and SAD cases would have a lower proportion of cases who 
had been in prison over the follow-up compared with schizophrenia cases was tested. 
There was no evidence that any of the groups differed in terms of having been to prison 
or not (Table 7-70). There was no evidence of any differences between any of the 
groups in terms of months in prison when all cases were included. If only cases who had 
attended prison were included in the analysis, there was evidence that PMD cases spent 
more time in prison compared with SAD cases (beta coefficient 6.50, 95% CI 0.13 to 
12.87, p=0.046) and that SAD cases spent more time in prison compared with bipolar 
cases (beta coefficient 2.00, 95% CI 0.41 to 3.59, p=0.014). There was also some very 
weak evidence that PMD cases spent more time in prison compared with bipolar cases 
(beta coefficient 8.50, 95% CI -1.43 to 18.43, p=0.093). 
 
The findings on time in prison based on the lifetime diagnosis analyses are different 
from the findings based on the baseline diagnosis analyses. The baseline analyses found 
evidence that more schizophrenia cases went to prison compared with PMD cases and 
that PMD cases spent longer in prison when all cases and when only incarcerated cases 
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were examined, both of which were not supported by the lifetime analyses. When 
examining time in prison only for cases who went to prison, the baseline analyses found 
strong evidence that the SAD cases spent more time in prison compared with PMD, 
whereas this analysis finds evidence of the opposite: that PMD cases spent more time in 
prison. The baseline diagnosis analyses found evidence that incarcerated SAD cases 
spent longer in prison compared with incarcerated bipolar cases which is supported by 
the lifetime diagnosis analyses. 
 
Table 7-69: Comparison of prison contacts by lifetime diagnosis 
 PMD (n35) SAD (n15) SZ (n170) BP (n54) 
 n (%) n (%) n (%) n (%) 























Months in prison (for all cases) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Months in prison (for incarcerated 
cases only) 
11.5 (5-18) 5 (5-5) 3 (1-6) 3 (2-4) 
SZ=schizophrenia; BP=bipolar; IQR=inter quartile range 
 
Table 7-70: OR, coefficients, CI and p value for comparisons between the groups 
for time in prison 
 PMD vs. SZ 
(n205) 
PMD vs. BP 
(n89) 
PMD vs. SAD 
(n50) 
SAD vs. SZ 
(n185) 
SAD vs. BP 
(n69) 





























-0.64 (-2.05 to 
0.76) 
0.55 (-0.52 to 
1.61) 
0.32 (-1.02 to 
1.67) 
-0.97 (-2.12 to 
0.18) 






3.00 (-7.86 to 
13.86) 
8.50 (-1.43 to 
18.43)* 
6.50 (0.13 to 
12.87)** 
-3.50 (-9.20 to 
2.20) 
2.00 (0.41 to 
3.59)** 
*p<0.1; **p<0.05; ***p<0.01; OR = odds ratio; CI = 95% confidence interval. 
 
The baseline analyses found that incarcerated SAD cases spent more time in prison 
compared with incarcerated schizophrenia cases which was not supported by the 
lifetime analyses. There was some weak evidence from the lifetime analyses that 
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incarcerated PMD cases were more likely to spend longer in prison compared with 
incarcerated bipolar cases which was not supported by the baseline analyses. 
 
7.6.2.2.5. Social outcomes summary by lifetime diagnosis 
The baseline and lifetime diagnosis analyses found the same differences between the 
groups in terms of social outcomes of employment status. However, there were some 
differences in findings in time in prison, relationship status and close confidants. One of 
the major changes is in the comparisons between PMD and schizophrenia cases. The 
baseline analyses found that schizophrenia cases were more likely to go to prison over 
the follow-up and spent longer time in prison whereas there was no evidence of this 
from the lifetime diagnosis analyses. The lifetime diagnosis analyses found evidence 
that PMD cases were more likely to have a close confidant at follow-up whereas the 
baseline analyses found no such evidence.  
 
There were also some differences in the comparisons between PMD and SAD cases. 
The baseline analyses found evidence that PMD cases were more likely to be in a 
relationship over the follow-up compared with SAD cases but this was not supported by 
the lifetime analyses. The baseline analyses also found evidence that incarcerated SAD 
cases spent more time in prison compared with PMD incarcerated cases. However, the 
lifetime analyses found the opposite with incarcerated PMD cases spending more time 




7.6.3. Service use over 10 years by lifetime diagnosis 
7.6.3.1. Binary hospitalisation by lifetime diagnosis 
Table 7-71 shows that PMD cases had the highest percentage of cases who were not 
admitted over the follow-up period with 20.9%. This was closely followed by SAD 
cases with 18.8%. Schizophrenia and bipolar cases had the lowest percentage of cases 
who were never admitted with 7.1% and 4.8% respectively (number in analyses: 317).   
 
Table 7-71: Comparison of hospitalisation data by lifetime diagnosis 
 PMD (n43) SAD (n16) SZ (n196) Mania (n62) 


















The hypothesis that PMD and SAD cases would have a lower proportion of cases 
admitted compared with schizophrenia cases was tested. There was evidence that PMD 
cases were less likely to be admitted over the follow-up compared with schizophrenia 
cases (OR 0.29, 95% CI 0.12-0.72, p=0.008) but there was no evidence of a difference 
between SAD and schizophrenia cases (OR 0.33, 95% CI 0.08-1.31, p=0.115) There 
was evidence that PMD cases were less likely to be admitted over the follow-up 
compared with bipolar cases (OR 0.19, 95% CI 0.05-0.76, p=0.019; Table 7-72) and 
there was some weak evidence that SAD cases were less likely to be admitted compared 
with bipolar cases (OR 0.22, 95% CI 0.04-1.22, p=0.083).  
 
Table 7-72: OR, CI and p value for comparisons between the groups on 
hospitalisation 
 PMD vs. SZ 
(n239) 
PMD vs. BP 
(n105) 
PMD vs. SAD 
(n59) 
SAD vs. SZ 
(n212) 
SAD vs. BP 
(n78) 
 OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) 










*p<0.1; **p<0.05; ***p<0.01; OR = odds ratio; CI = 95% confidence interval. 
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The finding based on the baseline diagnoses that PMD cases were less likely to be 
admitted compared with bipolar cases was supported by the lifetime diagnosis analyses. 
However, the lifetime analyses finding that PMD cases were less likely to be admitted 
compared with schizophrenia cases was not found based on the baseline analyses. The 
weak finding based on the lifetime diagnoses that SAD cases were less likely to be 
admitted compared with bipolar cases was not found based on the baseline analyses. 
 
7.6.3.2. Total number of hospitalisations by lifetime diagnosis 
The results based on the lifetime diagnoses were the same as the results based on the 
baseline diagnoses except the weak finding that SAD cases had a lower rate of 
admissions compared to schizophrenia was no longer supported (Appendix A).  
 
7.6.3.3. Total number of days hospitalised by lifetime diagnosis 
There were no differences in the findings on total number of days hospitalised between 
the baseline and lifetime diagnosis analyses (Appendix A). Both sets of analyses found 
evidence that PMD cases had less days hospitalised compared with schizophrenia cases.  
 
7.6.3.4. Percentage of the follow-up spent as an inpatient by lifetime diagnosis 
There were no differences in the findings on the percentage of the follow-up spent as an 
inpatient between the baseline and lifetime diagnosis analyses (Appendix A). 
 
7.6.3.5. Percentage of admissions which were compulsory by lifetime diagnosis 
Table 7-73 shows that PMD cases had the highest median percentage of compulsory 
admissions with 88.9%, SAD had the lowest with 25%, and the schizophrenia and 
bipolar cases scored between these two with 75% and 69.7% respectively (number in 
analyses: 205). 
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Table 7-73: Comparison of percentage of hospitalisations which were compulsory 
data by lifetime diagnosis 









Percentage of admissions compulsory 88.9 (0-100) 25 (0-100) 75 (25-100) 69.7 (33.3-
100) 
SZ=schizophrenia; BP=bipolar; IQR = Interquartile range. 
 
The hypothesis that PMD and SAD cases would have a lower proportion of cases being 
compulsorily admitted compared with schizophrenia cases was tested. There was no 
evidence to support this hypothesis and there was no evidence of any other differences 
between any of the groups (Table 7-74). 
 
Table 7-74: Coefficient, CI and p value for comparisons between the groups of the 
percentage of hospitalisations which were compulsory over the follow-up period 
 PMD vs. SZ 
(n150) 
PMD vs. BP 
(n73) 
PMD vs. SAD 
(n32) 
SAD vs. SZ 
(n132) 



































*p<0.1; **p<0.05; ***p<0.01; CI = 95% confidence interval. 
 
These findings, based on the lifetime diagnoses, that there are no differences between 
the groups are different from those based on the baseline diagnoses. The baseline 
analyses found evidence that PMD cases had a lower percentage of compulsory 
admissions compared with schizophrenia and bipolar cases, and weak evidence that 
SAD cases had a lower percentage of compulsory admissions compared with 
schizophrenia and bipolar cases. 
 
7.6.3.6. Having ever been admitted compulsorily by lifetime diagnosis 
There were no differences in the findings on having ever been admitted compulsorily 
between the baseline and lifetime diagnosis analyses (Appendix A). 
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7.6.3.7. Percentage of hospitalisations involving the police by lifetime diagnosis 
There were no differences in the findings on percentage of hospitalisations involving the 
police between the baseline and lifetime diagnosis analyses (Appendix A). 
 
7.6.3.8. Summary of service use by lifetime diagnosis 
Both baseline and lifetime diagnoses found evidence of the same differences between 
the groups in the following variables: total number of hospitalisations; total number of 
days hospitalised; percentage of the follow-up as an inpatient; having ever been 
admitted compulsorily; and percentage of hospitalisations involving the police. There 
were differences, however, in two service use outcomes: binary hospitalisations; and 
percentage of admissions which were compulsory.  
 
Binary hospitalisations based on the baseline analyses only found weak evidence of a 
difference between PMD and bipolar cases whereas lifetime diagnoses found evidence 
of differences between bipolar and PMD cases, PMD and schizophrenia cases and weak 
evidence of a difference between bipolar and SAD cases. The findings on the 
percentage of compulsory admissions from the baseline analyses that there was a 
difference between schizophrenia and PMD cases, PMD and bipolar cases, and SAD 
and bipolar cases was not supported by the lifetime diagnosis analyses. 
 
7.7. Overall summary of the chapter 
There are some important differences in findings when analyses are based on lifetime 
diagnoses compared with baseline diagnoses. One of these is that the lifetime diagnoses 
analyses identified PMD cases to be more likely to attempt suicide compared with 
schizophrenia cases. This was not identified by the baseline diagnosis analyses. There 
were also some differences between PMD and SAD cases identified by the lifetime 
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diagnosis analyses. These were that PMD cases had better outcomes on a number of 










CHAPTER 8. Discussion 
 
“If science proves some belief of Buddhism wrong, then Buddhism will have to 
change”439 











8.1. Aims of the chapter 
The aim of this chapter was to summarise the main findings, as well as to reflect on the 
limitations of the thesis and evaluate the findings in light of these limitations. The 
theoretical and clinical implications of the study are then discussed. This was done for 
the case control and cohort study separately as they addressed different questions and 
have different limitations associated with each. Finally, future research and final 
conclusions are considered. 
 
8.2. Risk factors 
8.2.1. Summary of results 
8.2.1.1. Hypotheses 
In this thesis, I set out to test a number of hypotheses about psychosocial risk factors, 
PMD and SAD. The following hypotheses were supported by the results:  
 PMD would be associated with being of non-white British ethnicity (Asian and 
‘other’ ethnicity). 
 SAD would be associated with being of non-white British ethnicity (Black 
African and African Caribbean). 
 PMD would be associated with being born outside the UK. 
 Lower educational attainment would be more frequent in PMD cases compared 
with controls. 
 Unemployment would be more frequent in PMD and SAD cases compared with 
controls. 
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 Factors associated with social isolation, such as living situation, relationship 
status and contact with friends, would be more frequent in PMD and SAD cases 
compared with controls. 
 Childhood adversity would be more frequent in PMD cases compared with 
controls. 
 Independent life events would be more frequent in PMD cases in the year prior 
to illness onset compared with controls. 
 
The following hypotheses were not supported by the results:  
 SAD would be associated with being born outside the UK. 
 PMD would be associated with being older (actually associated with being 
younger), with being female (no association) and being in the London site (no 
association). 
 SAD would be associated with being older (actually associated with being 
younger), with being female (actually associated with males) and being in the 
London site (no association). 
 Lower educational attainment would be more frequent in SAD cases compared 
with controls (no association). 
 Childhood adversity would be more frequent in SAD cases compared with 
controls (no association). 
 
The following hypotheses were unclear:  
 Independent life events would be more frequent in SAD cases in the year prior 
to illness onset compared with controls (no association). 
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8.2.1.2. Exploratory analysis of life events 
The exploratory analysis of the life events data showed evidence that PMD cases had 
the highest increased odds of having experienced both a life event and a life difficulty. 
There was evidence that schizophrenia cases had the highest increased odds of having 
experienced either a life event or a life difficulty. Both of these findings were supported 
by both the baseline and lifetime diagnosis analyses. 
 
There was evidence from the baseline and lifetime analyses that humiliation life 
difficulties were associated with an increased odds of PMD, SAD (lifetime analyses not 
available), schizophrenia and bipolar disorder. This was supported by both the baseline 
and life time diagnosis analyses. 
 
The exploration of humiliation events showed evidence of a strong link between PMD 
and humiliation life events as large odds ratios were reported and a temporal 
relationship was identified with larger odds ratios the closer to the onset of an event. 
This was supported by both the baseline and lifetime diagnosis analyses. This was the 
same for SAD cases but only for the baseline analyses. There was no evidence of a link 
between humiliation life events and bipolar disorder based on the baseline diagnoses but 
there was evidence of a link when based on the lifetime diagnoses. There was only very 
weak evidence of a link between humiliation life events and schizophrenia based on 
baseline and lifetime diagnosis analyses. 
 
Before going on to interpret the results, the methodological limitations of the study are 
examined. 
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8.2.2. Methodological considerations  
Consideration of the methodological limitations of epidemiological studies involves 
considering whether the observed association between an exposure and an outcome 
could be the result of: bias; chance; or confounding.
424
 These will now be discussed 
along with other key methodological considerations which are causality, study specific 
limitations and strengths. 
 
8.2.2.1. Bias 
Hennekens and Buring defined bias as “...any systematic error in an epidemiological 
study that results in an incorrect estimate of the association between exposure and odds 
of disease”.424 Of course bias is possible in any research study, but with epidemiological 
studies it is the effect of bias on the observed relationship between exposure and 
outcome which is of importance. Bias can be broken down into selection bias and 
information bias. 
 
8.2.2.1.1. Selection bias 
Selection bias has been defined as any error that arises in the process of identifying the 
study population.
424
 Specifically within case control studies, like this one, this is when 
the inclusion of subjects into the study on the basis of outcome is dependent on 
exposure.  Within this study selection bias could exist in three ways. Firstly, although 
the study population is described as an incidence sample, it is actually a help-seeking 
incidence sample. All new cases of psychosis who present to secondary services within 
a defined area were included. Therefore cases who may have newly developed 
psychosis but have not approached services would have been missed. There is also the 
possibility that not all cases who presented to services were successfully identified and 
included. There is the possibility that cases who have experienced some of the risk 
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factors that have been examined in this thesis are more likely to seek help. For example, 
cases who have experienced childhood adversity may have had more contact with health 
and social care services during childhood which may increase their probability of 
approaching services when problems develop in adulthood. This kind of bias could lead 
to an over estimation of childhood adversity in the psychosis cases. Similarly, cases 
with a family history of mental illness could have witnessed family members being 
sectioned and be less likely to seek help for mental health issues and those with social 
isolation may be less likely to come into contact with services as they have no friends or 
family to bring them to the attention of services. Both of these would lead to an 
underestimation of the association between these exposures and the outcome of having 
psychosis.  
 
A second form of selection bias comes from the interview status. Although all incidence 
cases were included in the study overall, only a proportion of these cases were 
interviewed. Of those interviewed, there was much missing data for the key risk factors 
being examined in this thesis, including childhood adversity and especially life events; 
those with missing data are, in effect, not selected into analyses. There were significant 
differences in missing data between cases and controls as would be expected due to the 
nature of the study but there were also significant differences between diagnostic groups 
in terms of family history, childhood adversity and a few indicators of social isolation. 
This could have led to selection bias. 
 
Finally, consideration of selection bias resulting in the differential recruitment of cases 
and controls must be considered. A random sample of controls matched by geographic 
location were recruited making the control sample comparable to the cases as this was 
considered the best way to get comparable controls. However, there is still the potential 
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for bias as controls are volunteers and not all who are approached, even if selected 
randomly, will agree to take part. Those who agree to participate may differ from those 
who do not on important characteristics. However, it is not possible to assess this but it 
must be borne in mind as a potential source of bias. Controls were examined to make 
sure they did not meet criteria to be a case. As mentioned, the selection of incidence 
cases through mental health services was biased in that it selected only those who came 
into contact with services. However, the alternative of interviewing all residents in the 
catchment area was beyond the scope of this thesis.  
 
8.2.2.1.2. Information Bias 
Information bias results when there are systematic differences in the way that data on 
exposure and/or outcome are obtained from each group within the study.
424
 This can 
lead to inaccurate results. Information bias can come in three forms, recall bias, 




Recall bias occurs when a particular study group recall experiences differently from 
other study groups and is a particular problem for case control studies.
424
 This is a 
significant issue within this thesis. Cases may tend to want to find an explanation for 
their illness and therefore may scrutinize their memory for past exposure more 
intensively compared with controls.
160
 This will lead to recall bias in estimates of 
association between exposure and disease. The disorder under investigation may also 
lead to bias by impairing the amount and accuracy of information provided.
160
 Within 
this thesis, comparing between different diagnoses may also lead to differences in 
findings as a result of differing function of illness between diagnoses rather than as a 
true difference between diagnoses. For example, schizophrenia is associated with 
cognitive deficits and memory problems.
440
 This could lead to an under reporting of risk 
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factors such as life events and childhood adversity, and therefore an underestimation of 
the association between childhood adversity and schizophrenia. Depression is associated 
with high levels of rumination
441
 (rumination is also a feature of PMD
442
). This 
rumination could relate to previous experiences and could result in cases looking for 
explanations of their current mental health and experiences. This could give rise to 
PMD cases being more likely to recall childhood adversity and could therefore lead to 
an overestimation of the association between childhood adversity and PMD. This is a 
potential alternative explanation for the findings from this thesis that life events and 
difficulties, and childhood adversity is associated with PMD. The finding of a temporal 
relationship in life events in the PMD cases, with higher odds ratios at time periods 
closer to onset could be a result of recall of life events being higher closer to interview. 
 
Interviewer bias occurs when there is a systematic difference between study groups in 
the eliciting, recording or interpreting of information from participants.
424
  Interviewer 
bias is a particular problem in case control studies in relation to exposure status as 
knowledge of the participant’s outcome status may lead to differential probing in the 
exposure history.
160, 424
 Interviewer bias could have occurred within this thesis as case 
and control status at baseline was clearly known by interviewers collecting data on 
exposure. This could have lead to differential questioning and probing of cases about 
their exposure in these areas. It was not possible to assess the extent of interviewer bias 
in this study and so must be borne in mind as a limitation. One way to overcome this 
issue in future studies could be to have interviewers examining exposure status blind to 
case control status, although this would be very hard to implement, especially as many 
cases were interviewed within a mental health setting. 
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Data collection methods were based on patient interview and self report as well as 
clinical records. Interviews were based on standardised, established questionnaires and 
were conducted by trained interviewers and were administered to cases and controls in 
the same way. This is likely to reduce the potential for bias. The combination of data 
collection via interview and notes is likely to have reduced bias in cases. However, 
clinical records were not available for controls and therefore, this strength could have 
become a source of bias, also as there was a difference in the method of exposure 
assessment between cases and controls. Also, information from case notes could be 
biased as they are dependent on what and how clinicians decide to record and 
inaccuracies are possible. As previously mentioned, blinding of study interviewers was 
not possible within the context of this study. Further to this, the context in which the 
interview is conducted can affect the responses given.
160
 As cases and controls were 
generally interviewed in differing locations (cases mostly in mental health settings and 
controls mostly in their own home), this could lead to a systematic bias between cases 
and controls. 
 
Misclassification bias is when participants are erroneously categorized into exposure or 
outcome groups
424
 and can be an alternative explanation for an observed association 
between an exposure and an outcome.
160
 Random misclassification is present in almost 
all types of epidemiological studies and will lead to a dilution of any true associations 
between exposures and outcomes. Bromet et al.
160
 highlighted that differential 
misclassification of exposure can lead to a masking or attenuating of an association. For 
example, if cases are unwilling to report past exposures that they may blame themselves 
for, e.g. life events or childhood adversity, but controls are not, this could lead to a 
masking of a true association. 
160
 In case control studies which use self-reported 
exposure, systematic misclassification bias is a potential serious problem, which can 
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lead to an overestimation or underestimation of the true association between exposure 
and outcome.
424
 Within this study, the majority of exposures examined were measured 
through participant self-report and/or clinical notes, both of which are potentially 
subject to misclassification bias. Unfortunately, misclassification bias is incredibly 
difficult to assess and thus, its effect within this thesis was not measureable. 
 
8.2.2.1.3. Bias conclusions 
As demonstrated in this section, there are many potential sources of bias in this study 
and Ioannidis points out that “...with increasing bias, the chances that a research finding 
is true diminish considerably”.443  Hennekens and Buring point out that unlike chance 
and confounding, bias cannot be measured quantitatively and therefore the role of bias 






Chance has been described by Ioannidis as: “...variability that causes some findings to 
be false by chance even though the study design, data, analysis and presentation are 
perfect.”443 There are three main issues to think about in the context of chance: 
interpretation of the p value and confidence interval; clinical versus statistical 
significance; and multiple testing. 
 
8.2.2.2.1. Interpretation of the p value and confidence interval 
Inference is a generalisation about a larger group based on a subset of those 
individuals.
424
 This is necessary within research as it is not normally possible to conduct 
research on an entire population, so samples of that population are used on which to 
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base inferences. When inferences are made, there is the potential that the inference will 
be imprecise or inaccurate as a result of chance or sampling variability.
424
 Therefore, 
hypothesis testing is needed to examine the degree to which sampling variability may 
account for the observed results. The hypothesis testing statistic is simply a test of the 
difference between the study finding and the findings that would be expected if the null 
hypothesis were true.
424
 The p value associated with the test statistic indicates the 
probability of obtaining the result, if the null hypothesis were true. The p value is 
usually set at 0.05 by convention, and at this level means that there is a 1 in 20 
probability of observing the finding as a result of chance alone.
424, 444
 However, within 
this thesis a p-value of 0.1 has been taken to indicate weak evidence of an association, 
0.5 to indicate moderate evidence and 0.01 to indicate strong evidence. This was to 
ensure no potential effects were missed due to a lack of power. Therefore, one in ten 
findings are likely to be due to chance. 
 
As the p value is a function of the size of the difference between two groups (or the 
strength of an association) and the sample size, then small (but relatively trivial) effect 
sizes may become statistically significant due to large sample sizes.
444
 Hence, 
Hennekens and Buring recommend that p values should be used as a guide only, and 
using the confidence interval surrounding the effect size to supplement this information. 
The confidence interval represents the likely range within which the true value lies, 
therefore the 95% confidence interval means that we can be 95% sure that the true 
effect size lies somewhere within the confidence interval range. Confidence intervals 
indicate the amount of variability in the estimate of the effect size. Wide confidence 
intervals indicate less precise estimates of the effect size and vice versa. Hennekens and 
Buring
424
 suggest that confidence intervals are particularly important when interpreting 
null findings as a narrow confidence interval and a non-significant p value support the 
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conclusion that the null hypothesis is true while a wide confidence interval and non-
significant p value indicate that the sample size may have been too small to detect a 
difference between groups. 
 
As a result of these two issues, both the p values and confidence intervals must be 
examined when interpreting the results of a study. Some of the findings for the SAD 
risk factors analyses have significant p values but very large confidence intervals 
demonstrating imprecise estimates of the effect sizes, therefore these results must be 
interpreted with caution. Some other findings reveal an effect size, similar or larger to 
effect sizes in other diagnostic groups which were statistically significant, but the 
confidence interval was wide and the effect size in the SAD group was not statistically 
significant. Therefore, rejecting the alternative hypothesis tied with these results must 
be done with caution.  One way to avoid lack of power leading to false negatives is to 
conduct power calculations. A power calculation was conducted within this thesis which 
indicated that there was sufficient power to identify moderate effects in the PMD group. 
However, this was an exploratory study of a large number of risk factors and outcomes 
in PMD and SAD, and power calculations were not conducted for all analyses. 
Additionally, due to the nature of this study (incidence sample), it was not possible to 
control the numbers recruited into the study other than by extending the recruitment 
period or extending the recruitment geographical locations, and to get enough SAD 
cases would take an extreme amount of extra resources as SAD is a very rare diagnosis. 
Additionally, the majority of the data had already been collected at the start of this 
thesis, thus recruiting more cases was not possible. In light of all these issues, it is most 
appropriate to say that due to low numbers and a lack of power, the findings on risk 
factors in SAD cases are inconclusive. 
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This issue of power is also relevant to the differences in findings between the baseline 
and lifetime diagnoses. The baseline analyses showed evidence that the following risk 
factors were associated with an increased odds of PMD compared with controls, but this 
was not supported by the life time diagnoses: being older; having not been born in the 
UK; never having had a long term relationship; and having contact with family less than 
monthly. This difference could be due to the lower numbers in the PMD group in the 
lifetime diagnosis analyses compared with the numbers in the PMD group in the 
baseline diagnosis analyses, and thus lower power. 
 
8.2.2.2.2. Clinical versus statistical significance 
As discussed above, even the smallest of differences between groups may reach 
statistical significance if the sample size is sufficiently large.
424
 Therefore, it is 
important to distinguish between statistically significant findings and clinically 
significant findings.
444
 This issue is discussed in relation to this thesis in section 
8.2.2.2.4 below. 
  
8.2.2.2.3. Multiple testing 
Within epidemiological studies, it is common to test the effect of a large number of risk 
factors on outcomes. However, Hennekens and Buring
424
 state that as the number of 
variables tested increases, so does the likelihood of finding a statistically significant 
difference due to chance. Within the risk factors results chapter, as more than 10 tests 
were conducted but a p value threshold of 0.1 was used, it is likely that at least one false 
positive finding is present. As it is impossible to determine which findings are the ones 
due to chance, this will simply have to remain a major limitation of the thesis. It is 
important to be conscious that there are likely to be spurious findings. 
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8.2.2.2.4. Chance conclusions 
This section has demonstrated that when interpreting results, it is vital to examine the 
effect size, the confidence interval, and the p value associated with the test statistic. An 
important message to take away from this discussion of chance especially in relation to 
the SAD analyses, is that “Absence of evidence is not evidence of absence.”444 
 
Bearing in mind the issues discussed in this section, the finding in the adjusted analyses 
that a lifetime diagnosis of PMD is associated with presence of childhood adversity and 
the number of different types of childhood adversity need to be re-evaluated. For 
presence of childhood adversity, the OR was 2.57 and the CI 1.02-6.44. Although this 
finding is statistically significant at the p value threshold of 0.05, the reasonably wide 
confidence interval indicates a less precise estimate of the effect.  
 
8.2.2.3. Confounding 
Confounding has been described as the possibility that an observed association between 
an exposure and an outcome is due, either completely or in part, to factors other than 
those under investigation.
424
 Confounders must be associated with the exposure and, 
independently, with the outcome. It is introduced not by the investigator or participant 
as in the case of bias, but is a function of the complex interrelationship between various 
exposures and outcomes.
424
 Confounding can lead to either an overestimation or 
underestimation of the true relationship between exposures and diseases and can even 
change the direction of the observed effect.
424
 Confounding is a potential problem in all 
studies and must always be considered as an alternative explanation for study findings, 
particularly in observational case-control and cohort designs.
424
 There are key 
components that a confounder must be to qualify as such. These are: the potential 
confounder must be independently associated with the outcome of interest, but the 
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association need not be causal; the confounder cannot be related to risk of disease only 
through its association with the exposure (thus, there must be an association between the 
confounder and disease even among non-exposed individuals); and the confounder 





There are various methods to control for the effects of confounding which fall under 
design stage methods (randomisation, restriction and matching) and analysis stage 
methods (stratification and multivariable analyses).  Multivariable analyses were used in 
this thesis as it allows for efficient estimation by controlling for multiple confounders 
simultaneously.
424
 Using multivariable analyses, the degree of confounding within a 
study is investigated by examining the difference between the crude and adjusted 
estimates.
424
 Within this thesis, adjustment for key demographic variables (age, centre, 
gender and ethnicity) was conducted. Due to low numbers, it was not sensible to control 
for other factors as this would seriously reduce the power of the analyses. However, it is 
possible that interactions exist among some of the variables which would require 
adjustment for each other, e.g. childhood adversity has been found to be associated with 
life events.
118-120
 This is something that would best be examined in another study with a 
larger sample size. 
 
A further major issue with confounders is that only confounders that have been 
measured can be adjusted for.
445
 However, there is nothing that can be done about 
unmeasured confounders other than to consider what they might be and appraise how 
they might have influenced the findings. Within this thesis, there are a huge number of 
unmeasured confounding variables, such as obstetric complications and cannabis use, 
and this must be borne in mind as a limitation. 
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8.2.2.4. Causality 
Schwartz & Susser stress that “…causation is not directly observable; it can only be 
inferred.”446 Bradford Hill447 has described what aspects of association should be 
considered before coming to a conclusion of causation. This was in relation to 
occupational medicine but is now more widely applied to many branches of medicine 
and science more widely. These aspects include: strength (the strength of the association 
must be large); consistency (repeated observation of the association in different 
samples, places, circumstances and times); specificity (no association with the exposure 
and outcomes other than the one under investigation); temporality (the exposure must 
precede the outcome); biological gradient (a dose response curve is present); plausibility 
(the association is biologically plausible); coherence (the association should not 
contradict what is already ‘known’); experiment (experimental data supports the causal 





One of the key criteria is temporality. Bromet et al. point out that in a case-control study 
“the exposure may plausibly be a consequence rather than a cause of the disease”.160 
Morgan et al.
448
 highlight that studying social factors in psychosis is difficult as the 
development of psychosis is frequently preceded or accompanied by a decline in social 
functioning (loss of employment, disintegration of social networks and downward social 
mobility). This makes it unclear whether social experience is a cause or consequence of 
the developing psychosis. This is discussed further in section 8.2.2.5 below. 
 
Of the other criteria, this thesis is unable to demonstrate consistency and coherence as 
no study has examined these risk factors in PMD cases previously. However, analogy is 
possible as these risk factors have been found to be associated with similar disorders 
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(see chapter 3), however, for this same reason specificity cannot be demonstrated as the 
risk factor of childhood adversity has been shown to be associated with other disorders 
(see chapter 3). Experimental data would not be ethical within the context of this thesis. 
A biological gradient is reported in the form of a linear association with number of 
childhood adversity factors but the strength of the effect size is small. The plausibility 
of the findings are good because disorders similar to PMD and SAD (schizophrenia and 
non-psychotic depression) have been associated with the same social risk factors (see 
chapter 3). In view of the fact that this thesis can only demonstrate a small number of 
the criteria, it should be borne in mind that Bradford Hill
447
 stated that no single one of 
these items can prove or disprove causality, but they can support the hypothesis of 
causality. 
 
8.2.2.5. Study specific limitations 
As well as limitations specific to epidemiological studies, this thesis was also subject to 
more specific limitations. One fundamental issue is diagnostic classification. This is a 
version of misclassification bias but is discussed here as it is a particular problem for 
psychiatric studies due to issues discussed in Chapter 2, and must also be borne in mind 
when interpreting the findings. Briefly, psychiatric classification differs from other 
‘disorders’ as there are no objective measures and a set of descriptive diagnoses must be 
used. Blurred sets of symptoms are used, not distinct typologies; therefore the results 
based on these classifications will also be blurred, leading to inaccurate and possibly 
completely wrong findings. A further complication with mental health research is co-
morbidity of psychiatric diagnoses,
446
 something which has not been examined or 





 point out some limitations with research on social processes as 
aetiological factors in psychosis including that epidemiological research often uses 
crude dichotomies, e.g. urban versus rural. This means that “the precise meaning of 
observed associations is unclear, and the social experiences that these variables may 
index remain unknown”.448 This is certainly true in this thesis with dichotomies such as 
abused versus not abused and experienced life event versus no life event experiences. 
However, within this thesis, variable categories were grouped into smaller number of 
categories (binary where possible) for clarity and to increase power. 
 
In terms of limitations of specific measures, there have been some criticisms of the 
LEDS. Dohrenwend et al.
415
 state that although the LEDS is based on a contextual 
approach and is therefore more precise than the previous approaches (namely the 
checklist approaches) the LEDS is also more ‘gross’ as it involves collapsing down the 
events, the social situation of the events and the personal history of the person involved 
into a single measure, in non-specific ways. This results in the inability to distinguish 
which of the components are salient in the research finding. However, Brown and 
Harris
132
 point out that there are no satisfactory alternatives as all the alternatives have 
more serious methodological limitations.  
 
There are also methodological issues, which are specific to studying psychosis cases. 
The first relates to incidence. Within this thesis, the aim was to examine risk factors and 
outcomes based on the study of incidence cases, i.e. new cases of the disorder. What we 
have actually examined is cases with a first contact with secondary treatment services. 
This is represented in figure 8-1. This means that cases who have low level psychosis 
and are being managed by a general practitioner or who never present to services are 
being missed. Thus, perhaps sampling from what are in effect administrative incidence 
 330 
cases leads to an oversampling from more unwell cases. The second specific issue is 
that psychosis cases often have prodromal periods and long durations of untreated 
psychosis (figure 8-1). This makes the date of onset very difficult to pinpoint. Hafner et 
al.
449
 stated that in such cases, the time between the true onset and the recruitment into 
the study is important in interpreting the results. In the context of the risk factor findings 
in this thesis, this delay between onset and first contact with services means that the 
temporal ordering of risk factors is difficult. This is reflected by the fact that the number 
of cases with data on life events in the year preceding onset is low as it cannot be 
accurately done for many cases due to long duration of untreated psychosis. Prodromal 
symptoms can also be a problem as premorbid signs and symptoms might in fact 




           
(From Bromet et al., 2006
160
) 
Figure 8-1: Temporal order in case-control studies 
 
Ioannidis states that “most published research findings are false” due to a combination 
of factors including: flexibility in designs, definitions, outcomes and analytic modes; 
lack of adherence to common standards; and financial and other interests and prejudices 
within a scientific field.
443
 In light of these methodological limitations, in relation to 
epidemiological studies, Ioannidis state that “Epidemiological studies of an exploratory 
nature perform even worse [than other types of studies], especially when underpowered, 
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but even well-powered epidemiological studies may have only a one in five chance of 
being true...”.443 This is worth considering in the interpretation of the results. 
 
A further methodological limitation is the exclusion of over 65 year olds. Due to the 
data available, only cases aged 16-65 were included in this thesis. This was because the 
original study aimed to examine an incidence sample of adults with psychosis. Over 65 
year olds were excluded as they are classed as an elderly population and this was not the 
aim of the original study, and resources did not allow recruitment from geriatric services 
as well as general adult mental health services.  
 
However, a review by Smith et al.
68
 has highlighted that in clinical samples, the 
prevalence of PMD increases with age, although in general population samples there 
been appears to be no difference in prevalence of PMD across age groups. However, in 
a more recent study, Crebbin et al.
1
 compared PMD and schizophrenia in a sample of 16 
year old plus incident psychosis cases. They reported that of the 105 new cases of PMD 
over 7 years, 31 cases (30%) were aged 65 years or older. Hence, approximately 30% of 
PMD cases could have been missed due to the age limits. Therefore, all the findings 
within this thesis may not be valid for PMD geriatric cases. This warrants further 
research. 
 
8.2.2.6. Methodological strengths 
While the methodological limitations listed above are substantial, there are also a 
number of methodological strengths which improve on previous research and thus can 
increase our confidence in the findings. The most significant of these is the accounting 
for diagnostic change. This thesis was based on an incidence sample, and most 
incidence studies which examine risk factors for disorder in psychiatry base their 
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analysis on initial diagnosis. However, as shown in chapter 4 and chapter 7, diagnostic 
stability is not high in psychosis cases and is especially low in diagnoses other than 
schizophrenia and bipolar disorder. In fact, Schwartz et al. stated that “… the 
psychiatric diagnoses people receive at the time of onset are often inaccurate. 
Longitudinal observation tends to clarify the nature of the patient’s illness”.160 This 
thesis has examined initial diagnosis but also lifetime diagnosis based on eight years 
plus of clinical information to get a more stable, and arguably, more accurate diagnosis. 
The analyses based on the baseline and lifetime diagnosis showed very similar results 
with the exception of childhood adversity. Childhood adversity was not significantly 
associated with a diagnosis of PMD at baseline, but it was significantly associated with 
a lifetime diagnosis of PMD. Childhood adversity may well have been undermined as a 
risk factor for PMD if only the baseline diagnosis had been used and an important 
finding missed. 
 
A further important methodological strength is having included a sample of all first 
episode cases presenting to services (not just inpatients as is often done). Chapter 4 
highlighted the importance of focussing on incident cases rather than prevalence cases 
as prevalence sampling increases the likelihood of sampling from a more severely ill 
population. This makes incidence samples preferable and is a strength of this thesis as a 
more accurate account of risk factors is gained. 
 
Other strengths of the methodology are having a research diagnosis (not just a diagnosis 
taken from the clinical notes) made by consensus, by a team of researchers and 
clinicians who were blind to ethnicity. Each part of this diagnosis process is a way of 
combating bias. Objective diagnosis based only on symptomology and sticking to the 
exact criteria set down in the ICD-10, rather than using clinical discretion and 
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judgement in making a diagnosis minimises the risk of bias and cultural interpretation 
(but does not rule it out). 
 
Perhaps the most important strength of this thesis is that although the results on risk 
factors in PMD and SAD have a number of methodological limitations, this is the only 
study that has examined risk factors associated with PMD and SAD, and as such, is a 
foundation on which to build and to inform for future in the area. 
 
8.2.3. Interpretation of the results 
Despite the methodological limitations of this study, the results are very informative. 
 
8.2.3.1. Generic risk factors 
The results showed that there was some evidence, be it from baseline or lifetime 
diagnoses, from the unadjusted or adjusted analyses, that most of the psychosocial risk 
factors were associated with all of the diagnoses (see Table 8-1). This shows a lack of 
specificity between the psychosocial risk factors examined here and PMD and SAD, 
thus suggesting these factors represent risks for psychosis in general or perhaps for 
mental illness in general. This lack of specificity could be due to several factors. The 
factors may have been measured too crudely (e.g. it may be the impact of 
unemployment rather than unemployment itself that is important), or the factors are 
interacting with other factors that dictate specificity (e.g. genetic risk via specific 
genes). 
 
However, the exploratory analyses of life events and difficulties indicate that there may 
be PMD and SAD specific risk factors in specific subtypes of life events and 
difficulties. This finding warrants further research. 
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Table 8-1: Overview of psychosocial risk factors and evidence of an association 
with each diagnostic group 
Predictors PMD SAD Schizophrenia Bipolar 
Younger x x x x 
Study centre: London    x x 

































Place of birth: Non-UK x  x  
Relationship Status: Single x x x x 
Ever had a long term relationship: No x x x x 
Living with: Alone x x x x 










Employment Status: Unemployed x x x x 
Ever worked: No x (reverse)  x x 
Contact with friends: Never / less than 
monthly 
x  x x 
Contact with family: Never / less than 
monthly 
x x x  
Close confidants: No x x x x 
Family history of any mental illness: Yes x x x x 
Family history of psychosis: Yes x x x x 
Parental history of any mental illness: 
Yes 
x x x x 
Parental history of psychosis: Yes x x x x 
Life Events: Yes x ?  x 
Life Difficulties: Yes x ? x x 
Childhood Adversity: Yes x  x x 
Number of Childhood Adversity Factors x x (reverse) x x 
 
8.2.3.2. Differences between baseline and lifetime analyses 
There were some important differences between the baseline and lifetime analyses. For 
example, in the baseline analyses, there was evidence that childhood adversity was 
associated with increased odds of schizophrenia only. However, based on the lifetime 
analyses, there was evidence that childhood adversity was associated with increased 
odds of schizophrenia and PMD.  
 
Differences in findings between baseline and lifetime diagnoses could be due to a 
number of reasons. Firstly, as the numbers in the lifetime analyses were lower, 
differences could be due to reduced power in being able to detect effects. This is a 
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salient point for analyses based on SAD cases as the numbers in some of the analyses 
were very small. Alternatively, differences could be due to changes in diagnosis.  
 
As the baseline and lifetime diagnoses reveal slightly different results in the risk factors 
analysis, an important question to be asked could be “which diagnosis is correct?” or 
“which diagnosis is better?”. There are limitations with using the baseline and lifetime 
diagnoses. As mentioned in Chapter 2, diagnostic classification systems are flawed and 
thus any analyses based on these diagnoses are flawed. Specifically, the baseline 
diagnosis has the limitation that in PMD and SAD cases, it is likely to change. This 
could be due to the fact that it is based on information from a limited period and thus 
diagnoses are inaccurate, or it could be that the disorder is actually evolving into 
another psychotic disorder. The lifetime diagnosis has the limitation that it is based on 
information over a long period of time, thus as diagnosis changes, risk factors measured 
at baseline may have also changed. Based on all these issues, it is clear that one is not 
better than the other, they are simply different and yield different results in the risk 
factors analysis, and until a more reliable diagnostic system is in place, our conclusions 
are limited.  
 
8.2.3.3. SAD cases 
The numbers of SAD cases were small making interpretation of the results difficult and 
adjusted analyses not possible. However, the unadjusted baseline and lifetime analyses 
showed evidence (to varying degrees) that the following factors were associated with an 
increased odds of receiving a diagnosis of SAD compared with being a control: being 
single; having no close confidants; having a family history of mental illness, family 
history of psychosis, parental history of mental illness, parental history of psychosis. 
There were also differences between the analyses. The baseline analyses showed 
 336 
evidence that the following were associated with an increased odds of receiving a 
lifetime diagnosis of SAD: living alone; having contact with family less than monthly; 
being unemployed; being male; being Black African; and never having had a long term 
relationship. The lifetime analyses showed evidence that the following were associated 
with an increased odds of receiving a lifetime diagnosis of SAD: being younger; and 
being African Caribbean. Due to small numbers in the SAD group, differences in 
findings between baseline and lifetime diagnoses are likely to be due to power issues (as 
the lifetime SAD group had even smaller numbers than the baseline SAD group). All 
that can be concluded is that psychosocial factors may be associated with SAD but as 
mentioned in section 8.2.3.1, this is not specific to SAD cases. 
 
8.2.3.4. Differences by centre 
There was evidence of an increased odds of being from London being associated with a 
diagnosis of schizophrenia and bipolar disorder in the baseline and lifetime diagnosis 
analyses. There was no such evidence for PMD and SAD groups. This difference could 
indicate that social context (described in chapter 3) is an important aetiological risk 
factor in schizophrenia and bipolar disorder, but not in PMD and SAD. Further research 
in this area could be informative as to the differences in aetiology between these 
disorders. 
 
8.2.4. Comparisons with previous research 
As discussed in chapter 3, there is very little previous research on the risk factors 
associated with PMD and SAD. Previous research has reported that PMD is more 




 and in Black African and African Caribbean 
ethnicities.
29
 None of these findings have been supported by this thesis. In the case of 
age differences, this could be due to this thesis using age as a continuous variable and 
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other studies grouping age into a categorical variable. Differences in gender and 
ethnicity findings could be due to this thesis examining these variables compared with a 
non-psychotic control group rather than calculating these variables based on population 
based data. It is important to note that the findings on ethnicity from this thesis are from 
the same study that has shown differences in IRR for PMD,
81
 the only difference being 
that odds ratios were used in this thesis. 
 
The single study that investigated childhood adversity and PMD, and reported an 
association between PMD and specific types of childhood adversity
130
 was based on the 
same dataset as this thesis, so the finding from this thesis of an association between 
PMD and any type of childhood adversity is not surprising.  
 
The single study which examined PMD and life events and found an association 
between the two
156
  was supported by the association between PMD, life events and life 
difficulties reported in this thesis. 
 
8.2.5. Theoretical implications 
Within the risk results chapter, a range of psychosocial risk factors were investigated for 
their association with PMD compared with other psychotic diagnoses. Kirkwood and 
Sterne note that “...examples where the results ‘hit you straight between the eyes’ are 
rare in medical research. This is because there is rarely such a one-to-one link between 
exposures and outcomes; there is usually a much more inherent variability from person 
to person.”444 This is supported by Schwartz & Susser who discuss the causes of disease 
as a “web of causation”.450 This is especially true in mental health. However, Schwartz 
& Susser have also highlighted that as risk factors work as a complex ‘web’ of 
interactions, by examining a single risk factor at a time, a full understanding of the 
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disease cannot be gained, and the “goal of causal explanation is to go beyond the 
identification of the causes of the disease to an understanding of the interplay among 
causes.”451 This suggests that an investigation of how these risk factors interact is 
needed. Within this study, it was not possible to look at interactions between key risk 
factors due to low power. However, this is a very important task for future research. 
 
Within this thesis, differences between analyses based on baseline and lifetime 
diagnoses have been examined. The finding that there were differences in the 
identification of risk factors in the aetiology of PMD (specifically on childhood 
adversity) highlights the importance of taking diagnostic stability into account. 
Research on aetiology based on only a baseline diagnosis may well be inaccurate if we 
assume that lifetime diagnoses are more relevant as they are based on more information. 
However, as discussed above, knowing which diagnosis is ‘right’ is fraught with 
problems and as discussed in Chapter 2, the current diagnostic classifications systems 
have many problems which limits conclusions. Nevertheless, future research into 
aetiology in PMD and SAD should take diagnostic change into account as this leads to 
differing results. This links to the issue of whether diagnostic stability is a reflection of 
genuine diagnostic change or simply a lack of reliability. Either of these two could be 
true. However, whether this is diagnostic change or lack of reliability will not influence 
a clinicians’ treatment, this will be dictated by the initial diagnosis and presenting 
clinical picture. Similarly, it will not change research diagnosis. As discussed in chapter 
2, this will not be resolved until diagnostic classification become more accurate. 
 
The DSM-5 offers no changes to the diagnosis of PMD. However, there are the 
following changes to the diagnosis of schizoaffective disorder: “Schizoaffective 
Disorder: The primary change to schizoaffective disorder is the requirement that a major 
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mood episode be present for a majority of the disorder’s total duration after Criterion A 
has been met… It makes schizoaffective disorder a longitudinal instead of a cross-
sectional diagnosis—more comparable to schizophrenia, bipolar disorder, and major 
depressive disorder, which are bridged by this condition.”452 It is stated that the change 
was made to improve the reliability, diagnostic stability, and validity of this disorder. It 
is yet to be seen if this change can improve the diagnostic stability of SAD and the 
influence of this change could have dramatically changed the results of this thesis if it 
had been published in time to be included here. Further research is needed to explore 
whether this change does improve reliability, diagnostic stability, and validity of this 
disorder. 
 
8.2.6. Clinical implications 
An association between a number of psychosocial risk factors and PMD and SAD has 
been established in this thesis. However, none of the risk factors identified in this thesis 
can be interpreted as having a causal effect due to the temporality issues surrounding 
prodromal periods, as discussed in section 8.2.2.5. If future research is able to indicate 
causality, this could indicate potential targets for prevention of disorder. In the 
meantime, the findings have indicated that cases who present with PMD are likely to be 
experiencing psychosocial inequality in the form of unemployment, social isolation 
(living alone, having no contact with friends or family, having no close confidants), life 
stress (life events and life difficulties) and possible psychological repercussions from 
childhood adversity. Thus, services are well placed to reduce this inequality. 
 
Additionally, although causation cannot be concluded and the risk factors identified 
may not be easy to incorporate into public health interventions, this study adds to the 
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8.3. Course and outcomes 
8.3.1. Summary of results 
8.3.1.1. Hypotheses 
The following hypotheses were supported by either the baseline of lifetime diagnosis 
analyses or both: 
1. PMD and SAD cases would have a lower prospective consistency compared 
with schizophrenia and bipolar disorder cases. 
2. PMD cases would have a higher proportion of cases with an episodic course of 
illness and less with a continuous course of illness compared with schizophrenia 
cases.  
3. PMD would have: longer remissions; shorter episodes; and will spend a smaller 
percentage of the follow-up psychotic, all compared with schizophrenia cases.  
4. PMD cases would have a higher proportion of cases who attempt suicide over 
the follow-up compared with schizophrenia and bipolar cases. 
5. SAD cases would have a higher rate of suicide attempts for those who do 
attempt, compared with schizophrenia and bipolar cases. 
6. PMD cases would have a higher proportion of cases who self-harm over the 
follow-up compared with schizophrenia. 
7. SAD cases would have a higher proportion of cases who self-harm over the 
follow-up compared with schizophrenia and bipolar cases. 
8. PMD and SAD cases would have a higher rate of self-harm events for those who 
do self-harm, compared with bipolar cases. 
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9. In terms of social outcomes over follow-up, PMD cases would have a higher 
proportion of cases who are: employed; in a stable relationship; have close 
confidants; and a lower proportion of cases who have been to prison, all 
compared with schizophrenia cases. 
10. In terms of social outcomes over follow-up, SAD cases would have a higher 
proportion of cases who are in a stable relationship compared with schizophrenia 
cases. 
11. In terms of service use, PMD cases would have: a lower proportion of cases 
admitted; less hospitalisations; less days hospitalised; a lower percentage of the 
follow-up spent as an inpatient; a lower percentage of compulsory admissions; a 
lower proportion of cases being compulsorily admitted; and a lower percentage 
of hospitalisations involving the police, all compared with schizophrenia. 
12. In terms of service use, SAD cases would have: less hospitalisations; a lower 
percentage of compulsory admissions; and a lower percentage of hospitalisations 
involving the police, all compared with schizophrenia. 
 
The following hypotheses were not supported by this thesis: 
1. PMD and SAD cases would have a higher retrospective consistency compared 
with schizophrenia and bipolar disorder cases (no difference with PMD cases, 
and SAD cases had lower retrospective consistency compared with 
schizophrenia and bipolar disorder). 
2. SAD cases would have a higher proportion of cases with an episodic course of 
illness and less with a continuous course of illness compared with schizophrenia 
cases (no difference). 
3. PMD would have more episodes compared with schizophrenia cases (PMD 
found to have fewer episodes). 
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4. SAD would have: longer remissions; more episodes; shorter episodes; and will 
spend a smaller percentage of the follow-up psychotic, all compared with 
schizophrenia cases (no difference on all variables). 
5. PMD and SAD cases would have a higher proportion of cases who die (from all 
causes) over the follow-up compared with schizophrenia and bipolar cases (no 
difference). 
6. PMD would have a higher rate of suicide attempts for those who do attempt, 
compared with schizophrenia and bipolar cases (no difference). 
7. SAD cases would have a higher proportion of cases who attempt suicide over 
the follow-up compared with schizophrenia and bipolar cases (no difference). 
8. PMD cases would have a higher proportion of cases who self-harm over the 
follow-up compared with bipolar cases (no difference). 
9. PMD and SAD cases would have a higher rate of self-harm events for those who 
do self-harm, compared with schizophrenia cases (no difference). 
10. In terms of social outcomes over follow-up, SAD cases would have a higher 
proportion of cases who are: employed (no difference); have close confidants 
(no difference); and a lower proportion of cases who have been to prison (no 
difference), all compared with schizophrenia cases. 
11. In terms of service use, SAD cases would have: a lower proportion of cases 
admitted; fewer days hospitalised; a lower percentage of the follow-up spent as 
an inpatient; and a lower proportion of cases being compulsorily admitted, all 
compared with schizophrenia (no difference for all variables). 
 
The hypothesis that PMD and SAD cases would have a higher proportion of cases who 
complete suicide over the follow-up compared with schizophrenia and bipolar cases 
could not be tested due to the small number of cases who completed suicide. 
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Before going on to interpret the outcome results, the methodological limitations of the 
study are examined. 
  
8.3.2. Methodological considerations  
Many of the methodological limitations considered in section 8.2.2 apply to the 
outcomes analyses and are discussed below. 
 
8.3.2.1. Bias 
8.3.2.1.1. Selection Bias 
As mentioned in section 8.2.2.1.1, selection bias is defined as any error that arises in the 
process of identifying the study population.
424
 In cohort studies, this is when the 
selection of an individual on the basis of their exposure or non-exposure is related to the 
outcome of interest. As previously discussed, most of the sample were help seeking 
individuals. This could relate to the service use outcomes, in that, cases who present to 
services for help may be more likely to represent to services in times of returning 
illness. This is turn could also relate to clinical outcomes as if a patient presents to 
services in times of returning illness, the illness is more likely to be treated and the 
episode will be shorter than those who do not re-present to services until the at crisis 
point which may only result in re-presenting due to other services intervening, e.g. 
police or A&E. However, selection bias in this form is unlikely to influence the 
outcome findings as in cohort studies exposure is ascertained before outcomes and 




However, the major source of bias in cohort studies is loss of participants over follow-
up.
424
 Differential loss to follow-up by exposure or outcome will lead to biased findings. 
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This is a problem within this thesis as the follow-up rate of all incidence cases was not 
100%. This could have led to biases in the outcomes data. Those lost to follow-up could 
be lost to follow-up as they are well and have therefore lost contact with services and 
are therefore more difficult to trace. They could also be lost to follow-up as they are in 
prison or dead but we have failed to find this information. There were no differences in 
the follow-up rates between the different diagnoses and the overall follow-up rate was 
high (81.6%) but there is the possibility that the less ill PMD cases were more likely to 
be followed up and more ill schizophrenia cases being more likely to be followed up. As 
there was no measure of severity at baseline, it was impossible to assess. 
 
8.3.2.1.2. Information Bias 
As mentioned in section 8.2.2.1.2, interviewer bias can be a problem in epidemiological 
studies. Ascertainment of the exposure status is a problem in case control studies but not 
in cohort studies. However, ascertainment of outcome status in cohort studies is a 
problem as exposure status will be known and could lead to differential eliciting, 
recording or interpretation of outcomes.
424
  Within this thesis, outcomes were gained 
through a combination of participant interview and clinical notes. Interviewers could 
have pressed cases with certain diagnoses more to illicit certain responses and similarly, 
clinical notes could have been interpreted differently between different diagnoses. It is 
likely that this kind of bias occurs subconsciously without the interview or notes 
reviewer even being aware of what is happening. This is a possible bias in this thesis as 
interviewers and note reviewers were not always blind to baseline diagnosis and is a 
limitation of the thesis. 
 
As discussed in section 8.2.2.1.2, misclassification bias is a problem in case control 
studies, but it is also a problem in cohort studies. At the beginning of this study, 
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participants were classified as cases or controls and cases were further classified as 
having a number of different types of psychotic diagnoses. This classification at the 
beginning of the study was open to misclassification bias as well as the classification of 
the outcomes (e.g. continuous course of illness versus episodic course of illness; or 
suicide attempters versus non-attempter). The potential misclassification bias in 
diagnosis was addressed by re-diagnosing cases at follow-up based on the entire follow-
up period information and a substantial difference in diagnosis was found between the 
two diagnoses. This is an improvement on many previous studies which did not account 
for misclassification bias in diagnosis. However, this study did not account for 
misclassification bias of case control status. Some controls could have become cases 
over the follow-up period but this was not measured. A potential improvement on 
similar future studies would be to follow-up controls as well as cases and use this 
information to address the case control misclassification bias. 
 
8.3.2.1.3. Bias conclusions 
As discussed in section 8.2.2.1.2, the role of bias in influencing an observed association 
must be considered in the interpretation of results. There is the possibility that 
interviewer bias was a problem within this thesis. However, it is not possible to know 
this for sure or to quantify the degree of bias. Therefore, the findings stand, but future 
research will be important to support, or in fact contradict these findings. 
 
8.3.2.2. Chance 
8.3.2.2.1. Interpretation of the p value and confidence interval 
As discussed in section 8.2.2.2.1, examining both the p-value and the confidence 
interval of each finding rather than just the p value is incredibly important. As in the 
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case control study, the cohort study used a p-value of 0.1. Therefore, one in ten findings 
are likely to be due to chance and this must be borne in mind when interpreting the 
results. 
 
8.3.2.2.2. Clinical versus statistical significance 
As discussed in section 8.2.2.2.2, consideration of the clinical not just statistical 
significance is of vital importance. Within this thesis, there are findings which are 
statistically significant and clinically significant. For example, the finding based on 
lifetime diagnosis that PMD cases spend 5.2% of the follow-up in a psychotic episode 
compared with 76.7% of schizophrenia cases. This makes a massive difference to 
prognosis in PMD and schizophrenia cases. Similarly, the finding that based on lifetime 
diagnosis that 37% of PMD cases attempted suicide compared with 17% of 
schizophrenia cases has important implications for risk prevention. However, the 
finding that based on the baseline diagnosis the PMD group had a median number of 
one admission compared with two admissions in the schizophrenia group is unlikely to 
be of much clinical significance as the numbers are so similar. 
 
8.3.2.2.3. Multiple testing 
As discussed in section 8.2.2.2.3, increasing numbers of statistical tests increase the 
likelihood of finding a statistically significant difference due to chance. Within the 
outcomes results chapter, multiple tests were conducted but a p value threshold of 0.1 
was used, it is likely that one in ten is a false positive finding. As with the risk factors 




8.3.2.2.4. Chance conclusions 
Due to the multiple comparisons within the outcomes data (and the wide confidence 
intervals in some analyses, which indicate imprecise estimate of the effects), it is likely 
that some of the findings were due to chance. It was not possible to determine which 
findings but this must be borne in mind as a major limitation of the study when 
interpreting the results. 
 
8.3.2.3. Confounding 
As with the risk factors findings, it is possible that confounding influenced the results. 
Within the outcomes analyses there was no adjustment for key demographic variables 
(age, centre, gender and ethnicity). These factors could be confounding the results. 
There could also be confounding by variables which have not been measured. 
Specifically of relevance to this thesis is that this was a naturalistic study so a major 
potential confounder is treatment received over the follow-up. As it is unethical to 




It is unlikely that the baseline diagnosis analyses have any reverse causality involved as 
the diagnosis is determined before the outcomes are measured. However, it is possible 
that reverse causality is present in the lifetime diagnoses as these were determined at the 
same time as outcomes. This could also explain diagnostic change as outcomes could 
influence decisions made about diagnosis.  
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8.3.2.5. Study specific limitations 
As discussed in section 8.2.2.5, issues surrounding diagnostic classifications are equally 
an issue within the outcome findings. Inaccurate diagnostic classification lead to 
inaccurate findings and current diagnostic classification is based on an imperfect 
descriptive system. This inevitably can only lead to imperfect findings but is an issue of 
psychiatry in general, not just a concern of this thesis.  
 
As with Morgan et al.’s448 issue surrounding the crude dichotomies used in research on 
risk factors, within the outcomes investigation, crude dichotomies have been used to 
simplify analyses. These include relationship status – ‘single/divorced/separated’ versus 
‘in a relationship’. These dichotomies are likely to over simplify the true nature of 
outcome for PMD cases. However, this thesis is the first long term (eight plus years) 
study based on an incidence sample and as such is a foundation for future research. 
Simplifications at this stage are likely to clarify what areas of research are focussed on 
in the future. 
 
As with the risk factors examination, the outcomes investigation is based on new cases 
of the disorder under examination rather than a true incidence sample. This is not a 
problem for the outcomes findings however, as the findings inform clinicians as to 
prognosis for cases who present with a certain diagnosis at first contact with services.   
 
Specific to the outcomes investigation, is an issue surrounding suicide attempts. Bromet 
et al.
160
 state that an issue with all suicide studies is that not all suicides are recognized 
and recorded as such, meaning that any estimation of the prevalence of suicide is an 
underestimation. Within this thesis that is a distinct possibility. However, the main 
focus on outcomes in this thesis was to compare outcomes between the different 
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disorders. Therefore, although it is possible that the reporting of suicide attempts was 
underestimated, it is unlikely that this differed by diagnosis. This means that we can 
have confidence in these results. 
 
As with the interpretation of the risk factors findings, Ioannidis’s declaration that “most 





As with the risk factors chapter, the exclusion of cases aged over 65 years means the 
findings may not be valid for geriatric cases of PMD. Based on previous literature, 30% 
of PMD cases could have been missed due to age limits. The finding that many cases 
with a diagnosis of psychotic depression go on to receive a schizophrenia diagnosis may 
well be specific to a younger age group and warrants further research. 
 
8.3.2.6. Methodological strengths 
As in section 8.2.2.6, strengths of the outcomes section of the thesis include: accounting 
for diagnostic change; included incidence cases of all first episode cases presenting to 
services (not just inpatients or a prevalence sample); using a research diagnosis made by 
consensus; and consensus diagnosis blind to ethnicity. Additionally, diagnosis at 
follow-up was made blind to baseline diagnosis. Importantly, this thesis has improved 
on all previous research by combining these methodological strengths and thus can 
uniquely inform future research in the area. 
 
8.3.3. Interpretation of the results 
Despite the methodological limitations of this study, the results are very informative. 
Table 8-2 gives an overview of the outcomes findings. 
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Table 8-2: Overview of the outcome results 










Diagnostic stability      
Prospective consistency PMD lower PMD 
lower 
= SAD lower SAD lower 
Retrospective consistency = = PMD 
higher 
SAD lower SAD lower 
Course of illness outcomes      








= / PMD 
more 
episodic 





Longest weeks of remission PMD 
longer 




Number of episodes PMD less PMD less = / PMD 
less 
= = 
Longest episode in months 
(including first episode) 
= / PMD 
shorter 
PMD 
longer / = 
= = SAD 
longer / = 
Percentage of time psychotic 
during follow-up 
PMD less PMD 
more / = 
= / PMD 
less 
= SAD more 
Mortality and suicidality 
outcomes 
     
Death = = = = = 
Completed suicide ? ? ? ? ? 
Suicide attempts = / PMD 
more 
= / PMD 
more 
= = / SAD 
more 
= / SAD 
more 




= = / SAD 
more 
= / SAD 
more 
Social outcomes      
Employment status PMD better = PMD 
better 
= SAD worse 
Relationship status PMD better = PMD 
better / = 
= / SAD 
better 
SAD worse 
/ =  
Close confidants = / PMD 
better  
= = = = 
Time in prison PMD better 
/ =  









Service use outcomes      
Binary hospitalisation = / PMD 
less 
PMD less = = = / SAD 
less 
Total number of hospitalisations PMD less PMD less = SAD less = 
Total number of days hospitalised PMD less = = = = 
Percentage of follow-up spent as 
an inpatient 
PMD less = = = = 
Percentage of admissions which 
were compulsory 




= SAD less / 
=  
SAD less / 
= 
Ever been compulsorily admitted PMD less PMD less = = SAD less 
Percentage of hospitalisations 
involving the police 
PMD less PMD less = SAD less SAD less 
= no difference in outcomes; ? comparison not possible; boxes with 2 entries indicates a difference 
between the baseline and lifetime analyses. 
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8.3.3.1. Diagnostic stability 
The diagnostic stability analyses indicated that PMD and SAD had low diagnostic 
stability with the majority of cases moving to a diagnosis of schizophrenia. Predictors of 
diagnostic change in PMD cases were being younger at first contact; being younger at 
onset and being single. This has important clinical implications (see section 8.3.6). 
 
8.3.3.2. Course of illness outcomes 
In terms of course of illness, both baseline and lifetime analyses found PMD cases to be 
more episodic in their illness and less continuous, have longer remissions, less episodes 
and spend less time psychotic compared with schizophrenia. Additionally the lifetime 
analyses found PMD cases to have shorter episodes compared with schizophrenia cases. 
Both the baseline and lifetime analyses found PMD cases were less episodic and more 
‘neither episodic nor continuous’ and have less episodes compared with bipolar disorder 
cases. Additionally the baseline analyses found PMD cases to have longer longest 
episodes and spent more time psychotic compared with bipolar disorder cases.  
The lifetime diagnosis analyses also found that PMD was more episodic, had longer 
remissions, had fewer episodes and spent less time psychotic over the follow-up 
compared with SAD, but there were no differences between these groups according to 
the baseline analyses.   
 
There were no significant differences between SAD and schizophrenia in either the 
baseline or lifetime analyses indicating a very similar course of illness in these cases. In 
comparison to bipolar cases in both baseline and lifetime analyses, SAD was found to 
be less episodic, more continuous and more ‘neither episodic nor continuous’ plus to 
have shorter remissions and to spend more time psychotic over follow-up. The baseline 
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analyses also found SAD cases to have a longer longest episode compared with bipolar 
cases.   
 
Based on the above, there is evidence that SAD and schizophrenia have a very similar 
course of illness, but that the other disorders differ from each other with PMD having a 
better course than schizophrenia and SAD, but a worse course than bipolar, and SAD 
having a worse course than bipolar. 
 
8.3.3.3. Mortality and suicidality outcomes 
There were no differences in deaths over follow-up and attempted suicide could not be 
assessed due to the low numbers. However, while the baseline analyses showed very 
little differences between the groups in self-harm and none in suicide attempts, the 
lifetime results were very different. They revealed evidence that PMD cases attempted 
suicide more compared with schizophrenia and bipolar cases, and that of those who 
attempted suicide, SAD cases attempted more times compared with schizophrenia and 
bipolar cases. They also showed that more PMD cases self-harmed compared with 
schizophrenia cases and more SAD cases self-harmed compared with schizophrenia and 
bipolar cases, and of those who self-harmed, PMD and SAD cases self-harmed more 
compared with bipolar cases. Suicide attempt and self-harm outcomes has important 
clinical implications (see section 8.3.6). 
 
8.3.3.4. Social outcomes 
In terms of social outcomes, both the baseline and lifetime analyses revealed that PMD 
cases had better employment and relationship outcomes compared with schizophrenia 
cases. Additionally, the baseline analyses showed evidence that the PMD cases had 
better outcomes on time in prison, and the lifetime analyses showed evidence that PMD 
 353 
cases had better outcomes in terms of close confidants. Compared with bipolar cases, 
there was only evidence of PMD cases having better social outcomes in the lifetime 
analysis of time in prison in which PMD had a worse outcome.  
 
Compared with bipolar cases, SAD cases had worse outcomes according to both 
baseline and lifetime diagnoses on employment status and time in prison. Additionally, 
the baseline analyses supported SAD cases having worse relationship status outcomes. 
The analyses comparing SAD with PMD and schizophrenia were not very consistent in 
indicating that one group had better outcomes than the others.  
 
These findings indicate that PMD cases have better social outcomes compared with 
schizophrenia cases, and SAD cases have worse social outcomes compared with bipolar 
cases. Other comparisons were not strongly indicative of a directional difference. 
 
Marwaha and Johnson in their review of schizophrenia and employment state that low 
employment rates appear to reflect an interaction between social and economic 
pressures.
453
 However, the findings of this thesis that statistically and clinically 
significantly higher numbers of PMD cases are employed compared with schizophrenia 
cases suggests that these issues might not be in play in PMD cases. 
 
8.3.3.5. Service use outcomes 
The results indicated that PMD cases had better service use outcomes compared with 
schizophrenia cases. Better service use outcomes are defined as less hospitalisations, 
days hospitalised, less time spent as an inpatient, compulsory admissions, and 
admissions involving the police. PMD cases also had better service use outcomes 
compared with bipolar cases on many of the variables. In light of the finding that PMD 
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cases are more likely to attempt suicide and self-harm, this finding is paradoxical. Logic 
would dictate that cases with a higher risk of suicide/self-harm are more in need of 
services. However, due to their better social outcomes, PMD cases may be more likely 
to have a social network which can be relied upon, which may reduce the need for 
inpatient care due to a reliance on informal care. 
 
There were no differences between PMD and SAD cases in terms of service use 
outcomes, but there were several differences between SAD and schizophrenia and 
bipolar cases. SAD cases had less hospitalisations, less hospitalisations involving the 
police, and according to the baseline analyses, less compulsory admissions compared 
with schizophrenia cases. SAD cases were less likely to be hospitalised, were less likely 
to have been compulsorily admitted, had less hospitalisations involving the police, and 
according to the baseline analyses, had less compulsory admissions compared with 
bipolar cases. 
 
These findings indicate that PMD and SAD cases have better service use outcomes 
compared with schizophrenia and bipolar cases. This has important clinical implications 
(see section 8.3.6). 
 
8.3.3.6. Differences between baseline and lifetime analyses 
There were some important differences between the baseline and lifetime analyses. For 
example, based on the lifetime diagnoses, PMD and SAD cases either had a higher 
proportion of cases who attempted suicide over the follow-up period or had a higher 
number of attempts for those who did attempt suicide compared with schizophrenia and 
bipolar cases. The baseline analyses supported no such difference. 
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As discussed in section 8.2.3.2, differences between the baseline and lifetime analyses 
could be due to power issues. However, in the outcomes analyses, over half the 
differences in findings involve lifetime diagnoses supporting a difference between 
groups where the baseline analyses found none. Therefore, power cannot be the issue in 
these instances. However, power could be the reason for instances where baseline 
diagnoses find a difference that is not supported by the lifetime diagnosis analyses. 
Instances where lifetime diagnoses support a difference between groups where the 
baseline analyses found none are likely to be due to diagnostic change.  
 
As discussed in section 8.2.3.2, it is not possible to say which diagnosis is correct as 
both baseline and lifetime diagnoses both have their limitations. This is especially 
pertinent in regard to the outcomes analyses as diagnosis could change on the basis of 
outcome information, thus confounding the results. For example, the finding that PMD 
cases had better outcomes on a number of course of illness variables which were not 
identified by the baseline analyses could be due to the fact that those who have a worse 
outcome are more likely to be assumed to have schizophrenia. Also, diagnosis is partly 
about prognosis so a change in between baseline and lifetime diagnosis is expected as it 
is based on clinical picture across follow-up which will have included some information 
on outcome, which will have influenced the diagnosis. However, as discussed above, 
the result based on each diagnosis is simply different, and until a more reliable 
diagnostic system is in place, our conclusions are limited.  
 
8.3.3.7. Differences between PMD and SAD  
There were some areas where there were no differences in outcomes between PMD and 
SAD cases, such as service use, mortality and suicidality, and prospective consistency. 
However, although as discussed in Chapter 2 there are some striking similarities in 
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diagnostic overlap between PMD and SAD, there were still some important differences. 
For example, based on lifetime diagnoses, PMD cases seem to have a better course of 
illness compared with SAD cases. However, based on the baseline diagnoses there were 
no differences in course of illness indicating that perhaps these disorders are so similar 
that differences in the course of the illness can determine them apart, but perhaps this is 
a superficial difference as there is no real evidence of differences in mortality and 
suicidality, social outcomes or service use. 
 
8.3.4. Comparisons with previous research 
As discussed in chapter 4, there is a fair amount of previous research on the course of 
illness and outcomes in cases with PMD but less so with SAD cases. The hypotheses of 
this thesis were created in line with previous research but only around half of the 
hypotheses were supported by the findings of this thesis. This is likely due to 
methodological differences between this thesis and previous research as this thesis was 
the first study to conduct a long-term follow-up of incidence cases and the first to 
account for diagnostic change.  
 
The consistent finding from previous literature that PMD cases are less characterised by 
a continuous course type and more by an episodic course type
200, 229, 258
 was supported 
by both the baseline and lifetime analyses, as was the consistent finding from previous 
literature that PMD cases have better employment outcomes compared with 
schizophrenia cases.
180, 227, 258, 259, 262
 However, the consistent finding that SAD cases 
have better employment outcome compared with schizophrenia cases
239, 258, 259, 262
 was 
not supported by either the baseline or lifetime analyses in this thesis. This could be due 
to power issues. 
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The finding from previous literature that more PMD cases self-harm compared with 
schizophrenia cases
1
 was supported by the lifetime analyses but not baseline analyses. 
 
8.3.5. Theoretical implications 
As with the risk factors analysis, the baseline and lifetime diagnosis analyses gave 
slightly differing results, some of which were clinically very important (attempted 
suicide and self-harm being higher in PMD and SAD cases). This difference is 
important to note and future research examining course and outcomes of illness should 
take diagnostic change into account as this can dramatically alter results. 
 
The finding that PMD cases had better social, course of illness and service use 
outcomes but were more likely to attempt suicide or self-harm seems incongruous. The 
clinical implications of this are discussed in section 8.3.6. However, there are also 
theoretical implications surrounding this in relation to the mechanism of this. For 
example, could it be that cases who have better outcomes in some areas are seen to be 
less in need of the support of mental health services and thus receive less support, 
leaving them vulnerable to suicidal or self-harming behaviour? Alternatively, could it be 
that PMD cases have less continuous difficulties but their episodes are more severe 
when they do occur, and this severity is characterised by suicidal and self-harming 
behaviour? Or could it be that due to their better social functioning, they are able to hide 
their illness until it becomes a crisis and suicidal and self-harming behaviour ensues? 
Further research into this could be very useful in informing harm reduction strategies 
and risk assessment in these cases.  
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8.3.6. Clinical implications 
There are a number of clinical implications which come out of the outcomes analyses. 
The first regards diagnostic stability. As diagnostic stability was low for PMD and SAD 
cases, and as the majority of changes moved to a diagnosis of schizophrenia, clinicians 
should look out for change in diagnosis in these groups as it has important implications 
in terms of treatment (i.e. a change in medication regime).  
Secondly, linked to diagnostic stability is the finding that a sizeable proportion of PMD 
cases become schizophrenia over time. In light of this, the decision by many early 
intervention services to exclude depressive psychosis cases from their remit should be 
re-evaluated. Excluding cases based on an initial diagnosis of PMD could lead to 
patients with schizophrenia (and other psychotic disorders) missing out on the benefit of 
early intervention services. 
 
Thirdly, the results indicate that clinicians should be concerned with suicide attempts in 
PMD cases as it was more likely to have occurred in these patients compared with 
schizophrenia and bipolar disorder cases. PMD and SAD cases were also more likely to 
self-harm compared with schizophrenia cases which is another important issue for 
clinicians to be aware of. 
 
Fourthly, PMD cases had better social and course of illness outcomes and had more 
positive service use outcomes. In light of these incongruous findings between 
suicide/self-harm outcomes and social/service use outcomes, clinicians should be aware 
of issues surrounding self-harm and suicide attempts even in cases who seem to be 
having a favourable outcome following first episode. Additionally, although clinicians 
may be cautiously optimistic about outcomes in PMD cases based on some of the social 
outcome results in this thesis regardless of the incongruous findings on suicide/self-
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harm, the finding that may cases switch to a diagnosis of schizophrenia may be reason 
for clinicians not to be overly optimistic with their PMD patients and their families. 
This raises the dilemma of the usefulness of giving a specific diagnosis during a first 
episode of psychosis and perhaps giving a diagnosis of psychosis and waiting until the 
clinical picture is clearer would be useful in terms of managing expectations. 
 
8.4. Future research 
As discussed above, there are various areas of research that spawn from this thesis. 
Firstly, due to the low numbers and therefore, difficulty in interpreting the results 
around the SAD group, further research is needed to understand the risk factors and 
long term outcomes in this group. Secondly, although a number of risk factors have 
been examined, examining the interaction of these factors was not possible due to power 
issues and a bigger sample is required to examine interactions. A bigger sample would 
also allow an investigation of specific types of life events and difficulties which were 
not examined within this thesis. Thirdly, as this is the first study to examine risk factors 
and long term outcomes in PMD cases, an attempt to replicate the results with a 
different sample could strengthen the findings and conclusions. In relation to this 
replication, Warner
93
 described the following outcome areas as vitally important in 
patients with psychosis: unemployment; poverty; homelessness; time in prison and 
social isolation. Within this thesis, poverty and homelessness has not been addressed, 
only unemployment, time in prison and social isolation. Thus future research should 
include poverty and homelessness. Fourthly, differences in risk between the centres of 
London and Nottingham could not be examined in more detail due to the limitations of 
the study. However, there are clear differences in the risk of PMD and SAD between the 
London and Nottingham sites. This could have been due to differential diagnostic 
classification between the sites which is a potential source of bias. However, it could 
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also be due to differences between the sites: urbanicity; population density; ethnic 
density; or deprivation levels (as described in section 5.4). It could also be due to a 
number of unknown factors. Future research could examine these factors in more depth 
to determine what neighbourhood level factors influence the aetiology of PMD and 
SAD. Finally, Morgan points out that there is a need to move on from the simple 
analyses of demographics to a “detailed consideration of the social phenomena that may 
underlie these broad associations”.62 Morgan states that this also need to occur for other 
area such as trauma – the association between mental illness and trauma is no longer 





The findings of this thesis suggest that accounting for diagnostic change when 
examining risk factors and course of illness in PMD and SAD cases is of particular 
importance. Analyses indicate that social risk factors play a part in the aetiology of 
PMD but no more so than in schizophrenia and bipolar cases. PMD cases appear to have 
better social and services use outcomes but are more at risk of self-harming or 
attempting suicide. Due to low numbers in the SAD group, the conclusions based on 
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Note: A study can be awarded a maximum of one star for each numbered item within the Selection, 
Outcome and Analyses categories. A maximum of two stars can be given for Comparability 
 
Selection 
1) Representativeness of the exposed cohort 
a) truly representative of the average _______________ (describe) in the community* 
(All potential patients or a random sample of potential patients or consecutive patients) 
b) somewhat representative of the average ______________ in the community* 
(80+% of the potential population and there is a full description of refusals) 
c) selected group of users e.g. nurses, volunteers 
(80+% of the potential population and no description of refusals or <80% of the potential population) 
d) no description of the derivation of the cohort 
(no description) 
 
2) Selection of the non exposed cohort 
a) drawn from the same community as the exposed cohort* 
b) drawn from a different source 
c) no description of the derivation of the non exposed cohort 
 
3) Ascertainment of exposure 
a) secure record (e.g. surgical records)* 
b) structured interview* 
c) written self report 
d) no description 
 
Comparability 
4) Comparability of cohorts on the basis of the design or analysis 
a) study controls for _____________ (select the most important factor)* 
b) study controls for any additional factor* 
c) study conducted multivariate analyses to control for confounders**  
 
Outcome 
5) Assessment of outcome 
a) independent blind assessment* 
b) record linkage* 
c) self report 
d) no description 
 
6) Was follow-up long enough for outcomes to occur (at least 1 year) 
a) yes (select an adequate follow-up period for outcome of interest)* 
b) no 
 
7) Adequacy of follow-up of cohorts 
a) complete follow-up - all subjects accounted for* 
(100% follow-up) 
b) subjects lost to follow-up unlikely to introduce bias - small number lost - > ____ % (select an 
adequate %) follow-up, or description provided of those lost)* 
(80% or over, or examined differences between followed-up and non-followed-up groups (with comparison)) 
c) follow-up rate < ____% (select an adequate %) and no description of those lost 
(Under 80% and/or no examining of differences between followed-up and non-followed-up groups) 




8) Have appropriate analyses been conducted? (continuous data analysed as a continuous variable and not 
transformed into categorical data and see ‘how to read a paper’) 
 a) Yes* 
 b) No 
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9) Have confidence intervals been reported? 
 a) Yes*               ______ 




* 1 point 




Appendix C Screening Schedule for Psychosis 
 
Screening Schedule for Psychosis 
There should be at least one “yes” in Section A or two in Section B 
 
A Has the patient ever presented any of the following: 
(i) Hallucinations or pseudo-hallucinations in any modality 
(ii) Delusions 
(iii) Marked thought and speech disorder (e.g. incoherence, irrelevance, thought blocking, neologisms, 
incomprehensibility of speech) other than simple retardation or acceleration 
(iv) Marked psychomotor disorder (e.g. negativism, mutism or stupor, catatonic excitement, constrained 
attitudes or unnatural postures maintained for long periods) other than simple retardation or acceleration 
(v) Emergence or marked exacerbation of bizarre and grossly inappropriate behaviour (e.g. talking or 
giggling to self, acts incomprehensible to others, loss of social constraints, etc) 
 
B A definite change of personality and behaviour manifested in any of the following: 
(i) Marked reduction or loss of interests, initiate and drive, leading to serious deterioration of the 
performance of usual activities and tasks 
(ii) Emergence or marked exacerbation of social withdrawal (active avoidance of communication with 
other people) 
(iii) Severe excitement, purposeless destructiveness or agression 
(iv) Episodic or persistent states of overwhelming fear or severe anxiety 
(v) Gross and persistent self-neglect 
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UNDERSTANDING THE CAUSES OF MENTAL HEALTH PROBLEMS 
Please read this carefully if you wish to participate in our study. 
Your participation is entirely voluntary. 
 
General information Sheet for Patients 
 
We are carrying out a study at the Maudsley/ Bethlem and South Western Hospital on new patients to try 
to find out which factors lead to the development of mental health problems in different sections of the 
population.  As illness can be caused by physical problems or by stress in people’s lives, we would like to 
find out how you are feeling at the moment as well as how you were before you came into the hospital, to 
see if any of your experiences played a part in why you became ill. 
 
We would like to come and speak to you on a few occasions while you are in hospital to find out how you 
are, and ask you about any difficulties or problems that you may be having. 
 
We would like to perform an MRI scan of your brain in the radiology department, which takes less than 
an hour.  This is a new type of scan which gives a clearer picture of the brain and does not involve X-
rays.  You will be accompanied by a member of staff during this who can answer any questions you 
might want to ask.  Later on, we would like to arrange for you to do some concentration and memory 
tests, which take about two hours. 
 
We would also like to have a chat with your closest relative, preferably your mother, or someone else 
who is close to you and who would know about recent events in your life. 
 
Finally, we would like to meet you again in a year’s time to ask how you are getting on. 
 
Anything you say will be treated in the strictest confidence. 
 
If you decide not to be a part of the study, this will not affect in any way the care you receive at the 
hospital.  If you do decide to take part you are free to withdraw from the study at any time without having 
to say why.  We hope you will agree to take part in this study so that your help may contribute to 
improving the care offered by hospitals. 
 
If you would like to ask any questions or want to find out about anything else at all, please telephone the 
research team on 0171 919 3492, and any of the researchers will be happy to speak to you.  Alternatively, 
please telephone Kevin Morgan on 0171 740 5186. 
 
The project is based at: 
The Social Psychiatry Section 
MRC Research Centre 
Institute of Psychiatry 
De Crespigny Park 









UNDERSTANDING THE CAUSES OF MENTAL HEALTH PROBLEMS 
 
Researchers: Professor J. Leff, Professor R. Murray 
 
PATIENT CONSENT FORM 
 
Brief information about the study 
 
We are studying the factors that lead to the development of mental health problems in different sections 
of the population.  As part of this study we are interviewing people like yourself who have made contact 
with the psychiatric services for the first time.  We would like to interview you to ask about things that 
might have happened to you in the past or difficulties you may have had recently that could explain why 
you have become ill.  The information you give us is strictly confidential and your name will not be used 
in any records we keep. 
 
It would also be very helpful if we could interview some of your relatives to find out whether anyone else 




I agree to being interviewed for this study.  I understand that I can withdraw from the interview at any 















UNDERSTANDING THE CAUSES OF MENTAL HEALTH PROBLEMS 
 
Researchers: Professor J. Leff, Professor R. Murray 
 
COMMUNITY CONSENT FORM 
 
Brief information about the study 
 
We are studying the factors that lead to the development of mental health problems in different sections 
of the population.  We are interviewing people in the community who are in good health, as well as 
patients, in order to compare their experiences. 
 
 
We would like to interview you to ask about things that may have happened to you in the past or 
difficulties that you may have had.  The information you give us is strictly confidential and your name 
will not be used in any records we keep.  It would also be very helpful if we could interview one of your 
parents to find out about your early childhood.  This interview would be very short and could be 



















PSYCHOSIS SCREENING QUESTIONNAIRE (PSQ) 
___________________________________________________________ 
 
Interviewer ……………………………………………………..     Date……………………………   
 
 










In this health survey we have to ask about a whole range of experiences.  Some of these experiences are 
quite rare.  However, I would be very much obliged if you would bear with us and answer the questions I 
am going to ask you now. 
 
     
Q1. Over the past year, have there been times when you felt very   
 happy indeed without a break for days on end? 
 
 
 (a)  Was there an obvious reason for this?     
 
 
 (b) Did your relatives or friends think it was strange or  




Q2. Over the past year, have you ever felt that your thoughts were  
 directly interfered with or controlled by some outside force or  
person? 
 
 (a) Did this come about in a way that many people would  




Q3. Over the past year, have there been times when you felt that 
 people were against you? 
 
 
 (a) Have there been times when you felt that people were 
  deliberately acting to harm you or your interests? 
 
 
 (b)  Have there been times when you felt that a group of  
  people was plotting to cause you serious harm or injury?                       If 2 stop 
 
 
Q4. Over the past year have there been times when you felt that 
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 something strange was going on? 
 
 
 (a)  Did you feel it was so strange that people would find 
  it very hard to believe?                           If 2 stop 
 
 
Q5. Over the past year, have there been times when you heard or 
 saw things that other people couldn't                                                                  If 1 or 2 
                                                                          stop     
        
 
 (a) Did you at any time hear voices saying quite a few  
  words or sentences when there was no-one around  
  that might account for it?                           If 2 stop 
 
 
Q6. Have you ever received treatment for any psychiatric or psychological 
 problem? 
 








Appendix H Medical Research Council Socio-demographic Schedule 
 
SOCIO- DEMOGRAPHIC SCALE 
 
 





Starting Time:                Finishing Time: 
 
 
        Date of interview:                                             Centre No: 
       
                                    
 
        
        Interviewer ID No.                                            Resp. ID No: 
 





      1. Male                        2.Female                                                      




2) Date of Birth: 





                                                                                                                  
              
 
 1. 16-25                        2. 26-35 
             3. 36-45                        4. 46-55                                                            




1.        Catholic      2.      Church of England 
             3.       Methodist                4.      Muslim                                           
             5.       Hindu                     6.      Sikh 
            7.       Pentecostal            8.      Rastafarian 
              9.       Baptist                   10.     Presbyterian 
            11.      Church of Ireland 12.     Jewish 
          13.      Other (please specify) 







5) Where were you born?                If UK go to Q10 on page 7 
 
 
Explicit town if UK……………………………... and hospital…………………… 




4. Indian sub-continent (India, Pakistan, Bangladesh) 
5. Caribbean 
6. Africa 
7. Asian Other (China, Vietnam, etc) 
8. Other (please specify……………) 
    
 




Note:  For Questions 7-10, please probe for as much information as possible  
           on all people that the respondent resided/s with, and rate each one. 
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7) Who did you live with before moving here?                             1= Yes         0= No 
  7.1 Mother         
  
            
7.2 Father 
           
    
7.3 Parents 
           
   
7.4 Sibling (s) 
           
   
7.5 Spouse/ Partner 
           




7.7 Grandparent(s)        
   
 
 7.8 Aunt(s)/ Uncle(s)        
   
 
7.9 Cousins         
   
 
7.10 Other relative(s)        
   
 
7.11 Step Mother         
  
 
7.12 Step Father 
  
 
 7.13 Step- children 
           
   
 7.14 Step-siblings 
           
            
 7.15 Adoptive Parents 
           
   
7.16 Adoptive sibling(s)        
  
 
7.17 Half sibling(s) 
 
           
 7.18 Family friend(s)        
  
 
7.19 Own friend(s)        
   
 
7.20 Alone 
     







8) Who did you come with?     1= Yes     0= No 
7.1 Mother         
   
          
7.2 Father 
           
    
7.3 Parents 
           
   
7.4 Sibling (s) 
           
   
7.5 Spouse/ Partner 
           




7.7 Grandparent(s)        
   
 
 7.8 Aunt(s)/ Uncle(s)        
   
 
7.9 Cousins         
   
 
7.10 Other relative(s)        
   
 
7.11 Step Mother         
  
 
7.12 Step Father 
  
 
 7.13 Step- children 
           
   
 7.14 Step-siblings 
           
            
 7.15 Adoptive Parents 
           
   
7.16 Adoptive sibling(s)        
  
 
7.17 Half sibling(s) 
 
           
 7.18 Family friend(s)        
  
 
7.19 Own friend(s)        
   
 
7.20 Alone 
     







9) When you came to the UK, with whom did you live?   1= Yes           0= No 
7.1 Mother         
   
          
7.2 Father 
           
    
7.3 Parents 
           
   
7.4 Sibling (s) 
           
   
7.5 Spouse/ Partner 
           




7.7 Grandparent(s)        
   
 
 7.8 Aunt(s)/ Uncle(s)        
   
 
7.9 Cousins         
   
 
7.10 Other relative(s)        
   
 
7.11 Step Mother         
  
 
7.12 Step Father 
  
 
 7.13 Step- children 
           
   
 7.14 Step-siblings 
           
            
 7.15 Adoptive Parents 
           
   
7.16 Adoptive sibling(s)        
  
 
7.17 Half sibling(s) 
 
           
 7.18 Family friend(s)        
  
 
7.19 Own friend(s)        
   
 
7.20 Alone 
       







10) With whom do you live now?    1= Yes           0= No 
7.1 Mother         
   
          
7.2 Father 
           
    
7.3 Parents 
           
   
7.4 Sibling (s) 
           
   
7.5 Spouse/ Partner 
           




7.7 Grandparent(s)        
   
 
 7.8 Aunt(s)/ Uncle(s)        
   
 
7.9 Cousins         
   
 
7.10 Other relative(s)        
   
 
7.11 Step Mother         
  
 
7.12 Step Father 
  
 
 7.13 Step- children 
           
   
 7.14 Step-siblings 
           
            
 7.15 Adoptive Parents 
           
   
7.16 Adoptive sibling(s)        
  
 
7.17 Half sibling(s) 
 
           
 7.18 Family friend(s)        
  
 
7.19 Own friend(s)        
   
 
7.20 Alone 
     






11) Indicate total number in house hold ……………………… 
           
  
 
12) (Do not ask this question) Rate type of household from Q.10 
  1. Single person 
  2. Couple        
         3. Couple + children 
  4. Single parent and children 
  5. Grandparents/ couple + children 
  6. Grandparents/ single parent + children 
  7. Siblings + children 
  8. Friend 
  9. Other (Specify) ……………………………………………… 
 
 
13) Who is the head of your household? ………………………………………… 
 (ie. main income earner/spiritual head/main decision maker) 
       [If single person only, go to Q.15] 
 
0. Self (Patient/ control) 
1. Spouse/ co-habitee 
2. Parent          
3. Son/ daughter 
4. Sibling 
5. Other relative (specify) …………. 
6. Friend 
7. Co-resident 
8. Other (specify) ………….. 
 
14) What is your position in the household? ………………………………… 
       [for those in non-single person households go to Q.17] 
1. Spouse/ co-habitee 
2. Parent 
3. Son/ daughter 
4. Sibling 




15) When was the last time that you lived with others? ………………….. 
  0. Within the last year 
  1. Within last 1-2 years        
  2. Within last 2-3 years 
  3. More than 3 years ago 
 
16) Is there any reason why you live alone? 





0. No reason 
1. Positive decision 








17) Where did you live during the first 16 years of your life, starting with place born, all different towns 
since and the number of years you lived there? 
 










18) How old were you when you left your parental/ care giving home? ……………….. 
           
      
 
19) When did you move to this town/ area? dd/mm/yy ……./……../……… 




1. Less than 6 months ago      2. 6-12 months ago 
  3. 1-2 years ago  4. 2-4 years ago 
 5. 5 years ago and over   
           
   
20) How many addresses have you lived at in the last 3 years? 
       (1,2, 3 etc) ………         
           
   
21) When did you move to this address? dd/mm/yy ……/……./…….. 
                                  
 
 1. Less than 6 months ago      2. 6-12 months ago 
 3. 1-2 years ago       4. 2-4 years ago         








22) Interviewers- Rate type of current accommodation: 
  1. Detached house 
  2. Semi- detached house 
  3. Terraced house 
  4. Flat\ Maisonette in house 
  5. Purpose built flat 
  6. Multi- storey block/flat 
  7. Bedsitter 
  8. Hostel 
  9. Squat 
            10. Other ( specify ) ………………. 
           
  
 
23) Do you own the house/ flat or is it rented accommodation? 
 
1. Yes: Self/Joint owner occupied 
2. No: Family owner occupied 
3. No: Private rented 
4. No: Local authority rented 
5. No: Housing association rented 





24) How many rooms do you have in you accommodation? (1, 2, 3, etc.) 
      ( Excluding kitchen and bathroom ) 
 


























  25) What is your current relationship status? 
  1. Married/ Living with someone 
  2. Single in steady relationship        
  3. Single in casual relationship(s) 
  4. Single- no partner 
  5. Divorced 
  6. Widowed 
  7. Separated 
 
 26) Have you ever: 
 26a)  been divorced? 
 (0= never, 1= once, 2= twice, etc) 
           
  
 26b)      been separated? 
  (0= never, 1= once, 2= twice, etc) 
           
   
 26c)  been widowed? 
(0= never, 1= once, 2= twice, etc) 
          
   
26d)  lived with a long-term partner (over 2 years)? 
(0= never, 1= once, 2= twice, etc) 
           
   
 
 27) How many children do you have? 
 (0= none, 1= one, etc) 
                                
 
 28) Have you ever lost a child? [Probe for miscarriage/ death] 
         (0= none, 1= one, etc)        
   
 
 
 If applicable    28a) How old was the child? ……………………… 
           
  
 
   
28b) How old were you?............................................ 
            
 
 
  28c) What happened? .........................................................................................................       
    
   ……………………………………………………………………………………………. 
 
 
 29) Is your mother alive?     [ If no go to 31] 
    0= No  1=Yes  2=Don’t know 
           
   
 
 30) How old is your mother now? ...................... 
           




32) Where was your mother born?      [ If UK. Go to 34 ] 
 
 
Explicit town if UK ............................... and country if abroad........................................ 
  1.  UK 
  2.  Ireland 
  3.  Europe 
               4.  Indian sub-continent (India, Pakistan, Bangladesh) 
               5.  Caribbean 
               6.  Africa 
               7.  Asian Other (China, Vietnam, etc) 
               8.  Other (please specify..................................) 
 
  33) How old was your mother when she came to UK?............................. 




  34) Is your father alive?       [If no go to 36 ] 
 
 0=No  1=Yes  2= Don’t know 
           
   
 
  35) How old is your father now?....................................... 




 36) How old were you when he died?       




37) Where was your father born?                           [ If UK. go to 39] 
 
 
Explicit town if UK............................. and country if abroad............................................  
 1.  UK 
  2.  Ireland 
  3.  Europe 
               4.  Indian sub-continent (India, Pakistan, Bangladesh) 
               5.  Caribbean         
 6.  Africa  
               7.  Asian Other (China, Vietnam, etc) 
               8.  Other (please specify..................................) 
 
 
 38) How old was he when he came to the UK?............................. 
           
   
 
39) Were you ever separated from your mother before aged 17?....           [ If no go to 42]  
               0= No  1=Yes 
 
 




41) How long was it for? ..................... 
                 1. less than 1 year   2. 1-2 years                                                                
   3. 2-4 years                              4. 4+ years 
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   42) Were you ever separated from your father before aged 17?                  [ If no go to 45 ] 
              0= No             1=Yes 
 
           
   
 
 43) How old were you? .................... 
           
   
 
 44) How long was it for? .................. 
     1. less than 1 year   2. 1-2 years                                                                
   3. 2-4 years                              4. 4+ years                                                                
 
 
  45) [If separated from either or both parents, press reason for the separation: eg. migration, parent     







  46) Who looked after you during this time? .................... 
  1. Grandparent/s        
  2. Aunts/ Uncle/s 
  3. Sibling/s 
  4. Step- parent/s 
  5. Other relatives ( specify )..................... 
  6. Adoptive parent/s 
  7. Family friend/s 
  8. Foster parents/ Social services care 




   47) Who was your main care giver for most of your childhood? ........................ 
    0.  Natural parent/s       
    1.  Grandparent/s 
                 2.  Aunts/ Uncle/s 
    3.  Sibling/s  
                  4.  Step- parent/s  
    5.  Other relatives ( specify ) .......................... 
    6.  Adoptive parent/s 
    7.  Family friend/s  
    8.  Foster parents/ Social services care 
                               9.  Other ( specify ) ...............................................  
 
 
47a)    If the answer is natural, step or adoptive parent/s, please specify if the main caregiver was: 
    1.  Mother 
    2.  Father 
                 3.  Both                     









48) How many brothers and sisters do you have? 
 ( Draw a genealogy on reverse of sheet detailing gender, ages and date of births of siblings.  Ensure 
that it includes information on full and half siblings, and also on shared parents, if applicable) 
 
 
 48a) Brothers (0,1,2,3.............).................. 
            
  
 48b) Sisters (0,1,2,3................).................. 
            
 
 48c) Total (0,1,2,3..................).................. 




49) Have you any who have died? 
  
48a) Brothers (0,1,2,3.............).................. 
            
  
 48b) Sisters (0,1,2,3................).................. 
            
 
 48c) Total (0,1,2,3..................).................. 
            
 
 






50) What is/ was your position in the family? ................... 
   1. Eldest         
   2. Middle 
   3. Youngest 
                4. Twin 
   5. Only Child 
 
51) Do you share the same two parents with all your siblings? 
0= No   1= Yes 
           





   52) Where did you go to secondary school? (name and address of school) 
   .....................................................................................................................  
   1. UK 
   2. Ireland         
   3. Europe 
   4. Indian sub- continent (India, Pakistan, Bangladesh) 
   5. Caribbean 
   6. Africa 
   7. Asian Other (China, Vietnam, etc) 
   8. Other 
   9. More than one country ( specify ) ..................................... 
 
  53) What was the highest level of education you reached? 
 Write qualifications attained below and where attained 
 1. No qualifications 
 2. GCSE/ CSE 
 3. O’ levels 
 4. A’ levels 
 5. Vocational/ college (B.Tecs/NVQs etc) 
 6. Teaching/HND/ nursing 
 7. University/ Professional qualifications 





54) Have you ever needed remedial education   [ If ‘no’ go to Q.57] 
  1. Yes 
  2. No 
            
55) What special help did you receive? .................................................... 
  1. Reading and/ or writing 
  2. Maths          
  3. Both 1 and 2 
  4. Other ( specify ) ........................ 
  
 Write verbatim the type of education received 
 
56) At what age did you receive this help? ................................. 
 
                            
 
 
57) Have you ever been studying during the past year?................................. 
                         [ If no go to 60 ] 
      0. No 
   1. Yes, full-time student 
   2. Yes, part-time student 
   3. Yes, part-time student and part-time working 
   4. Yes, part-time student and full-time working   
   5. Yes, full-time student and full- time working  
   6. Yes, have been a student for some time but have discontinued 









58) What kind of education were you receiving? ................................     
  0. General (eg. reading, writing and arithmetic) 
  1. Specialised- training for a trade or apprenticeship (specify).......................... 
  2. Specialised- academic (specify nature of course) .......................................... 
 
59) How have you done in your studies in the last year? ........................ 
  0.  Excellent 
  1.  Good 
  2.  Fair          
  3.  Poor 
 
60) Since you left .................................. have you had any further skills training/formal education? 
Or [Apart from this last year] have you had any other type of formal education? 
  0. Yes 
  1. No         
  
 
61) If yes, what kind and how long attended? 
 











  62) Are you currently employed?         [ if no go to Q.77] 
  1. Yes 
  0. No 
  
 63) In total, how many years have you been employed? 
  1. Less than 1 year 
  2. >1-<3 
  3. >3-<5 
  4.>4-<10 
  5.>10 
  9. Not known 
            
 64) Have you changed jobs in the last 12 months? ......................... 
  0. No change 
  1. One change 
  2. Two changes 
  3. Three or more changes 
            
 65) If applicable, in what way has it changed? ( promotions, demotions etc.) ..................................... 
  0. Same status 
  1. Lower status 
  2. Higher status 
            
 66) Please give your current job title? ..................................................................................... ................ 
  [please rate in one of the following categories] 
  1. Professional 
  2. Intermediate occupations 
  3. Skilled occupations (non-manual) 
  4. Skilled occupations (manual) 
  5. Partly skilled 
  6. Unskilled occupations 
  7. Armed forces 
            
   67) In your current occupation, are you working: 
  1. At home in sub-contracted work 
  2. Self employed 
  3. In a family business       
  4. For others 
  5. Other (specify) ............................................ 
 
   68) Are you working full-time or part-time? ..................... 
  0. Full- time only, normal conditions     
  1. Full- time only, sheltered conditions 
  2. Part-time only, normal conditions 
  3. Part- time only, sheltered conditions 
  4. Some full-time and some part-time periods, normal conditions 
  5. Some full-time and some part-time periods, sheltered conditions 
  6. Other ( specify ) 
   
  69) What is your annual salary like for that job? 
  0. <6000        
  1. 6,000- 8,500 
  2. 8,500- 12,000 
  3. 12,000- 15,000 
  4. 15,000- 20,000 
  5. 20,000- 25,000 






 70) What was/ is the degree of responsibility in your job?.............................. 
  0. Little: works under constant supervision      
  1. Moderate: works mainly on his/own with occ.supervision 
  2. High: person supervises others 
  3. Nature of work doesn’t involve supervision by others 
 
 71) How have you been doing in your job in the last year? .............................. 
  0. Attends work regularly, performance adequate for job    
  1. Attends work regularly, performance good 
  2. Absent from work occasionally, decline in work standard 
      or person feels they are struggling to cope 
  3. Absent from work frequently, has been fired because of poor  
      Performance or gross neglect at work 
 
 
72) Is this the kind of work you have been doing for the most of your life? 
    1. Yes 
    2. No         
   
73) If no, then what has been your main occupation? (title).................................. 
             
  [please rate in one of the following categories] 
   1. Professional 
   2. Intermediate occupations 
   3. Skilled occupations (non-manual) 
   4. Skilled occupations (manual) 
   5. Partly skilled 
   6. Unskilled occupations 
   7. Armed forces 
 
  74) Do you have another job in addition to your regular job outside the home? 
 (title) ..............................         [If no go to 76] 
 
  0. No other job 
  1. Professional 
  2. Intermediate occupations 
  3. Skilled occupations (non-manual) 
  4. Skilled occupations (manual) 
  5. Partly skilled 
  6. Unskilled occupations 
  7. Armed forces 
           
   
75) What is your annual salary for this job? 
   
0. <6000        
 1. 6,000- 8,500 
  2. 8,500- 12,000 
  3. 12,000- 15,000 
  4. 15,000- 20,000 
  5. 20,000- 25,000 












76) In the last 2 years have you ever worked in another job in addition to your regular 
        job?    ( title ) ............................................................. 
  0. No other job            [ If no go to Q. 86 ] 
  1. Professional 
  2. Intermediate occupations 
  3. Skilled occupations (non-manual) 
  4. Skilled occupations (manual) 
  5. Partly skilled 
  6. Unskilled occupations 
  7. Armed forces 
77) Did you ever work in the last 12 months? ..........................          [ If more than 0 go to Q.80] 
      (Rate employment in the past 1 year) 
  0. No work 
  1. Has had 1 or more months of unemployment 
  2. Working practically all the time      
   
 
 78) Why haven’t you worked? ............................ 
  0. House-person 
  1. Student        
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  2. Physical Disability 
  3. Mental Illness 
  4. Unable to find job 
  5. Retired 
  6. Other ( specify )................................. 
 
  79) Have you ever had a paid job?      [ If no go to Q.85] 
  1. Yes 
  0. No 
   
 80) What was the last occupation you had? ( title ).............. 
0. No other job                      
  1. Professional 
  2. Intermediate occupations 
  3. Skilled occupations (non-manual) 
  4. Skilled occupations (manual) 
  5. Partly skilled 
  6. Unskilled occupations 
  7. Armed forces 
           
  
81) How many years ago was that? (1,2,3 etc.)................. 
            
 
 
82) Was it full-time or part-time?............................................ 
  0. Full- time only, normal conditions     
  1. Full- time only, sheltered conditions 
  2. Part-time only, normal conditions 
  3. Part- time only, sheltered conditions 
  4. Some full-time and some part-time periods, normal conditions 
  5. Some full-time and some part-time periods, sheltered conditions 
  6. Other ( specify ) 









83) At that time were you working: 
  1. At home 
  2. For yourself        
  3. In a family business 
  4. For others 
 
   84) What were your earnings like?................................................ 
0. <6000         
  1. 6,000- 8,500 
  2. 8,500- 12,000         
  3. 12,000- 15,000 
  4. 15,000- 20,000 
  5. 20,000- 25,000 
  6. 25,000+ 
 
   85) As you are not working are you able to claim benefits? If so, which ones?            
1. Yes  2. No 
  1. Housing     
           
     
2. Family 
           
     
3. Income 
           
     
4. Disability 
          
 
5. Other 
         
   
86) Apart from formal paid work, have you done any type of voluntary work in the past two years/ 
including odd jobs helping friends? 
  1. Yes 
  0. No 
 
     
 
I WOULD NOW LIKE TO ASK YOU SOME QUESTIONS ABOUT YOUR FAMILY’S 
OCCUPATIONS. 
 
   87) If applicable what type of work does your partner do? ( title ) ................................................ 
0. Unemployed                      
  1. Professional 
  2. Intermediate occupations 
  3. Skilled occupations (non-manual) 
  4. Skilled occupations (manual) 
  5. Partly skilled 
  6. Unskilled occupations 
  7. Armed forces 
  8. Student 
  9. Retired 
  10. House-person 









88) What was/is your father’s main occupation? ( title).................................................................. ... 
0. Unemployed                      
  1. Professional         238,  
  2. Intermediate occupations 
  3. Skilled occupations (non-manual) 
  4. Skilled occupations (manual) 
  5. Partly skilled 
  6. Unskilled occupations 
  7. Armed forces 
  8. Student 
  9. Retired 
   89) What was your father’s occupation when you were born? (title) ............................................ 
0. Unemployed                      
  1. Professional 
  2. Intermediate occupations 
  3. Skilled occupations (non-manual) 
  4. Skilled occupations (manual) 
  5. Partly skilled 
  6. Unskilled occupations 
  7. Armed forces 
  8. Student 
  9. Retired 
90) What was/is your mother’s main occupation? ( title).....................................................................  
0. Unemployed                      
  1. Professional          
  2. Intermediate occupations 
  3. Skilled occupations (non-manual) 
  4. Skilled occupations (manual) 
  5. Partly skilled 
  6. Unskilled occupations 
  7. Armed forces 
  8. Student 
  9. Retired 
91) What was your Mother’s occupation when you were born? (title)................................. 
  0. Unemployed                      
  1. Professional         
  2. Intermediate occupations 
  3. Skilled occupations (non-manual) 
  4. Skilled occupations (manual) 
  5. Partly skilled 
  6. Unskilled occupations 
  7. Armed forces 
  8. Student 
  9. Retired         
92) If you are not the head of the household ( and if applicable), what is the occupation of the head        
the household that you live in? 
  0. Unemployed                      
  1. Professional          
  2. Intermediate occupations 
  3. Skilled occupations (non-manual) 
  4. Skilled occupations (manual) 
  5. Partly skilled 
  6. Unskilled occupations 
  7. Armed forces 
  8. Student 
  9. Retired 
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CONFIDANTS/ SUPPORT NETWORK 
 
 93) How often do you visit or speak to friend(s)/neighbour(s)/ work associates outside of work? 
  1. Visit/Speak to daily 
  2. Visit/Speak to weekly 
  3. Visit/Speak to fortnightly 
  4. Visit/Speak to monthly 
  5. < than above 
  0. Never 
           
   







94) [If applicable] Do your friends live close to you? 
  0. No 
  1. Yes locally (same area) 
  2. Yes (same town) 
           
   
 
95) How often to you visit/ speak to your close family (including in-laws)? 
1. Visit/Speak to daily 
  2. Visit/Speak to weekly 
  3. Visit/Speak to fortnightly 
  4. Visit/Speak to monthly 
           
   
 









96) Do your close family live near you? 
 0. No 
 1. Yes (same are) 
 2. Yes (same town) 
           
  
97) Do you have any close confidants? 
 1.Yes  0. No 
           
   
 98) If yes, who (check family and friends above).....................................................................................                                                          
      
         ........................................................................................................................................................... 
 
  99) Would it have been the same person a year ago? 
 1.Yes  0. No 





101) How often do you visit/ speak to your confidants? 
1. Visit/Speak to daily 
  2. Visit/Speak to weekly 
  3. Visit/Speak to fortnightly 
  4. Visit/Speak to monthly 
  5. < than above 
            






 102) If you had a worrying/ upsetting problem who would you discuss it with first? 
 1. Partner   2. Parent 
 3. Sibling   4. Other relative 
 5. Friend- female   6. Friend- male  
 7. No one in particular  8. Don’t share problems 
            
103) Anyone else? 
 1. Partner   2. Parent 
 3. Sibling   4. Other relative 
 5. Friend- female   6. Friend- male  
 7. No one in particular  8. Don’t share problems 
           
  
104) How helpful are they when you confide in them? 
 1. Very helpful  2. Fairly helpful 
 3. Not very  4. Critical but truthful 
 5. Too critical 
           
  
105) What about emotional support and advice/listening 
1. Very helpful  2. Fairly helpful 
 3. Not very  4. Critical but truthful 
 5. Too critical 
           
   
 106) How else do they help you? ....................................................................................  
          ..................................................................................................................................  
          ............................................................................................................................. ..... 
 
   107) Are you registered with a GP? 
              1. Yes    0. No 
            
   108) [If no] is there any particular reason? .............................................................................  
 
 
   109) Would you go to the GP if you had a stressful problem? 
 1. Yes    0.No 
 
           
      
   110)  [If no] is there any particular reason? .............................................................................  
    ......................................................................................................................................... 
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Name ………………………………………….. ….. ……..       Date……………………………   
 
 
          






This questionnaire is part of a research survey concerning aspects of childhood. 
We are equally interested in people with TYPICAL or ATYPICAL experiences. 
 
We would be very grateful if you could fill in all of the following questions  
about yourself. 
 





1.  WHO BROUGHT YOU UP BEFORE AGE 17 
 
Please write below the Parent Figures who brought you up in childhood.  List each family arrangement  
with different parent figures which lasted one year or longer. 
Consider natural parent, step-parent (including parent's live-in partner), aunt, friend of the family, 
adoptive parent, foster parent etc. 
 
Fill in the first family arrangement below.  For example, if this was with your natural parents, write in 
'Mother' and 'Father' and age '0';  or if this was with just your mother write in 'Mother', put ‘No father 
figure’ in the father column, and age '0'. 
 
 





1a 1b 1c 
 
 
If this was your only family up to the age of 17, then SKIP to the starred question below. 
 
If you have lived in more than just one family arrangement, such as with mother and stepfather, then list 
them below, together with the age you were when the arrangement began. 
 
Family arrangement Mother figure Father figure Your age at 
start 

















1m 1n 1o 
 
1p **Were you ever in a children's home or institution before age 17?   YES   NO 
     (please circle the appropriate answer) 
 
If 'YES' fill in the boxes below.  If 'NO' skip to question 2 overleaf 
 
TYPE OF INSTITUTION 
e.g. local authority care, hospital, boarding school 
age when you 
started 













2.  PARENTAL LOSS 
 







2a. Did either parent die before you were aged 17?  
YES    NO 
 
YES   NO 











2d. Have you ever been separated from your parent 
      for one year or more before the age of 17? 
 
 
YES    NO 
 
YES   NO 
 
 








At what age were you first separated? 2e 2f 
How long was this separation, in years? 2g 2h 
Please circle the reason for the separation:   
Parent's illness (2i) YES    NO YES    NO 
Parent's work (2j) YES    NO YES    NO 
Parents' divorce or separation (2k) YES    NO YES    NO 
Abandoned by parent or never knew parent (2l) YES    NO YES    NO 
Other reason (2m) YES    NO YES    NO 
 







3.  Please circle the appropriate numbers to describe your Mother Figure, as you remember her in  
your first 17 years.   If you had more than one, choose the one you were with the longest, or the one you 
found most difficult to live with. 
 
3a.  Which mother figure are you describing below? 
 1. Natural mother  
 2. Step-mother/father's live-in partner        
 3. Other relative e.g aunty, grandmother 
 4. Other non-relative e.g. foster mother, godmother 




 Unsure  No, 
not at 
all 
3b She was very difficult  to please 1 2 3 4 5 
3c She was concerned about my worries 1 2 3 4 5 
3d She was interested in how I did at  
     school 
1 2 3 4 5 
3e She made me feel unwanted 1 2 3 4 5 
3f  She tried to make me feel better  
     when I was upset 
1 2 3 4 5 
3g She was very critical of me 1 2 3 4 5 
3h She would leave me unsupervised 
     before I was 10 years old 
1 2 3 4 5 
3i  She would usually have time to talk 
     to me 
1 2 3 4 5 
3j She would hit me 1 2 3 4 5 
3k At times she made me feel I was a 
     nuisance 
1 2 3 4 5 
3l  She often picked on me unfairly 1 2 3 4 5 
3m She was there if I needed her 1 2 3 4 5 
3n She was interested in who my 
      friends were 
1 2 3 4 5 
3o She was concerned about my 
     whereabouts 
1 2 3 4 5 
3p She cared for me when I was ill 1 2 3 4 5 
3q She neglected my basic needs (e.g. 
      food and clothes) 
1 2 3 4 5 
3r  She did not like me as much as my 
     brothers and sisters (leave blank if no 
     siblings) 
1 2 3 4 5 
 
3s. Do you want to add anything about your mother?………………………………….. 
     ………………………………………………………………………………………….. 
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4.  Please circle the appropriate numbers to describe your Father Figure, as you remember him in your 
first 17 years.   If you had more than one, choose the one you were with the longest, or the one you found 
most difficult to live with. 
 
4a.  Which father figure are you describing below? 
 1. Natural father  
 2. Step-father/mother's live-in partner        
 3. Other relative e.g uncle, grandfather 
 4. Other non-relative e.g. foster father, adoptive father 




 Unsure  No, 
not at 
all 
4b He was very difficult  to please 1 2 3 4 5 
4c He was concerned about my worries 1 2 3 4 5 
4d He was interested in how I did at  
     school 
1 2 3 4 5 
4e He made me feel unwanted 1 2 3 4 5 
4f  He tried to make me feel better  
     when I was upset 
1 2 3 4 5 
4g He was very critical of me 1 2 3 4 5 
4h He would leave me unsupervised 
     before I was 10 years old 
1 2 3 4 5 
4i  He would usually have time to talk 
     to me 
1 2 3 4 5 
4j  He would hit me 1 2 3 4 5 
4k At times he made me feel I was a 
     nuisance 
1 2 3 4 5 
4l  He often picked on me unfairly 1 2 3 4 5 
4m He was there if I needed him 1 2 3 4 5 
4n He was interested in who my 
      friends were 
1 2 3 4 5 
4o He was concerned about my 
     whereabouts 
1 2 3 4 5 
4p He cared for me when I was ill 1 2 3 4 5 
4q He neglected my basic needs (e.g. 
      food and clothes) 
1 2 3 4 5 
4r  He did not like me as much as my 
     brothers and sisters (leave blank if no 
     siblings) 
1 2 3 4 5 
 




5. CLOSE RELATIONSHIPS IN CHILDHOOD 
    (please circle as appropriate – if you circle NO to any question, SKIP the rest of 
     that section and go on to the next one) 
 
5a  When you were a child or teenager, were there any ADULTS you could go to 
       with your problems or to discuss your feelings?           
        YES     NO 
 
5b  If YES: Who was that?  (circle more than one if relevant) 
      
 1.  mother / mother figure 
 2.  father / father figure 
 3.  other relative 
 4.  family friend 
 5.  teacher, vicar etc 
 6.  other (describe) ………………………………. 
 
5d  Do you want to note anything about the relationship(s)? ………………………… 
 
 
5e Were there other CHILDREN/TEENAGERS your age that you could discuss  
      your  problems and feelings with? 
 
             YES     NO 
 
5f  If YES: Who was that?        (circle more than one if relevant) 
 
 1.  sister 
 2.  brother 
 3.  other relative 
 4.  close friend 
 5. other less close friend(s) 
 6. other person (describe)……………………………….. 
 
5h  Do you want to note anything about the relationship(s)?……………………… 
 
 
5i Who would you describe as the TWO CLOSEST people to you as a  
    child/teenager?        (circle up to two) 
 
 1.  mother / mother figure 
 2.  father / father figure 
 3.  sister or brother 
 4.  other relative 
 5.  family friend (adult) 
 6.  friend your age 
 7. other (describe) …………………………………………. 
 
5k  Do you want to note anything about the relationship(s)?………………………… 
 
 463 
6.  PHYSICAL PUNISHMENT BEFORE AGE 17 BY PARENT FIGURE OR 
     OTHER HOUSEHOLD MEMBER 
 
6a  When you were a child or teenager were you ever hit repeatedly with an implement (such as a belt or 
stick) or punched, kicked or burnt by someone in the household?  
          YES     NO 
 


















Did the hitting happen on more than 




YES    NO 
 
 
YES    NO 
How were you hit? 6e 
1. belt or stick 
2. punched/kicked 




1. belt or stick 
2. punched/kicked 
3. hit with hand 
4. other 
 
Were you ever injured e.g. bruises, 








YES    NO 
Was this person so angry they seemed 








YES    NO 
 






6j. Did you experience this from anyone else in the household?     YES      NO 
 






7.  UNWANTED SEXUAL EXPERIENCES BEFORE AGE 17 
      (please circle as appropriate) 
 
7a. When you were a child or teenager did you ever have     YES  NO  UNSURE 
      any unwanted sexual experiences? 
 
7b.  Did anyone force you or persuade you to have sexual     YES  NO  UNSURE 
       intercourse against your wishes before age 17? 
 
7c.  Can you remember any upsetting sexual experiences      YES  NO  UNSURE 
        before age 17 with a related adult or someone in 
        authority e.g. a teacher? 
 
If NO to all these, then SKIP to question 8 overleaf 










Was the other person someone you knew? 
 
7f 
       YES     NO     
      
     YES    NO 
Was the other person a relative? 
 
7g 
       YES     NO      
       
     YES    NO 
Did the other person live in your household? 
 
7h 
       YES     NO      
      
     YES    NO 
Did this person do it to you on more than one occasion? 7i 
       YES     NO      
 
      YES    NO 
Did it involve touching private parts of your body? 7j 
       YES     NO      
 
      YES    NO 
Did it involve touching private parts of the other person's 
body? 
7k 
       YES     NO      
 
      YES    NO 
Did it involve sexual intercourse? 
 
7l 
       YES     NO      
 
      YES    NO 
 
 















8.  YOUR CURRENT RELATIONSHIPS AND WORK 
      (Please circle or write in your answer – if you circle NO to any question, SKIP the 
       rest of  that section and go on to the next one) 
 
 
8a.  Do you have a partner?                  YES            NO 
 
If YES: 
 8b.  Are your currently living with your partner? 
  0.  No 
  1.  Yes, cohabiting 
  2.  Yes, married 
 
 8c.  Does your partner work? 
  0.  No 
  1.  Student only 
  2.  Part-time employment 
  3.  Full-time employment 
 
 8d.  What is your partner's job?  ……………………………………………….. 
 
 
8e.  Do you have children?     YES    NO   EXPECTING FIRST BABY 
 
If YES: 
 8f.  How many children do you have? ………………………… 
 
 8g.  How many are currently living with you? ……………………. 
 
 8h.  How old is your eldest child?…………………………………. 
 
 8i.  How old is your youngest child?……………………………. 
 
 8j.  Do any of your partner's children live with you     YES      NO 
       (i.e. your step-children) 
 
 8k  Are you currently employed? 
  0.  No 
  1.  Student only 
  2.  Part-time employment 
  3.  Full-time employment 
 
 8l.  If YES, what is your job? ……………………………………………. 
 
 
8m.  Your gender:      MALE      FEMALE 
 
8n.  Your current age ………………………… 
 
 
Thank you for your help with this questionnaire. We realise that it is difficult to give a true picture of your 
childhood experience in a questionnaire, so if you have any comments you would like to add, please write 
them below. Your responses will be treated in the strictest confidence. 
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Appendix K Life Events and Difficulties Schedule 
 
 
Five Year Events and Difficulties Checklist 
 
Starting Time:          Finishing Time:  
 
 
         Date of interview:                                        Centre No: 
 
                                                                  1,6                  7,8 
     
 
         Interviewer ID No.                                      Resp ID No. 
           
                                                                       11-14 
 
 
Having recently spent time talking about the past year, we are also interested in any experiences or events 
that have happened prior to the past year (but within the past five years) which have involved: yourself, 
your partner, your children, other family members and close friends. 
 
Listed below are a number of events.  If you have experienced any events of that nature could you 
indicate approximately the month and year in which it occurred. 
 
Could you also indicate whether any of these experiences have occurred because of your: 
(appearance/colour/ethnicity/religion/etc (as appropriate)? 
 
   Coding relationship to respondent: 
        Spouse/ Partner   = 1 Children =2 Mother  =3 
        Father                  = 4 Sibling =5 Grandparent =6 
        Close Friends       = 7 Friends =8 Other  =9 
 
SECTION I  HEALTH/ ILLNESS               Rel         Yes/No            Year and Month 
1. Onset of a serious illness in you,  
  your partner or your children                    ……..           ………..             …………………… 
 
2. Accident causing serious injury to            
  you, your partner or your children            ……..           ………..             …………………… 
 
3. A death in your household or 
 immediate family                                          .…….           ………..            …………………... 
 
4. Unwanted pregnancy- to you, your 
 Partner or any of your children                  ……..           ………..            ……………………  
 
5. Have you, your partner or any of  
 your children had an abortion, a  
 miscarriage, stillbirth or child  
 born with serious health problems              ……..          ………            ……………………... 
 
Could you indicate whether any of these experiences have occurred because of your appearance/colour/ 
ethnicity/religion etc (as appropriate)?  
……………………………………………………………………………………………….. 
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SECTION IV                       HOUSING  Rel           Yes/No              Year and Month                  
6. A major disappointment for you such 
 as an application for rehousing or 
 a loan being rejected                                   ……        …………..          ……………………… 
 
Could you indicate whether any of these experiences have occurred because of your appearance/colour/ 






SECTION V                 EMPLOYMENT  Rel           Yes/No             Year and Month 
7. Loss of a job or retirement to you 
 or anyone else in your household                ……        ………….          ……………………… 
 
Could you indicate whether any of these experiences have occurred because of your appearance/colour/ 






SECTION VII            MARITAL/ COHABITING Rel           Yes/No             Year and Month 
8. A serious row or rift with your 
 spouse/ partner                                             …….         …………          ……………………..  
 
9. A serious row or rift with someone 
 in the immediate family or with 
 whom you felt very close                             ……..        ………….          …………………….. 
 
Could you indicate whether any of these experiences have occurred because of your appearance/colour/ 






SECTION X               CRISES                                   Rel           Yes/No              Year and Month 
10. A serious breach of the law by you 
 Your partner or your children                    …….         …………          ……………………... 
                                                                   
Could you indicate whether any of these experiences have occurred because of your appearance/colour/ 






ONGOING DIFFICULTIES    Rel           Yes/No              Year and Month 
11. Any news of a shocking or revealing  
 nature about your partner or your  
 children                                                           …….        …………           ……………………..  
 
12. Serious chronic illness- yours, 
 your spouse/partner, your children’s 
 or anyone else in the household                   ……..       ………….          ……………………... 
 





14. Serious financial difficulties                         ……..       ………….          ……………………... 
 
15. Problems concerning unemployment 
              - yours or your spouse/ partner’s                 ……..       ………….          …………………….. 
 
16. Describe below any other particularly 
 unpleasant or disappointing event 
 or difficulty that has occurred.                    ……..       ……….....         ……………………… 
 
Could you indicate whether any of these experiences have occurred because of your appearance/colour/ 















































UNDERSTANDING THE CAUSES AND OUTCOME OF MENTAL HEALTH PROBLEMS 
Please read this carefully if you wish to participate in our study. 
Your participation is entirely voluntary 
 
Consent form and general information sheet for participants 
 
About six years ago you made contact with psychiatric services for the first time in your life. We would like to 
come and speak to you to find out how you are now, and ask you about any difficulties or problems that you 
may be having, or may have had over the last six years.  As part of the AESOP study, we are also trying to find 
out more about the changes in concentration, memory and thought that happen in mental illness and how those 
changes relate to the symptoms and long-term outcome of the illness. We would also like to do some 
concentration and memory tests, which take about two hours.  We would also like to ask you some questions 
about your behaviour in childhood and adulthood, and whether you have experienced any aggressive behaviour 
in adulthood. These tests will be similar to the ones you did six years ago.   Normally, all the interviews and 
assessments will be completed over three appointments, each lasting about 2 ½ hours. 
 
Anything you say will be treated in the strictest confidence.   You will not be identified by name, but by a code 
number.  If you decide not to be part of the study, this will not affect in any way the care you receive.  If you do 
decide to take part you are free to withdraw from the study at any time without having to say why.  Withdrawal 
from the study will not affect in any way, the care you receive.   We hope you will agree to take part in this 
study so that your help may contribute to improving the care offered by hospitals.  Participation in the study 
may not be of direct benefit to you, but may prove beneficial to others. If you would like to ask any questions 
or want to find out about anything else at all, please telephone Ms Jolanta Zanelli on 020 7848 0534 (see 
further contact details below).  If she is not there when you call, other members of the research team will be 




I agree to being interviewed for this study.  I understand that my participation is entirely voluntary and that I 
can withdraw from the interviews at any stage and that it will not affect any treatment that I may be receiving.   
 
Signed ………………………………………….      
Date ………………………………………. 
 
I confirm that the person above has been given all the information provided on this information sheet and that 
they have agreed to participate in the study. 
 
Witness ………………………………………….      
Date ……………………………………… 
 
Contact: Ms Jolanta Zanelli  (020 7848 0534) 
Section of General Psychiatry PO63 
Institute of Psychiatry 
De Crespigny Park, London  SE5 8AF 
 
AESOP Research Team:   
Principal Investigator:  Prof. Robin Murray 
Dr Paola Dazzan                Dr Paul Fearon   
Dr Julia Lappin               Dr Craig Morgan  
Dr Kris Naudts               Ms Helen Fisher 
Dr Rina Dutta 
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Appendix N Life chart 
 
AMENDED LIFE CHART SCHEDULE 
 
CLINICAL COURSE AND SYMPTOMS 
 
CURRENT MENTAL STATE        □ 
Is the patient now (last 30 days) in a psychotic episode?      
0 = No 
1 = Yes 
2 = Yes, but not continuous with episode in inclusion 
 
REMISSION          
a) What is longest period (in weeks) during which the patient has had a remission of psychotic 
symptoms?           □ 
b) Has the patient had a remission of psychotic symptoms for a period of at least 6 months since 
the initial evaluation?         □ 
0 = No  1 = Yes         
b) If YES above, for how many weeks was the patient in the episode of inclusion (i.e. baseline 
episode)           □ 
 
USUAL SYMPTOM SEVERITY (during psychotic episodes only)    □ 
0 = No further episodes         
1 = Mild 
2 = Moderate 
3 = Severe 
Note: Use SCAN rating criteria 
‘The severity of a symptom can be assessed in terms of duration, persistence, degree of 
interference with other mental functions, distress, impairment of everyday activities, effect on 
other people, and contact with services of various kinds.’ 
SCAN Rating Scales 
0 Symptom(s) did not occur during period 
1 Symptom(s) definitely occurred during period, but probably uncommon or transitory 
OR of such a minor degree it is not appropriate for use in classification 
2 Symptom(s) definitely present, on multiple occasions or for part of time, during period 
AND at a level sufficient to use in classification 
3 Symptom was more or less continuously present throughout the period/episode AND 
present in severe form 
 
PRESENCE OF NEGATIVE SYMPTOMS      □ 
0 = No           
1 = Yes, for less than 6 months 
2 = Yes, for more than 6 months 
i.e. a) Marked reduction or loss of interests, initiative and drive, leading to serious deterioration of 
the performance of usual activities and tasks b) Emergence or marked exacerbation of social withdrawal 
(active avoidance of communication with other people) e) Gross and persistent self-neglect 
 
COURSE TYPE          □ 
1 = Episodic, no episode lasted over 6 months       
2 = Continuous, no remission lasted over 6 months (Primarily symptoms A) 
3 = Continuous, no remission lasted over 6 months (Primarily symptoms B) 
4 = Continuous, no remission lasted over 6 months (Primarily symptoms A & B) 
5 = Neither episodic nor continuous, at least 1 episode & 1 remission lasted over 6 months 
 
NUMBER OF PSYCHOTIC EPISODES (Do NOT include first episode)   □ 
(See Appendix 1 for definition of psychotic episode. Each “psychotic episode”    
must be separated by at least 6 months spent in remission). 
00 = Patient presently in remission from episode of inclusion 
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MONTHS OF LONGEST PSYCHOTIC EPISODE     □ 
 
NON-PSYCHOTIC EPISODE(S)       □ 
(Only rate if treatment was received)        
0 = No 
1 = Yes 
If yes, include details (i.e. type of non-psychotic episode and number of episodes): 
 
SUICIDE ATTEMPT(S)         □ 
a) Rate the number of suicide attempts by the patient since the index episode of    
evaluation (if in any doubt re: intention, rate as deliberate self-harm) 
0 = None 
 
DELIBERATE SELF-HARM        □ 
a) Rate the number of episodes of deliberate self-harm by the patient since the index 
episode of evaluation (if in any doubt re: intention, rate as deliberate self-harm) 
0 = None 
b) Record details of suicide attempts and episodes of deliberate self-harm 
 
DRUG ABUSE/DEPENDENCE        □ 
a) Rate illicit drug taking and/or abuse of illicit drugs over life course   
0 = None 
1 = Sporadic drug taking or occasional abuses reported, no evidence for frequent or regular use 
(i.e. less than one month) 
2 = Sporadic drug taking or occasional abuses reported, but there is reason to suspect frequent or 
regular use (i.e. more than one month) 
3 = Frequent or regular use definitely present (i.e. more than one month) 
4 = Substance abuse (Maladaptive use leading to any of the following: 
 (1) failure to fulfil major role obligations due to substance 
 (2) substance exacerbating or leading to social or interpersonal problems  
 (3) recurrent abuse when physically hazardous (e.g. driving) or substance related legal 
 problems) 
5=Substance dependence (Maladaptive use leading to 3 of the following: 
 (1) increased tolerance  
 (2) symptoms of withdrawal  
 (3) substance taken in larger amounts over a longer period than originally intended  
 (4) persistent desire or unsuccessful attempts to cut down  
 (5) much time spent in activities to obtain the substance or recovering from effects  
 (6) impairment of social, occupational or recreational activities due to substance  
 (7) persistent use despite harmful physical or psychological effects of substance. 
7 = Drug taking a definite possibility but impossible to assess the frequency and extent of use 
 
b) If a rating of 1, 2, 3, 4,5 or 7 was made above, specify whatever information is available 
about the nature of the substance(s) taken by the patient. For each substance used, specify age 
of first use. 
0 = No 
1 = Yes 
2 = Suspected/uncertain 
8 = Not applicable/not inquired 
9 = No information/impossible to assess 
 
 
     Age 1st Used 
Morphine or heroin    __________ 
Opium      __________ 
Amphetamines or derivatives   __________ 
Hashish or marijuana    __________ 
Hallucinogens (LSD and others)   __________ 
Cocaine and cocopaste    __________ 
Barbituates     __________ 
Non-barbiturate sedatives and tranquillisers  __________ 
Other, specify     __________ 
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ALCOHOL ABUSE/DEPENDENCE       □ 
a) Rate the patient’s drinking habits over life course       
0 = Does not drink at all 
1 = Only occasional social drinking (mean 10 units or less per week) 
2 = Moderate alcohol use (mean 21 units or less per week) 
3 = Excessive alcohol use (mean more than 21 unit per week regularly) 
4 = Alcohol abuse (Maladaptive use leading to any of the following: 
 (1) failure to fulfil major role obligations due to alcohol  
 (2) substance exacerbating or leading to social or interpersonal problems  
 (3) recurrent abuse when physically hazardous (e.g. driving) or alcohol related legal problems) 
5 = Alcohol dependence (Maladaptive use leading to 3 of the following  
 (1) increased tolerance  
 (2) symptoms of withdrawal  
 (3) alcohol taken in larger amounts over a longer period than originally intended  
 (4) persistent desire or unsuccessful attempts to cut down  
 (5) much time spent drinking the substance or recovering from effects  
 (6) impairment of social, occupational or recreational activities due to alcohol  
 (7) persistent use despite harmful physical or psychological effects of alcohol 
9 = No information/Not known 
 
b) If a rating of 3, 4, 5 or 7 was made above, specify whatever information is available about the 
nature of the substance(s) taken by the patient 
 

















SERVICE USE AND TREATMENT 
 
HAS THE PATIENT BEEN IN CONTACT WITH SERVICES AT ANY POINT 
DURING THE FOLLOW-UP PERIOD?       □ 
0 = No 
1 = Yes 
If YES, continue 
 
If NO, is this because:         □ 
0 = None were offered 
1 = Patient did not attend 





TOTAL NUMBER OF HOSPITAL ADMISSIONS 
@ f.u.  □ 
@ 6 yrs  □ 
@ 3 yrs  □ 
 
TOTAL NUMBER OF PERIODS OF COMMUNITY TREATMENT 
@ f.u.  □ 
@ 6 yrs  □ 
@ 3 yrs  □ 
 
INPATIENT – complete one of these for each admission 
3.2.1 Date of Admission   □ 
3.2.2 Date of Discharge   □ 
3.2.3 Ward Type   □ 
3.2.4a MHA Status on Admission  □ 
3.2.4b MHA Status during Admission □ 
3.2.5 MHA Section(s)    □ 
3.2.6 Source of Referral   □ 
3.2.7 Reason for Admission  □ 
3.2.8 Family involvement  □ 
3.2.9 Police or CJA Involvement  □ 
 
OUTPATIENT – complete one of these for each outpatient period 
3.3.1 Date of Referral    □ 
3.3.2a Date Last Seen    □ 
3.3.2b Date of Discharge or Hospital Admission □ 
3.3.3 Source of Referral    □ 
3.3.4 Type of Contact     □ 
3.3.5 Reason Contact Ended   □ 
 
 
OTHER TREATMENT ITEMS 
Overall Compliance/Attendance        □ 
Rate patient’s compliance/attendance at community/follow-up services 
1 = Regular compliance/attendance [1-33% missed appointments] 
2 = Irregular compliance/attendance [34-66% missed appointments] 
3 = None compliance/attendance [67-100% missed appointments] 
 
Reason for Irregular or None Attendance 
What was the reason(s) why the patient did not fully attend follow-up appointments? 
 
Current treatment status 
Patient’s treatment status at the time of interview 
@ f.u.  □ 
@ 6 yrs  □ 
@ 3 yrs  □ 
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0 = Not in any form of treatment 
1 = Inpatient psychiatric facility (includes general hospital psychiatric wards) 
2 = Standard outpatient/CMHT 
3 = Assertive outreach 
4 = Acute home treatment/crisis intervention 
5 = Other, specify 
6 = More than one above, specify 
 
Traditional treatment         □ 
A great variety of traditional healing practices exists and the particular form applied should be described 
in a narrative          
0 = No 
1 = Yes 
9 = Uncertain 
































SOCIODEMOGRAPHIC CHANGES DURING THE FOLLOW-UP 
PERIOD 
 
TYPE OF LIVING ARRANGEMENTS 
No. of changes following first episode interview 
Type of living arrangements 
No. of people in household 
Approx. length of residence (in weeks) 
 
MONTHS IN PRISON DURING FOLLOW-UP PERIOD     □ 
 
ANY OTHER SUGGESTIONS OF ANTI-SOCIAL/OFFENDING BEHAVIOUR?  □ 
0 = No 1 = Yes           
 
TYPE OF ACCOMMODATION AT FOLLOW-UP     □ 
0 = Self/joint owner occupied 
1 = Family owner occupied 
2 = Private rented 
3 = Local Authority rented 
4 = Housing Association rented 
5 = Other (specify) 
 
CURRENT MARITAL STATUS        □ 
Rate the patient’s current marital status 
0 = Married or common law marriage 
1 = In steady relationship 
2 = Single, no partner 
3 = Divorced 
4 = Separated 
5 = Widowed 
6 = Other, specify 
 
MAIN MARITAL STATUS DURING FOLLOW-UP PERIOD    □ 
Rate the patient’s main marital status during follow-up period 
0 = Married or common law marriage 
1 = In steady relationship 
2 = Single, no partner 
3 = Divorced 
4 = Separated 
5 = Widowed 
6 = Other, specify 
 
CURRENT PARENTAL STATUS 
Rate patient’s current parental status 
0 = No children 
1 = Parent, living with partner 
2 = Single parent 
3 = Parent, children live with other parent 
4 = Parent, children live with relatives 
5 = Parent, children in care 
 
PAST PARENTAL STATUS        □ 
Rate patient’s parental status during majority of follow-up period 
0 = No children 
1 = Parent, living with partner 
2 = Single parent 
3 = Parent, children live with other parent 
4 = Parent, children live with relatives 




CURRENT EMPLOYMENT STATUS (LAST 30 DAYS)     □ 
Has the patient been employed at a paid job (i.e. an earning occupation) in the last 30 days? 
0 = No 
1 = Yes, specify job 
2 = Student 
 
REASONS FOR CURRENT UNEMPLOYMENT (LAST 30 DAYS)   □ 
If the patient has not had a paid job in the last 30 days, rate the reasons for unemployment 
0 = Related to the patient’s mental illness (inc.’s hospitalisation, simple refusal to work, etc.) 
1 = Unrelated to the patient’s mental illness 
2 = Other, specify 
3 = Combination of the above, specify 
 
PAST EMPLOYMENT         □ 
Rate employment (or earning job) since index episode (exclude last 30 days) 
0 = Has been employed 75-100% of the time 
1 = Has been employed 50-75% of the time 
2 = Has been employed 25-50% of the time 
3 = Has been employed 0-25% of the time 
 
REASONS FOR PAST UNEMPLOYMENT      □ 
Rate reason for unemployment since index episode (exclude last 30 days) 
0 = Related to the patient’s mental illness (inc.’s hospitalisation, simple refusal to work, etc.) 
1 = Unrelated to the patient’s mental illness 
2 = Other, specify 
3 = Combination of the above, specify 
 
EDUCATION          □ 
Since the index episode has the patient undertaken an educational programme (including vocational 
training), of at least 10 weeks duration? 
0 = No 
1 = Yes 
 
SOCIAL NETWORK: CHANGES 
 
HAS THE PATIENT’S RELATIONSHIP WITH FAMILY/FRIENDS BEEN AFFECTED BY 
HIS/HER ILLNESS?         □ 
(NB: Friends here refers only to very close friends the patient had at baseline) 
1 = Yes 
2 = No 
 
IF YES, HOW          □ 
1 = Increased frequency of contact 
2 = Decreased frequency of contact 
 
FOR EITHER OF THE ABOVE, DETERMINE THE DEGREE OF CHANGE  □ 
1 = To a large extent (e.g. change from low to high frequency or vice versa) 
2 = To a moderate extent (e.g. change from medium to high frequency or vice versa) 
3 = To a small extent (e.g. change from low to medium frequency or vice versa) 
ENSURE THAT THE CHANGE IS FROM THE PRE-MORBID follow-upNCTIONING LEVEL. 
 
IF THE PATIENT SEES LESS OF ANY FAMILY MEMBER(S)/FRIEND(S), WHY IS THIS? 
0 = Because of illness         □ 
1 = Family quarrels 
2 = Moved away 
3 = Drifted apart 
4 = Died 




SOCIAL NETWORK: CURRENT 
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HOW OFTEN DO YOU VISIT OR SPEAK TO FAMILY/FRIEND(S)?   □ 
0 = Daily      3 = Monthly 
1 = Weekly   4 = < than above 
2 = Fortnightly  5 = Never 
 
DO YOU HAVE ANY CLOSE CONFIDANTS?      □ 
1 = Yes   2 = No 
 
HOW OFTEN DO YOU VISIT/SPEAK TO CONFIDANTS?    □ 
0 = Daily  4 = < than above 
1 = Weekly  5 = Never 
2 = Fortnightly 
3 = Monthly 
 
FATHER’S EMPLOYMENT AT BIRTH 
























PATIENTS WHO DIED SINCE THE INITIAL EVALUATION 
 
Date of death 
 
Was the death medically certified?       □ 
0 = No 
1 = Yes 
9 = No information/not known 
 
Cause of death_____________________________________________ 
 
Immediate cause (if known) __________________________________ 
 
Underlying cause (if known) _________________________________ 
 
Contributory cause(s) (if known) _____________________________ 
 
If death was due to suicide, specify method      □ 
0 = Death not due to suicide 
1 = Self-poisoning with medicaments 
2 = Firearms 
3 = Hanging 
4 = Jumping from heights 
5 = Stabbing 
6 = Drowning 
7 = Other, specify 































Antipsychotic Treatment over follow-up period 
 
Complete one for each medication 
1. Name of antipsychotic: 
Dose and delivery method 
Date of commencement: 
Date of treatment discontinuation: 
Time on treatment (weeks): 
Reason for discontinuation: 
[1= change to alternative antipsychotic; 2= discontinued by treating physician; 
3=discontinued by patient; 4=other] 
Adherence to antipsychotic over this period: 




Appendix O Risk factors adjusted analyses 
 
Table: Adjusted odds ratios adjusted for gender, age, centre and ethnicity and 95% CIs for baseline diagnosis of PMD, schizophrenia and 
bipolar compared with controls 














































































































































































Employment Status:  



























































Contact with friends:          
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Daily – monthly 



















Contact with family: 
Daily – monthly 

































































































































































































































































































Table: Adjusted odds ratios adjusted for gender, age, centre and ethnicity and 95% CIs for lifetime diagnosis of PMD, schizophrenia and 
bipolar compared with controls 
 PMD (n51) vs. controls Schizophrenia (n225) vs. controls Bipolar (n73) vs. controls 
 aOR (2dp) 95% CI 
(2dp) 
P (3dp) aOR (2dp) 95% CI 
(2dp) 
P (3dp) aOR (2dp) 95% CI 
(2dp) 
P (3dp) 
































































































































































Employment Status:  



























































Contact with friends: 
Daily – monthly 




























Contact with family: 
Daily – monthly 





























 PMD (n51) vs. controls Schizophrenia (n225) vs. controls Bipolar (n73) vs. controls 
 aOR (2dp) 95% CI 
(2dp) 
P (3dp) aOR (2dp) 95% CI 
(2dp) 






























































































































































































STATA unable to calculate 




STATA unable to calculate 





STATA unable to calculate 
































Number of Childhood Adversity Factors 1.26 1.02-1.57 0.036 1.21 1.03-1.42 0.020 1.15 0.91-1.46 0.241 
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Appendix P Outcome results 
 
Death - n320/368 
Table 8-3: Comparison of deaths by lifetime diagnosis 
 PMD (n44) SAD (n17) SZ (n196) BP (n63) 
 n/N (%) n/N (%) n/N (%) n/N (%) 
Dead 4/44 (9.1) 1/17 (5.9) 12/196 (6.1) 5/63 (7.9) 
SZ=schizophrenia; BP=bipolar 
 
Table 8-4: OR, CI and p value for comparisons between the groups in the proportion of cases who 
died over follow-up 
 PMD vs. SZ 
(n240) 
PMD vs. BP 
(n107) 
PMD vs. SAD 
(n61) 
SAD vs. SZ 
(n213) 
SAD vs. BP 
(n80) 
 OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) 
Death 1.53 (0.47-5.00) 1.16 (0.29-4.59) 1.60 (0.17-15.44) 0.96 (0.12-7.85) 0.73 (0.08-6.66) 
*p<0.1; **p<0.05; ***p<0.01; OR = odds ratio; CI = 95% confidence interval; $ Unable to calculate odds ratios as no SAD cases 
died over follow-up. 
 
Completed suicide – n15/22  
Table 8-5: Comparison of completed suicide outcome variables by lifetime diagnosis 
 PMD (n3) SAD (n1) SZ (n7) BP (n4) 
 n/N (%) n/N (%) n/N (%) n/N (%) 
Completed suicides 1/3 (33.3) 1/1 (100) 5/7 (71.4) 2/4 (50.0) 
SZ=schizophrenia; BP=bipolar 
 
Table 8-6: OR, CI and p value for comparisons between the groups in the completed suicide 
proportions over follow-up 
 PMD vs. SZ 
(n10) 
PMD vs. BP (n7) PMD vs. sad 
(n4) 
SAD vs. SZ (n8) SAD vs. BP (n5) 
 OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) 
Death 5.0 (0.27-91.52) 2.0 (0.09-44.35) $ $ $ 
*p<0.1; **p<0.05; ***p<0.01; OR = odds ratio; CI = 95% confidence interval; $ Unable to calculate odds ratios as all the SAD 
cases committed suicide. 
 
Employment status – n257/368  
Table 8-7: Comparison of employment status by lifetime diagnosis 
 PMD (n30) SAD (n15) SZ (n165) BP (n47) 
 n (%) n (%) n (%) n (%) 



























Table 8-8: OR, CI and p value for comparisons between the groups of the employment status over 
the follow-up period 
 PMD vs. SZ 
(n195) 
PMD vs. BP (n77) PMD vs. SAD 
(n45) 
SAD vs. SZ 
(n180) 
SAD vs. BP 
(n62) 











1.19 (0.41-3.41) 2.36 (0.43-12.87) 1.54 (0.32-7.47) 0.50 (0.10-2.58) 
*p<0.1; **p<0.05; ***p<0.01; OR = odds ratio; CI = 95% confidence interval. 
 
Total number of hospitalisations – n92/368 
Table 8-9: Comparison of total hospitalisations by lifetime diagnosis 











1 (1-2) 2 (1-4) 3 (1-6) 2.5 (1-4) 
SZ=schizophrenia; BP=bipolar; IQR = Interquartile range. 
 
Table 8-10: IRR, CI and p value for comparisons between the groups of the total hospitalisations 
over the follow-up period 
 PMD vs. SZ 
(n218) 
PMD vs. BP 
(n97) 
PMD vs. SAD 
(n55) 
SAD vs. SZ 
(n195) 
SAD vs. BP 
(n74) 
 IRR (CI) IRR (CI) IRR (CI) IRR (CI) IRR (CI) 








*p<0.1; **p<0.05; ***p<0.01; IRR = incidence rate ratio; CI = 95% confidence interval. 
 
Percentage of follow-up spent as an inpatient – n250/368 
Table 8-11: Comparison of percentage of the follow-up as inpatient data by lifetime diagnosis 
 PMD (n36) SAD (n12) SZ (n149) Mania (n53) 
 Median (IQR) Median (IQR) Median (IQR) Median (IQR) 
Percentage of follow-up as an 
inpatient  
0.68% (0.07-3.28%) 2.06% (0.28-8.96%) 3.54% (1.29-
11.13%) 
1.80% (1.07-4.11%) 
SZ=schizophrenia; BP=bipolar; IQR = Interquartile range. 
 
Table 8-12: Coefficient, CI and p value for comparisons between the groups of the percentage as an 
inpatient over the follow-up period 
 PMD vs. SZ 
(n185) 
PMD vs. BP 
(n89) 
PMD vs. SAD 
(n48) 
SAD vs. SZ 
(n161) 











follow-up as an 
inpatient 
-4.71 (-8.74 to 
-0.69)** 
0.02 (-3.82 to 
3.86) 
-4.80 (-14.39 to 
4.78) 
0.09 (-9.21 to 
9.39) 
4.82 (-3.80 to 
13.44) 
*p<0.1; **p<0.05; ***p<0.01; CI = 95% confidence interval. 
 498 
Ever having been admitted compulsorily – n246/368 
Table 8-13: Comparison of compulsory hospitalisation data by lifetime diagnosis 
 PMD (n34) SAD (n12) SZ (n147) Mania (n53) 
 N (%) N (%) N (%) N (%) 

















Table 8-14: OR, CI and p value for comparisons between the groups of compulsory admissions 
 PMD vs. SZ 
(n181) 
PMD vs. BP 
(n87) 
PMD vs. SAD 
(n46) 
SAD vs. SZ 
(n159) 
SAD vs. BP 
(n65) 
 OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) 




1.00 (0.27-3.73) 0.39 (0.12-1.27) 0.33 (0.09-
1.18)* 
*p<0.1; **p<0.05; ***p<0.01; OR = odds ratio; CI = 95% confidence interval. 
 
Total number of days hospitalised – n250/368 
Table 8-15: Comparison of hospitalisation days data by lifetime diagnosis 
 PMD (n36) SAD (n12) SZ (n149) Mania (n53) 
 Median (IQR) Median (IQR) Median (IQR) Median (IQR) 
Total number of days hospitalised 25.2 (0-123) 74.5 (11-336.5) 130 (48-363) 69 (32-154) 
SZ=schizophrenia; BP=bipolar; IQR = Interquartile range. 
 
Table 8-16: Coefficients, CI and p value for comparisons between the groups of the hospitalisation 
days over the follow-up period 
 PMD vs. SZ 
(n185) 
PMD vs. BP 
(n89) 
PMD vs. SAD 
(n48) 
SAD vs. SZ 
(n161) 
SAD vs. BP 
(n65) 
 Coefficient (CI) Coefficient (CI) Coefficient (CI) Coefficient (CI) Coefficient (CI) 












*p<0.1; **p<0.05; ***p<0.01; CI = 95% confidence interval. 
 
Percentage of hospitalisations involving the police – n219/368 
Table 8-17: Comparison of police involvement in hospitalisation data by lifetime diagnosis 
 PMD (n33) SAD (n11) SZ (n128) Mania (n47) 
 Median (IQR) Median (IQR) Median (IQR) Median (IQR) 
Percentage of hospitalisations involving police 0 (0-0) 0 (0-50) 20 (0-55) 0 (0-54.5) 




Table 8-18: Coefficients, CI and p value for comparisons between the groups of police involvement 
in hospitalisations over the follow-up period 
 PMD vs. SZ 
(n161) 
PMD vs. BP (n80) PMD vs. SAD 
(n44) 
SAD vs. SZ 
(n139) 
SAD vs. BP 
(n58) 





-24.34 (-36.58 to -
12.10)*** 
-18.28 (-33.54 to -
3.01)** 
-13.72 (-35.41 to 
7.97) 
-10.62 (-31.28 to 
10.05) 
-4.56 (-26.99 to 
17.88) 
*p<0.1; **p<0.05; ***p<0.01; CI = 95% confidence interval. 
 
